13. Literaturverzeichnis – Mammakarzinom
1. Sørensen, K, Van den Broucke, S, Fullam, J, Doyle, G, Pelikan, J, Slonska, Z, et.al. Health literacy and public health: a systematic review and integration of definitions and models., BMC Public Health, 2012. 12 (): p. 80., https://pubmed.ncbi.nlm.nih.gov/22276600/
2. Sieber, W. J., Kaplan, R. M., Informed adherence: the need for shared medical decision making, Control Clin Trials, 2000. 21(5 Suppl): p. 233s-40s., https://www.ncbi.nlm.nih.gov/pubmed/11018581
3. Weinstein, James N, Editorial: The missing piece: Embracing shared decision making to reform health careLWW, 2000.
4. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, Bmj, 2004. 328(7444): p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
5. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15(1): p. 7-20., https://www.ncbi.nlm.nih.gov/pubmed/17024500
6. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59(2): p. 148-57., https://www.ncbi.nlm.nih.gov/pubmed/16257619
7. Beauchamp, Tom L, Childress, James F, Principles of biomedical ethicsOxford University Press, USA, 2001.
8. Zheng, H, Yang, L, Hu, J, Yang, Y, Frequency and Influencing Factors of Shared Decision Making Among Breast Cancer Patients Receiving Surgery: A Systematic Review and Meta-Analysis., Clin Breast Cancer, 2023. 23 (1)(1): p. e20-e31., https://pubmed.ncbi.nlm.nih.gov/36357267/
9. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23(24): p. 5526-33., https://www.ncbi.nlm.nih.gov/pubmed/16110013
10. Wagner, Katja, Koller, M, Keil, Astrid, Trott, Diana, Engenhart-Cabillic, Rita, Pfab, R, et.al. Strahlentherapie bei chirurgischen und nichtchirurgischen Patienten Therapieerwartungen, Lebensqualität und Arzteinschätzungen, Der Chirurg, 1998. 69(3): p. 252-258., https://pubmed.ncbi.nlm.nih.gov/9576035/
11. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73(3): p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394
12. Albert, U-S, Koller, M, Wagner, U, Schulz, K-D, Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer, Inflammation Research, 2004. 53: p. S136-S141., https://www.ncbi.nlm.nih.gov/pubmed/15338065
13. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603., https://www.ncbi.nlm.nih.gov/pubmed/25071125
14. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602., https://www.ncbi.nlm.nih.gov/pubmed/15520059
15. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53., https://www.ncbi.nlm.nih.gov/pubmed/15939716
16. Kautz-Freimuth, S, Redaèlli, M, Shukri, A, Kentenich, H, Simic, D, Mildenberger, V, et.al. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial., BMC Med Inform Decis Mak, 2023. 23 (1)(1): p. 223., https://pubmed.ncbi.nlm.nih.gov/37845719/
17. Gilligan, T, Coyle, N, Frankel, RM, Berry, DL, Bohlke, K, Epstein, RM, et.al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline., J Clin Oncol, 2017. 35 (31)(31): p. 3618-3632., https://pubmed.ncbi.nlm.nih.gov/28892432/
18. Nicholas Zdenkowski, , Butow, P, Tesson, S, Boyle, F, A systematic review of decision aids for patients making a decision about treatment for early breast cancer., Breast, 2016. 26 (): p. 31-45., https://pubmed.ncbi.nlm.nih.gov/27017240/
19. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), HTA-Bericht Behandlungsgespräche: Führt eine gemeinsame Entscheidungsfindung von Arzt und Patient bei der Therapiewahl zu besseren Ergebnissen? Projekt: HT22-01, 06.09.2023., https://www.iqwig.de/presse/pressemitteilungen/pressemitteilungen-detailseite_100418.html
20. Runowicz, Carolyn D, Leach, Corinne R, Henry, N Lynn, Henry, Karen S, Mackey, Heather T, Cowens‐Alvarado, Rebecca L, et.al. American Cancer society/American society of clinical oncology breast Cancer survivorship care guideline, CA: a cancer journal for clinicians, 2016. 66(1): p. 43-73., https://pubmed.ncbi.nlm.nih.gov/26641959/
21. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatient*innen, Version 2.1, 2023. AWMF-Registernummer: 032-051OL:, https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie
22. Wanchai, A, Anderson, EA, Armer, JM, A systematic review of m-health apps on managing side effects of breast cancer treatment., Support Care Cancer, 2022. 31 (1)(1): p. 86., https://pubmed.ncbi.nlm.nih.gov/36574048/
23. Singleton, AC, Raeside, R, Hyun, KK, Partridge, SR, Di Tanna, GL, Hafiz, N, et.al. Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses., J Clin Oncol, 2022. 40 (20)(20): p. 2257-2270., https://pubmed.ncbi.nlm.nih.gov/35500200/
24. Horn, A, Jírů-Hillmann, S, Widmann, J, Montellano, FA, Salmen, J, Pryss, R, et.al. Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors., J Cancer Surviv, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37906420/
25. Stock, S, Isselhard, A, Jünger, S, Peters, S, Schneider, G, Haarig, F, et.al. [DNVF Memorandum Health Literacy (Part 2) - Operationalisation and Measuring of Health Literacy from a Health Services Research Perspective]., Gesundheitswesen, 2022. 84 (4)(4): p. e26-e41., https://pubmed.ncbi.nlm.nih.gov/35472769/
26. RKI, Brustdrüse, in in Krebs in Deutschland, 2023. p. 78 - 81., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2023/kid_2023_c50_brust.pdf?__blob=publicationFile
27. (ECIBC), European Commission Initiative on Breast Cancer, Evidencereport update, 2016., http://ecibc.jrc.ec.europa.eu/recommendations/list/3
28. Organization, World Health, WHO position paper on mammography screeningWorld Health Organization, 2014., https://pubmed.ncbi.nlm.nih.gov/25642524/
29. Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., et.al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies, J Med Screen, 2012. 19 Suppl 1: p. 14-25., https://pubmed.ncbi.nlm.nih.gov/22972807/
30. (IARC)., International Agency for Research on Cancer, Breast Cancer Screening. IARC Handbook of Cancer Prevention., 2016. 15:, http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016
31. Siu, A. L., Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 2016. 164(4): p. 279-96., https://www.ncbi.nlm.nih.gov/pubmed/26757170
32. ECIBC, European guidelines on breast cancer screening and diagnosis, 2023., https://cancer-screening-and-care.jrc.ec.europa.eu/en/ecibc/european-breast-cancer-guidelines?topic=61&usertype=60&updatef2=0.%20Download%2001.10.2024
33. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., et.al. Breast-cancer screening--viewpoint of the IARC Working Group, N Engl J Med, 2015. 372(24): p. 2353-8., https://www.ncbi.nlm.nih.gov/pubmed/26039523
34. Wolf, AMD, Oeffinger, KC, Shih, TY, Walter, LC, Church, TR, Fontham, ETH, et.al. Screening for lung cancer: 2023 guideline update from the American Cancer Society., CA Cancer J Clin, 2024. 74 (1)(1): p. 50-81., https://pubmed.ncbi.nlm.nih.gov/37909877/
35. Trentham-Dietz, A, Chapman, CH, Jayasekera, J, Lowry, KP, Heckman-Stoddard, BM, Hampton, JM, et.al. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force., JAMA, 2024. 331 (22)(22): p. 1947-1960., https://pubmed.ncbi.nlm.nih.gov/38687505/
36. Braun, B, Khil, L, Tio, J, Krause-Bergmann, B, Fuhs, A, Heidinger, O, et.al. Differences in Breast Cancer Characteristics by Mammography Screening Participation or Non-Participation., Dtsch Arztebl Int, 2018. 115 (31-32)(31-32): p. 520-527., https://pubmed.ncbi.nlm.nih.gov/30149831/
37. Tabár, L, Dean, PB, Chen, TH, Yen, AM, Chen, SL, Fann, JC, et.al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening., Cancer, 2019. 125 (4)(4): p. 515-523., https://pubmed.ncbi.nlm.nih.gov/30411328/
38. Trocchi, P, Kuss, O, Kääb-Sanyal, V, Heidinger, O, Stang, A, Trends in surgical treatment for breast cancer in Germany after the implementation of the mammography screening program., Eur J Epidemiol, 2019. 34 (12)(12): p. 1143-1150., https://pubmed.ncbi.nlm.nih.gov/31650416/
39. Zorzi, M, Puliti, D, Vettorazzi, M, De Lisi, V, Falcini, F, Federico, M, et.al. Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997-2001)., Br J Cancer, 2006. 95 (9)(9): p. 1265-8., https://pubmed.ncbi.nlm.nih.gov/17043685/
40. Jahresbericht Evaluation 2021, Deutsches Mammographie-Screening-Programm.Kooperationsgemeinschaft Mammographie, November 2023.
41. Carter, JL, Coletti, RJ, Harris, RP, Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods., BMJ, 2015. 350 (): p. g7773., https://pubmed.ncbi.nlm.nih.gov/25569206/
42. Lauby-Secretan, B, Loomis, D, Straif, K, Breast-Cancer Screening--Viewpoint of the IARC Working Group., N Engl J Med, 2015. 373 (15)(15): p. 1479., https://pubmed.ncbi.nlm.nih.gov/26444742/
43. Myers, E. R., Moorman, P., Gierisch, J. M., Havrilesky, L. J., Grimm, L. J., Ghate, S., et.al. Benefits and Harms of Breast Cancer Screening: A Systematic Review, Jama, 2015. 314(15): p. 1615-34., https://www.ncbi.nlm.nih.gov/pubmed/26501537
44. Perry, N., Broeders, M., de Wolf, C., Tornberg, S., Holland, R., von Karsa, L., European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document, Ann Oncol, 2008. 19(4): p. 614-22., https://www.ncbi.nlm.nih.gov/pubmed/18024988
45. Heywang-Köbrunner, SH, Schreer, I, Hacker, A, Noftz, MR, Katalinic, A, Conclusions for mammography screening after 25-year follow-up of the Canadian National Breast Cancer Screening Study (CNBSS)., Eur Radiol, 2016. 26 (2)(2): p. 342-50., https://pubmed.ncbi.nlm.nih.gov/26017741/
46. Gemeinsamer Bundesausschuss, Krebsfrüherkennungs-Richtlinie, Richtlinie über die Früherkennung von Krebserkrankungen – KFE-RL, 2023. In Kraft getreten am: 01.07.2024:, https://www.g-ba.de/downloads/62-492-3478/KFE-RL_2023-09-21_iK-2024-07-01.pdf
47. Bundesamt der Justiz, Gesetz zum Schutz vor der schädlichen Wirkung ionisierender Strahlung (Strahlenschutzgesetz - StrlSchG), 2024., https://www.gesetze-im-internet.de/strlschg/__84.html
48. Albert, Ute Susann, Altland, H, Duda, V, Stufe-3-Leitlinie Brustkrebs-Früherkennung in DeutschlandZuckschwerdt München, 2008.
49. Group., Duke Evidence Synthesis, Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines.Duke Clinical Research Institute, Durham, NC: Guidelines Development Group, 2014., http://www.cancer.org/acs/groups/content/documents/document/acspc-046315.pdf
50. Organization, World Health, WHO position paper on mammography screeningWorld Health Organization, 2014., https://pubmed.ncbi.nlm.nih.gov/25642524/
51. Siu, A. L., Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 2016. 164(4): p. 279-96., https://www.ncbi.nlm.nih.gov/pubmed/26757170
52. (IARC)., International Agency for Research on Cancer, Breast Cancer Screening. IARC Handbook of Cancer Prevention., 2016. 15:, http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016
53. Plevritis, SK, Munoz, D, Kurian, AW, Stout, NK, Alagoz, O, Near, AM, et.al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012., JAMA, 2018. 319 (2)(2): p. 154-164., https://pubmed.ncbi.nlm.nih.gov/29318276/
54. Pace, L. E., Keating, N. L., A systematic assessment of benefits and risks to guide breast cancer screening decisions, Jama, 2014. 311(13): p. 1327-35., https://www.ncbi.nlm.nih.gov/pubmed/24691608
55. Gemeinsamer Bundesausschuss, Mammographie-Screening -eine Entscheidungshilfe, 2023., https://www.g-ba.de/downloads/17-98-2232/2023-09-21_G-BA_Entscheidungshilfe_Mammographie_bf.pdf
56. Chen, TH, Yen, AM, Fann, JC, Gordon, P, Chen, SL, Chiu, SY, et.al. Clarifying the debate on population-based screening for breast cancer with mammography: A systematic review of randomized controlled trials on mammography with Bayesian meta-analysis and causal model., Medicine (Baltimore), 2017. 96 (3)(3): p. e5684., https://pubmed.ncbi.nlm.nih.gov/28099330/
57. Duffy, SW, Tabar, L, Chen, THH, Yen, AMF, Dean, PB, Smith, RA, A plea for more careful scholarship in reviewing evidence: the case of mammographic screening., BJR Open, 2023. 5 (1)(1): p. 20230041., https://pubmed.ncbi.nlm.nih.gov/37942497/
58. Nicholson, WK, Silverstein, M, Wong, JB, Barry, MJ, Chelmow, D, Coker, TR, et.al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement., JAMA, 2024. 331 (22)(22): p. 1918-1930., https://pubmed.ncbi.nlm.nih.gov/38687503/
59. Stout, NK, Miglioretti, DL, Su, YR, Lee, CI, Abraham, L, Alagoz, O, et.al. Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density., JAMA Intern Med, 2024. 184 (10)(10): p. 1222-1231., https://pubmed.ncbi.nlm.nih.gov/39186304/
60. Hübner, J, Katalinic, A, Waldmann, A, Kraywinkel, K, Long-term Incidence and Mortality Trends for Breast Cancer in Germany., Geburtshilfe Frauenheilkd, 2020. 80 (6)(6): p. 611-618., https://pubmed.ncbi.nlm.nih.gov/32565551/
61. Katalinic, A, Eisemann, N, Kraywinkel, K, Noftz, MR, Hübner, J, Breast cancer incidence and mortality before and after implementation of the German mammography screening program., Int J Cancer, 2020. 147 (3)(3): p. 709-718., https://pubmed.ncbi.nlm.nih.gov/31675126/
62. bfs, Brustkrebsfrüherkennung mittels Röntgenmammographie bei Frauenab 70 Jahren Wissenschaftliche Bewertung des Bundesamtes für Strahlenschutz, Wissenschaftliche Bewertung des Bundesamtes für Strahlenschutz gemäß § 84 Absatz 3 Strahlenschutzgesetz, 2022., https://doris.bfs.de/jspui/bitstream/urn:nbn:de:0221-2022102634826/6/44-22-WissBericht_MSP70.pdf
63. IQWIG- Bericht 1383, Überprüfung der Altersgrenzen im Mammografie-Screening-Programm, 2022., https://www.iqwig.de/download/s21-01_altersgrenzen-im-mammografie-screening-programm_abschlussbericht_v1-1.pdf
64. Hölzel, D, Halfter, K, Schubert-Fritschle, G, Engel, J, Expanding mammography screening for women aged 40-80 years: evidence from a modeling approach using real-world data., Sci Rep, 2023. 13 (1)(1): p. 16229., https://pubmed.ncbi.nlm.nih.gov/37758770/
65. Canelo-Aybar, Carlos, Ferreira, Diogenes S, Ballesteros, Mónica, Posso, Margarita, Montero, Nadia, Solà, Ivan, et.al. Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast CancerSAGE Publications, Journal of Medical Screening, 2021. 28(4): p. 389 - 404., https://doi.org/10.1177/0969141321993866
66. Moss, S. M., Wale, C., Smith, R., Evans, A., Cuckle, H., Duffy, S. W., Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial, Lancet Oncol, 2015. 16(9): p. 1123-32., https://www.ncbi.nlm.nih.gov/pubmed/26206144
67. bfs, Brustkrebsfrüherkennung mittels Röntgenmammographie bei Frauen unter 50 Jahren Wissenschaftliche Bewertung des Bundesamtes für Strahlenschutz gemäß § 84 Absatz 3 Strahlenschutzgesetz BfS-55/23, 2023., https://doris.bfs.de/jspui/bitstream/urn:nbn:de:0221-2023110840049/3/BfS-55-23.pdf
68. USPSTF Bulletin, Task Force Issues Final Recommendation Statement on Screening for Breast Cancer All women should be screened every other year starting at age 40, 30.04.2024., https://www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/file/supporting_documents/breast-cancer-screening-final-rec-bulletin.pdf
69. Miglioretti, DL, Lange, J, van den Broek, JJ, Lee, CI, van Ravesteyn, NT, Ritley, D, et.al. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study., Ann Intern Med, 2016. 164 (4)(4): p. 205-14., https://pubmed.ncbi.nlm.nih.gov/26756460/
70. National Institute for Health and Care Excellence (NICE), Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019. No. 164:, https://pubmed.ncbi.nlm.nih.gov/31940157/
71. Lee, A, Mavaddat, N, Wilcox, AN, Cunningham, AP, Carver, T, Hartley, S, et.al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors., Genet Med, 2019. 21 (8)(8): p. 1708-1718., https://pubmed.ncbi.nlm.nih.gov/30643217/
72. Hamad, W, Michell, MJ, Myles, JP, Gilbert, FJ, Chen, Y, Jin, H, et.al. Diagnostic performance of tomosynthesis plus synthetic mammography versus full-field digital mammography with or without tomosynthesis in breast cancer screening: A systematic review and meta-analysis., Int J Cancer, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39394862/
73. Heywang-Köbrunner, SH, Jänsch, A, Hacker, A, Weinand, S, Vogelmann, T, Digital breast tomosynthesis (DBT) plus synthesised two-dimensional mammography (s2D) in breast cancer screening is associated with higher cancer detection and lower recalls compared to digital mammography (DM) alone: results of a systematic review and meta-analysis., Eur Radiol, 2022. 32 (4)(4): p. 2301-2312., https://pubmed.ncbi.nlm.nih.gov/34694451/
74. Lin, H, Zhang, Y, Wu, L, Li, C, Diagnostic accuracy of digital breast tomosynthesis and digital mammography in women with dense or non-dense breast tissue: A systematic review and meta-analysis., Adv Clin Exp Med, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39087824/
75. Heindel, W, Weigel, S, Gerß, J, Hense, HW, Sommer, A, Krischke, M, et.al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial., Lancet Oncol, 2022. 23 (5)(5): p. 601-611., https://pubmed.ncbi.nlm.nih.gov/35427470/
76. Alabousi, M, Wadera, A, Kashif Al-Ghita, M, Kashef Al-Ghetaa, R, Salameh, JP, Pozdnyakov, A, et.al. Performance of Digital Breast Tomosynthesis, Synthetic Mammography, and Digital Mammography in Breast Cancer Screening: A Systematic Review and Meta-Analysis., J Natl Cancer Inst, 2021. 113 (6)(6): p. 680-690., https://pubmed.ncbi.nlm.nih.gov/33372954/
77. Weigel, S, Heindel, W, Hense, HW, Decker, T, Gerß, J, Kerschke, L, Breast Density and Breast Cancer Screening with Digital Breast Tomosynthesis: A TOSYMA Trial Subanalysis., Radiology, 2023. 306 (2)(2): p. e221006., https://pubmed.ncbi.nlm.nih.gov/36194110/
78. Heywang-Köbrunner, SH, Jänsch, A, Hacker, A, Weinand, S, Vogelmann, T, Tomosynthesis with synthesised two-dimensional mammography yields higher cancer detection compared to digital mammography alone, also in dense breasts and in younger women: A systematic review and meta-analysis., Eur J Radiol, 2022. 152 (): p. 110324., https://pubmed.ncbi.nlm.nih.gov/35576720/
79. Li, T, Houssami, N, Noguchi, N, Zeng, A, Marinovich, ML, Differential detection by breast density for digital breast tomosynthesis versus digital mammography population screening: a systematic review and meta-analysis., Br J Cancer, 2022. 127 (1)(1): p. 116-125., https://pubmed.ncbi.nlm.nih.gov/35352019/
80. Libesman, S, Zackrisson, S, Hofvind, S, Seidler, AL, Bernardi, D, Lång, K, et.al. An individual participant data meta-analysis of breast cancer detection and recall rates for digital breast tomosynthesis versus digital mammography population screening., Clin Breast Cancer, 2022. 22 (5)(5): p. e647-e654., https://pubmed.ncbi.nlm.nih.gov/35246389/
81. Opitz, M, Zensen, S, Breuckmann, K, Bos, D, Forsting, M, Hoffmann, O, et.al. Breast Radiation Exposure of 3D Digital Breast Tomosynthesis Compared to Full-Field Digital Mammography in a Clinical Follow-Up Setting., Diagnostics (Basel), 2022. 12 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/35204547/
82. Loveland, J, Mackenzie, A, Radiation doses received in the UK breast screening programmes 2019-2023., Br J Radiol, 2024. 97 (1156)(1156): p. 787-793., https://pubmed.ncbi.nlm.nih.gov/38291906/
83. Canelo-Aybar, C, Carrera, L, Beltrán, J, Posso, M, Rigau, D, Lebeau, A, et.al. Digital breast tomosynthesis compared to diagnostic mammographic projections (including magnification) among women recalled at screening mammography: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)., Cancer Med, 2021. 10 (7)(7): p. 2191-2204., https://pubmed.ncbi.nlm.nih.gov/33675147/
84. Houssami, N, Zackrisson, S, Blazek, K, Hunter, K, Bernardi, D, Lång, K, et.al. Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening., Eur J Cancer, 2021. 148 (): p. 14-23., https://pubmed.ncbi.nlm.nih.gov/33706172/
85. Ohuchi, N, Suzuki, A, Sobue, T, Kawai, M, Yamamoto, S, Zheng, YF, et.al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial., Lancet, 2016. 387 (10016)(10016): p. 341-348., https://pubmed.ncbi.nlm.nih.gov/26547101/
86. Harada-Shoji, N, Suzuki, A, Ishida, T, Zheng, YF, Narikawa-Shiono, Y, Sato-Tadano, A, et.al. Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection Among Women Aged 40-49 Years With Varying Breast Density Undergoing Screening Mammography: A Secondary Analysis of a Randomized Clinical Trial., JAMA Netw Open, 2021. 4 (8)(8): p. e2121505., https://pubmed.ncbi.nlm.nih.gov/34406400/
87. Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., et.al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force, Ann Intern Med, 2016. 164(4): p. 268-78., https://www.ncbi.nlm.nih.gov/pubmed/26757021
88. Rebolj, M, Assi, V, Brentnall, A, Parmar, D, Duffy, SW, Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis., Br J Cancer, 2018. 118 (12)(12): p. 1559-1570., https://pubmed.ncbi.nlm.nih.gov/29736009/
89. Yuan, WH, Hsu, HC, Chen, YY, Wu, CH, Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis., Br J Cancer, 2020. 123 (4)(4): p. 673-688., https://pubmed.ncbi.nlm.nih.gov/32528118/
90. Yang, X, Leslie, G, Doroszuk, A, Schneider, S, Allen, J, Decker, B, et.al. Cancer Risks Associated With Germline , J Clin Oncol, 2020. 38 (7)(7): p. 674-685., https://pubmed.ncbi.nlm.nih.gov/31841383/
91. Hadadi, I, Rae, W, Clarke, J, McEntee, M, Ekpo, E, Diagnostic Performance of Adjunctive Imaging Modalities Compared to Mammography Alone in Women with Non-Dense and Dense Breasts: A Systematic Review and Meta-Analysis., Clin Breast Cancer, 2021. 21 (4)(4): p. 278-291., https://pubmed.ncbi.nlm.nih.gov/33846098/
92. Glechner, A, Wagner, G, Mitus, JW, Teufer, B, Klerings, I, Böck, N, et.al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk., Cochrane Database Syst Rev, 2023. 3 (3)(3): p. CD009632., https://pubmed.ncbi.nlm.nih.gov/36999589/
93. Sprague, BL, Ichikawa, L, Eavey, J, Lowry, KP, Rauscher, GH, O'Meara, ES, et.al. Performance of Supplemental US Screening in Women with Dense Breasts and Varying Breast Cancer Risk: Results from the Breast Cancer Surveillance Consortium., Radiology, 2024. 312 (2)(2): p. e232380., https://pubmed.ncbi.nlm.nih.gov/39105648/
94. Zhang, X, Chen, J, Zhou, Y, Mao, F, Lin, Y, Shen, S, et.al. Diagnostic value of an automated breast volume scanner compared with a hand-held ultrasound: a meta-analysis., Gland Surg, 2019. 8 (6)(6): p. 698-711., https://pubmed.ncbi.nlm.nih.gov/32042678/
95. Berg, WA, Zuley, ML, Chang, TS, Gizienski, TA, Chough, DM, Böhm-Vélez, M, et.al. Prospective Multicenter Diagnostic Performance of Technologist-Performed Screening Breast Ultrasound After Tomosynthesis in Women With Dense Breasts (the DBTUST)., J Clin Oncol, 2023. 41 (13)(13): p. 2403-2415., https://pubmed.ncbi.nlm.nih.gov/36626696/
96. Bakker, MF, de Lange, SV, Pijnappel, RM, Mann, RM, Peeters, PHM, Monninkhof, EM, et.al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue., N Engl J Med, 2019. 381 (22)(22): p. 2091-2102., https://pubmed.ncbi.nlm.nih.gov/31774954/
97. Veenhuizen, SGA, de Lange, SV, Bakker, MF, Pijnappel, RM, Mann, RM, Monninkhof, EM, et.al. Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial., Radiology, 2021. 299 (2)(2): p. 278-286., https://pubmed.ncbi.nlm.nih.gov/33724062/
98. Comstock, CE, Gatsonis, C, Newstead, GM, Snyder, BS, Gareen, IF, Bergin, JT, et.al. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening., JAMA, 2020. 323 (8)(8): p. 746-756., https://pubmed.ncbi.nlm.nih.gov/32096852/
99. Mann, RM, Athanasiou, A, Baltzer, PAT, Camps-Herrero, J, Clauser, P, Fallenberg, EM, et.al. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI)., Eur Radiol, 2022. 32 (6)(6): p. 4036-4045., https://pubmed.ncbi.nlm.nih.gov/35258677/
100. Niell, BL, Jochelson, MS, Amir, T, Brown, A, Adamson, M, Baron, P, et.al. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update., J Am Coll Radiol, 2024. 21 (6S)(6S): p. S126-S143., https://pubmed.ncbi.nlm.nih.gov/38823941/
101. Bevers, TB, Niell, BL, Baker, JL, Bennett, DL, Bonaccio, E, Camp, MS, et.al. NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023., J Natl Compr Canc Netw, 2023. 21 (9)(9): p. 900-909., https://pubmed.ncbi.nlm.nih.gov/37673117/
102. Kerlikowske, K, Zhu, W, Su, YR, Sprague, BL, Stout, NK, Onega, T, et.al. Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density., J Natl Cancer Inst, 2024. 116 (2)(2): p. 249-257., https://pubmed.ncbi.nlm.nih.gov/37897090/
103. Hickman, SE, Woitek, R, Le, EPV, Im, YR, Mouritsen Luxhøj, C, Aviles-Rivero, AI, et.al. Machine Learning for Workflow Applications in Screening Mammography: Systematic Review and Meta-Analysis., Radiology, 2022. 302 (1)(1): p. 88-104., https://pubmed.ncbi.nlm.nih.gov/34665034/
104. Byng, D, Strauch, B, Gnas, L, Leibig, C, Stephan, O, Bunk, S, et.al. AI-based prevention of interval cancers in a national mammography screening program., Eur J Radiol, 2022. 152 (): p. 110321., https://pubmed.ncbi.nlm.nih.gov/35512511/
105. Marinovich, ML, Wylie, E, Lotter, W, Lund, H, Waddell, A, Madeley, C, et.al. Artificial intelligence (AI) for breast cancer screening: BreastScreen population-based cohort study of cancer detection., EBioMedicine, 2023. 90 (): p. 104498., https://pubmed.ncbi.nlm.nih.gov/36863255/
106. Koch, HW, Larsen, M, Bartsch, H, Kurz, KD, Hofvind, S, Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases., Eur Radiol, 2023. 33 (5)(5): p. 3735-3743., https://pubmed.ncbi.nlm.nih.gov/36917260/
107. Elhakim, MT, Stougaard, SW, Graumann, O, Nielsen, M, Lång, K, Gerke, O, et.al. Breast cancer detection accuracy of AI in an entire screening population: a retrospective, multicentre study., Cancer Imaging, 2023. 23 (1)(1): p. 127., https://pubmed.ncbi.nlm.nih.gov/38124111/
108. Lång, K, Josefsson, V, Larsson, AM, Larsson, S, Högberg, C, Sartor, H, et.al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study., Lancet Oncol, 2023. 24 (8)(8): p. 936-944., https://pubmed.ncbi.nlm.nih.gov/37541274/
109. Dembrower, K, Crippa, A, Colón, E, Eklund, M, Strand, F, Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study., Lancet Digit Health, 2023. 5 (10)(10): p. e703-e711., https://pubmed.ncbi.nlm.nih.gov/37690911/
110. Eisemann, N, Bunk, S, Mukama, T, Baltus, H, Elsner, SA, Gomille, T, et.al. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening., Nat Med, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/39775040/
111. Fisches, ZV, Ball, M, Mukama, T, Štih, V, Payne, NR, Hickman, SE, et.al. Strategies for integrating artificial intelligence into mammography screening programmes: a retrospective simulation analysis., Lancet Digit Health, 2024. 6 (11)(11): p. e803-e814., https://pubmed.ncbi.nlm.nih.gov/39455193/
112. Kerlikowske, Karla, Zhu, Weiwei, Tosteson, Anna NA, Sprague, Brian L, Tice, Jeffrey A, Lehman, Constance D, et.al. Identifying women with dense breasts at high risk for interval cancer: a cohort study, Annals of internal medicine, 2015. 162(10): p. 673-681., https://pubmed.ncbi.nlm.nih.gov/25984843/
113. Brentnall, A. R., Harkness, E. F., Astley, S. M., Donnelly, L. S., Stavrinos, P., Sampson, S., et.al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort, Breast Cancer Res, 2015. 17(1): p. 147., https://www.ncbi.nlm.nih.gov/pubmed/26627479
114. Wanders, JOP, Holland, K, Karssemeijer, N, Peeters, PHM, Veldhuis, WB, Mann, RM, et.al. The effect of volumetric breast density on the risk of screen-detected and interval breast cancers: a cohort study., Breast Cancer Res, 2017. 19 (1)(1): p. 67., https://pubmed.ncbi.nlm.nih.gov/28583146/
115. Hodgson, Robert, Heywang-Köbrunner, Sylvia H, Harvey, Susan C, Edwards, Mary, Shaikh, Javed, Arber, Mick, et.al. Systematic review of 3D mammography for breast cancer screening, The Breast, 2016. 27: p. 52-61., https://www.ncbi.nlm.nih.gov/pubmed/27212700
116. Melnikow, J., Fenton, J. J., Whitlock, E. P., Miglioretti, D. L., Weyrich, M. S., Thompson, J. H., et.al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force, Ann Intern Med, 2016. 164(4): p. 268-78., https://www.ncbi.nlm.nih.gov/pubmed/26757021
117. Ohuchi, N., Suzuki, A., Sobue, T., Kawai, M., Yamamoto, S., Zheng, Y. F., et.al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial, Lancet, 2016. 387(10016): p. 341-8., https://www.ncbi.nlm.nih.gov/pubmed/26547101
118. Tagliafico, Alberto S, Calabrese, Massimo, Mariscotti, Giovanna, Durando, Manuela, Tosto, Simona, Monetti, Francesco, et.al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial, Journal of Clinical Oncology, 2016. 34(16): p. 1882-1888., https://www.ncbi.nlm.nih.gov/pubmed/26962097
119. Kerlikowske, K, Zhu, W, Tosteson, AN, Sprague, BL, Tice, JA, Lehman, CD, et.al. Identifying women with dense breasts at high risk for interval cancer: a cohort study., Ann Intern Med, 2015. 162 (10)(10): p. 673-81., https://pubmed.ncbi.nlm.nih.gov/25984843/
120. Colin, C, Schott, AM, Valette, PJ, Mammographic density is not a worthwhile examination to distinguish high cancer risk women in screening., Eur Radiol, 2014. 24 (10)(10): p. 2412-6., https://pubmed.ncbi.nlm.nih.gov/24972955/
121. BCSC risk calculator, 2024., https://www.bcsc-research.org/index.php/tools
122. Kerlikowske, K, Chen, S, Golmakani, MK, Sprague, BL, Tice, JA, Tosteson, ANA, et.al. Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population., J Natl Cancer Inst, 2022. 114 (5)(5): p. 676-685., https://pubmed.ncbi.nlm.nih.gov/35026019/
123. Brentnall, A. R., Harkness, E. F., Astley, S. M., Donnelly, L. S., Stavrinos, P., Sampson, S., et.al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort, Breast Cancer Res, 2015. 17(1): p. 147., https://www.ncbi.nlm.nih.gov/pubmed/26627479
124. Weigel, S, Heindel, W, Dietz, C, Meyer-Johann, U, Graewingholt, A, Hense, HW, Stratification of Breast Cancer Risk in Terms of the Influence of Age and Mammographic density., Rofo, 2020. 192 (7)(7): p. 678-685., https://pubmed.ncbi.nlm.nih.gov/32106324/
125. Larsen, M, Lynge, E, Lee, CI, Lång, K, Hofvind, S, Mammographic density and interval cancers in mammographic screening: Moving towards more personalized screening., Breast, 2023. 69 (): p. 306-311., https://pubmed.ncbi.nlm.nih.gov/36966656/
126. Kusumaningtyas, N, Supit, NISH, Murtala, B, Muis, M, Chandra, M, Sanjaya, E, et.al. A systematic review and meta-analysis of correlation of automated breast density measurement., Radiography (Lond), 2024. 30 (5)(5): p. 1455-1467., https://pubmed.ncbi.nlm.nih.gov/39164186/
127. Eom, HJ, Cha, JH, Choi, WJ, Cho, SM, Jin, K, Kim, HH, Mammographic density assessment: comparison of radiologists, automated volumetric measurement, and artificial intelligence-based computer-assisted diagnosis., Acta Radiol, 2024. 65 (7)(7): p. 708-715., https://pubmed.ncbi.nlm.nih.gov/38825883/
128. Rhiem, K, Bücker-Nott, HJ, Hellmich, M, Fischer, H, Ataseven, B, Dittmer-Grabowski, C, et.al. Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort., Breast J, 2019. 25 (3)(3): p. 455-460., https://pubmed.ncbi.nlm.nih.gov/30953388/
129. Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., et.al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer, J Med Genet, 2016. 53(7): p. 465-71., https://www.ncbi.nlm.nih.gov/pubmed/26928436
130. Nelson, HD, Pappas, M, Cantor, A, Haney, E, Holmes, R, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2019. 322 (7)(7): p. 666-685., https://pubmed.ncbi.nlm.nih.gov/31429902/
131. Kuchenbaecker, KB, Hopper, JL, Barnes, DR, Phillips, KA, Mooij, TM, Roos-Blom, MJ, et.al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers., JAMA, 2017. 317 (23)(23): p. 2402-2416., https://pubmed.ncbi.nlm.nih.gov/28632866/
132. Engel, C, Fischer, C, Zachariae, S, Bucksch, K, Rhiem, K, Giesecke, J, et.al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance., Int J Cancer, 2020. 146 (4)(4): p. 999-1009., https://pubmed.ncbi.nlm.nih.gov/31081934/
133. Engel, C, Rhiem, K, Hahnen, E, Loibl, S, Weber, KE, Seiler, S, et.al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history., BMC Cancer, 2018. 18 (1)(1): p. 265., https://pubmed.ncbi.nlm.nih.gov/29514593/
134. Rhiem, K, Zachariae, S, Waha, A, Grill, S, Hester, A, Golatta, M, et.al. Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer., Breast Care (Basel), 2023. 18 (2)(2): p. 106-112., https://pubmed.ncbi.nlm.nih.gov/37261134/
135. Rolfes, M, Borde, J, Möllenhoff, K, Kayali, M, Ernst, C, Gehrig, A, et.al. Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer., Cancers (Basel), 2022. 14 (13)(13):, https://pubmed.ncbi.nlm.nih.gov/35805063/
136. Dorling, L, Carvalho, S, Allen, J, González-Neira, A, Luccarini, C, Wahlström, C, et.al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women., N Engl J Med, 2021. 384 (5)(5): p. 428-439., https://pubmed.ncbi.nlm.nih.gov/33471991/
137. Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkas, K., Roberts, J., et.al. Breast-cancer risk in families with mutations in PALB2, N Engl J Med, 2014. 371(6): p. 497-506., https://www.ncbi.nlm.nih.gov/pubmed/25099575
138. Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., et.al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene, Nat Genet, 2010. 42(5): p. 410-4., https://www.ncbi.nlm.nih.gov/pubmed/20400964
139. Yang, X, Song, H, Leslie, G, Engel, C, Hahnen, E, Auber, B, et.al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D., J Natl Cancer Inst, 2020. 112 (12)(12): p. 1242-1250., https://pubmed.ncbi.nlm.nih.gov/32107557/
140. Song, H, Dicks, EM, Tyrer, J, Intermaggio, M, Chenevix-Trench, G, Bowtell, DD, et.al. Population-based targeted sequencing of 54 candidate genes identifies , J Med Genet, 2021. 58 (5)(5): p. 305-313., https://pubmed.ncbi.nlm.nih.gov/32546565/
141. Lühnen J, Albrecht M, Mühlhauser I, A, Steckelberg, Leitlinie evidenzbasierte Gesundheitsinformation., 2017.
142. Légaré, F, Adekpedjou, R, Stacey, D, Turcotte, S, Kryworuchko, J, Graham, ID, et.al. Interventions for increasing the use of shared decision making by healthcare professionals., Cochrane Database Syst Rev, 2018. 7 (7)(7): p. CD006732., https://pubmed.ncbi.nlm.nih.gov/30025154/
143. Stacey, D, Lewis, KB, Smith, M, Carley, M, Volk, R, Douglas, EE, et.al. Decision aids for people facing health treatment or screening decisions., Cochrane Database Syst Rev, 2024. 1 (1)(1): p. CD001431., https://pubmed.ncbi.nlm.nih.gov/38284415/
144. Jull, J, Köpke, S, Smith, M, Carley, M, Finderup, J, Rahn, AC, et.al. Decision coaching for people making healthcare decisions., Cochrane Database Syst Rev, 2021. 11 (11)(11): p. CD013385., https://pubmed.ncbi.nlm.nih.gov/34749427/
145. Mühlhauser, I., Steckelberg, A., Evidenzbasierte Patienteninformation: Wünsche der Betroffenen., Deutsches Ärzteblatt, 2009. 106(51-52): p. A-2554–A-2556.
146. Koch, K, [Cornerstones of evidence-based health information]., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2021. 64 (5)(5): p. 568-572., https://pubmed.ncbi.nlm.nih.gov/33881550/
147. Honrado, E., Osorio, A., Palacios, J., Benitez, J., Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations, Oncogene, 2006. 25(43): p. 5837-45., https://www.ncbi.nlm.nih.gov/pubmed/16998498
148. Speiser, D, Kendel, F, Fechner, K, Olbrich, C, Stegen, S, Häring, S, et.al. iKNOWgynetics - A web-based learning concept to empower primary care gynecologists to participate in the care of patients with a family history of breast and ovarian cancer., J Genet Couns, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37452466/
149. Isselhard, A, Töpper, M, Berger-Höger, B, Steckelberg, A, Fischer, H, Vitinius, F, et.al. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study., Trials, 2020. 21 (1)(1): p. 501., https://pubmed.ncbi.nlm.nih.gov/32513307/
150. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Version 1.1, 2014. AWMF-Registernummer: 032/051OL:, https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie
151. Plon, SE, Eccles, DM, Easton, D, Foulkes, WD, Genuardi, M, Greenblatt, MS, et.al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results., Hum Mutat, 2008. 29 (11)(11): p. 1282-91., https://pubmed.ncbi.nlm.nih.gov/18951446/
152. Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et.al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology., Genet Med, 2015. 17 (5)(5): p. 405-24., https://pubmed.ncbi.nlm.nih.gov/25741868/
153. Tavtigian, SV, Greenblatt, MS, Harrison, SM, Nussbaum, RL, Prabhu, SA, Boucher, KM, et.al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework., Genet Med, 2018. 20 (9)(9): p. 1054-1060., https://pubmed.ncbi.nlm.nih.gov/29300386/
154. Tavtigian, SV, Harrison, SM, Boucher, KM, Biesecker, LG, Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines., Hum Mutat, 2020. 41 (10)(10): p. 1734-1737., https://pubmed.ncbi.nlm.nih.gov/32720330/
155. Hauke, J, Horvath, J, Groß, E, Gehrig, A, Honisch, E, Hackmann, K, et.al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer., Cancer Med, 2018. 7 (4)(4): p. 1349-1358., https://pubmed.ncbi.nlm.nih.gov/29522266/
156. Lühnen J, Albrecht M, Mühlhauser I, A, Steckelberg, Leitlinie evidenzbasierte Gesundheitsinformation., 2017., http://www.leitlinie-gesundheitsinformation.de/
157. Bick, U, Engel, C, Krug, B, Heindel, W, Fallenberg, EM, Rhiem, K, et.al. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer., Breast Cancer Res Treat, 2019. 175 (1)(1): p. 217-228., https://pubmed.ncbi.nlm.nih.gov/30725383/
158. Lakhani, S. R., Ellis, I., Schnitt, S., Tan, P. H., Van de Vijver, M., WHO Classification of Tumours of the BreastIARC Press, 2012.
159. Honrado, E., Osorio, A., Palacios, J., Benitez, J., Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations, Oncogene, 2006. 25(43): p. 5837-45., https://www.ncbi.nlm.nih.gov/pubmed/16998498
160. Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., et.al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J Clin Oncol, 2008. 26(26): p. 4282-8., https://www.ncbi.nlm.nih.gov/pubmed/18779615
161. Mavaddat, N, Dorling, L, Carvalho, S, Allen, J, González-Neira, A, Keeman, R, et.al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes., JAMA Oncol, 2022. 8 (3)(3): p. e216744., https://pubmed.ncbi.nlm.nih.gov/35084436/
162. Evans, D. G., Lennard, F., Pointon, L. J., Ramus, S. J., Gayther, S. A., Sodha, N., et.al. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study, Cancer Epidemiol Biomarkers Prev, 2009. 18(7): p. 2123-31., https://www.ncbi.nlm.nih.gov/pubmed/19567506
163. Evans, D. G., Kesavan, N., Lim, Y., Gadde, S., Hurley, E., Massat, N. J., et.al. MRI breast screening in high-risk women: cancer detection and survival analysis, Breast Cancer Res Treat, 2014. 145(3): p. 663-72., https://www.ncbi.nlm.nih.gov/pubmed/24687378
164. Phi, X. A., Saadatmand, S., De Bock, G. H., Warner, E., Sardanelli, F., Leach, M. O., et.al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis, Br J Cancer, 2016. 114(6): p. 631-7., https://www.ncbi.nlm.nih.gov/pubmed/26908327
165. (ASC), American Cancer Society, Breast cancer early detection and diagnosis. American Cancer Society screenings recommendation for women at higher than average risk., 2016., www.cancer.org
166. Passaperuma, K., Warner, E., Causer, P. A., Hill, K. A., Messner, S., Wong, J. W., et.al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations, Br J Cancer, 2012. 107(1): p. 24-30., https://www.ncbi.nlm.nih.gov/pubmed/22588560
167. Sessa, C, Balmaña, J, Bober, SL, Cardoso, MJ, Colombo, N, Curigliano, G, et.al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline., Ann Oncol, 2023. 34 (1)(1): p. 33-47., https://pubmed.ncbi.nlm.nih.gov/36307055/
168. Evans, D. G., Clayton, R., Donnai, P., Shenton, A., Lalloo, F., Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk, Eur J Hum Genet, 2009. 17(11): p. 1381-5., https://www.ncbi.nlm.nih.gov/pubmed/19367322
169. Obdeijn, I. M., Winter-Warnars, G. A., Mann, R. M., Hooning, M. J., Hunink, M. G., Tilanus-Linthorst, M. M., Should we screen BRCA1 mutation carriers only with MRI? A multicenter study, Breast Cancer Res Treat, 2014. 144(3): p. 577-82., https://www.ncbi.nlm.nih.gov/pubmed/24567197
170. Saadatmand, S., Obdeijn, I. M., Rutgers, E. J., Oosterwijk, J. C., Tollenaar, R. A., Woldringh, G. H., et.al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC), Int J Cancer, 2015. 137(7): p. 1729-38., https://www.ncbi.nlm.nih.gov/pubmed/25820931
171. Audeh, M. W., Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition, Pharmgenomics Pers Med, 2014. 7: p. 307-16., https://www.ncbi.nlm.nih.gov/pubmed/25342917
172. Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., et.al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, 2014. 147(2): p. 401-5., https://www.ncbi.nlm.nih.gov/pubmed/25129345
173. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et.al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol, 2010. 28(3): p. 375-9., https://www.ncbi.nlm.nih.gov/pubmed/20008645
174. Liu, M., Mo, Q. G., Wei, C. Y., Qin, Q. H., Huang, Z., He, J., Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis, Oncol Lett, 2013. 5(3): p. 983-991., https://www.ncbi.nlm.nih.gov/pubmed/23426861
175. Telli, M., Optimizing chemotherapy in triple-negative breast cancer: the role of platinum, Am Soc Clin Oncol Educ Book, 2014. p. e37-42., https://www.ncbi.nlm.nih.gov/pubmed/24857126
176. Turner, N. C., Tutt, A. N., Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?, Breast Cancer Res, 2012. 14(6): p. 115., https://www.ncbi.nlm.nih.gov/pubmed/23146216
177. Geyer, CE, Garber, JE, Gelber, RD, Yothers, G, Taboada, M, Ross, L, et.al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer., Ann Oncol, 2022. 33 (12)(12): p. 1250-1268., https://pubmed.ncbi.nlm.nih.gov/36228963/
178. Robson, ME, Im, SA, Senkus, E, Xu, B, Domchek, SM, Masuda, N, et.al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer., Eur J Cancer, 2023. 184 (): p. 39-47., https://pubmed.ncbi.nlm.nih.gov/36893711/
179. Litton, JK, Hurvitz, SA, Mina, LA, Rugo, HS, Lee, KH, Gonçalves, A, et.al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial., Ann Oncol, 2020. 31 (11)(11): p. 1526-1535., https://pubmed.ncbi.nlm.nih.gov/32828825/
180. Carbine, NE, Lostumbo, L, Wallace, J, Ko, H, Risk-reducing mastectomy for the prevention of primary breast cancer., Cochrane Database Syst Rev, 2018. 4 (4)(4): p. CD002748., https://pubmed.ncbi.nlm.nih.gov/29620792/
181. Lafarge, S., Sylvain, V., Ferrara, M., Bignon, Y. J., Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway, Oncogene, 2001. 20(45): p. 6597-606., https://www.ncbi.nlm.nih.gov/pubmed/11641785
182. Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., et.al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis, Cancer Res, 2003. 63(19): p. 6221-8., https://www.ncbi.nlm.nih.gov/pubmed/14559807
183. Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A, et.al. Germline mutation status, pathological complete response and disease-free survival rates in triple-negative breast cancer (GeparSixto trial), A Randomized Clinical Trial., JAMA Oncology in press, 2017., https://pubmed.ncbi.nlm.nih.gov/28715532/
184. Caramelo, O, Silva, C, Caramelo, F, Frutuoso, C, Pinto, L, Almeida-Santos, T, Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis., Hered Cancer Clin Pract, 2022. 20 (1)(1): p. 34., https://pubmed.ncbi.nlm.nih.gov/36085046/
185. Tutt, A, Tovey, H, Cheang, MCU, Kernaghan, S, Kilburn, L, Gazinska, P, et.al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial., Nat Med, 2018. 24 (5)(5): p. 628-637., https://pubmed.ncbi.nlm.nih.gov/29713086/
186. Tung, NM, Robson, ME, Ventz, S, Santa-Maria, CA, Nanda, R, Marcom, PK, et.al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes., J Clin Oncol, 2020. 38 (36)(36): p. 4274-4282., https://pubmed.ncbi.nlm.nih.gov/33119476/
187. Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., et.al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review, Clin Cancer Res, 2016. 22(15): p. 3971-81., https://www.ncbi.nlm.nih.gov/pubmed/26979395
188. De Felice, F., Marchetti, C., Musella, A., Palaia, I., Perniola, G., Musio, D., et.al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis, Ann Surg Oncol, 2015. 22(9): p. 2876-80., https://www.ncbi.nlm.nih.gov/pubmed/25808098
189. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et.al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, Jama, 2010. 304(9): p. 967-75., https://www.ncbi.nlm.nih.gov/pubmed/20810374
190. Evans, D. G., Ingham, S. L., Baildam, A., Ross, G. L., Lalloo, F., Buchan, I., et.al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer, Breast Cancer Res Treat, 2013. 140(1): p. 135-42., https://www.ncbi.nlm.nih.gov/pubmed/23784379
191. Lindor, N. M., Goldgar, D. E., Tavtigian, S. V., Plon, S. E., Couch, F. J., BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management, Oncologist, 2013. 18(5): p. 518-24., https://www.ncbi.nlm.nih.gov/pubmed/23615697
192. Heemskerk-Gerritsen, B. A., Menke-Pluijmers, M. B., Jager, A., Tilanus-Linthorst, M. M., Koppert, L. B., Obdeijn, I. M., et.al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis, Ann Oncol, 2013. 24(8): p. 2029-35., https://www.ncbi.nlm.nih.gov/pubmed/23576707
193. Lostumbo, L., Carbine, N. E., Wallace, J., Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, 2010. p. Cd002748., https://www.ncbi.nlm.nih.gov/pubmed/21069671
194. Meijers-Heijboer, H., van Geel, B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., et.al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med, 2001. 345(3): p. 159-64., https://www.ncbi.nlm.nih.gov/pubmed/11463009
195. Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van 't Veer, L., Garber, J. E., et.al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 2004. 22(6): p. 1055-62., https://www.ncbi.nlm.nih.gov/pubmed/14981104
196. Heemskerk-Gerritsen, BAM, Jager, A, Koppert, LB, Obdeijn, AI, Collée, M, Meijers-Heijboer, HEJ, et.al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers., Breast Cancer Res Treat, 2019. 177 (3)(3): p. 723-733., https://pubmed.ncbi.nlm.nih.gov/31302855/
197. Robson, M., Svahn, T., McCormick, B., Borgen, P., Hudis, C. A., Norton, L., et.al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series, Cancer, 2005. 103(1): p. 44-51., https://www.ncbi.nlm.nih.gov/pubmed/15558796
198. Mavaddat, N, Antoniou, AC, Mooij, TM, Hooning, MJ, Heemskerk-Gerritsen, BA, Noguès, C, et.al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers., Breast Cancer Res, 2020. 22 (1)(1): p. 8., https://pubmed.ncbi.nlm.nih.gov/31948486/
199. Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., et.al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2009. 27(35): p. 5887-92., https://www.ncbi.nlm.nih.gov/pubmed/19858402
200. Rhiem, K., Engel, C., Graeser, M., Zachariae, S., Kast, K., Kiechle, M., et.al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study, Breast Cancer Res, 2012. 14(6): p. R156., https://www.ncbi.nlm.nih.gov/pubmed/23216834
201. Mavaddat, N, Pharoah, PD, Michailidou, K, Tyrer, J, Brook, MN, Bolla, MK, et.al. Prediction of breast cancer risk based on profiling with common genetic variants., J Natl Cancer Inst, 2015. 107 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/25855707/
202. Kuchenbaecker, KB, McGuffog, L, Barrowdale, D, Lee, A, Soucy, P, Dennis, J, et.al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers., J Natl Cancer Inst, 2017. 109 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/28376175/
203. Michailidou, K, Lindström, S, Dennis, J, Beesley, J, Hui, S, Kar, S, et.al. Association analysis identifies 65 new breast cancer risk loci., Nature, 2017. 551 (7678)(7678): p. 92-94., https://pubmed.ncbi.nlm.nih.gov/29059683/
204. Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., et.al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer, J Clin Oncol, 2006. 24(16): p. 2437-43., https://www.ncbi.nlm.nih.gov/pubmed/16636335
205. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et.al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2004. 22(12): p. 2328-35., https://www.ncbi.nlm.nih.gov/pubmed/15197194
206. Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., et.al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study, J Clin Oncol, 2008. 26(8): p. 1331-7., https://www.ncbi.nlm.nih.gov/pubmed/18268356
207. Kotsopoulos, Joanne, Huzarski, Tomasz, Gronwald, Jacek, Singer, Christian F, Moller, Pal, Lynch, Henry T, et.al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers, JNCI: Journal of the National Cancer Institute, 2017. 109(1):, https://www.ncbi.nlm.nih.gov/pubmed/27601060
208. Fakkert, I. E., Mourits, M. J., Jansen, L., van der Kolk, D. M., Meijer, K., Oosterwijk, J. C., et.al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers, Cancer Prev Res (Phila), 2012. 5(11): p. 1291-7., https://www.ncbi.nlm.nih.gov/pubmed/23009828
209. Xiao, YL, Wang, K, Liu, Q, Li, J, Zhang, X, Li, HY, Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review., Clin Breast Cancer, 2019. 19 (1)(1): p. e48-e65., https://pubmed.ncbi.nlm.nih.gov/30470623/
210. Eleje, GU, Eke, AC, Ezebialu, IU, Ikechebelu, JI, Ugwu, EO, Okonkwo, OO, Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations., Cochrane Database Syst Rev, 2018. 8 (8)(8): p. CD012464., https://pubmed.ncbi.nlm.nih.gov/30141832/
211. Gaba, F, Blyuss, O, Tan, A, Munblit, D, Oxley, S, Khan, K, et.al. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in , Cancers (Basel), 2023. 15 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/36900415/
212. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et.al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, Jama, 2010. 304(9): p. 967-75., https://www.ncbi.nlm.nih.gov/pubmed/20810374
213. Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., et.al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, Lancet Oncol, 2006. 7(3): p. 223-9., https://www.ncbi.nlm.nih.gov/pubmed/16510331
214. Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., et.al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study, J Clin Oncol, 2008. 26(8): p. 1331-7., https://www.ncbi.nlm.nih.gov/pubmed/18268356
215. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et.al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2004. 22(12): p. 2328-35., https://www.ncbi.nlm.nih.gov/pubmed/15197194
216. Kotsopoulos, Joanne, Huzarski, Tomasz, Gronwald, Jacek, Singer, Christian F, Moller, Pal, Lynch, Henry T, et.al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers, JNCI: Journal of the National Cancer Institute, 2017. 109(1):, https://www.ncbi.nlm.nih.gov/pubmed/27601060
217. Heemskerk-Gerritsen, B. A., Seynaeve, C., van Asperen, C. J., Ausems, M. G., Collee, J. M., van Doorn, H. C., et.al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction, J Natl Cancer Inst, 2015. 107(5):, https://www.ncbi.nlm.nih.gov/pubmed/25788320
218. Moyer, V. A., Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 2014. 160(4): p. 271-81., https://www.ncbi.nlm.nih.gov/pubmed/24366376
219. Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et.al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 2015. 136(3): p. 668-77., https://www.ncbi.nlm.nih.gov/pubmed/24947112
220. van den Broek, A. J., van 't Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., et.al. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers, J Clin Oncol, 2016. 34(5): p. 409-18., https://www.ncbi.nlm.nih.gov/pubmed/26700119
221. Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., et.al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers, BMC Womens Health, 2014. 14: p. 150., https://www.ncbi.nlm.nih.gov/pubmed/25494812
222. Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I., et.al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers, JAMA Oncol, 2015. 1(3): p. 306-13., https://www.ncbi.nlm.nih.gov/pubmed/26181175
223. Plon, S. E., Eccles, D. M., Easton, D., Foulkes, W. D., Genuardi, M., Greenblatt, M. S., et.al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, 2008. 29(11): p. 1282-91., https://www.ncbi.nlm.nih.gov/pubmed/18951446
224. Akdeniz, D, Schmidt, MK, Seynaeve, CM, McCool, D, Giardiello, D, van den Broek, AJ, et.al. Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis., Breast, 2019. 44 (): p. 1-14., https://pubmed.ncbi.nlm.nih.gov/30580169/
225. Robson, M., Svahn, T., McCormick, B., Borgen, P., Hudis, C. A., Norton, L., et.al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series, Cancer, 2005. 103(1): p. 44-51., https://www.ncbi.nlm.nih.gov/pubmed/15558796
226. Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., et.al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 2009. 27(35): p. 5887-92., https://www.ncbi.nlm.nih.gov/pubmed/19858402
227. Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., et.al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers, Gynecol Oncol, 2005. 96(1): p. 222-6., https://www.ncbi.nlm.nih.gov/pubmed/15589605
228. Rhiem, K., Engel, C., Graeser, M., Zachariae, S., Kast, K., Kiechle, M., et.al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study, Breast Cancer Res, 2012. 14(6): p. R156., https://www.ncbi.nlm.nih.gov/pubmed/23216834
229. Lostumbo, L., Carbine, N. E., Wallace, J., Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, 2010. p. Cd002748., https://www.ncbi.nlm.nih.gov/pubmed/21069671
230. van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J., et.al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers, Br J Cancer, 2005. 93(3): p. 287-92., https://www.ncbi.nlm.nih.gov/pubmed/16052221
231. Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et.al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis, Int J Cancer, 2015. 136(3): p. 668-77., https://www.ncbi.nlm.nih.gov/pubmed/24947112
232. Boughey, J. C., Hoskin, T. L., Degnim, A. C., Sellers, T. A., Johnson, J. L., Kasner, M. J., et.al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer, Ann Surg Oncol, 2010. 17(10): p. 2702-9., https://www.ncbi.nlm.nih.gov/pubmed/20853163
233. Fayanju, O. M., Stoll, C. R., Fowler, S., Colditz, G. A., Margenthaler, J. A., Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis, Ann Surg, 2014. 260(6): p. 1000-10., https://www.ncbi.nlm.nih.gov/pubmed/24950272
234. Kreienberg, R, Wöckel, A, Wischnewsky, M, Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: An evaluation of 8323 patients., Breast, 2018. 40 (): p. 54-59., https://pubmed.ncbi.nlm.nih.gov/29698925/
235. Schrodi, S, Tillack, A, Niedostatek, A, Werner, C, Schubert-Fritschle, G, Engel, J, No Survival Benefit for Patients with Treatment in Certified Breast Centers-A Population-based Evaluation of German Cancer Registry Data., Breast J, 2015. 21 (5)(5): p. 490-500., https://pubmed.ncbi.nlm.nih.gov/26130502/
236. WiZen – Wirksamkeit der Versorgung in onkologischen Zentren, Beschlusstext u Ergebnisbericht, 2022., https://innovationsfonds.g-ba.de/beschluesse/wizen-wirksamkeit-der-versorgung-in-onkologischen-zentren.111
237. Jahresbericht Qualitätssicherung 2021, Ergebnisse des deutschen Mammographie-Screening-Programms. Kooperationsgemeinschaft Mammographie, 2023., https://fachservice.mammo-programm.de/download/qualitaetsberichte/Quali-2021-Webversion_-2023-12-07.pdf
238. Deutsche Krebsgesellschaft e.V., Jahresbericht der zertifizierten Brustkrebszentren, Auditjahr 2022., https://www.krebsgesellschaft.de/jahresberichte.html?file=files/dkg/deutsche-krebsgesellschaft/content/pdf/Zertifizierung/Jahresberichte%20mit%20DOI%20und%20ISBN/qualitaetsindikatoren_brustkrebs_2023-A1_230713.pdf&cid=114269
239. 3. Checkliste zur Erfassung einer möglichen erblichen Belastung für Brust- und/oder Eierstockkrebs, 2023., https://www.krebsgesellschaft.de/zertdokumente.html?file=files/dkg/deutsche-krebsgesellschaft/content/pdf/Zertifizierung/Checklisten-und-Algorithmen/checkliste_erbliche_belastung_brust_gyn-230206.xlsx&cid=116700
240. Bierbaum, V, Schmitt, J, Klinkhammer-Schalke, M, Schoffer, O, Assessment of the Potential of Concentrating Cancer Care in Hospitals With Certification Through Survival Analysis., Gesundheitswesen, 2023. 85 (S 03)(S 03): p. S197-S204., https://pubmed.ncbi.nlm.nih.gov/37751756/
241. Regierungskommission für eine moderne und bedarfsgerechte Krankenhausversorgung, Fünfte Stellungnahme. Verbesserung von Qualität und Sicherheit der Gesundheitsversorgung, Potenzialanalyse anhand exemplarischer Erkrankungen., 2023., https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/K/Krankenhausreform/5_Stellungnahme_Potenzialanalyse_bf_Version_1.1.pdf
242. Speroff, L., The meaning of mammographic breast density in users of postmenopausal hormone therapy, Maturitas, 2002. 41(3): p. 171-5., https://www.ncbi.nlm.nih.gov/pubmed/11886762
243. Morrow, M., Chatterton, R. T., Jr., Rademaker, A. W., Hou, N., Jordan, V. C., Hendrick, R. E., et.al. A prospective study of variability in mammographic density during the menstrual cycle, Breast Cancer Res Treat, 2010. 121(3): p. 565-74., https://www.ncbi.nlm.nih.gov/pubmed/19669673
244. Scaranelo, A. M., Carrillo, M. C., Fleming, R., Jacks, L. M., Kulkarni, S. R., Crystal, P., Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density, Radiology, 2013. 267(3): p. 692-700., https://www.ncbi.nlm.nih.gov/pubmed/23418005
245. Chiarelli, A. M., Prummel, M. V., Muradali, D., Shumak, R. S., Majpruz, V., Brown, P., et.al. Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection, Breast Cancer Res Treat, 2015. 154(2): p. 377-87., https://www.ncbi.nlm.nih.gov/pubmed/26518019
246. Houssami, N., Hayes, D. F., Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer?, CA Cancer J Clin, 2009. 59(5): p. 290-302., https://www.ncbi.nlm.nih.gov/pubmed/19679690
247. Kerlikowske, K., Zhu, W., Hubbard, R. A., Geller, B., Dittus, K., Braithwaite, D., et.al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy, JAMA Intern Med, 2013. 173(9): p. 807-16., https://www.ncbi.nlm.nih.gov/pubmed/23552817
248. Banks, E., Reeves, G., Beral, V., Bull, D., Crossley, B., Simmonds, M., et.al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect, Breast Cancer Res, 2006. 8(1): p. R8., https://www.ncbi.nlm.nih.gov/pubmed/16417651
249. Holm, J., Humphreys, K., Li, J., Ploner, A., Cheddad, A., Eriksson, M., et.al. Risk factors and tumor characteristics of interval cancers by mammographic density, J Clin Oncol, 2015. 33(9): p. 1030-7., https://www.ncbi.nlm.nih.gov/pubmed/25646195
250. Nothacker, M., Duda, V., Hahn, M., Warm, M., Degenhardt, F., Madjar, H., et.al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review, BMC Cancer, 2009. 9: p. 335., https://www.ncbi.nlm.nih.gov/pubmed/19765317
251. Ko, MJ, Park, DA, Kim, SH, Ko, ES, Shin, KH, Lim, W, et.al. Accuracy of Digital Breast Tomosynthesis for Detecting Breast Cancer in the Diagnostic Setting: A Systematic Review and Meta-Analysis., Korean J Radiol, 2021. 22 (8)(8): p. 1240-1252., https://pubmed.ncbi.nlm.nih.gov/34047504/
252. Kolb, TM, Lichy, J, Newhouse, JH, Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations., Radiology, 2002. 225 (1)(1): p. 165-75., https://pubmed.ncbi.nlm.nih.gov/12355001/
253. Oh, KE, Vasandani, N, Anwar, A, Radiomics to Differentiate Malignant and Benign Breast Lesions: A Systematic Review and Diagnostic Test Accuracy Meta-Analysis., Cureus, 2023. 15 (11)(11): p. e49015., https://pubmed.ncbi.nlm.nih.gov/38024014/
254. Phi, X. A., Saadatmand, S., De Bock, G. H., Warner, E., Sardanelli, F., Leach, M. O., et.al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis, Br J Cancer, 2016. 114(6): p. 631-7., https://www.ncbi.nlm.nih.gov/pubmed/26908327
255. Bennani-Baiti, B., Bennani-Baiti, N., Baltzer, P. A., Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis, PLoS One, 2016. 11(8): p. e0160346., https://www.ncbi.nlm.nih.gov/pubmed/27482715
256. Bennani-Baiti, B, Baltzer, PA, MR Imaging for Diagnosis of Malignancy in Mammographic Microcalcifications: A Systematic Review and Meta-Analysis., Radiology, 2017. 283 (3)(3): p. 692-701., https://pubmed.ncbi.nlm.nih.gov/27788035/
257. NICE, The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment, 2009 (Update 2014).
258. NZGG, Management of Early Breast Cancer - Evidence-based Best Practice Guideline, New Zealand Guidelines Group, 2009., https://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf
259. Huang, Y, Zheng, S, Lin, Y, Accuracy and Utility of Preoperative Ultrasound-Guided Axillary Lymph Node Biopsy for Invasive Breast Cancer: A Systematic Review and Meta-Analysis., Comput Intell Neurosci, 2022. 2022 (): p. 3307627., https://pubmed.ncbi.nlm.nih.gov/36203726/
260. NZGG, Management of Early Breast Cancer - Evidence-based Best Practice Guideline, New Zealand Guidelines Group, 2009., https://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf
261. Berg, W. A., Bandos, A. I., Mendelson, E. B., Lehrer, D., Jong, R. A., Pisano, E. D., Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666, J Natl Cancer Inst, 2016. 108(4):, https://www.ncbi.nlm.nih.gov/pubmed/26712110
262. Houssami, N., Irwig, L., Simpson, J. M., McKessar, M., Blome, S., Noakes, J., Sydney Breast Imaging Accuracy Study: Comparative sensitivity and specificity of mammography and sonography in young women with symptoms, AJR Am J Roentgenol, 2003. 180(4): p. 935-40., https://www.ncbi.nlm.nih.gov/pubmed/12646432
263. Kolb, T. M., Lichy, J., Newhouse, J. H., Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations, Radiology, 2002. 225(1): p. 165-75., https://www.ncbi.nlm.nih.gov/pubmed/12355001
264. NICE, The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment, 2009 [addendum 2014].
265. Müller-Schimpfle, M, Graf, O, Madjar, H, al., et, Diskussionspapier - BI-RADS die 5. - eine Kurzmitteilung aus deutsch- /österreichischer Sicht, Rofo, 2016. p. 346-352.
266. Bader, W, Vogel-Minea, CM, Blohmer, JU, Duda, V, Eichler, C, Fallenberg, E, et.al. Best Practice Guideline - DEGUM Recommendations on Breast Ultrasound., Ultraschall Med, 2022. 43 (6)(6): p. 570-582., https://pubmed.ncbi.nlm.nih.gov/34921376/
267. Pillai, A, Voruganti, T, Barr, R, Langdon, J, Diagnostic Accuracy of Shear-Wave Elastography for Breast Lesion Characterization in Women: A Systematic Review and Meta-Analysis., J Am Coll Radiol, 2022. 19 (5)(5): p. 625-634.e0., https://pubmed.ncbi.nlm.nih.gov/35358483/
268. Liu, B, Zheng, Y, Huang, G, Lin, M, Shan, Q, Lu, Y, et.al. Breast Lesions: Quantitative Diagnosis Using Ultrasound Shear Wave Elastography-A Systematic Review and Meta--Analysis., Ultrasound Med Biol, 2016. 42 (4)(4): p. 835-47., https://pubmed.ncbi.nlm.nih.gov/26778289/
269. Wu, H, Wang, C, An, Q, Qu, X, Wu, X, Yan, Y, Comparing the accuracy of shear wave elastography and strain elastography in the diagnosis of breast tumors: A systematic review and meta-analysis., Medicine (Baltimore), 2022. 101 (44)(44): p. e31526., https://pubmed.ncbi.nlm.nih.gov/36343055/
270. Xue, Y, Yao, S, Li, X, Zhang, H, Value of shear wave elastography in discriminating malignant and benign breast lesions: A meta-analysis., Medicine (Baltimore), 2017. 96 (42)(42): p. e7412., https://pubmed.ncbi.nlm.nih.gov/29049174/
271. Bin, L, Huihui, Y, Weiping, Y, Changyuan, W, Qinghong, Q, Weiyu, M, Value of Three-Dimensional Ultrasound in Differentiating Malignant From Benign Breast Tumors: A Systematic Review and Meta-Analysis., Ultrasound Q, 2019. 35 (1)(1): p. 68-73., https://pubmed.ncbi.nlm.nih.gov/30807546/
272. Vogel-Minea, CM, Bader, W, Blohmer, JU, Duda, V, Eichler, C, Fallenberg, EM, et.al. Best Practice Guideline - DEGUM Recommendations on Breast Ultrasound., Ultraschall Med, 2023. 44 (5)(5): p. 520-536., https://pubmed.ncbi.nlm.nih.gov/37072031/
273. Le Boulc'h, M, Gilhodes, J, Steinmeyer, Z, Molière, S, Mathelin, C, Pretherapeutic Imaging for Axillary Staging in Breast Cancer: A Systematic Review and Meta-Analysis of Ultrasound, MRI and FDG PET., J Clin Med, 2021. 10 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/33917590/
274. Li, Z, Gao, Y, Gong, H, Feng, W, Ma, Q, Li, J, et.al. Different Imaging Modalities for the Diagnosis of Axillary Lymph Node Metastases in Breast Cancer: A Systematic Review and Network Meta-Analysis of Diagnostic Test Accuracy., J Magn Reson Imaging, 2023. 57 (5)(5): p. 1392-1403., https://pubmed.ncbi.nlm.nih.gov/36054564/
275. Wurstlein, R., Degenhardt, F., Duda, V., Madjar, H., Merz, E., Mundinger, A., et.al. [Evaluation of the nationwide DEGUM breast ultrasound training program], Ultraschall Med, 2014. 35(4): p. 345-9., https://www.ncbi.nlm.nih.gov/pubmed/24563421
276. Bennani-Baiti, B., Bennani-Baiti, N., Baltzer, P. A., Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis, PLoS One, 2016. 11(8): p. e0160346., https://www.ncbi.nlm.nih.gov/pubmed/27482715
277. Fancellu, A., Turner, R. M., Dixon, J. M., Pinna, A., Cottu, P., Houssami, N., Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ, Br J Surg, 2015. 102(8): p. 883-93., https://www.ncbi.nlm.nih.gov/pubmed/25919321
278. Houssami, N., Turner, R., Morrow, M., Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes, Ann Surg, 2013. 257(2): p. 249-55., https://www.ncbi.nlm.nih.gov/pubmed/23187751
279. Plana, M. N., Carreira, C., Muriel, A., Chiva, M., Abraira, V., Emparanza, J. I., et.al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis, Eur Radiol, 2012. 22(1): p. 26-38., https://www.ncbi.nlm.nih.gov/pubmed/21847541
280. Eisen, A, Fletcher, GG, Fienberg, S, George, R, Holloway, C, Kulkarni, S, et.al. Breast Magnetic Resonance Imaging for Preoperative Evaluation of Breast Cancer: A Systematic Review and Meta-Analysis., Can Assoc Radiol J, 2024. 75 (1)(1): p. 118-135., https://pubmed.ncbi.nlm.nih.gov/37593787/
281. Cozzi, A, Magni, V, Zanardo, M, Schiaffino, S, Sardanelli, F, Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance., Radiology, 2022. 302 (3)(3): p. 568-581., https://pubmed.ncbi.nlm.nih.gov/34904875/
282. Pötsch, N, Vatteroni, G, Clauser, P, Helbich, TH, Baltzer, PAT, Contrast-enhanced Mammography versus Contrast-enhanced Breast MRI: A Systematic Review and Meta-Analysis., Radiology, 2022. 305 (1)(1): p. 94-103., https://pubmed.ncbi.nlm.nih.gov/36154284/
283. Boughey, JC, Rosenkranz, KM, Ballman, KV, McCall, L, Haffty, BG, Cuttino, LW, et.al. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)., J Clin Oncol, 2023. 41 (17)(17): p. 3184-3193., https://pubmed.ncbi.nlm.nih.gov/36977292/
284. Xiang, W, Rao, H, Zhou, L, A meta-analysis of contrast-enhanced spectral mammography versus MRI in the diagnosis of breast cancer., Thorac Cancer, 2020. 11 (6)(6): p. 1423-1432., https://pubmed.ncbi.nlm.nih.gov/32233072/
285. Abdullah, P, Alabousi, M, Ramadan, S, Zawawi, I, Zawawi, M, Bhogadi, Y, et.al. Synthetic 2D Mammography Versus Standard 2D Digital Mammography: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis., AJR Am J Roentgenol, 2021. 217 (2)(2): p. 314-325., https://pubmed.ncbi.nlm.nih.gov/32966115/
286. Dahabreh, I. J., Wieland, L. S., Adam, G. P., Halladay, C., Lau, J., Trikalinos, T. A., AHRQ Comparative Effectiveness Reviews, in Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to the 2009 Report, 2014, Agency for Healthcare Research and Quality (US): Rockville (MD)., https://www.ncbi.nlm.nih.gov/pubmed/25275206
287. Knuttel, FM, Menezes, GL, van Diest, PJ, Witkamp, AJ, van den Bosch, MA, Verkooijen, HM, Meta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen., Br J Surg, 2016. 103 (6)(6): p. 644-655., https://pubmed.ncbi.nlm.nih.gov/26990850/
288. Bruening, W., Fontanarosa, J., Tipton, K., Treadwell, J. R., Launders, J., Schoelles, K., Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions, Ann Intern Med, 2010. 152(4): p. 238-46., https://www.ncbi.nlm.nih.gov/pubmed/20008742
289. Huang, XC, Hu, XH, Wang, XR, Zhou, CX, Wang, FF, Yang, S, et.al. A comparison of diagnostic performance of vacuum-assisted biopsy and core needle biopsy for breast microcalcification: a systematic review and meta-analysis., Ir J Med Sci, 2018. 187 (4)(4): p. 999-1008., https://pubmed.ncbi.nlm.nih.gov/29549564/
290. Ahn, H. S., Kim, S. M., Jang, M., La Yun, B., Kim, S. W., Kang, E., et.al. Comparison of sonography with sonographically guided fine-needle aspiration biopsy and core-needle biopsy for initial axillary staging of breast cancer, J Ultrasound Med, 2013. 32(12): p. 2177-84., https://www.ncbi.nlm.nih.gov/pubmed/24277901
291. Ganott, M. A., Zuley, M. L., Abrams, G. S., Lu, A. H., Kelly, A. E., Sumkin, J. H., et.al. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer, ISRN Oncol, 2014. 2014: p. 703160., https://www.ncbi.nlm.nih.gov/pubmed/24649373
292. Rao, R., Lilley, L., Andrews, V., Radford, L., Ulissey, M., Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy, Ann Surg Oncol, 2009. 16(5): p. 1170-5., https://www.ncbi.nlm.nih.gov/pubmed/19263171
293. Rautiainen, S., Masarwah, A., Sudah, M., Sutela, A., Pelkonen, O., Joukainen, S., et.al. Axillary lymph node biopsy in newly diagnosed invasive breast cancer: comparative accuracy of fine-needle aspiration biopsy versus core-needle biopsy, Radiology, 2013. 269(1): p. 54-60., https://www.ncbi.nlm.nih.gov/pubmed/23771915
294. Balasubramanian, I, Fleming, CA, Corrigan, MA, Redmond, HP, Kerin, MJ, Lowery, AJ, Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis., Br J Surg, 2018. 105 (10)(10): p. 1244-1253., https://pubmed.ncbi.nlm.nih.gov/29972239/
295. Bolivar, A. V., Alonso-Bartolome, P., Garcia, E. O., Ayensa, F. G., Ultrasound-guided core needle biopsy of non-palpable breast lesions: a prospective analysis in 204 cases, Acta Radiol, 2005. 46(7): p. 690-5., https://www.ncbi.nlm.nih.gov/pubmed/16372687
296. Fishman, J. E., Milikowski, C., Ramsinghani, R., Velasquez, M. V., Aviram, G., US-guided core-needle biopsy of the breast: how many specimens are necessary?, Radiology, 2003. 226(3): p. 779-82., https://www.ncbi.nlm.nih.gov/pubmed/12601206
297. Schulz-Wendtland, R., Aichinger, U., Kramer, S., Tartsch, M., Kuchar, I., Magener, A., et.al. [Sonographical breast biopsy: how many core biopsy specimens are needed?], Rofo, 2003. 175(1): p. 94-8., https://www.ncbi.nlm.nih.gov/pubmed/12525988
298. Gruber, I, Oberlechner, E, Heck, K, Hoopmann, U, Böer, B, Fugunt, R, et.al. Percutaneous Ultrasound-Guided Core Needle Biopsy: Comparison of 16-Gauge versus 14-Gauge Needle and the Effect of Coaxial Guidance in 1065 Breast Biopsies - A Prospective Randomized Clinical Noninferiority Trial., Ultraschall Med, 2020. 41 (5)(5): p. 534-543., https://pubmed.ncbi.nlm.nih.gov/31791085/
299. Aribal, E, Çelik, L, Yilmaz, C, Demirkiran, C, Guner, DC, Effects of iron oxide particles on MRI and mammography in breast cancer patients after a sentinel lymph node biopsy with paramagnetic tracers., Clin Imaging, 2021. 75 (): p. 22-26., https://pubmed.ncbi.nlm.nih.gov/33486148/
300. Christenhusz, A, Pouw, JJ, Simonis, FFJ, Douek, M, Ahmed, M, Klaase, JM, et.al. Breast MRI in patients after breast conserving surgery with sentinel node procedure using a superparamagnetic tracer., Eur Radiol Exp, 2022. 6 (1)(1): p. 3., https://pubmed.ncbi.nlm.nih.gov/35083595/
301. Genson, CC, Blane, CE, Helvie, MA, Waits, SA, Chenevert, TL, Effects on breast MRI of artifacts caused by metallic tissue marker clips., AJR Am J Roentgenol, 2007. 188 (2)(2): p. 372-6., https://pubmed.ncbi.nlm.nih.gov/17242244/
302. Diaz, L. K., Wiley, E. L., Venta, L. A., Are malignant cells displaced by large-gauge needle core biopsy of the breast?, AJR Am J Roentgenol, 1999. 173(5): p. 1303-13., https://www.ncbi.nlm.nih.gov/pubmed/10541110
303. Knight, R., Horiuchi, K., Parker, S. H., Ratzer, E. R., Fenoglio, M. E., Risk of needle-track seeding after diagnostic image-guided core needle biopsy in breast cancer, Jsls, 2002. 6(3): p. 207-9., https://www.ncbi.nlm.nih.gov/pubmed/12166757
304. Banys-Paluchowski, M, Kühn, T, Masannat, Y, Rubio, I, de Boniface, J, Ditsch, N, et.al. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)., Cancers (Basel), 2023. 15 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/36831516/
305. Dave, RV, Barrett, E, Morgan, J, Chandarana, M, Elgammal, S, Barnes, N, et.al. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study., Br J Surg, 2022. 109 (3)(3): p. 274-282., https://pubmed.ncbi.nlm.nih.gov/35089321/
306. Athanasiou, C, Mallidis, E, Tuffaha, H, Comparative effectiveness of different localization techniques for non-palpable breast cancer. A systematic review and network meta-analysis., Eur J Surg Oncol, 2022. 48 (1)(1): p. 53-59., https://pubmed.ncbi.nlm.nih.gov/34656392/
307. Banys-Paluchowski, M, Rubio, IT, Karadeniz Cakmak, G, Esgueva, A, Krawczyk, N, Paluchowski, P, et.al. Intraoperative Ultrasound-Guided Excision of Non-Palpable and Palpable Breast Cancer: Systematic Review and Meta-Analysis., Ultraschall Med, 2022. 43 (4)(4): p. 367-379., https://pubmed.ncbi.nlm.nih.gov/35760079/
308. Davey, MG, O'Donnell, JPM, Boland, MR, Ryan, ÉJ, Walsh, SR, Kerin, MJ, et.al. Optimal localization strategies for non-palpable breast cancers -A network meta-analysis of randomized controlled trials., Breast, 2022. 62 (): p. 103-113., https://pubmed.ncbi.nlm.nih.gov/35151049/
309. Pantiora, E, Jazrawi, A, Hersi, AF, Abdsaleh, S, Ahlstedt, H, Molnar, E, et.al. Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial., JAMA Surg, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/38150215/
310. den Dekker, BM, Christenhusz, A, van Dalen, T, Jongen, LM, van der Schaaf, MC, Dassen, AE, et.al. A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial., BMC Cancer, 2022. 22 (1)(1): p. 305., https://pubmed.ncbi.nlm.nih.gov/35317766/
311. Hayes, MK, Update on Preoperative Breast Localization., Radiol Clin North Am, 2017. 55 (3)(3): p. 591-603., https://pubmed.ncbi.nlm.nih.gov/28411682/
312. Filipe, MD, Patuleia, SIS, de Jong, VMT, Vriens, MR, van Diest, PJ, Witkamp, AJ, Network Meta-analysis for the Diagnostic Approach to Pathologic Nipple Discharge., Clin Breast Cancer, 2020. 20 (6)(6): p. e723-e748., https://pubmed.ncbi.nlm.nih.gov/32665191/
313. Berger, N, Luparia, A, Di Leo, G, Carbonaro, LA, Trimboli, RM, Ambrogi, F, et.al. Diagnostic Performance of MRI Versus Galactography in Women With Pathologic Nipple Discharge: A Systematic Review and Meta-Analysis., AJR Am J Roentgenol, 2017. 209 (2)(2): p. 465-471., https://pubmed.ncbi.nlm.nih.gov/28537847/
314. Jiwa, N, Kumar, S, Gandhewar, R, Chauhan, H, Nagarajan, V, Wright, C, et.al. Diagnostic Accuracy of Nipple Discharge Fluid Cytology: A Meta-Analysis and Systematic Review of the Literature., Ann Surg Oncol, 2022. 29 (3)(3): p. 1774-1786., https://pubmed.ncbi.nlm.nih.gov/34839426/
315. Department of Health, National Clinical Guideline - Diagnosis, staging and treatment of patients with Breast Cancer. National Clinical Guideline No. 7., 2015.
316. Sun, Z., Yi, Y. L., Liu, Y., Xiong, J. P., He, C. Z., Comparison of whole-body PET/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: a meta-analysis, Eur J Gynaecol Oncol, 2015. 36(6): p. 672-6., https://www.ncbi.nlm.nih.gov/pubmed/26775349
317. Dayes, IS, Metser, U, Hodgson, N, Parpia, S, Eisen, AF, George, R, et.al. Impact of , J Clin Oncol, 2023. 41 (23)(23): p. 3909-3916., https://pubmed.ncbi.nlm.nih.gov/37235845/
318. Grimm, LJ, Rahbar, H, Abdelmalak, M, Hall, AH, Ryser, MD, Ductal Carcinoma in Situ: State-of-the-Art Review., Radiology, 2022. 302 (2)(2): p. 246-255., https://pubmed.ncbi.nlm.nih.gov/34931856/
319. Virnig, B. A., Tuttle, T. M., Shamliyan, T., Kane, R. L., Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes, J Natl Cancer Inst, 2010. 102(3): p. 170-8., https://www.ncbi.nlm.nih.gov/pubmed/20071685
320. Giannakeas, V, Sopik, V, Narod, SA, Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer., JAMA Netw Open, 2020. 3 (9)(9): p. e2017124., https://pubmed.ncbi.nlm.nih.gov/32936299/
321. Lebeau, A., Kuhn, T., Updates in the treatment of ductal carcinoma in situ of the breast, Curr Opin Obstet Gynecol, 2016. 28(1): p. 49-58., https://www.ncbi.nlm.nih.gov/pubmed/26694830
322. Van Zee, K. J., Barrio, A. V., Tchou, J., Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ, JAMA Oncol, 2016. 2(3): p. 397-8., https://www.ncbi.nlm.nih.gov/pubmed/26967180
323. Duffy, S. W., Dibden, A., Michalopoulos, D., Offman, J., Parmar, D., Jenkins, J., et.al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study, Lancet Oncol, 2016. 17(1): p. 109-14., https://www.ncbi.nlm.nih.gov/pubmed/26655422
324. Shamliyan, T., Wang, S. Y., Virnig, B. A., Tuttle, T. M., Kane, R. L., Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ, J Natl Cancer Inst Monogr, 2010. 2010(41): p. 121-9., https://www.ncbi.nlm.nih.gov/pubmed/20956815
325. Tunon-de-Lara, C., Lemanski, C., Cohen-Solal-Le-Nir, C., de Lafontan, B., Charra-Brunaud, C., Gonzague-Casabianca, L., et.al. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk, Eur J Surg Oncol, 2010. 36(12): p. 1165-71., https://www.ncbi.nlm.nih.gov/pubmed/20889280
326. Wang, S. Y., Shamliyan, T., Virnig, B. A., Kane, R., Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis, Breast Cancer Res Treat, 2011. 127(1): p. 1-14., https://www.ncbi.nlm.nih.gov/pubmed/21327465
327. Habel, L. A., Dignam, J. J., Land, S. R., Salane, M., Capra, A. M., Julian, T. B., Mammographic density and breast cancer after ductal carcinoma in situ, J Natl Cancer Inst, 2004. 96(19): p. 1467-72., https://www.ncbi.nlm.nih.gov/pubmed/15467036
328. Lagios, MD, Pathologic procedures for mammographically-detected ductal carcinomain situ, in Ductal carcinoma in situ of the breast., Silverstein, Mel E. Recht Abram E. Lagios Michael D. , Editor. 2002, Lippincott Williams & Wilkins: Philadelphia. p. 189–193., https://www.ncbi.nlm.nih.gov/pubmed/2536582
329. Lakhani, S. R.%A Ellis, I%A Schnitt, S%A Tan, P. H.%A Vijver, MJ van de, WHO Classification of Tumours of the BreastIARC Press, World Health Organization classification of tumours, 2012. p. 240 p..
330. Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H., et.al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial, Br J Cancer, 2010. 103(1): p. 94-100., https://www.ncbi.nlm.nih.gov/pubmed/20517310
331. Pang, J. M., Gorringe, K. L., Fox, S. B., Ductal carcinoma in situ - update on risk assessment and management, Histopathology, 2016. 68(1): p. 96-109., https://www.ncbi.nlm.nih.gov/pubmed/26768032
332. Dillon, M. F., Mc Dermott, E. W., O'Doherty, A., Quinn, C. M., Hill, A. D., O'Higgins, N., Factors affecting successful breast conservation for ductal carcinoma in situ, Ann Surg Oncol, 2007. 14(5): p. 1618-28., https://www.ncbi.nlm.nih.gov/pubmed/17443388
333. Maffuz, A., Barroso-Bravo, S., Najera, I., Zarco, G., Alvarado-Cabrero, I., Rodriguez-Cuevas, S. A., Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ, J Exp Clin Cancer Res, 2006. 25(2): p. 223-7., https://www.ncbi.nlm.nih.gov/pubmed/16918134
334. Sigal-Zafrani, B., Lewis, J. S., Clough, K. B., Vincent-Salomon, A., Fourquet, A., Meunier, M., et.al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications, Mod Pathol, 2004. 17(1): p. 81-8., https://www.ncbi.nlm.nih.gov/pubmed/14657957
335. Kantor, O., Winchester, D. J., Breast conserving therapy for DCIS--does size matter?, J Surg Oncol, 2014. 110(1): p. 75-81., https://www.ncbi.nlm.nih.gov/pubmed/24861481
336. MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., et.al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins, Am J Surg, 2005. 190(4): p. 521-5., https://www.ncbi.nlm.nih.gov/pubmed/16164913
337. Asjoe, F. T., Altintas, S., Huizing, M. T., Colpaert, C., Marck, E. V., Vermorken, J. B., et.al. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis, Breast J, 2007. 13(4): p. 359-67., https://www.ncbi.nlm.nih.gov/pubmed/17593040
338. Lagios, M. D., Margolin, F. R., Westdahl, P. R., Rose, M. R., Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence, Cancer, 1989. 63(4): p. 618-24., http://www.loc.gov/catdir/enhancements/fy0711/2002016284-d.html
339. Roque, R, Cordeiro, MR, Armas, M, Caramelo, F, Caseiro-Alves, F, Figueiredo-Dias, M, The accuracy of magnetic resonance imaging in predicting the size of pure ductal carcinoma in situ: a systematic review and meta-analysis., NPJ Breast Cancer, 2022. 8 (1)(1): p. 77., https://pubmed.ncbi.nlm.nih.gov/35768442/
340. Versteegden, DPA, Keizer, LGG, Schlooz-Vries, MS, Duijm, LEM, Wauters, CAP, Strobbe, LJA, Performance characteristics of specimen radiography for margin assessment for ductal carcinoma in situ: a systematic review., Breast Cancer Res Treat, 2017. 166 (3)(3): p. 669-679., https://pubmed.ncbi.nlm.nih.gov/28831674/
341. Marinovich, M. L., Azizi, L., Macaskill, P., Irwig, L., Morrow, M., Solin, L. J., et.al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis, Ann Surg Oncol, 2016. 23(12): p. 3811-3821., https://www.ncbi.nlm.nih.gov/pubmed/27527715
342. Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., et.al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ, J Clin Oncol, 2016. 34(33): p. 4040-4046., https://www.ncbi.nlm.nih.gov/pubmed/27528719
343. National Institute for Health and Care Excellence (NICE), Early and locally advanced breast cancer: diagnosis and management, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/30102508/
344. NCCN Guidelines, Breast Cancer, 2024. Version 5.2024:, https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
345. Wapnir, IL, Dignam, JJ, Fisher, B, Mamounas, EP, Anderson, SJ, Julian, TB, et.al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS., J Natl Cancer Inst, 2011. 103 (6)(6): p. 478-88., https://pubmed.ncbi.nlm.nih.gov/21398619/
346. Morrow, M, Van Zee, KJ, Solin, LJ, Houssami, N, Chavez-MacGregor, M, Harris, JR, et.al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ., J Clin Oncol, 2016. 34 (33)(33): p. 4040-4046., https://pubmed.ncbi.nlm.nih.gov/27528719/
347. Marinovich, ML, Azizi, L, Macaskill, P, Irwig, L, Morrow, M, Solin, LJ, et.al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis., Ann Surg Oncol, 2016. 23 (12)(12): p. 3811-3821., https://pubmed.ncbi.nlm.nih.gov/27527715/
348. Brouwer de Koning, SG, Vrancken Peeters, MTFD, Jóźwiak, K, Bhairosing, PA, Ruers, TJM, Tumor Resection Margin Definitions in Breast-Conserving Surgery: Systematic Review and Meta-analysis of the Current Literature., Clin Breast Cancer, 2018. 18 (4)(4): p. e595-e600., https://pubmed.ncbi.nlm.nih.gov/29731404/
349. Macdonald, H. R., Silverstein, M. J., Lee, L. A., Ye, W., Sanghavi, P., Holmes, D. R., et.al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast, Am J Surg, 2006. 192(4): p. 420-2., https://www.ncbi.nlm.nih.gov/pubmed/16978941
350. Hughes, L. L., Wang, M., Page, D. L., Gray, R., Solin, L. J., Davidson, N. E., et.al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 2009. 27(32): p. 5319-24., https://www.ncbi.nlm.nih.gov/pubmed/19826126
351. Kim, D, Ki, Y, Kim, W, Park, D, Joo, J, Jeon, H, et.al. Comparison of local recurrence after mastectomy for pure ductal carcinoma , J Cancer Res Ther, 2020. 16 (6)(6): p. 1197-1202., https://pubmed.ncbi.nlm.nih.gov/33342773/
352. Solin, LJ, Gray, R, Hughes, LL, Wood, WC, Lowen, MA, Badve, SS, et.al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study., J Clin Oncol, 2015. 33 (33)(33): p. 3938-44., https://pubmed.ncbi.nlm.nih.gov/26371148/
353. Lyman, G. H., Temin, S., Edge, S. B., Newman, L. A., Turner, R. R., Weaver, D. L., et.al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 2014. 32(13): p. 1365-83., https://pubmed.ncbi.nlm.nih.gov/24663048/
354. Davey, MG, O'Flaherty, C, Cleere, EF, Nohilly, A, Phelan, J, Ronane, E, et.al. Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis., BJS Open, 2022. 6 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/35380620/
355. Lyman, GH, Somerfield, MR, Bosserman, LD, Perkins, CL, Weaver, DL, Giuliano, AE, Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update., J Clin Oncol, 2017. 35 (5)(5): p. 561-564., https://pubmed.ncbi.nlm.nih.gov/27937089/
356. Shapiro-Wright, H. M., Julian, T. B., Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ, J Natl Cancer Inst Monogr, 2010. 2010(41): p. 145-9., https://www.ncbi.nlm.nih.gov/pubmed/20956820
357. Tunon-de-Lara, C., Chauvet, M. P., Baranzelli, M. C., Baron, M., Piquenot, J., Le-Bouedec, G., et.al. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study, Ann Surg Oncol, 2015. 22(12): p. 3853-60., https://www.ncbi.nlm.nih.gov/pubmed/25777085
358. Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V., Sun, P., Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ, JAMA Oncol, 2015. 1(7): p. 888-96., https://www.ncbi.nlm.nih.gov/pubmed/26291673
359. Goodwin, A., Parker, S., Ghersi, D., Wilcken, N., Post-operative radiotherapy for ductal carcinoma in situ of the breast, Cochrane Database Syst Rev, 2013. p. Cd000563., https://www.ncbi.nlm.nih.gov/pubmed/24259251
360. Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., et.al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial, J Clin Oncol, 2014. 32(32): p. 3613-8., https://www.ncbi.nlm.nih.gov/pubmed/25311220
361. Sagara, Y., Freedman, R. A., Vaz-Luis, I., Mallory, M. A., Wong, S. M., Aydogan, F., et.al. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study, J Clin Oncol, 2016. 34(11): p. 1190-6., https://www.ncbi.nlm.nih.gov/pubmed/26834064
362. Correa, C, McGale, P, Taylor, C, Wang, Y, Clarke, M, Davies, C, et.al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast., J Natl Cancer Inst Monogr, 2010. 2010 (41)(41): p. 162-77., https://pubmed.ncbi.nlm.nih.gov/20956824/
363. McCormick, B, Winter, K, Hudis, C, Kuerer, HM, Rakovitch, E, Smith, BL, et.al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation., J Clin Oncol, 2015. 33 (7)(7): p. 709-15., https://pubmed.ncbi.nlm.nih.gov/25605856/
364. Chua, BH, Link, EK, Kunkler, IH, Whelan, TJ, Westenberg, AH, Gruber, G, et.al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study., Lancet, 2022. 400 (10350)(10350): p. 431-440., https://pubmed.ncbi.nlm.nih.gov/35934006/
365. Offersen, BV, Alsner, J, Nielsen, HM, Jakobsen, EH, Nielsen, MH, Krause, M, et.al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial., J Clin Oncol, 2020. 38 (31)(31): p. 3615-3625., https://pubmed.ncbi.nlm.nih.gov/32910709/
366. Strnad, V, Ott, OJ, Hildebrandt, G, Kauer-Dorner, D, Knauerhase, H, Major, T, et.al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial., Lancet, 2016. 387 (10015)(10015): p. 229-38., https://pubmed.ncbi.nlm.nih.gov/26494415/
367. Whelan, TJ, Julian, JA, Berrang, TS, Kim, DH, Germain, I, Nichol, AM, et.al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial., Lancet, 2019. 394 (10215)(10215): p. 2165-2172., https://pubmed.ncbi.nlm.nih.gov/31813635/
368. Vicini, FA, Cecchini, RS, White, JR, Arthur, DW, Julian, TB, Rabinovitch, RA, et.al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial., Lancet, 2019. 394 (10215)(10215): p. 2155-2164., https://pubmed.ncbi.nlm.nih.gov/31813636/
369. Stuart, K. E., Houssami, N., Taylor, R., Hayen, A., Boyages, J., Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis, BMC Cancer, 2015. 15: p. 890., https://www.ncbi.nlm.nih.gov/pubmed/26555555
370. Subhedar, P., Olcese, C., Patil, S., Morrow, M., Van Zee, K. J., Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years, Ann Surg Oncol, 2015. 22(10): p. 3273-81., https://www.ncbi.nlm.nih.gov/pubmed/26215193
371. Miller, K. L., Marks, L. B., Barrier, R. C., Jr., Leight, G. S., Clough, R. W., Prosnitz, R. G., et.al. Increased sectioning of pathologic specimens with ductal carcinoma in situ of the breast: are there clinical consequences?, Clin Breast Cancer, 2003. 4(3): p. 198-202., https://www.ncbi.nlm.nih.gov/pubmed/14499013
372. Wehner, P., Lagios, M. D., Silverstein, M. J., DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines, Ann Surg Oncol, 2013. 20(10): p. 3175-9., https://www.ncbi.nlm.nih.gov/pubmed/23975306
373. Rutgers, E. J., Quality control in the locoregional treatment of breast cancer, Eur J Cancer, 2001. 37(4): p. 447-53., https://www.ncbi.nlm.nih.gov/pubmed/11267852
374. Sagara, Y., Mallory, M. A., Wong, S., Aydogan, F., DeSantis, S., Barry, W. T., et.al. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study, JAMA Surg, 2015. 150(8): p. 739-45., https://www.ncbi.nlm.nih.gov/pubmed/26039049
375. Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., et.al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial, Lancet, 2016. 387(10015): p. 229-38., https://www.ncbi.nlm.nih.gov/pubmed/26494415
376. Yan, Y, Zhang, L, Tan, L, Ma, X, Zhang, Y, Shao, S, et.al. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis., Pathol Oncol Res, 2020. 26 (1)(1): p. 521-531., https://pubmed.ncbi.nlm.nih.gov/30499075/
377. Cuzick, J, Sestak, I, Forbes, JF, Dowsett, M, Cawthorn, S, Mansel, RE, et.al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial., Lancet, 2020. 395 (10218)(10218): p. 117-122., https://pubmed.ncbi.nlm.nih.gov/31839281/
378. Lazzeroni, M, Puntoni, M, Guerrieri-Gonzaga, A, Serrano, D, Boni, L, Buttiron Webber, T, et.al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study., J Clin Oncol, 2023. 41 (17)(17): p. 3116-3121., https://pubmed.ncbi.nlm.nih.gov/36917758/
379. Guerrieri-Gonzaga, A., Lazzeroni, M., Botteri, E., Serrano, D., Rotmensz, N., Varricchio, M. C., et.al. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study, Ann Oncol, 2013. 24(7): p. 1859-66., https://www.ncbi.nlm.nih.gov/pubmed/23532115
380. Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., et.al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24, J Clin Oncol, 2012. 30(12): p. 1268-73., https://www.ncbi.nlm.nih.gov/pubmed/22393101
381. Staley, H., McCallum, I., Bruce, J., Postoperative tamoxifen for ductal carcinoma in situ, Cochrane Database Syst Rev, 2012. 10: p. Cd007847., https://www.ncbi.nlm.nih.gov/pubmed/23076938
382. Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., et.al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS, J Natl Cancer Inst, 2011. 103(6): p. 478-88., https://www.ncbi.nlm.nih.gov/pubmed/21398619
383. Cuzick, J., Sestak, I., Pinder, S. E., Ellis, I. O., Forsyth, S., Bundred, N. J., et.al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, Lancet Oncol, 2011. 12(1): p. 21-9., https://www.ncbi.nlm.nih.gov/pubmed/21145284
384. Wheelwright, S, Matthews, L, Jenkins, V, May, S, Rea, D, Fairbrother, P, et.al. Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study., Trials, 2023. 24 (1)(1): p. 670., https://pubmed.ncbi.nlm.nih.gov/37838682/
385. Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Non-randomized, Multicenter, Non-inferiority Trial; Standard Therapy Approach Versus Active Surveillance, https://clinicaltrials.gov/study/NCT02492607
386. Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial, https://clinicaltrials.gov/study/NCT02926911
387. Loibl, S, André, F, Bachelot, T, Barrios, CH, Bergh, J, Burstein, HJ, et.al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol, 2024. 35 (2)(2): p. 159-182., https://pubmed.ncbi.nlm.nih.gov/38101773/
388. Calhoun, B. C., Collins, L. C., Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature, Histopathology, 2016. 68(1): p. 138-51., https://www.ncbi.nlm.nih.gov/pubmed/26768035
389. Fox, SB, Webster, F, Chen, CJ, Chua, B, Collins, L, Foschini, MP, et.al. Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR)., Histopathology, 2022. 81 (4)(4): p. 467-476., https://pubmed.ncbi.nlm.nih.gov/35869801/
390. Rubio, IT, Wyld, L, Marotti, L, Athanasiou, A, Regitnig, P, Catanuto, G, et.al. European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO., Eur J Surg Oncol, 2024. 50 (1)(1): p. 107292., https://pubmed.ncbi.nlm.nih.gov/38061151/
391. Who COTEB, WHO Classification of Tumours - Breast Tumours.International Agency for Research on Cancer, 2019.
392. Elfgen, C, Leo, C, Kubik-Huch, RA, Muenst, S, Schmidt, N, Quinn, C, et.al. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)., Virchows Arch, 2023. 483 (1)(1): p. 5-20., https://pubmed.ncbi.nlm.nih.gov/37330436/
393. Collins, L. C., Aroner, S. A., Connolly, J. L., Colditz, G. A., Schnitt, S. J., Tamimi, R. M., Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies, Cancer, 2016. 122(4): p. 515-20., https://www.ncbi.nlm.nih.gov/pubmed/26565738
394. Buckley, E., Sullivan, T., Farshid, G., Hiller, J., Roder, D., Risk profile of breast cancer following atypical hyperplasia detected through organized screening, Breast, 2015. 24(3): p. 208-12., https://www.ncbi.nlm.nih.gov/pubmed/25681318
395. Hartmann, L. C., Radisky, D. C., Frost, M. H., Santen, R. J., Vierkant, R. A., Benetti, L. L., et.al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study, Cancer Prev Res (Phila), 2014. 7(2): p. 211-7., https://www.ncbi.nlm.nih.gov/pubmed/24480577
396. Degnim, A. C., Visscher, D. W., Berman, H. K., Frost, M. H., Sellers, T. A., Vierkant, R. A., et.al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study, J Clin Oncol, 2007. 25(19): p. 2671-7., https://www.ncbi.nlm.nih.gov/pubmed/17563394
397. Youn, I., Kim, M. J., Moon, H. J., Kim, E. K., Absence of Residual Microcalcifications in Atypical Ductal Hyperplasia Diagnosed via Stereotactic Vacuum-Assisted Breast Biopsy: Is Surgical Excision Obviated?, J Breast Cancer, 2014. 17(3): p. 265-9., https://www.ncbi.nlm.nih.gov/pubmed/25320625
398. Mesurolle, B., Perez, J. C., Azzumea, F., Lemercier, E., Xie, X., Aldis, A., et.al. Atypical ductal hyperplasia diagnosed at sonographically guided core needle biopsy: frequency, final surgical outcome, and factors associated with underestimation, AJR Am J Roentgenol, 2014. 202(6): p. 1389-94., https://www.ncbi.nlm.nih.gov/pubmed/24848840
399. Khoury, T., Chen, X., Wang, D., Kumar, P., Qin, M., Liu, S., et.al. Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions, Histopathology, 2015. 67(1): p. 106-20., https://www.ncbi.nlm.nih.gov/pubmed/25529860
400. Caplain, A., Drouet, Y., Peyron, M., Peix, M., Faure, C., Chassagne-Clement, C., et.al. Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution, Am J Surg, 2014. 208(2): p. 260-7., https://www.ncbi.nlm.nih.gov/pubmed/24680949
401. Eby, P. R., Ochsner, J. E., DeMartini, W. B., Allison, K. H., Peacock, S., Lehman, C. D., Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge, AJR Am J Roentgenol, 2009. 192(1): p. 229-34., https://www.ncbi.nlm.nih.gov/pubmed/19098204
402. Degnim, A. C., King, T. A., Surgical management of high-risk breast lesions, Surg Clin North Am, 2013. 93(2): p. 329-40., https://www.ncbi.nlm.nih.gov/pubmed/23464689
403. Yu, Y. H.A Liang, C.A Yuan, X. Z., Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review, Breast Cancer Res Treat, 2010. 120(2): p. 469-79., https://www.ncbi.nlm.nih.gov/pubmed/20130983
404. Sneige, N., Lim, S. C., Whitman, G. J., Krishnamurthy, S., Sahin, A. A., Smith, T. L., et.al. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision, Am J Clin Pathol, 2003. 119(2): p. 248-53., https://www.ncbi.nlm.nih.gov/pubmed/12579995
405. Ely, K. A., Carter, B. A., Jensen, R. A., Simpson, J. F., Page, D. L., Core biopsy of the breast with atypical ductal hyperplasia: a probabilistic approach to reporting, Am J Surg Pathol, 2001. 25(8): p. 1017-21., https://www.ncbi.nlm.nih.gov/pubmed/11474285
406. Nguyen, C. V., Albarracin, C. T., Whitman, G. J., Lopez, A., Sneige, N., Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision, Ann Surg Oncol, 2011. 18(3): p. 752-61., https://www.ncbi.nlm.nih.gov/pubmed/20972636
407. Allison, K. H., Eby, P. R., Kohr, J., DeMartini, W. B., Lehman, C. D., Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade, Hum Pathol, 2011. 42(1): p. 41-50., https://www.ncbi.nlm.nih.gov/pubmed/20970167
408. Wagoner, M. J., Laronga, C., Acs, G., Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision, Am J Clin Pathol, 2009. 131(1): p. 112-21., https://www.ncbi.nlm.nih.gov/pubmed/19095574
409. Kohr, J. R., Eby, P. R., Allison, K. H., DeMartini, W. B., Gutierrez, R. L., Peacock, S., et.al. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications, Radiology, 2010. 255(3): p. 723-30., https://www.ncbi.nlm.nih.gov/pubmed/20173103
410. Morrow, M., Schnitt, S. J., Norton, L., Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, 2015. 12(4): p. 227-38., https://www.ncbi.nlm.nih.gov/pubmed/25622978
411. Port, ER, Park, A, Borgen, PI, Morris, E, Montgomery, LL, Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia., Ann Surg Oncol, 2007. 14 (3)(3): p. 1051-7., https://pubmed.ncbi.nlm.nih.gov/17206485/
412. Page, D. L., Kidd, T. E., Jr., Dupont, W. D., Simpson, J. F., Rogers, L. W., Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease, Hum Pathol, 1991. 22(12): p. 1232-9., https://www.ncbi.nlm.nih.gov/pubmed/1748429
413. Dabbs, D. J., Schnitt, S. J., Geyer, F. C., Weigelt, B., Baehner, F. L., Decker, T., et.al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry, Am J Surg Pathol, 2013. 37(7): p. e1-11., https://www.ncbi.nlm.nih.gov/pubmed/23759937
414. King, TA, Pilewskie, M, Muhsen, S, Patil, S, Mautner, SK, Park, A, et.al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk., J Clin Oncol, 2015. 33 (33)(33): p. 3945-52., https://pubmed.ncbi.nlm.nih.gov/26371145/
415. van Maaren, MC, Ávila, AO, van Manen, JG, Menke-Pluijmers, MB, Veltman, J, Bart, J, et.al. Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis., Breast, 2021. 59 (): p. 376-382., https://pubmed.ncbi.nlm.nih.gov/34428722/
416. Nakhlis, F., Gilmore, L., Gelman, R., Bedrosian, I., Ludwig, K., Hwang, E. S., et.al. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020), Ann Surg Oncol, 2016. 23(3): p. 722-8., https://www.ncbi.nlm.nih.gov/pubmed/26542585
417. Brogi, E, The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS., Virchows Arch, 2022. 481 (6)(6): p. 823-837., https://pubmed.ncbi.nlm.nih.gov/35567633/
418. Bagaria, S. P., Shamonki, J., Kinnaird, M., Ray, P. S., Giuliano, A. E., The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?, Ann Surg Oncol, 2011. 18(7): p. 1845-51., https://www.ncbi.nlm.nih.gov/pubmed/21287281
419. Ross, D. S., Hoda, S. A., Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases, Am J Surg Pathol, 2011. 35(5): p. 750-6., https://www.ncbi.nlm.nih.gov/pubmed/21415700
420. Singh, K, Sung, CJ, Quddus, MR, Descriptive study comparing outcomes of classic and nonclassic lobular carcinoma in situ (florid and pleomorphic) initially diagnosed on core needle biopsy., Breast J, 2020. 26 (12)(12): p. 2350-2356., https://pubmed.ncbi.nlm.nih.gov/33047861/
421. Khoury, T, Karabakhtsian, RG, Mattson, D, Yan, L, Syriac, S, Habib, F, et.al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases., Histopathology, 2014. 64 (7)(7): p. 981-93., https://pubmed.ncbi.nlm.nih.gov/24372322/
422. Reis-Filho, J. S., Simpson, P. T., Jones, C., Steele, D., Mackay, A., Iravani, M., et.al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity, J Pathol, 2005. 207(1): p. 1-13., https://www.ncbi.nlm.nih.gov/pubmed/15957152
423. Masannat, YA, Husain, E, Roylance, R, Heys, SD, Carder, PJ, Ali, H, et.al. Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ., Breast, 2018. 38 (): p. 120-124., https://pubmed.ncbi.nlm.nih.gov/29310036/
424. Brogi, E., Murray, M. P., Corben, A. D., Lobular carcinoma, not only a classic, Breast J, 2010. 16 Suppl 1: p. S10-4., https://www.ncbi.nlm.nih.gov/pubmed/21050299
425. Sinn, H. P., Helmchen, B., Heil, J., Aulmann, S., [Lobular neoplasms and invasive lobular breast cancer], Pathologe, 2014. 35(1): p. 45-53., https://www.ncbi.nlm.nih.gov/pubmed/24435155
426. Pinder, Sarah E., Shaaban, Abeer M., In situ lobular proliferations of the breast, Mini-Symposium: Breast Pathology, 2018. 24(2): p. 58 - 63., https://www.sciencedirect.com/science/article/pii/S1756231717301925
427. Schnitt, S. J., Vincent-Salomon, A., Columnar cell lesions of the breast, Adv Anat Pathol, 2003. 10(3): p. 113-24., https://www.ncbi.nlm.nih.gov/pubmed/12717115
428. Abdel-Fatah, T. M., Powe, D. G., Hodi, Z., Reis-Filho, J. S., Lee, A. H., Ellis, I. O., Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family, Am J Surg Pathol, 2008. 32(4): p. 513-23., https://www.ncbi.nlm.nih.gov/pubmed/18223478
429. Brandt, S. M., Young, G. Q., Hoda, S. A., The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions, Adv Anat Pathol, 2008. 15(3): p. 140-6., https://www.ncbi.nlm.nih.gov/pubmed/18434766
430. Aulmann, S., Braun, L., Mietzsch, F., Longerich, T., Penzel, R., Schirmacher, P., et.al. Transitions between flat epithelial atypia and low-grade ductal carcinoma in situ of the breast, Am J Surg Pathol, 2012. 36(8): p. 1247-52., https://www.ncbi.nlm.nih.gov/pubmed/22790863
431. Sinn, H. P., Breast cancer precursors: lessons learned from molecular genetics, J Mol Med (Berl), 2009. 87(2): p. 113-5., https://www.ncbi.nlm.nih.gov/pubmed/19139833
432. Lopez-Garcia, M. A., Geyer, F. C., Lacroix-Triki, M., Marchio, C., Reis-Filho, J. S., Breast cancer precursors revisited: molecular features and progression pathways, Histopathology, 2010. 57(2): p. 171-92., https://www.ncbi.nlm.nih.gov/pubmed/20500230
433. Strickland, S, Turashvili, G, Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?, Curr Oncol, 2022. 29 (8)(8): p. 5664-5681., https://pubmed.ncbi.nlm.nih.gov/36005185/
434. Cullinane, C, Byrne, J, Kelly, L, O Sullivan, M, Antony Corrigan, M, Paul Redmond, H, The positive predictive value of vacuum assisted biopsy (VAB) in predicting final histological diagnosis for breast lesions of uncertain malignancy (B3 lesions): A systematic review & meta-analysis., Eur J Surg Oncol, 2022. 48 (7)(7): p. 1464-1474., https://pubmed.ncbi.nlm.nih.gov/35491362/
435. Wahab, RA, Lee, SJ, Mulligan, ME, Zhang, B, Mahoney, MC, Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis., Radiol Imaging Cancer, 2021. 3 (1)(1): p. e200116., https://pubmed.ncbi.nlm.nih.gov/33778758/
436. Yu, CC, Cheung, YC, Ueng, SH, Chen, SC, Impact of Non-Calcified Specimen Pathology on the Underestimation of Malignancy for the Incomplete Retrieval of Suspicious Calcifications Diagnosed as Flat Epithelial Atypia or Atypical Ductal Hyperplasia by Stereotactic Vacuum-Assisted Breast Biopsy., Korean J Radiol, 2020. 21 (11)(11): p. 1220-1229., https://pubmed.ncbi.nlm.nih.gov/32729266/
437. Rudin, AV, Hoskin, TL, Fahy, A, Farrell, AM, Nassar, A, Ghosh, K, et.al. Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis., Ann Surg Oncol, 2017. 24 (12)(12): p. 3549-3558., https://pubmed.ncbi.nlm.nih.gov/28831724/
438. Beck, AC, Bayard, S, Plitas, G, Sevilimedu, V, Kuba, MG, Garcia, P, et.al. Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?, Ann Surg Oncol, 2023. 30 (10)(10): p. 6061-6069., https://pubmed.ncbi.nlm.nih.gov/37493892/
439. Chester, R., Bokinni, O., Ahmed, I., Kasem, A., UK national survey of management of breast lobular carcinoma in situ, Ann R Coll Surg Engl, 2015. 97(8): p. 574-7., https://www.ncbi.nlm.nih.gov/pubmed/26492902
440. Shin, S. J., Lal, A., De Vries, S., Suzuki, J., Roy, R., Hwang, E. S., et.al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ, Hum Pathol, 2013. 44(10): p. 1998-2009., https://www.ncbi.nlm.nih.gov/pubmed/23809857
441. Masannat, Y. A., Bains, S. K., Pinder, S. E., Purushotham, A. D., Challenges in the management of pleomorphic lobular carcinoma in situ of the breast, Breast, 2013. 22(2): p. 194-6., https://www.ncbi.nlm.nih.gov/pubmed/23357705
442. Abbassi-Rahbar, S, Sack, S, Larson, KE, Wagner, JL, Kilgore, LJ, Balanoff, CR, et.al. Multidisciplinary Review of Intraductal Papilloma of the Breast can Identify Patients who may Omit Surgical Excision., Ann Surg Oncol, 2021. 28 (10)(10): p. 5768-5774., https://pubmed.ncbi.nlm.nih.gov/34338925/
443. Ni, Y, Tse, GM, Papillary lesions of the breast - review and practical issues., Semin Diagn Pathol, 2022. 39 (5)(5): p. 344-354., https://pubmed.ncbi.nlm.nih.gov/35718581/
444. Petrolla, A, Hicks, DG, Skinner, KA, Wang, X, Detailed Morphologic Evaluation of Breast Papillary Lesions on Core Biopsy Is Critical for Accurate Classification and Clinical Management: The Experience of an Academic Institute., Clin Breast Cancer, 2022. 22 (4)(4): p. e552-e557., https://pubmed.ncbi.nlm.nih.gov/34998709/
445. Wen, X., Cheng, W., Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors, Ann Surg Oncol, 2013. 20(1): p. 94-101., https://www.ncbi.nlm.nih.gov/pubmed/22878621
446. Li, X, Gao, H, Xu, M, Wu, Y, Gao, D, Breast papillary lesions diagnosed and treated using ultrasound-guided vacuum-assisted excision., BMC Surg, 2020. 20 (1)(1): p. 204., https://pubmed.ncbi.nlm.nih.gov/32933518/
447. Ma, Z, Arciero, CA, Styblo, TM, Wang, H, Cohen, MA, Li, X, Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center., Breast Cancer Res Treat, 2020. 183 (3)(3): p. 577-584., https://pubmed.ncbi.nlm.nih.gov/32705378/
448. Choi, HY, Kim, SM, Jang, M, Yun, B, Kang, E, Kim, EK, et.al. Benign Breast Papilloma without Atypia: Outcomes of Surgical Excision versus US-guided Directional Vacuum-assisted Removal or US Follow-up., Radiology, 2019. 293 (1)(1): p. 72-80., https://pubmed.ncbi.nlm.nih.gov/31429678/
449. Ni, Y. B., Tse, G. M., Pathological criteria and practical issues in papillary lesions of the breast - a review, Histopathology, 2016. 68(1): p. 22-32., https://www.ncbi.nlm.nih.gov/pubmed/26768027
450. Ueng, S. H., Mezzetti, T., Tavassoli, F. A., Papillary neoplasms of the breast: a review, Arch Pathol Lab Med, 2009. 133(6): p. 893-907., https://www.ncbi.nlm.nih.gov/pubmed/19492881
451. Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., et.al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 2014. 32(14): p. 1507-15., https://pubmed.ncbi.nlm.nih.gov/24516019/
452. Committee, National Clinical Effectiveness, Diagnosis, staging and treatment of patients with breast cancer: national clinical guideline no. 7, 2015.
453. Houssami, N., Macaskill, P., Marinovich, M. L., Morrow, M., The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis, Ann Surg Oncol, 2014. 21(3): p. 717-30., https://www.ncbi.nlm.nih.gov/pubmed/24473640
454. Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., et.al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 2014. 32(14): p. 1507-15., https://pubmed.ncbi.nlm.nih.gov/24516019/
455. Buchholz, T. A., Somerfield, M. R., Griggs, J. J., El-Eid, S., Hammond, M. E., Lyman, G. H., et.al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline, J Clin Oncol, 2014. 32(14): p. 1502-6., https://www.ncbi.nlm.nih.gov/pubmed/24711553
456. Jones, H. A., Antonini, N., Hart, A. A., Peterse, J. L., Horiot, J. C., Collin, F., et.al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial, J Clin Oncol, 2009. 27(30): p. 4939-47., https://www.ncbi.nlm.nih.gov/pubmed/19720914
457. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 365(9472): p. 1687-717., https://www.ncbi.nlm.nih.gov/pubmed/15894097
458. Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., et.al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23, J Clin Oncol, 2001. 19(4): p. 931-42., https://www.ncbi.nlm.nih.gov/pubmed/11181655
459. Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et.al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, N Engl J Med, 2002. 347(16): p. 1227-32., https://www.ncbi.nlm.nih.gov/pubmed/12393819
460. Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., et.al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 2002. 347(16): p. 1233-41., https://www.ncbi.nlm.nih.gov/pubmed/12393820
461. Wald, N. J., Murphy, P., Major, P., Parkes, C., Townsend, J., Frost, C., UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening, Bmj, 1995. 311(7014): p. 1189-93., https://www.ncbi.nlm.nih.gov/pubmed/7488893
462. Weaver, D. L., Krag, D. N., Ashikaga, T., Harlow, S. P., O'Connell, M., Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study, Cancer, 2000. 88(5): p. 1099-107., https://www.ncbi.nlm.nih.gov/pubmed/10699901
463. McCahill, L. E., Single, R. M., Aiello Bowles, E. J., Feigelson, H. S., James, T. A., Barney, T., et.al. Variability in reexcision following breast conservation surgery, Jama, 2012. 307(5): p. 467-75., https://www.ncbi.nlm.nih.gov/pubmed/22298678
464. de Boniface, J, Szulkin, R, Johansson, ALV, Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women., JAMA Surg, 2021. 156 (7)(7): p. 628-637., https://pubmed.ncbi.nlm.nih.gov/33950173/
465. Reimer, T, Stachs, A, Veselinovic, K, Polata, S, Müller, T, Kühn, T, et.al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer., EClinicalMedicine, 2023. 55 (): p. 101756., https://pubmed.ncbi.nlm.nih.gov/36457648/
466. Li, S, Li, X, Li, D, Zhao, Q, Zhu, L, Wu, T, A meta-analysis of randomized controlled trials comparing breast-conserving surgery and mastectomy in terms of patient survival rate and quality of life in breast cancer., Int J Qual Health Care, 2024. 36 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/38753325/
467. Rajan, KK, Fairhurst, K, Birkbeck, B, Novintan, S, Wilson, R, Savović, J, et.al. Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis., BJS Open, 2024. 8 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/38758563/
468. Agarwal, S, Pappas, L, Neumayer, L, Kokeny, K, Agarwal, J, Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer., JAMA Surg, 2014. 149 (3)(3): p. 267-74., https://pubmed.ncbi.nlm.nih.gov/24429935/
469. van Maaren, MC, de Munck, L, de Bock, GH, Jobsen, JJ, van Dalen, T, Linn, SC, et.al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study., Lancet Oncol, 2016. 17 (8)(8): p. 1158-1170., https://pubmed.ncbi.nlm.nih.gov/27344114/
470. Christiansen, P, Carstensen, SL, Ejlertsen, B, Kroman, N, Offersen, B, Bodilsen, A, et.al. Breast conserving surgery versus mastectomy: overall and relative survival-a population based study by the Danish Breast Cancer Cooperative Group (DBCG)., Acta Oncol, 2018. 57 (1)(1): p. 19-25., https://pubmed.ncbi.nlm.nih.gov/29168674/
471. de Boniface, J, Szulkin, R, Johansson, ALV, Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women., JAMA Surg, 2021. 156 (7)(7): p. 628-637., https://pubmed.ncbi.nlm.nih.gov/33950173/
472. Hofvind, S, Holen, Å, Aas, T, Roman, M, Sebuødegård, S, Akslen, LA, Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics., Eur J Surg Oncol, 2015. 41 (10)(10): p. 1417-22., https://pubmed.ncbi.nlm.nih.gov/26253193/
473. Gentilini, O., Botteri, E., Rotmensz, N., Da Lima, L., Caliskan, M., Garcia-Etienne, C. A., et.al. Conservative surgery in patients with multifocal/multicentric breast cancer, Breast Cancer Res Treat, 2009. 113(3): p. 577-83., https://www.ncbi.nlm.nih.gov/pubmed/18330695
474. Lynch, S. P., Lei, X., Hsu, L., Meric-Bernstam, F., Buchholz, T. A., Zhang, H., et.al. Breast cancer multifocality and multicentricity and locoregional recurrence, Oncologist, 2013. 18(11): p. 1167-73., https://www.ncbi.nlm.nih.gov/pubmed/24136008
475. Neri, A., Marrelli, D., Megha, T., Bettarini, F., Tacchini, D., De Franco, L., et.al. "Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases", BMC Surg, 2015. 15: p. 1., https://www.ncbi.nlm.nih.gov/pubmed/25586679
476. Patani, N., Carpenter, R., Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer, Breast J, 2010. 16(3): p. 222-32., https://www.ncbi.nlm.nih.gov/pubmed/20565467
477. Shaikh, T., Tam, T. Y., Li, T., Hayes, S. B., Goldstein, L., Bleicher, R., et.al. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type, Breast J, 2015. 21(2): p. 121-6., https://www.ncbi.nlm.nih.gov/pubmed/25597248
478. Tan, M. P., Sitoh, N. Y., Sim, A. S., Breast conservation treatment for multifocal and multicentric breast cancers in women with small-volume breast tissue, ANZ J Surg, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25475622
479. Wolters, R., Wockel, A., Janni, W., Novopashenny, I., Ebner, F., Kreienberg, R., et.al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients, Breast Cancer Res Treat, 2013. 142(3): p. 579-90., https://www.ncbi.nlm.nih.gov/pubmed/24258258
480. Yerushalmi, R., Tyldesley, S., Woods, R., Kennecke, H. F., Speers, C., Gelmon, K. A., Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?, Ann Oncol, 2012. 23(4): p. 876-81., https://www.ncbi.nlm.nih.gov/pubmed/21810730
481. Hennigs, A, Fuchs, V, Sinn, HP, Riedel, F, Rauch, G, Smetanay, K, et.al. Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?, Ann Surg Oncol, 2016. 23 (6)(6): p. 1831-7., https://pubmed.ncbi.nlm.nih.gov/26732272/
482. Chan, BK, Wiseberg-Firtell, JA, Jois, RH, Jensen, K, Audisio, RA, Localization techniques for guided surgical excision of non-palpable breast lesions., Cochrane Database Syst Rev, 2015. 2015 (12)(12): p. CD009206., https://pubmed.ncbi.nlm.nih.gov/26718728/
483. Lin, C, Wang, KY, Chen, HL, Xu, YH, Pan, T, Chen, YD, Specimen mammography for intraoperative margin assessment in breast conserving surgery: a meta-analysis., Sci Rep, 2022. 12 (1)(1): p. 18440., https://pubmed.ncbi.nlm.nih.gov/36323863/
484. Manhoobi, IP, Bodilsen, A, Nijkamp, J, Pareek, A, Tramm, T, Redsted, S, et.al. Diagnostic accuracy of radiography, digital breast tomosynthesis, micro-CT and ultrasound for margin assessment during breast surgery: A systematic review and meta-analysis., Acad Radiol, 2022. 29 (10)(10): p. 1560-1572., https://pubmed.ncbi.nlm.nih.gov/34996687/
485. Bartelink, H., Horiot, J. C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., et.al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 2007. 25(22): p. 3259-65., https://www.ncbi.nlm.nih.gov/pubmed/17577015
486. Koch, CA, Corey, G, Liu, ZA, Han, K, Fyles, A, Partial Breast Irradiation and Surgical Clip Usage for Tumor Bed Delineation After Breast-Conserving Surgery in Canada: A Radiation Oncology Perspective., Adv Radiat Oncol, 2021. 6 (4)(4): p. 100701., https://pubmed.ncbi.nlm.nih.gov/34409206/
487. Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., et.al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 2015. 26(7): p. 1280-91., https://www.ncbi.nlm.nih.gov/pubmed/26019189
488. Schulz-Wendtland, R, Dankerl, P, Bani, MR, Fasching, PA, Heusinger, K, Lux, MP, et.al. Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy., Geburtshilfe Frauenheilkd, 2017. 77 (2)(2): p. 169-175., https://pubmed.ncbi.nlm.nih.gov/28331239/
489. Hoffmann, J., Wallwiener, D., Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients, BMC Cancer, 2009. 9: p. 108., https://www.ncbi.nlm.nih.gov/pubmed/19356240
490. Chatterjee, A, Gass, J, Patel, K, Holmes, D, Kopkash, K, Peiris, L, et.al. A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons., Ann Surg Oncol, 2019. 26 (11)(11): p. 3436-3444., https://pubmed.ncbi.nlm.nih.gov/30977016/
491. Clough, KB, Kaufman, GJ, Nos, C, Buccimazza, I, Sarfati, IM, Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery., Ann Surg Oncol, 2010. 17 (5)(5): p. 1375-91., https://pubmed.ncbi.nlm.nih.gov/20140531/
492. Brackstone, M., Fletcher, G. G., Dayes, I. S., Madarnas, Y., SenGupta, S. K., Verma, S., Locoregional therapy of locally advanced breast cancer: a clinical practice guideline, Curr Oncol, 2014. 22(Suppl 1): p. S54-66., https://www.ncbi.nlm.nih.gov/pubmed/25848339
493. Fisher, B., Anderson, S., Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project, World J Surg, 1994. 18(1): p. 63-9., https://www.ncbi.nlm.nih.gov/pubmed/8197778
494. Voogd, A. C., Nielsen, M., Peterse, J. L., Blichert-Toft, M., Bartelink, H., Overgaard, M., et.al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials, J Clin Oncol, 2001. 19(6): p. 1688-97., https://www.ncbi.nlm.nih.gov/pubmed/11250998
495. De La Cruz, L., Moody, A. M., Tappy, E. E., Blankenship, S. A., Hecht, E. M., Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review, Ann Surg Oncol, 2015. 22(10): p. 3241-9., https://www.ncbi.nlm.nih.gov/pubmed/26242363
496. Endara, M., Chen, D., Verma, K., Nahabedian, M. Y., Spear, S. L., Breast reconstruction following nipple-sparing mastectomy: a systematic review of the literature with pooled analysis, Plast Reconstr Surg, 2013. 132(5): p. 1043-54., https://www.ncbi.nlm.nih.gov/pubmed/23924650
497. Lanitis, S., Tekkis, P. P., Sgourakis, G., Dimopoulos, N., Al Mufti, R., Hadjiminas, D. J., Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies, Ann Surg, 2010. 251(4): p. 632-9., https://www.ncbi.nlm.nih.gov/pubmed/20224371
498. Piper, M., Peled, A. W., Foster, R. D., Moore, D. H., Esserman, L. J., Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications, Ann Plast Surg, 2013. 70(4): p. 435-7., https://www.ncbi.nlm.nih.gov/pubmed/23486127
499. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Nelson, D. O., Clarke, C. A., Gomez, S. L., Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011, Jama, 2014. 312(9): p. 902-14., https://www.ncbi.nlm.nih.gov/pubmed/25182099
500. Dawood, S, Merajver, SD, Viens, P, Vermeulen, PB, Swain, SM, Buchholz, TA, et.al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment., Ann Oncol, 2011. 22 (3)(3): p. 515-523., https://pubmed.ncbi.nlm.nih.gov/20603440/
501. Smith, BL, Tang, R, Rai, U, Plichta, JK, Colwell, AS, Gadd, MA, et.al. Oncologic Safety of Nipple-Sparing Mastectomy in Women with Breast Cancer., J Am Coll Surg, 2017. 225 (3)(3): p. 361-365., https://pubmed.ncbi.nlm.nih.gov/28728962/
502. Colwell, AS, Christensen, JM, Nipple-Sparing Mastectomy and Direct-to-Implant Breast Reconstruction., Plast Reconstr Surg, 2017. 140 (5S Advances in Breast Reconstruction)(5S Advances in Breast Reconstruction): p. 44S-50S., https://pubmed.ncbi.nlm.nih.gov/29064921/
503. Zaborowski, AM, Roe, S, Rothwell, J, Evoy, D, Geraghty, J, McCartan, D, et.al. A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer., J Surg Oncol, 2023. 127 (3)(3): p. 361-368., https://pubmed.ncbi.nlm.nih.gov/36208279/
504. Youn, S, Lee, E, Peiris, L, Olson, D, Lesniak, D, Rajaee, N, Spare the Nipple: A Systematic Review of Tumor Nipple-Distance and Oncologic Outcomes in Nipple-Sparing Mastectomy., Ann Surg Oncol, 2023. 30 (13)(13): p. 8381-8388., https://pubmed.ncbi.nlm.nih.gov/37620525/
505. Mota, BS, Riera, R, Ricci, MD, Barrett, J, de Castria, TB, Atallah, ÁN, et.al. Nipple- and areola-sparing mastectomy for the treatment of breast cancer., Cochrane Database Syst Rev, 2016. 11 (11)(11): p. CD008932., https://pubmed.ncbi.nlm.nih.gov/27898991/
506. Mota, BS, Bevilacqua, JLB, Barrett, J, Ricci, MD, Munhoz, AM, Filassi, JR, et.al. Skin-sparing mastectomy for the treatment of breast cancer., Cochrane Database Syst Rev, 2023. 3 (3)(3): p. CD010993., https://pubmed.ncbi.nlm.nih.gov/36972145/
507. Copson, ER, Maishman, TC, Tapper, WJ, Cutress, RI, Greville-Heygate, S, Altman, DG, et.al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study., Lancet Oncol, 2018. 19 (2)(2): p. 169-180., https://pubmed.ncbi.nlm.nih.gov/29337092/
508. Lambertini M, Sonnenblick A, Agostinetto E et al., BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing SurgerySan Antonio Breast Cancer Symposium, 2024.
509. Potter, S., Brigic, A., Whiting, P. F., Cawthorn, S. J., Avery, K. N., Donovan, J. L., et.al. Reporting clinical outcomes of breast reconstruction: a systematic review, J Natl Cancer Inst, 2011. 103(1): p. 31-46., https://www.ncbi.nlm.nih.gov/pubmed/21131574
510. Seabrook, M, Navas, AS, Rao, A, Meta-analysis and systematic review of long-term oncological safety of immediate breast reconstruction in patients with locally advanced breast cancer., J Plast Reconstr Aesthet Surg, 2025. 100 (): p. 45-54., https://pubmed.ncbi.nlm.nih.gov/39602924/
511. Bargon, CA, Young-Afat, DA, Ikinci, M, Braakenburg, A, Rakhorst, HA, Mureau, MAM, et.al. Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction-A systematic review and meta-analysis., Cancer, 2022. 128 (19)(19): p. 3449-3469., https://pubmed.ncbi.nlm.nih.gov/35894936/
512. Tukiama, R, Vieira, RAC, Moura, ECR, Oliveira, AGC, Facina, G, Zucca-Matthes, G, et.al. Oncologic safety of breast reconstruction with autologous fat grafting: A systematic review and meta-analysis., Eur J Surg Oncol, 2022. 48 (4)(4): p. 727-735., https://pubmed.ncbi.nlm.nih.gov/34972623/
513. Wang, K, Yu, Z, Rong, X, Tang, J, Dang, J, Li, H, et.al. Meta-Analysis of the Oncological Safety of Autologous Fat Grafting After Breast Cancer on Basic Science and Clinical Studies., Aesthetic Plast Surg, 2023. 47 (4)(4): p. 1245-1257., https://pubmed.ncbi.nlm.nih.gov/36542092/
514. Lo Torto, F, Patanè, L, Abbaticchio, D, Pagnotta, A, Ribuffo, D, Autologous Fat Grafting (AFG): A Systematic Review to Evaluate Oncological Safety in Breast Cancer Patients., J Clin Med, 2024. 13 (15)(15):, https://pubmed.ncbi.nlm.nih.gov/39124636/
515. Kuruvilla, AS, Yan, Y, Rathi, S, Wang, F, Weichman, KE, Ricci, JA, Oncologic Safety in Autologous Fat Grafting After Breast Conservation Therapy: A Systematic Review and Meta-analysis of the Literature., Ann Plast Surg, 2023. 90 (1)(1): p. 106-110., https://pubmed.ncbi.nlm.nih.gov/36534109/
516. Yu, W, Wang, Z, Dai, Y, Zhao, S, Chen, H, Wang, S, et.al. Autologous fat grafting for postoperative breast reconstruction: A systemic review., Regen Ther, 2024. 26 (): p. 1010-1017., https://pubmed.ncbi.nlm.nih.gov/39553540/
517. Sun, Y, Liu, Q, Zhu, J, Hu, H, Lu, L, Ying, J, et.al. Optimal Strategies for Autologous Fat Grafting in Breast Augmentation and Reconstruction: A Systematic Review and Network Meta-Analysis., Plast Reconstr Surg, 2025. 155 (2)(2): p. 243e-255e., https://pubmed.ncbi.nlm.nih.gov/39874946/
518. Zhang, X, Cai, L, Yin, B, Han, X, Li, F, Total breast reconstruction using large-volume condensed and viable fat grafting after mastectomy., J Plast Reconstr Aesthet Surg, 2021. 74 (5)(5): p. 966-973., https://pubmed.ncbi.nlm.nih.gov/33341385/
519. Al Qurashi, AA, Shah Mardan, QNM, Alzahrani, IA, AlAlwan, AQ, Bafail, A, Alaa Adeen, AM, et.al. Efficacy of Exclusive Fat Grafting for Breast Reconstruction: An Updated Systematic Review and Meta-analysis., Aesthetic Plast Surg, 2024. 48 (23)(23): p. 4979-4985., https://pubmed.ncbi.nlm.nih.gov/38772941/
520. Goncalves, R, Mota, BS, Sobreira-Lima, B, Ricci, MD, Soares, JM, Munhoz, AM, et.al. The oncological safety of autologous fat grafting: a systematic review and meta-analysis., BMC Cancer, 2022. 22 (1)(1): p. 391., https://pubmed.ncbi.nlm.nih.gov/35410265/
521. Li, M, Shi, Y, Li, Q, Guo, X, Han, X, Li, F, Oncological Safety of Autologous Fat Grafting in Breast Reconstruction: A Meta-analysis Based on Matched Cohort Studies., Aesthetic Plast Surg, 2022. 46 (3)(3): p. 1189-1200., https://pubmed.ncbi.nlm.nih.gov/34981157/
522. Calabrese, C, Distante, V, Orzalesi, L, Immediate reconstruction with mammaplasty in conservative breast cancer treatment: Long-term results. Focus Rec Breast Cancer Surg, Osp Ital Chir, 2001. 7: p. 38-46.
523. Lee, KT, Mun, GH, Prosthetic breast reconstruction in previously irradiated breasts: A meta-analysis., J Surg Oncol, 2015. 112 (5)(5): p. 468-75., https://pubmed.ncbi.nlm.nih.gov/26374273/
524. Zugasti, A, Hontanilla, B, The Impact of Adjuvant Radiotherapy on Immediate Implant-based Breast Reconstruction Surgical and Satisfaction Outcomes: A Systematic Review and Meta-analysis., Plast Reconstr Surg Glob Open, 2021. 9 (11)(11): p. e3910., https://pubmed.ncbi.nlm.nih.gov/34765389/
525. Awadeen, A, Fareed, M, Elameen, AM, The Impact of Postmastectomy Radiation Therapy on the Outcomes of Prepectoral Implant-Based Breast Reconstruction: A Systematic Review and Meta-Analysis., Aesthetic Plast Surg, 2023. 47 (1)(1): p. 81-91., https://pubmed.ncbi.nlm.nih.gov/35879475/
526. Kroll, S. S., Khoo, A., Singletary, S. E., Ames, F. C., Wang, B. G., Reece, G. P., et.al. Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up, Plast Reconstr Surg, 1999. 104(2): p. 421-5., https://www.ncbi.nlm.nih.gov/pubmed/10654685
527. Bohmert, H., Gabka, CJ., Plastic and reconstructive surgery of the breast, Thieme.
528. Plastische ChirurgieKrupp, S., 1994.
529. Magill, LJ, Robertson, FP, Jell, G, Mosahebi, A, Keshtgar, M, Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients undergoing one- and two-stage implant-based breast reconstruction: A systematic review and meta-analysis., J Plast Reconstr Aesthet Surg, 2017. 70 (10)(10): p. 1329-1335., https://pubmed.ncbi.nlm.nih.gov/28743588/
530. Kuruvilla, AS, Gopman, JM, Cham, S, Henderson, PW, Nipple-areolar tattoo: Comprehensive review of history, theory, technique, and outcomes., J Plast Reconstr Aesthet Surg, 2022. 75 (2)(2): p. 544-549., https://pubmed.ncbi.nlm.nih.gov/34728157/
531. Hammond, JB, Teven, CM, Bernard, RW, Lucas, HD, Casey, WJ, Siebeneck, ET, et.al. 3D Nipple-Areolar Tattoo: It's Technique, Outcomes, and Utilization., Aesthetic Plast Surg, 2021. 45 (2)(2): p. 453-458., https://pubmed.ncbi.nlm.nih.gov/32968821/
532. Rice, M, Colavitti, G, Jackson, P, Wilson, S, Nipple Areola Complex Reconstruction: An 8-Year Experience With Modified Technique and Systematic Review., Eplasty, 2024. 24 (): p. e36., https://pubmed.ncbi.nlm.nih.gov/39224406/
533. Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., et.al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 2010. 11(10): p. 927-33., https://www.ncbi.nlm.nih.gov/pubmed/20863759
534. Brackstone, M, Baldassarre, FG, Perera, FE, Cil, T, Chavez Mac Gregor, M, Dayes, IS, et.al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline., J Clin Oncol, 2021. 39 (27)(27): p. 3056-3082., https://pubmed.ncbi.nlm.nih.gov/34279999/
535. Gentilini, OD, Botteri, E, Sangalli, C, Galimberti, V, Porpiglia, M, Agresti, R, et.al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial., JAMA Oncol, 2023. 9 (11)(11): p. 1557-1564., https://pubmed.ncbi.nlm.nih.gov/37733364/
536. Reimer, T, Stachs, A, Veselinovic, K, Kühn, T, Heil, J, Polata, S, et.al. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial., N Engl J Med, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39665649/
537. Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., et.al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, Jama, 2011. 305(6): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/21304082
538. Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., et.al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial, Lancet Oncol, 2013. 14(4): p. 297-305., https://www.ncbi.nlm.nih.gov/pubmed/23491275
539. Tinterri, C, Gentile, D, Gatzemeier, W, Sagona, A, Barbieri, E, Testori, A, et.al. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial., Ann Surg Oncol, 2022. 29 (9)(9): p. 5732-5744., https://pubmed.ncbi.nlm.nih.gov/35552930/
540. de Boniface, J, Filtenborg Tvedskov, T, Rydén, L, Szulkin, R, Reimer, T, Kühn, T, et.al. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases., N Engl J Med, 2024. 390 (13)(13): p. 1163-1175., https://pubmed.ncbi.nlm.nih.gov/38598571/
541. Giuliano, AE, Ballman, KV, McCall, L, Beitsch, PD, Brennan, MB, Kelemen, PR, et.al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial., JAMA, 2017. 318 (10)(10): p. 918-926., https://pubmed.ncbi.nlm.nih.gov/28898379/
542. Hortobagyi, GN, Lacko, A, Sohn, J, Cruz, F, Ruiz Borrego, M, Manikhas, A, et.al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial., Ann Oncol, 2025. 36 (2)(2): p. 149-157., https://pubmed.ncbi.nlm.nih.gov/39442617/
543. Johnston, SRD, Toi, M, O'Shaughnessy, J, Rastogi, P, Campone, M, Neven, P, et.al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial., Lancet Oncol, 2023. 24 (1)(1): p. 77-90., https://pubmed.ncbi.nlm.nih.gov/36493792/
544. Galimberti, V, Cole, BF, Viale, G, Veronesi, P, Vicini, E, Intra, M, et.al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial., Lancet Oncol, 2018. 19 (10)(10): p. 1385-1393., https://pubmed.ncbi.nlm.nih.gov/30196031/
545. Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., et.al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, Jama, 2011. 305(6): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/21304082
546. Giuliano, A. E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., et.al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial, Ann Surg, 2016. 264(3): p. 413-20., https://www.ncbi.nlm.nih.gov/pubmed/27513155
547. Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J., Mansel, R. E., et.al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 2014. 15(12): p. 1303-10., https://www.ncbi.nlm.nih.gov/pubmed/25439688
548. Zarifmahmoudi, L, Aghaee, A, Treglia, G, Sadeghi, R, Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients., Breast Cancer, 2022. 29 (1)(1): p. 50-64., https://pubmed.ncbi.nlm.nih.gov/34341902/
549. Classe, JM, Loaec, C, Gimbergues, P, Alran, S, de Lara, CT, Dupre, PF, et.al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study., Breast Cancer Res Treat, 2019. 173 (2)(2): p. 343-352., https://pubmed.ncbi.nlm.nih.gov/30343457/
550. Kuehn, Thorsten, Bauerfeind, Ingo, Fehm, Tanja, Fleige, Barbara, Hausschild, Maik, Helms, Gisela, et.al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, The lancet oncology, 2013. 14(7): p. 609-618., https://www.ncbi.nlm.nih.gov/pubmed/15611971
551. Boughey, J. C., Suman, V. J., Mittendorf, E. A., Ahrendt, G. M., Wilke, L. G., Taback, B., et.al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial, Jama, 2013. 310(14): p. 1455-61., https://www.ncbi.nlm.nih.gov/pubmed/24101169
552. Hartmann, S, Kühn, T, Hauptmann, M, Stickeler, E, Thill, M, Lux, MP, et.al. Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study., Geburtshilfe Frauenheilkd, 2022. 82 (9)(9): p. 932-940., https://pubmed.ncbi.nlm.nih.gov/36110892/
553. Banys-Paluchowski, M, Gasparri, ML, de Boniface, J, Gentilini, O, Stickeler, E, Hartmann, S, et.al. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study., Cancers (Basel), 2021. 13 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/33805367/
554. Simons, JM, van Nijnatten, TJA, van der Pol, CC, van Diest, PJ, Jager, A, van Klaveren, D, et.al. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer., JAMA Surg, 2022. 157 (11)(11): p. 991-999., https://pubmed.ncbi.nlm.nih.gov/36069889/
555. Kuemmel, S, Heil, J, Bruzas, S, Breit, E, Schindowski, D, Harrach, H, et.al. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer., JAMA Surg, 2023. 158 (8)(8): p. 807-815., https://pubmed.ncbi.nlm.nih.gov/37285140/
556. Cabioglu, N, Karanlik, H, Igci, A, Muslumanoglu, M, Gulcelik, MA, Uras, C, et.al. Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03., Ann Surg Oncol, 2025. 32 (2)(2): p. 952-966., https://pubmed.ncbi.nlm.nih.gov/39623189/
557. Montagna, G, Mrdutt, MM, Sun, SX, Hlavin, C, Diego, EJ, Wong, SM, et.al. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy., JAMA Oncol, 2024. 10 (6)(6): p. 793-798., https://pubmed.ncbi.nlm.nih.gov/38662396/
558. Montagna, G, Laws, A, Ferrucci, M, Mrdutt, MM, Sun, SX, Bademler, S, et.al. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study., J Clin Oncol, 2024. 43 (7)(7): p. JCO2401052., https://pubmed.ncbi.nlm.nih.gov/39509672/
559. Lee, A. H., Anderson, N., Carder, P., Cooke, J., Deb, R., Ellis, I. O., et.al. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. G 150The Royal College of Pathologists, 2016. p. 1-74., https://www.researchgate.net/publication/339146516_Guidelines_for_non-operative_diagnostic_procedures_and_reporting_in_breast_cancer_screening_February_2017_Royal_College_of_Pathologists_Publication_G150
560. Ellis, I, Webster, F, Allison, KH, Dang, C, Gobbi, H, Kulka, J, et.al. Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR)., Histopathology, 2024. 85 (3)(3): p. 418-436., https://pubmed.ncbi.nlm.nih.gov/38719547/
561. Bossuyt, V, Provenzano, E, Symmans, WF, Webster, F, Allison, KH, Dang, C, et.al. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)., Histopathology, 2024. 84 (7)(7): p. 1111-1129., https://pubmed.ncbi.nlm.nih.gov/38443320/
562. Cserni, G, Brogi, E, Cody, HS, Deb, R, Farshid, G, O'Toole, S, et.al. Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting., Arch Pathol Lab Med, 2022. 146 (11)(11): p. 1308-1318., https://pubmed.ncbi.nlm.nih.gov/36270029/
563. Wolff, AC, Somerfield, MR, Dowsett, M, Hammond, MEH, Hayes, DF, McShane, LM, et.al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update., J Clin Oncol, 2023. 41 (22)(22): p. 3867-3872., https://pubmed.ncbi.nlm.nih.gov/37284804/
564. Denduluri, N, Somerfield, MR, Chavez-MacGregor, M, Comander, AH, Dayao, Z, Eisen, A, et.al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update., J Clin Oncol, 2021. 39 (6)(6): p. 685-693., https://pubmed.ncbi.nlm.nih.gov/33079579/
565. Wolff, AC, Hammond, MEH, Allison, KH, Harvey, BE, Mangu, PB, Bartlett, JMS, et.al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update., J Clin Oncol, 2018. 36 (20)(20): p. 2105-2122., https://pubmed.ncbi.nlm.nih.gov/29846122/
566. Allison, KH, Hammond, MEH, Dowsett, M, McKernin, SE, Carey, LA, Fitzgibbons, PL, et.al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update., J Clin Oncol, 2020. 38 (12)(12): p. 1346-1366., https://pubmed.ncbi.nlm.nih.gov/31928404/
567. Andre, F, Ismaila, N, Allison, KH, Barlow, WE, Collyar, DE, Damodaran, S, et.al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update., J Clin Oncol, 2022. 40 (16)(16): p. 1816-1837., https://pubmed.ncbi.nlm.nih.gov/35439025/
568. Henry, NL, Somerfield, MR, Dayao, Z, Elias, A, Kalinsky, K, McShane, LM, et.al. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update., J Clin Oncol, 2022. 40 (27)(27): p. 3205-3221., https://pubmed.ncbi.nlm.nih.gov/35759724/
569. Cserni, G., Amendoeira, I., Apostolikas, N., Bellocq, J. P., Bianchi, S., Bussolati, G., et.al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines, Eur J Cancer, 2003. 39(12): p. 1654-67., https://www.ncbi.nlm.nih.gov/pubmed/12888359
570. Langer, I., Guller, U., Berclaz, G., Koechli, O. R., Moch, H., Schaer, G., et.al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study, Breast Cancer Res Treat, 2009. 113(1): p. 129-36., https://www.ncbi.nlm.nih.gov/pubmed/18297394
571. Radi, MJ, Calcium oxalate crystals in breast biopsies. An overlooked form of microcalcification associated with benign breast disease., Arch Pathol Lab Med, 1989. 113 (12)(12): p. 1367-9., https://pubmed.ncbi.nlm.nih.gov/2589947/
572. Ellis, IO, Rakha, EA, Tse, GM, Tan, PH, An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative., Histopathology, 2023. 82 (1)(1): p. 189-197., https://pubmed.ncbi.nlm.nih.gov/36482273/
573. Elston, C. W., Ellis, I. O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 1991. 19(5): p. 403-10., https://www.ncbi.nlm.nih.gov/pubmed/1757079
574. Brierley, James, Gospodarowicz, M. K., Wittekind, Ch (Hrsg.), TNM classification of malignant tumoursJohn Wiley & Sons, Inc., 2017.
575. Faragalla, H, Plotkin, A, Barnes, P, Lu, FI, Kos, Z, Mulligan, AM, et.al. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force., Curr Oncol, 2023. 30 (3)(3): p. 3079-3090., https://pubmed.ncbi.nlm.nih.gov/36975446/
576. Nielsen, TO, Leung, SCY, Rimm, DL, Dodson, A, Acs, B, Badve, S, et.al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group., J Natl Cancer Inst, 2021. 113 (7)(7): p. 808-819., https://pubmed.ncbi.nlm.nih.gov/33369635/
577. NICE, Early and locally advanced breast cancer: diagnosis and treatment. CG80National Institute for Health and Care Excellence (NICE), 2009 (last update 2017). p. 1-26., nice.org.uk/guidance/cg80
578. Brierley, James D. (Editor); , Giuliani Meredith (Editor); , O'Sullivan, Brian (Editor);, Rous, Brian (Editor);, Van Eycken, Elizabeth (Editor), TNM Classification of Malignant Tumours, 9th Edition, 2025.
579. Burstein, HJ, DeMichele, A, Fallowfield, L, Somerfield, MR, Henry, NL, Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update., J Clin Oncol, 2024. 42 (12)(12): p. 1450-1453., https://pubmed.ncbi.nlm.nih.gov/38478799/
580. Burstein, HJ, DeMichele, A, Somerfield, MR, Henry, NL, Testing for , J Clin Oncol, 2023. 41 (18)(18): p. 3423-3425., https://pubmed.ncbi.nlm.nih.gov/37196213/
581. Gennari, A, André, F, Barrios, CH, Cortés, J, de Azambuja, E, DeMichele, A, et.al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer., Ann Oncol, 2021. 32 (12)(12): p. 1475-1495., https://pubmed.ncbi.nlm.nih.gov/34678411/
582. Yeung, C, Hilton, J, Clemons, M, Mazzarello, S, Hutton, B, Haggar, F, et.al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review., Cancer Metastasis Rev, 2016. 35 (3)(3): p. 427-37., https://pubmed.ncbi.nlm.nih.gov/27405651/
583. Schrijver, WAME, Suijkerbuijk, KPM, van Gils, CH, van der Wall, E, Moelans, CB, van Diest, PJ, Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis., J Natl Cancer Inst, 2018. 110 (6)(6): p. 568-580., https://pubmed.ncbi.nlm.nih.gov/29315431/
584. Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., et.al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 2013. 31(31): p. 3997-4013., https://www.ncbi.nlm.nih.gov/pubmed/24101045
585. Nothacker, M., Lelgemann, M., Giersiepen, K., S, Weinbrenner, Evidenzbericht 2007 zur S3-Leitlinie Brustkrebsfrüherkennung in Deutschland.Ärztliches Zentrum für Qualität in der der Medizin (ÄZQ), 2007. p. 1-281., https://register.awmf.org/assets/guidelines/077-001_S3_Brustkrebs-Frueherkennung_evidenz_02-2008_02-2011.pdf
586. Wolff, A. C., Hammond, M. E., Hicks, D. G., Allison, K. H., Bartlett, J. M., Bilous, M., et.al. Reply to E.A. Rakha et al, J Clin Oncol, 2015. 33(11): p. 1302-4., https://www.ncbi.nlm.nih.gov/pubmed/25753441
587. Rüschoff, J., Lebeau, A., Kreipe, H., Sinn, P., Gerharz, C. D., Koch, W., et.al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany, Mod Pathol, 2017. 30(2): p. 217-226., https://www.ncbi.nlm.nih.gov/pubmed/27767099
588. Acs, B, Leung, SCY, Kidwell, KM, Arun, I, Augulis, R, Badve, SS, et.al. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study., Mod Pathol, 2022. 35 (10)(10): p. 1362-1369., https://pubmed.ncbi.nlm.nih.gov/35729220/
589. Cortes, J, Cescon, DW, Rugo, HS, Nowecki, Z, Im, SA, Yusof, MM, et.al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial., Lancet, 2020. 396 (10265)(10265): p. 1817-1828., https://pubmed.ncbi.nlm.nih.gov/33278935/
590. Schmid, P, Adams, S, Rugo, HS, Schneeweiss, A, Barrios, CH, Iwata, H, et.al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer., N Engl J Med, 2018. 379 (22)(22): p. 2108-2121., https://pubmed.ncbi.nlm.nih.gov/30345906/
591. Lebeau, A., Turzynski, A., Braun, S., Behrhof, W., Fleige, B., Schmitt, W. D., et.al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies, J Clin Oncol, 2010. 28(20): p. 3264-70., https://www.ncbi.nlm.nih.gov/pubmed/20498397
592. NZGG, Management of Early Breast CancerNew Zealand Guidelines Group (NZGG), Evidence-based Best Practice Guideline, 2009. p. 1-255., http://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf
593. Bundred, N. J., Prognostic and predictive factors in breast cancer, Cancer Treat Rev, 2001. 27(3): p. 137-42., https://www.ncbi.nlm.nih.gov/pubmed/11417963
594. Carter, C. L., Allen, C., Henson, D. E., Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 1989. 63(1): p. 181-7., https://www.ncbi.nlm.nih.gov/pubmed/2910416
595. Page, D. L., Jensen, R. A., Simpson, J. F., Routinely available indicators of prognosis in breast cancer, Breast Cancer Res Treat, 1998. 51(3): p. 195-208., https://www.ncbi.nlm.nih.gov/pubmed/10068079
596. Page, D. L., Rogers, L. W., Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia, Hum Pathol, 1992. 23(10): p. 1095-7., https://www.ncbi.nlm.nih.gov/pubmed/1328030
597. Rakha, E. A., Agarwal, D., Green, A. R., Ashankyty, I., Ellis, I. O., Ball, G., et.al. Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer, Histopathology, 2017. 70(4): p. 622-631., https://www.ncbi.nlm.nih.gov/pubmed/27782306
598. Rosen, P. P., Groshen, S., Kinne, D. W., Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study, J Clin Oncol, 1991. 9(9): p. 1650-61., https://www.ncbi.nlm.nih.gov/pubmed/1875222
599. Rosen, P. P., Groshen, S., Kinne, D. W., Norton, L., Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up, J Clin Oncol, 1993. 11(11): p. 2090-100., https://www.ncbi.nlm.nih.gov/pubmed/8229123
600. NICE, Early and locally advanced breast cancer: diagnosis and treatment. CG80National Institute for Health and Care Excellence (NICE), 2009 (last update 2017). p. 1-26., nice.org.uk/guidance/cg80
601. Fisher, E. R., Redmond, C., Fisher, B., Bass, G., Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients, Cancer, 1990. 65(9 Suppl): p. 2121-8., https://www.ncbi.nlm.nih.gov/pubmed/2328478
602. Elston, C. W., Ellis, I. O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 1991. 19(5): p. 403-10., https://www.ncbi.nlm.nih.gov/pubmed/1757079
603. Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., et.al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment, J Clin Oncol, 2016. 34(20): p. 2341-9., https://www.ncbi.nlm.nih.gov/pubmed/26926676
604. Rakha, E. A., El-Sayed, M. E., Lee, A. H., Elston, C. W., Grainge, M. J., Hodi, Z., et.al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma, J Clin Oncol, 2008. 26(19): p. 3153-8., https://www.ncbi.nlm.nih.gov/pubmed/18490649
605. Schwartz, Arnold M., Henson, Donald Earl, Chen, Dechang, Rajamarthandan, Sivasankari, Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161 708 Cases of Breast Cancer From the SEER Program, Archives of Pathology & Laboratory Medicine, 2014. 138(8): p. 1048-1052., https://www.ncbi.nlm.nih.gov/pubmed/25076293
606. Schwartz, Arnold M., Henson, Donald Earl, Chen, Dechang, Rajamarthandan, Sivasankari, Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161 708 Cases of Breast Cancer From the SEER Program, Archives of Pathology & Laboratory Medicine, 2014. 138(8): p. 1048-1052., https://www.ncbi.nlm.nih.gov/pubmed/25076293
607. Gujam, F. J., Going, J. J., Edwards, J., Mohammed, Z. M., McMillan, D. C., The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Crit Rev Oncol Hematol, 2014. 89(2): p. 231-41., https://www.ncbi.nlm.nih.gov/pubmed/24075309
608. Rakha, E. A., Martin, S., Lee, A. H., Morgan, D., Pharoah, P. D., Hodi, Z., et.al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma, Cancer, 2012. 118(15): p. 3670-80., https://www.ncbi.nlm.nih.gov/pubmed/22180017
609. Colleoni, M., Rotmensz, N., Maisonneuve, P., Sonzogni, A., Pruneri, G., Casadio, C., et.al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer, Ann Oncol, 2007. 18(10): p. 1632-40., https://www.ncbi.nlm.nih.gov/pubmed/17716986
610. Colleoni, M., Rotmensz, N., Maisonneuve, P., Sonzogni, A., Pruneri, G., Casadio, C., et.al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer, Ann Oncol, 2007. 18(10): p. 1632-40., https://www.ncbi.nlm.nih.gov/pubmed/17716986
611. Gujam, F. J., Going, J. J., Edwards, J., Mohammed, Z. M., McMillan, D. C., The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Crit Rev Oncol Hematol, 2014. 89(2): p. 231-41., https://www.ncbi.nlm.nih.gov/pubmed/24075309
612. Lin, Y, Zhang, Y, Fang, H, Hu, Q, Duan, H, Zhang, L, et.al. Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis., Jpn J Clin Oncol, 2023. 53 (1)(1): p. 35-45., https://pubmed.ncbi.nlm.nih.gov/36156086/
613. Zhong, YM, Tong, F, Shen, J, Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis., BMC Cancer, 2022. 22 (1)(1): p. 102., https://pubmed.ncbi.nlm.nih.gov/35073848/
614. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et.al. Molecular portraits of human breast tumours, Nature, 2000. 406(6797): p. 747-52., https://www.ncbi.nlm.nih.gov/pubmed/10963602
615. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et.al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 2001. 98(19): p. 10869-74., https://www.ncbi.nlm.nih.gov/pubmed/11553815
616. Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., et.al. Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 2009. 27(8): p. 1160-7., https://www.ncbi.nlm.nih.gov/pubmed/19204204
617. Sestak, I, Buus, R, Cuzick, J, Dubsky, P, Kronenwett, R, Denkert, C, et.al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial., JAMA Oncol, 2018. 4 (4)(4): p. 545-553., https://pubmed.ncbi.nlm.nih.gov/29450494/
618. Sestak, I, Buus, R, Cuzick, J, Dubsky, P, Kronenwett, R, Ferree, S, et.al. Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC, Cancer Research, 2017. 77(4 Supplement): p. S6-05-S6-05.
619. Sestak, I, Cuzick, J, Dowsett, M, Lopez-Knowles, E, Filipits, M, Dubsky, P, et.al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score., J Clin Oncol, 2015. 33 (8)(8): p. 916-22., https://pubmed.ncbi.nlm.nih.gov/25332252/
620. Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., Carey, L. A., Perou, C. M., Molecular characterization of basal-like and non-basal-like triple-negative breast cancer, Oncologist, 2013. 18(2): p. 123-33., https://www.ncbi.nlm.nih.gov/pubmed/23404817
621. Sinn, HP, Varga, Z, [Triple-negative breast cancer : Classification, current concepts, and therapy-related factors]., Pathologie (Heidelb), 2023. 44 (1)(1): p. 32-38., https://pubmed.ncbi.nlm.nih.gov/36595080/
622. Petrelli, F., Viale, G., Cabiddu, M., Barni, S., Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients, Breast Cancer Res Treat, 2015. 153(3): p. 477-91., https://www.ncbi.nlm.nih.gov/pubmed/26341751
623. Nitz, U., Gluz, O., Huober, J., Kreipe, H. H., Kates, R. E., Hartmann, A., et.al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression, Ann Oncol, 2014. 25(8): p. 1551-7., https://www.ncbi.nlm.nih.gov/pubmed/24827128
624. Nitz, U, Gluz, O, Huober, J, Kreipe, HH, Kates, RE, Hartmann, A, et.al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression., Ann Oncol, 2017. 28 (11)(11): p. 2899., https://pubmed.ncbi.nlm.nih.gov/27634692/
625. Sonnenblick, A., Francis, P. A., Azim, H. A., Jr., de Azambuja, E., Nordenskjold, B., Gutierez, J., et.al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer, Eur J Cancer, 2015. 51(12): p. 1481-9., https://www.ncbi.nlm.nih.gov/pubmed/26074397
626. Petrelli, F., Viale, G., Cabiddu, M., Barni, S., Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients, Breast Cancer Res Treat, 2015. 153(3): p. 477-91., https://www.ncbi.nlm.nih.gov/pubmed/26341751
627. Nitz, U., Gluz, O., Huober, J., Kreipe, H. H., Kates, R. E., Hartmann, A., et.al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression, Ann Oncol, 2014. 25(8): p. 1551-7., https://www.ncbi.nlm.nih.gov/pubmed/24827128
628. Denkert, C., Budczies, J., von Minckwitz, G., Wienert, S., Loibl, S., Klauschen, F., Strategies for developing Ki67 as a useful biomarker in breast cancer, Breast, 2015. 24 Suppl 2: p. S67-72., https://www.ncbi.nlm.nih.gov/pubmed/26283598
629. Inwald, E. C., Klinkhammer-Schalke, M., Hofstadter, F., Zeman, F., Koller, M., Gerstenhauer, M., et.al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry, Breast Cancer Res Treat, 2013. 139(2): p. 539-52., https://www.ncbi.nlm.nih.gov/pubmed/23674192
630. Dowsett, M, Smith, IE, Ebbs, SR, Dixon, JM, Skene, A, A'Hern, R, et.al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer., J Natl Cancer Inst, 2007. 99 (2)(2): p. 167-70., https://pubmed.ncbi.nlm.nih.gov/17228000/
631. Smith, I, Robertson, J, Kilburn, L, Wilcox, M, Evans, A, Holcombe, C, et.al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial., Lancet Oncol, 2020. 21 (11)(11): p. 1443-1454., https://pubmed.ncbi.nlm.nih.gov/33152284/
632. Nitz, UA, Gluz, O, Kümmel, S, Christgen, M, Braun, M, Aktas, B, et.al. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer., J Clin Oncol, 2022. 40 (23)(23): p. 2557-2567., https://pubmed.ncbi.nlm.nih.gov/35404683/
633. Smith, I, Robertson, J, Kilburn, L, Wilcox, M, Evans, A, Holcombe, C, et.al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial., Lancet Oncol, 2020. 21 (11)(11): p. 1443-1454., https://pubmed.ncbi.nlm.nih.gov/33152284/
634. Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., et.al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2016. 34(10): p. 1134-50., https://www.ncbi.nlm.nih.gov/pubmed/26858339
635. Buus, R., Sestak, I., Kronenwett, R., Denkert, C., Dubsky, P., Krappmann, K., et.al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy, J Natl Cancer Inst, 2016. 108(11):, https://www.ncbi.nlm.nih.gov/pubmed/27400969
636. Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., et.al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer, N Engl J Med, 2016. 375(8): p. 717-29., https://www.ncbi.nlm.nih.gov/pubmed/27557300
637. Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., et.al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, 2015. 373(21): p. 2005-14., https://www.ncbi.nlm.nih.gov/pubmed/26412349
638. NICE, Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, 2024.
639. Early Breast Cancer Trialists' Collaborative, Group, Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., et.al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 2012. 379(9814): p. 432-44., https://www.ncbi.nlm.nih.gov/pubmed/22152853
640. Sparano, JA, Gray, RJ, Makower, DF, Pritchard, KI, Albain, KS, Hayes, DF, et.al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer., N Engl J Med, 2018. 379 (2)(2): p. 111-121., https://pubmed.ncbi.nlm.nih.gov/29860917/
641. Kalinsky, K, Barlow, WE, Gralow, JR, Meric-Bernstam, F, Albain, KS, Hayes, DF, et.al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer., N Engl J Med, 2021. 385 (25)(25): p. 2336-2347., https://pubmed.ncbi.nlm.nih.gov/34914339/
642. Nielsen, T, Wallden, B, Schaper, C, Ferree, S, Liu, S, Gao, D, et.al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens., BMC Cancer, 2014. 14 (): p. 177., https://pubmed.ncbi.nlm.nih.gov/24625003/
643. Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., et.al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors, Clin Cancer Res, 2011. 17(18): p. 6012-20., https://www.ncbi.nlm.nih.gov/pubmed/21807638
644. Nitz, UA, Gluz, O, Kümmel, S, Christgen, M, Braun, M, Aktas, B, et.al. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer., J Clin Oncol, 2022. 40 (23)(23): p. 2557-2567., https://pubmed.ncbi.nlm.nih.gov/35404683/
645. Gnant, M., Filipits, M., Greil, R., Stoeger, H., Rudas, M., Bago-Horvath, Z., et.al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone, Ann Oncol, 2014. 25(2): p. 339-45., https://www.ncbi.nlm.nih.gov/pubmed/24347518
646. Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., et.al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer, Ann Oncol, 2013. 24(3): p. 640-7., https://www.ncbi.nlm.nih.gov/pubmed/23035151
647. Lænkholm, AV, Jensen, MB, Eriksen, JO, Rasmussen, BB, Knoop, AS, Buckingham, W, et.al. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer., J Clin Oncol, 2018. 36 (8)(8): p. 735-740., https://pubmed.ncbi.nlm.nih.gov/29369732/
648. Nitz, U, Gluz, O, Christgen, M, Kates, RE, Clemens, M, Malter, W, et.al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial., Breast Cancer Res Treat, 2017. 165 (3)(3): p. 573-583., https://pubmed.ncbi.nlm.nih.gov/28664507/
649. Sparano, JA, Crager, M, Gray, RJ, Tang, G, Hoag, J, Baehner, FL, et.al. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival., NEJM Evid, 2024. 3 (8)(8): p. EVIDoa2300267., https://pubmed.ncbi.nlm.nih.gov/39041867/
650. Vallon-Christersson, J, Häkkinen, J, Hegardt, C, Saal, LH, Larsson, C, Ehinger, A, et.al. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series., Sci Rep, 2019. 9 (1)(1): p. 12184., https://pubmed.ncbi.nlm.nih.gov/31434940/
651. Harnan, S, Tappenden, P, Cooper, K, Stevens, J, Bessey, A, Rafia, R, et.al. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis., Health Technol Assess, 2019. 23 (30)(30): p. 1-328., https://pubmed.ncbi.nlm.nih.gov/31264581/
652. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment., Ont Health Technol Assess Ser, 2020. 20 (10)(10): p. 1-234., https://pubmed.ncbi.nlm.nih.gov/32284770/
653. Penault-Llorca, F, Dalenc, F, Chabaud, S, Cottu, P, Allouache, D, Cameron, D, et.al. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial., ESMO Open, 2024. 9 (5)(5): p. 103443., https://pubmed.ncbi.nlm.nih.gov/38692082/
654. Klein, E, Kiechle, M, Josipovic, A, Anders, SI, Noske, A, Mogler, C, et.al. Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer., Breast Cancer Res Treat, 2024. 207 (1)(1): p. 119-127., https://pubmed.ncbi.nlm.nih.gov/38722442/
655. Constantinidou, A, Marcou, Y, Toss, MS, Simmons, T, Bernhisel, R, Hughes, E, et.al. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer., Clin Cancer Res, 2022. 28 (20)(20): p. 4435-4443., https://pubmed.ncbi.nlm.nih.gov/36043530/
656. Jensen, MB, Lænkholm, AV, Nielsen, TO, Eriksen, JO, Wehn, P, Hood, T, et.al. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer., Breast Cancer Res, 2018. 20 (1)(1): p. 79., https://pubmed.ncbi.nlm.nih.gov/30053900/
657. Lopes Cardozo, JMN, Drukker, CA, Rutgers, EJT, Schmidt, MK, Glas, AM, Witteveen, A, et.al. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial., J Clin Oncol, 2022. 40 (12)(12): p. 1335-1345., https://pubmed.ncbi.nlm.nih.gov/35061525/
658. Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., et.al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 2010. 28(16): p. 2784-95., https://www.ncbi.nlm.nih.gov/pubmed/20404251
659. Early Breast Cancer Trialists' Collaborative, Group, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., et.al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 2011. 378(9793): p. 771-84., https://www.ncbi.nlm.nih.gov/pubmed/21802721
660. Freedman, O. C., Fletcher, G. G., Gandhi, S., Mates, M., Dent, S. F., Trudeau, M. E., et.al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline, Curr Oncol, 2015. 22(Suppl 1): p. S95-S113., https://www.ncbi.nlm.nih.gov/pubmed/25848344
661. Early Breast Cancer Trialists' Collaborative, Group, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., et.al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 2011. 378(9793): p. 771-84., https://www.ncbi.nlm.nih.gov/pubmed/21802721
662. Freedman, O. C., Fletcher, G. G., Gandhi, S., Mates, M., Dent, S. F., Trudeau, M. E., et.al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline, Curr Oncol, 2015. 22(Suppl 1): p. S95-S113., https://www.ncbi.nlm.nih.gov/pubmed/25848344
663. Early Breast Cancer Trialists' Collaborative, Group, Ovarian ablation for early breast cancer, Cochrane Database Syst Rev, 2000. p. CD000485., https://pubmed.ncbi.nlm.nih.gov/10908474/
664. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 365(9472): p. 1687-717., https://www.ncbi.nlm.nih.gov/pubmed/15894097
665. Nothacker, M., Lelgemann, M., Giersiepen, K., S, Weinbrenner, Evidenzbericht 2007 zur S3-Leitlinie Brustkrebsfrüherkennung in Deutschland.Ärztliches Zentrum für Qualität in der der Medizin (ÄZQ), 2007. p. 1-281., https://register.awmf.org/assets/guidelines/077-001_S3_Brustkrebs-Frueherkennung_evidenz_02-2008_02-2011.pdf
666. Reddy, SM, Barcenas, CH, Sinha, AK, Hsu, L, Moulder, SL, Tripathy, D, et.al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity., Br J Cancer, 2018. 118 (1)(1): p. 17-23., https://pubmed.ncbi.nlm.nih.gov/29235566/
667. Landmann, A, Farrugia, DJ, Zhu, L, Diego, EJ, Johnson, RR, Soran, A, et.al. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?, Am J Clin Pathol, 2018. 150 (1)(1): p. 34-42., https://pubmed.ncbi.nlm.nih.gov/29741562/
668. Fujii, T, Kogawa, T, Dong, W, Sahin, AA, Moulder, S, Litton, JK, et.al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer., Ann Oncol, 2017. 28 (10)(10): p. 2420-2428., https://pubmed.ncbi.nlm.nih.gov/28961844/
669. Villegas, SL, Nekljudova, V, Pfarr, N, Engel, J, Untch, M, Schrodi, S, et.al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials., Eur J Cancer, 2021. 148 (): p. 159-170., https://pubmed.ncbi.nlm.nih.gov/33743484/
670. Dieci, MV, Griguolo, G, Bottosso, M, Tsvetkova, V, Giorgi, CA, Vernaci, G, et.al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy., NPJ Breast Cancer, 2021. 7 (1)(1): p. 101., https://pubmed.ncbi.nlm.nih.gov/34341356/
671. Poon, IK, Tsang, JY, Li, J, Chan, SK, Shea, KH, Tse, GM, The significance of highlighting the oestrogen receptor low category in breast cancer., Br J Cancer, 2020. 123 (8)(8): p. 1223-1227., https://pubmed.ncbi.nlm.nih.gov/32713939/
672. Rhodes, A, Jasani, B, Balaton, AJ, Barnes, DM, Miller, KD, Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening., J Clin Pathol, 2000. 53 (9)(9): p. 688-96., https://pubmed.ncbi.nlm.nih.gov/11041059/
673. Beltjens, F, Molly, D, Bertaut, A, Richard, C, Desmoulins, I, Loustalot, C, et.al. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer., Int J Cancer, 2021. 149 (1)(1): p. 200-213., https://pubmed.ncbi.nlm.nih.gov/33634878/
674. Rakha, EA, El-Sayed, ME, Green, AR, Paish, EC, Powe, DG, Gee, J, et.al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype., J Clin Oncol, 2007. 25 (30)(30): p. 4772-8., https://pubmed.ncbi.nlm.nih.gov/17876012/
675. Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., Mamounas, E., Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy, Eur J Cancer, 2012. 48(18): p. 3342-54., https://www.ncbi.nlm.nih.gov/pubmed/22766518
676. von Minckwitz, G., Untch, M., Nuesch, E., Loibl, S., Kaufmann, M., Kummel, S., et.al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 2011. 125(1): p. 145-56., https://www.ncbi.nlm.nih.gov/pubmed/21042932
677. Erbes, T, Stickeler, E, Rücker, G, Buroh, S, Asberger, J, Dany, N, et.al. BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis., Clin Breast Cancer, 2016. 16 (4)(4): p. e119-32., https://pubmed.ncbi.nlm.nih.gov/27067040/
678. Li, S, Zhang, Y, Zhang, P, Xue, S, Chen, Y, Sun, L, et.al. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis., Breast, 2022. 66 (): p. 97-109., https://pubmed.ncbi.nlm.nih.gov/36219945/
679. von Minckwitz, G., Untch, M., Nuesch, E., Loibl, S., Kaufmann, M., Kummel, S., et.al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 2011. 125(1): p. 145-56., https://www.ncbi.nlm.nih.gov/pubmed/21042932
680. Xia, G, Zhang, Z, Jiang, Q, Wang, H, Wang, J, Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis., Medicine (Baltimore), 2024. 103 (6)(6): p. e36810., https://pubmed.ncbi.nlm.nih.gov/38335394/
681. Zhang, G, Xie, W, Liu, Z, Lin, C, Piao, Y, Xu, L, et.al. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer., Tumori, 2014. 100 (2)(2): p. 136-42., https://pubmed.ncbi.nlm.nih.gov/24852856/
682. Chen, X, He, C, Han, D, Zhou, M, Wang, Q, Tian, J, et.al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis., Future Oncol, 2017. 13 (9)(9): p. 843-857., https://pubmed.ncbi.nlm.nih.gov/28075166/
683. Chen, L, Wu, F, Chen, X, Chen, Y, Deng, L, Cai, Q, et.al. Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis., NPJ Breast Cancer, 2023. 9 (1)(1): p. 46., https://pubmed.ncbi.nlm.nih.gov/37258524/
684. Tao, M, Chen, S, Zhang, X, Zhou, Q, Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis., Medicine (Baltimore), 2017. 96 (51)(51): p. e9384., https://pubmed.ncbi.nlm.nih.gov/29390540/
685. Wang, H, Zhang, S, Yee, D, Basu, S, Beckwith, H, Potter, D, et.al. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis., Breast Cancer, 2021. 28 (3)(3): p. 618-629., https://pubmed.ncbi.nlm.nih.gov/33387284/
686. Amoroso, V., Generali, D., Buchholz, T., Cristofanilli, M., Pedersini, R., Curigliano, G., et.al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013), J Natl Cancer Inst Monogr, 2015. 2015(51): p. 90-6., https://www.ncbi.nlm.nih.gov/pubmed/26063896
687. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., et.al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 2014. 384(9938): p. 164-72., https://www.ncbi.nlm.nih.gov/pubmed/24529560
688. Berruti, A., Amoroso, V., Gallo, F., Bertaglia, V., Simoncini, E., Pedersini, R., et.al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies, J Clin Oncol, 2014. 32(34): p. 3883-91., https://www.ncbi.nlm.nih.gov/pubmed/25349292
689. Litton, JK, Gonzalez-Angulo, AM, Warneke, CL, Buzdar, AU, Kau, SW, Bondy, M, et.al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer., J Clin Oncol, 2008. 26 (25)(25): p. 4072-7., https://pubmed.ncbi.nlm.nih.gov/18757321/
690. Denkert, C., Loibl, S., Muller, B. M., Eidtmann, H., Schmitt, W. D., Eiermann, W., et.al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial, Ann Oncol, 2013. 24(11): p. 2786-93., https://www.ncbi.nlm.nih.gov/pubmed/23970015
691. Caldarella, A., Crocetti, E., Paci, E., Ki67 in breast cancer: a useful prognostic marker?, Ann Oncol, 2014. 25(2): p. 542., https://www.ncbi.nlm.nih.gov/pubmed/24412822
692. Denkert, C., von Minckwitz, G., Reply to Ki67 in breast cancer: a useful prognostic marker!, Ann Oncol, 2014. 25(2): p. 542-3., https://www.ncbi.nlm.nih.gov/pubmed/24431345
693. Ingold Heppner, B., Untch, M., Denkert, C., Pfitzner, B. M., Lederer, B., Schmitt, W., et.al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer, Clin Cancer Res, 2016. 22(23): p. 5747-5754., https://www.ncbi.nlm.nih.gov/pubmed/27189162
694. Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., et.al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00, Breast Cancer Res Treat, 2016. 158(2): p. 323-31., https://www.ncbi.nlm.nih.gov/pubmed/27372069
695. Wang, K., Xu, J., Zhang, T., Xue, D., Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis, Oncotarget, 2016. 7(28): p. 44288-44298., https://www.ncbi.nlm.nih.gov/pubmed/27329588
696. Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et.al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann Oncol, 2015. 26(2): p. 259-71., https://www.ncbi.nlm.nih.gov/pubmed/25214542
697. Kunkler, IH, Williams, LJ, Jack, WJL, Cameron, DA, Dixon, JM, Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer., N Engl J Med, 2023. 388 (7)(7): p. 585-594., https://pubmed.ncbi.nlm.nih.gov/36791159/
698. Matuschek, C., Bolke, E., Haussmann, J., Mohrmann, S., Nestle-Kramling, C., Gerber, P. A., et.al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials, Radiat Oncol, 2017. 12(1): p. 60., https://www.ncbi.nlm.nih.gov/pubmed/28335784
699. Fastner, G, Sedlmayer, F, Widder, J, Metz, M, Geinitz, H, Kapp, K, et.al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial., Eur J Cancer, 2020. 127 (): p. 12-20., https://pubmed.ncbi.nlm.nih.gov/31962198/
700. Blamey, R. W., Bates, T., Chetty, U., Duffy, S. W., Ellis, I. O., George, D., et.al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial, Eur J Cancer, 2013. 49(10): p. 2294-302., https://www.ncbi.nlm.nih.gov/pubmed/23523089
701. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., et.al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 366(9503): p. 2087-106., https://www.ncbi.nlm.nih.gov/pubmed/16360786
702. Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., et.al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 2011. 378(9804): p. 1707-16., https://www.ncbi.nlm.nih.gov/pubmed/22019144
703. Potter, R., Gnant, M., Kwasny, W., Tausch, C., Handl-Zeller, L., Pakisch, B., et.al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer, Int J Radiat Oncol Biol Phys, 2007. 68(2): p. 334-40., https://www.ncbi.nlm.nih.gov/pubmed/17363187
704. Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., et.al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343, J Clin Oncol, 2013. 31(19): p. 2382-7., https://www.ncbi.nlm.nih.gov/pubmed/23690420
705. Kunkler, I. H., Williams, L. J., Jack, W. J., Cameron, D. A., Dixon, J. M., Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial, Lancet Oncol, 2015. 16(3): p. 266-73., https://www.ncbi.nlm.nih.gov/pubmed/25637340
706. Fyles, Anthony W, McCready, David R, Manchul, Lee A, Trudeau, Maureen E, Merante, Patricia, Pintilie, Melania, et.al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer, New England Journal of Medicine, 2004. 351(10): p. 963-970.
707. Kauer-Dorner, D., Potter, R., Resch, A., Handl-Zeller, L., Kirchheiner, K., Meyer-Schell, K., et.al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial, Radiother Oncol, 2012. 102(1): p. 96-101., https://www.ncbi.nlm.nih.gov/pubmed/21907439
708. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., et.al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005. 366(9503): p. 2087-106., https://www.ncbi.nlm.nih.gov/pubmed/16360786
709. Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., et.al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 2011. 378(9804): p. 1707-16., https://www.ncbi.nlm.nih.gov/pubmed/22019144
710. Hughes, K. S., Schnaper, L. A., Bellon, J. R., Cirrincione, C. T., Berry, D. A., McCormick, B., et.al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343, J Clin Oncol, 2013. 31(19): p. 2382-7., https://www.ncbi.nlm.nih.gov/pubmed/23690420
711. Kunkler, I. H., Williams, L. J., Jack, W. J., Cameron, D. A., Dixon, J. M., Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial, Lancet Oncol, 2015. 16(3): p. 266-73., https://www.ncbi.nlm.nih.gov/pubmed/25637340
712. Fyles, Anthony W, McCready, David R, Manchul, Lee A, Trudeau, Maureen E, Merante, Patricia, Pintilie, Melania, et.al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer, New England Journal of Medicine, 2004. 351(10): p. 963-970.
713. Sedlmayer, F., Sautter-Bihl, M. L., Budach, W., Dunst, J., Fastner, G., Feyer, P., et.al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer, Strahlenther Onkol, 2013. 189(10): p. 825-33., https://www.ncbi.nlm.nih.gov/pubmed/24002382
714. Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., et.al. Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 2013. 368(11): p. 987-98., https://www.ncbi.nlm.nih.gov/pubmed/23484825
715. Poortmans, Philip M, Collette, Sandra, Kirkove, Carine, Van Limbergen, Erik, Budach, Volker, Struikmans, Henk, et.al. Internal mammary and medial supraclavicular irradiation in breast cancer, New England Journal of Medicine, 2015. 373(4): p. 317-327., https://www.ncbi.nlm.nih.gov/pubmed/26200978
716. Thorsen, L. B., Offersen, B. V., Dano, H., Berg, M., Jensen, I., Pedersen, A. N., et.al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer, J Clin Oncol, 2016. 34(4): p. 314-20., https://www.ncbi.nlm.nih.gov/pubmed/26598752
717. Whelan, Timothy J, Olivotto, Ivo A, Parulekar, Wendy R, Ackerman, Ida, Chua, Boon H, Nabid, Abdenour, et.al. Regional nodal irradiation in early-stage breast cancer, New England Journal of Medicine, 2015. 373(4): p. 307-316., https://pubmed.ncbi.nlm.nih.gov/26200977/
718. Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., et.al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831, J Clin Oncol, 2009. 27(16): p. 2638-44., https://www.ncbi.nlm.nih.gov/pubmed/19349549
719. Donovan, E., Bleakley, N., Denholm, E., Evans, P., Gothard, L., Hanson, J., et.al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy, Radiother Oncol, 2007. 82(3): p. 254-64., https://www.ncbi.nlm.nih.gov/pubmed/17224195
720. Mukesh, M. B., Barnett, G. C., Wilkinson, J. S., Moody, A. M., Wilson, C., Dorling, L., et.al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis, J Clin Oncol, 2013. 31(36): p. 4488-95., https://www.ncbi.nlm.nih.gov/pubmed/24043742
721. McCormick, B., Hunt, M., Intensity-modulated radiation therapy for breast: is it for everyone?, Semin Radiat Oncol, 2011. 21(1): p. 51-4., https://www.ncbi.nlm.nih.gov/pubmed/21134654
722. Staffurth, J, A review of the clinical evidence for intensity-modulated radiotherapy, Clinical oncology, 2010. 22(8): p. 643-657., https://www.ncbi.nlm.nih.gov/pubmed/20673708
723. Berrington de Gonzalez, A., Curtis, R. E., Kry, S. F., Gilbert, E., Lamart, S., Berg, C. D., et.al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries, Lancet Oncol, 2011. 12(4): p. 353-60., https://www.ncbi.nlm.nih.gov/pubmed/21454129
724. Wiltink, Lisette M, Nout, Remi A, Fiocco, Marta, Meershoek-Klein Kranenbarg, Elma, Jürgenliemk-Schulz, Ina M, Jobsen, Jan J, et.al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials, Journal of Clinical Oncology, 2014. 33(15): p. 1640-1646., https://pubmed.ncbi.nlm.nih.gov/25534376/
725. Meattini, I, Becherini, C, Boersma, L, Kaidar-Person, O, Marta, GN, Montero, A, et.al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer., Lancet Oncol, 2022. 23 (1)(1): p. e21-e31., https://pubmed.ncbi.nlm.nih.gov/34973228/
726. Krug, D, Baumann, R, Combs, SE, Duma, MN, Dunst, J, Feyer, P, et.al. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward., Strahlenther Onkol, 2021. 197 (4)(4): p. 269-280., https://pubmed.ncbi.nlm.nih.gov/33507331/
727. Wang, SL, Fang, H, Hu, C, Song, YW, Wang, WH, Jin, J, et.al. Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China., J Clin Oncol, 2020. 38 (31)(31): p. 3604-3614., https://pubmed.ncbi.nlm.nih.gov/32780661/
728. Marta, GN, Riera, R, Pacheco, RL, Cabrera Martimbianco, AL, Meattini, I, Kaidar-Person, O, et.al. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials., Breast, 2022. 62 (): p. 84-92., https://pubmed.ncbi.nlm.nih.gov/35131647/
729. Bentzen, S. M., Agrawal, R. K., Aird, E. G., Barrett, J. M., Barrett-Lee, P. J., Bliss, J. M., et.al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet Oncol, 2008. 9(4): p. 331-41., https://www.ncbi.nlm.nih.gov/pubmed/18356109
730. Owen, J. R., Ashton, A., Bliss, J. M., Homewood, J., Harper, C., Hanson, J., et.al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial, Lancet Oncol, 2006. 7(6): p. 467-71., https://www.ncbi.nlm.nih.gov/pubmed/16750496
731. Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., et.al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials, Lancet Oncol, 2013. 14(11): p. 1086-94., https://www.ncbi.nlm.nih.gov/pubmed/24055415
732. Whelan, Timothy J, Pignol, Jean-Philippe, Levine, Mark N, Julian, Jim A, MacKenzie, Robert, Parpia, Sameer, et.al. Long-term results of hypofractionated radiation therapy for breast cancer, New England Journal of Medicine, 2010. 362(6): p. 513-520., https://www.ncbi.nlm.nih.gov/pubmed/20147717
733. Yarnold, J., Ashton, A., Bliss, J., Homewood, J., Harper, C., Hanson, J., et.al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial, Radiother Oncol, 2005. 75(1): p. 9-17., https://www.ncbi.nlm.nih.gov/pubmed/15878095
734. Trialists' Group, The START, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, The Lancet, 2008. 371(9618): p. 1098-1107., https://pubmed.ncbi.nlm.nih.gov/18355913/
735. Shaitelman, S. F., Schlembach, P. J., Arzu, I., Ballo, M., Bloom, E. S., Buchholz, D., et.al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial, JAMA Oncol, 2015. 1(7): p. 931-41., https://www.ncbi.nlm.nih.gov/pubmed/26247543
736. Hickey, BE, James, ML, Lehman, M, Hider, PN, Jeffery, M, Francis, DP, et.al. Fraction size in radiation therapy for breast conservation in early breast cancer., Cochrane Database Syst Rev, 2016. 7 (7)(7): p. CD003860., https://pubmed.ncbi.nlm.nih.gov/27425588/
737. Lee, SF, Kennedy, SKF, Caini, S, Wong, HCY, Yip, PL, Poortmans, PM, et.al. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis., BMJ, 2024. 386 (): p. e079089., https://pubmed.ncbi.nlm.nih.gov/39260879/
738. Wang, SL, Fang, H, Song, YW, Wang, WH, Hu, C, Liu, YP, et.al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial., Lancet Oncol, 2019. 20 (3)(3): p. 352-360., https://pubmed.ncbi.nlm.nih.gov/30711522/
739. Wong, JS, Uno, H, Tramontano, AC, Fisher, L, Pellegrini, CV, Abel, GA, et.al. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial., JAMA Oncol, 2024. 10 (10)(10): p. 1370-1378., https://pubmed.ncbi.nlm.nih.gov/39115975/
740. Poppe, M.M., Le-Rademacher, J., Haffty, B.G., Jr, Hansen, E.K., Agarwal, J., Wagner, J., et.al. A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)Elsevier, International Journal of Radiation Oncology, Biology, Physics, 2024. 120(2): p. S11., https://doi.org/10.1016/j.ijrobp.2024.07.002
741. Murray Brunt, A, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, et.al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial., Lancet, 2020. 395 (10237)(10237): p. 1613-1626., https://pubmed.ncbi.nlm.nih.gov/32580883/
742. Brunt, AM, Haviland, JS, Sydenham, M, Agrawal, RK, Algurafi, H, Alhasso, A, et.al. Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer., J Clin Oncol, 2020. 38 (28)(28): p. 3261-3272., https://pubmed.ncbi.nlm.nih.gov/32663119/
743. Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Bloomfield, DJ, Chan, C, et.al. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT., Health Technol Assess, 2023. 27 (25)(25): p. 1-176., https://pubmed.ncbi.nlm.nih.gov/37991196/
744. Meattini, I, Becherini, C, Boersma, L, Kaidar-Person, O, Marta, GN, Montero, A, et.al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer., Lancet Oncol, 2022. 23 (1)(1): p. e21-e31., https://pubmed.ncbi.nlm.nih.gov/34973228/
745. Krug, D, Baumann, R, Combs, SE, Duma, MN, Dunst, J, Feyer, P, et.al. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward., Strahlenther Onkol, 2021. 197 (4)(4): p. 269-280., https://pubmed.ncbi.nlm.nih.gov/33507331/
746. Vicini, F, Broughman, J, Halima, A, Mayo, Z, Obi, E, Al-Hilli, Z, et.al. Delivery of Adjuvant Radiation in 5 Days or Less After Lumpectomy for Breast Cancer: A Systematic Review., Int J Radiat Oncol Biol Phys, 2022. 112 (5)(5): p. 1090-1104., https://pubmed.ncbi.nlm.nih.gov/34921906/
747. Lai, J, Hu, S, Luo, Y, Zheng, R, Zhu, Q, Chen, P, et.al. Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer., Breast Cancer, 2020. 27 (2)(2): p. 299-307., https://pubmed.ncbi.nlm.nih.gov/31707586/
748. Simonetto, C, Eidemüller, M, Gaasch, A, Pazos, M, Schönecker, S, Reitz, D, et.al. Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy., Radiother Oncol, 2019. 131 (): p. 202-207., https://pubmed.ncbi.nlm.nih.gov/30097250/
749. Jagsi, R, Griffith, KA, Moran, JM, Ficaro, E, Marsh, R, Dess, RT, et.al. A Randomized Comparison of Radiation Therapy Techniques in the Management of Node-Positive Breast Cancer: Primary Outcomes Analysis., Int J Radiat Oncol Biol Phys, 2018. 101 (5)(5): p. 1149-1158., https://pubmed.ncbi.nlm.nih.gov/30012527/
750. Pierce, LJ, Feng, M, Griffith, KA, Jagsi, R, Boike, T, Dryden, D, et.al. Recent Time Trends and Predictors of Heart Dose From Breast Radiation Therapy in a Large Quality Consortium of Radiation Oncology Practices., Int J Radiat Oncol Biol Phys, 2017. 99 (5)(5): p. 1154-1161., https://pubmed.ncbi.nlm.nih.gov/28927756/
751. Zagar, TM, Kaidar-Person, O, Tang, X, Jones, EE, Matney, J, Das, SK, et.al. Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study., Int J Radiat Oncol Biol Phys, 2017. 97 (5)(5): p. 903-909., https://pubmed.ncbi.nlm.nih.gov/28333011/
752. Bartlett, FR, Donovan, EM, McNair, HA, Corsini, LA, Colgan, RM, Evans, PM, et.al. The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy., Clin Oncol (R Coll Radiol), 2017. 29 (3)(3): p. e51-e56., https://pubmed.ncbi.nlm.nih.gov/27890346/
753. Piroth, MD, Baumann, R, Budach, W, Dunst, J, Feyer, P, Fietkau, R, et.al. Heart toxicity from breast cancer radiotherapy : Current findings, assessment, and prevention., Strahlenther Onkol, 2019. 195 (1)(1): p. 1-12., https://pubmed.ncbi.nlm.nih.gov/30310926/
754. Duma, MN, Baumann, R, Budach, W, Dunst, J, Feyer, P, Fietkau, R, et.al. Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO)., Strahlenther Onkol, 2019. 195 (10)(10): p. 861-871., https://pubmed.ncbi.nlm.nih.gov/31321461/
755. Giordano, SH, Kuo, YF, Freeman, JL, Buchholz, TA, Hortobagyi, GN, Goodwin, JS, Risk of cardiac death after adjuvant radiotherapy for breast cancer., J Natl Cancer Inst, 2005. 97 (6)(6): p. 419-24., https://pubmed.ncbi.nlm.nih.gov/15770005/
756. Nilsson, G, Holmberg, L, Garmo, H, Duvernoy, O, Sjögren, I, Lagerqvist, B, et.al. Distribution of coronary artery stenosis after radiation for breast cancer., J Clin Oncol, 2012. 30 (4)(4): p. 380-6., https://pubmed.ncbi.nlm.nih.gov/22203772/
757. van den Bogaard, VA, Ta, BD, van der Schaaf, A, Bouma, AB, Middag, AM, Bantema-Joppe, EJ, et.al. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures., J Clin Oncol, 2017. 35 (11)(11): p. 1171-1178., https://pubmed.ncbi.nlm.nih.gov/28095159/
758. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials., Lancet, 2023. 402 (10416)(10416): p. 1991-2003., https://pubmed.ncbi.nlm.nih.gov/37931633/
759. Schönecker, S, Angelini, L, Gaasch, A, Zinn, A, Konnerth, D, Heinz, C, et.al. Surface-based deep inspiration breath-hold radiotherapy in left-sided breast cancer: final results from the SAVE-HEART study., ESMO Open, 2024. 9 (12)(12): p. 103993., https://pubmed.ncbi.nlm.nih.gov/39631360/
760. Aznar, MC, Carrasco de Fez, P, Corradini, S, Mast, M, McNair, H, Meattini, I, et.al. ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy., Radiother Oncol, 2023. 185 (): p. 109734., https://pubmed.ncbi.nlm.nih.gov/37301263/
761. Kindts, I, Laenen, A, Depuydt, T, Weltens, C, Tumour bed boost radiotherapy for women after breast-conserving surgery., Cochrane Database Syst Rev, 2017. 11 (11)(11): p. CD011987., https://pubmed.ncbi.nlm.nih.gov/29105051/
762. Antonini, N., Jones, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., et.al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882, Radiother Oncol, 2007. 82(3): p. 265-71., https://www.ncbi.nlm.nih.gov/pubmed/17126434
763. Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., et.al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial, Lancet Oncol, 2015. 16(1): p. 47-56., https://www.ncbi.nlm.nih.gov/pubmed/25500422
764. Vrieling, C., van Werkhoven, E., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., et.al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial, JAMA Oncol, 2017. 3(1): p. 42-48., https://www.ncbi.nlm.nih.gov/pubmed/27607734
765. Romestaing, P., Lehingue, Y., Carrie, C., Coquard, R., Montbarbon, X., Ardiet, J. M., et.al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France, J Clin Oncol, 1997. 15(3): p. 963-8., https://www.ncbi.nlm.nih.gov/pubmed/9060534
766. Forster, T, Hommertgen, A, Häfner, MF, Arians, N, König, L, Harrabi, SB, et.al. Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial., Radiother Oncol, 2021. 163 (): p. 165-176., https://pubmed.ncbi.nlm.nih.gov/34480960/
767. Forster, T, Köhler, C, Dorn, M, Häfner, MF, Arians, N, König, L, et.al. Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients' and Physicians' Assessment from the Randomized IMRT-MC2 Trial., Cancers (Basel), 2022. 14 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/35740675/
768. Forster, T, Köhler, C, Dorn, M, Häfner, MF, Arians, N, König, L, et.al. Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial., Int J Radiat Oncol Biol Phys, 2023. 117 (4)(4): p. 857-868., https://pubmed.ncbi.nlm.nih.gov/37244626/
769. Coles, CE, Haviland, JS, Kirby, AM, Griffin, CL, Sydenham, MA, Titley, JC, et.al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial., Lancet, 2023. 401 (10394)(10394): p. 2124-2137., https://pubmed.ncbi.nlm.nih.gov/37302395/
770. Montero, A, Ciérvide, R, Cañadillas, C, Álvarez, B, García-Aranda, M, Alonso, R, et.al. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer., Clin Transl Radiat Oncol, 2023. 41 (): p. 100651., https://pubmed.ncbi.nlm.nih.gov/37388711/
771. Pfaffendorf, C, Vonthein, R, Krockenberger-Ziegler, K, Dellas, K, Schreiber, A, Uhlemann, D, et.al. Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials., Breast, 2022. 64 (): p. 136-142., https://pubmed.ncbi.nlm.nih.gov/35691249/
772. Choi, KH, Ahn, SJ, Jeong, JU, Yu, M, Kim, JH, Jeong, BK, et.al. Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03., Radiother Oncol, 2021. 154 (): p. 179-186., https://pubmed.ncbi.nlm.nih.gov/32980384/
773. Joseph, K, Vos, LJ, Gabos, Z, Pervez, N, Chafe, S, Tankel, K, et.al. Skin Toxicity in Early Breast Cancer Patients Treated with Field-In-Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy: Results of a Phase III Randomised Controlled Trial., Clin Oncol (R Coll Radiol), 2021. 33 (1)(1): p. 30-39., https://pubmed.ncbi.nlm.nih.gov/32711920/
774. Hamilton, DG, Bale, R, Jones, C, Fitzgerald, E, Khor, R, Knight, K, et.al. Impact of tumour bed boost integration on acute and late toxicity in patients with breast cancer: A systematic review., Breast, 2016. 27 (): p. 126-35., https://pubmed.ncbi.nlm.nih.gov/27113229/
775. Fastner, G, Reitsamer, R, Gaisberger, C, Hitzl, W, Urbański, B, Murawa, D, et.al. Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)., Cancers (Basel), 2022. 14 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/35326548/
776. Ciabattoni, A, Gregucci, F, Fastner, G, Cavuto, S, Spera, A, Drago, S, et.al. IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study., Breast Cancer Res, 2021. 23 (1)(1): p. 46., https://pubmed.ncbi.nlm.nih.gov/33849606/
777. Fastner, G, Reitsamer, R, Urbański, B, Kopp, P, Murawa, D, Adamczyk, B, et.al. Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459)., Radiother Oncol, 2020. 146 (): p. 136-142., https://pubmed.ncbi.nlm.nih.gov/32151790/
778. Kaiser, J, Kronberger, C, Moder, A, Kopp, P, Wallner, M, Reitsamer, R, et.al. Intraoperative Tumor Bed Boost With Electrons in Breast Cancer of Clinical Stages I Through III: Updated 10-Year Results., Int J Radiat Oncol Biol Phys, 2018. 102 (1)(1): p. 92-101., https://pubmed.ncbi.nlm.nih.gov/29970317/
779. Stoian, R, Erbes, T, Zamboglou, C, Scholber, J, Gainey, M, Sachpazidis, I, et.al. Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis., Strahlenther Onkol, 2021. 197 (9)(9): p. 812-819., https://pubmed.ncbi.nlm.nih.gov/33938966/
780. Ahn, SG, Bae, SJ, Lee, HW, Yoon, CI, Kim, JW, Lee, IJ, et.al. A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients., Breast Cancer Res Treat, 2019. 174 (1)(1): p. 157-163., https://pubmed.ncbi.nlm.nih.gov/30467660/
781. Sarria, GR, Ramos, ML, Palacios, A, Del Castillo, R, Castro, F, Calvo, A, et.al. Long-Term Outcomes of an International Cooperative Study of Intraoperative Radiotherapy Upfront Boost With Low Energy X-Rays in Breast Cancer., Front Oncol, 2022. 12 (): p. 850351., https://pubmed.ncbi.nlm.nih.gov/35371998/
782. Díaz-Gavela, AA, Cerro Peñalver, ED, Sanchez-Garcia, S, Pardo-Perez, E, Thuissard-Vasallo, IJ, Andreu-Vázquez, C, et.al. Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center., Brachytherapy, 2024. 23 (3)(3): p. 342-354., https://pubmed.ncbi.nlm.nih.gov/38522961/
783. Strnad, V, Major, T, Polgar, C, Lotter, M, Guinot, JL, Gutierrez-Miguelez, C, et.al. ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost - GEC-ESTRO Breast Cancer Working Group practical recommendations., Radiother Oncol, 2018. 128 (3)(3): p. 411-420., https://pubmed.ncbi.nlm.nih.gov/29691075/
784. de Freitas, TB, Lopes de Barros Lima, KM, de Andrade Carvalho, H, de Azevedo Marques, P, Belfort Mattos, FT, Franco Fonseca, AS, et.al. What a difference a clip makes! Analysis of boost volume definition in radiation therapy for conservative breast surgery., Eur J Surg Oncol, 2018. 44 (9)(9): p. 1312-1317., https://pubmed.ncbi.nlm.nih.gov/30041975/
785. Dzhugashvili, M, Tournay, E, Pichenot, C, Dunant, A, Pessoa, E, Khallel, A, et.al. 3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity., Radiat Oncol, 2009. 4 (): p. 70., https://pubmed.ncbi.nlm.nih.gov/20042124/
786. Aldosary, G, Caudrelier, JM, Arnaout, A, Chang, L, Tse, T, Foottit, C, et.al. Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?, Breast Cancer Res Treat, 2021. 186 (2)(2): p. 343-352., https://pubmed.ncbi.nlm.nih.gov/33484375/
787. van Mourik, AM, Elkhuizen, PH, Minkema, D, Duppen, JC, van Vliet-Vroegindeweij, C, Multiinstitutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines., Radiother Oncol, 2010. 94 (3)(3): p. 286-91., https://pubmed.ncbi.nlm.nih.gov/20199818/
788. Strnad, V, Hannoun-Levi, JM, Guinot, JL, Lössl, K, Kauer-Dorner, D, Resch, A, et.al. Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery., Radiother Oncol, 2015. 115 (3)(3): p. 342-8., https://pubmed.ncbi.nlm.nih.gov/26104975/
789. Major, T, Gutiérrez, C, Guix, B, van Limbergen, E, Strnad, V, Polgár, C, Recommendations from GEC ESTRO Breast Cancer Working Group (II): Target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving open cavity surgery., Radiother Oncol, 2016. 118 (1)(1): p. 199-204., https://pubmed.ncbi.nlm.nih.gov/26776444/
790. Major, T, Gutiérrez, C, Guix, B, Mózsa, E, Hannoun-Levi, JM, Lössl, K, et.al. Interobserver variations of target volume delineation in multicatheter partial breast brachytherapy after open cavity surgery., Brachytherapy, 2015. 14 (6)(6): p. 925-32., https://pubmed.ncbi.nlm.nih.gov/26209477/
791. Aly, M. M., Abo-Madyan, Y., Jahnke, L., Wenz, F., Glatting, G., Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH), Radiat Oncol, 2016. 11: p. 16., https://www.ncbi.nlm.nih.gov/pubmed/26830843
792. Van Parijs, Hilde, Reynders, Truus, Heuninckx, Karina, Verellen, Dirk, Storme, Guy, De Ridder, Mark, Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost, BioMed research international, 2014. 2014:, https://www.ncbi.nlm.nih.gov/pubmed/25162031
793. McDonald, M. W., Godette, K. D., Whitaker, D. J., Davis, L. W., Johnstone, P. A., Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost, Int J Radiat Oncol Biol Phys, 2010. 77(2): p. 523-30., https://www.ncbi.nlm.nih.gov/pubmed/19775834
794. Hörner-Rieber, J, Forster, T, Hommertgen, A, Haefner, MF, Arians, N, König, L, et.al. Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)., Int J Radiat Oncol Biol Phys, 2021. 109 (5)(5): p. 1311-1324., https://pubmed.ncbi.nlm.nih.gov/33321192/
795. Fastner, G, Gaisberger, C, Kaiser, J, Scherer, P, Ciabattoni, A, Petoukhova, A, et.al. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer., Radiother Oncol, 2020. 149 (): p. 150-157., https://pubmed.ncbi.nlm.nih.gov/32413529/
796. Polgar, C., Van Limbergen, E., Potter, R., Kovacs, G., Polo, A., Lyczek, J., et.al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009), Radiother Oncol, 2010. 94(3): p. 264-73., https://www.ncbi.nlm.nih.gov/pubmed/20181402
797. Polgar, C., Fodor, J., Major, T., Sulyok, Z., Kasler, M., Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial, Radiother Oncol, 2013. 108(2): p. 197-202., https://www.ncbi.nlm.nih.gov/pubmed/23742961
798. Veronesi, U., Orecchia, R., Maisonneuve, P., Viale, G., Rotmensz, N., Sangalli, C., et.al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial, Lancet Oncol, 2013. 14(13): p. 1269-77., https://www.ncbi.nlm.nih.gov/pubmed/24225155
799. Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., et.al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 2014. 383(9917): p. 603-13., https://www.ncbi.nlm.nih.gov/pubmed/24224997
800. Polgar, C., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., et.al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial, Lancet Oncol, 2017. 18(2): p. 259-268., https://www.ncbi.nlm.nih.gov/pubmed/28094198
801. Strnad, V, Polgár, C, Ott, OJ, Hildebrandt, G, Kauer-Dorner, D, Knauerhase, H, et.al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial., Lancet Oncol, 2023. 24 (3)(3): p. 262-272., https://pubmed.ncbi.nlm.nih.gov/36738756/
802. Offersen, BV, Alsner, J, Nielsen, HM, Jakobsen, EH, Nielsen, MH, Stenbygaard, L, et.al. Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial., J Clin Oncol, 2022. 40 (36)(36): p. 4189-4197., https://pubmed.ncbi.nlm.nih.gov/35930754/
803. Coles, CE, Griffin, CL, Kirby, AM, Titley, J, Agrawal, RK, Alhasso, A, et.al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial., Lancet, 2017. 390 (10099)(10099): p. 1048-1060., https://pubmed.ncbi.nlm.nih.gov/28779963/
804. Meduri, B, Baldissera, A, Iotti, C, Scheijmans, LJEE, Stam, MR, Parisi, S, et.al. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial., J Clin Oncol, 2023. 41 (12)(12): p. 2201-2210., https://pubmed.ncbi.nlm.nih.gov/36623246/
805. Meattini, I, Marrazzo, L, Saieva, C, Desideri, I, Scotti, V, Simontacchi, G, et.al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial., J Clin Oncol, 2020. 38 (35)(35): p. 4175-4183., https://pubmed.ncbi.nlm.nih.gov/32840419/
806. Goldberg, M, Bridhikitti, J, Khan, AJ, McGale, P, Whelan, TJ, A Meta-Analysis of Trials of Partial Breast Irradiation., Int J Radiat Oncol Biol Phys, 2023. 115 (1)(1): p. 60-72., https://pubmed.ncbi.nlm.nih.gov/36155214/
807. Haussmann, J, Budach, W, Strnad, V, Corradini, S, Krug, D, Schmidt, L, et.al. Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer-A Meta-Analysis of Randomized Trials., Cancers (Basel), 2021. 13 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/34199281/
808. Haussmann, J, Budach, W, Corradini, S, Krug, D, Jazmati, D, Tamaskovics, B, et.al. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials., Radiat Oncol, 2023. 18 (1)(1): p. 181., https://pubmed.ncbi.nlm.nih.gov/37919752/
809. Haussmann, J, Budach, W, Corradini, S, Krug, D, Tamaskovics, B, Bölke, E, et.al. No Difference in Overall Survival and Non-Breast Cancer Deaths after Partial Breast Radiotherapy Compared to Whole Breast Radiotherapy-A Meta-Analysis of Randomized Trials., Cancers (Basel), 2020. 12 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/32824414/
810. Shaitelman, SF, Anderson, BM, Arthur, DW, Bazan, JG, Bellon, JR, Bradfield, L, et.al. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline., Pract Radiat Oncol, 2024. 14 (2)(2): p. 112-132., https://pubmed.ncbi.nlm.nih.gov/37977261/
811. Anderson, B, Arthur, D, Hannoun-Levi, JM, Kamrava, M, Khan, A, Kuske, R, et.al. Partial breast irradiation: An updated consensus statement from the American brachytherapy society., Brachytherapy, 2022. 21 (6)(6): p. 726-747., https://pubmed.ncbi.nlm.nih.gov/36117086/
812. Strnad, V, Krug, D, Sedlmayer, F, Piroth, MD, Budach, W, Baumann, R, et.al. DEGRO practical guideline for partial-breast irradiation., Strahlenther Onkol, 2020. 196 (9)(9): p. 749-763., https://pubmed.ncbi.nlm.nih.gov/32350554/
813. Goldberg, M, Bridhikitti, J, Khan, AJ, McGale, P, Whelan, TJ, A Meta-Analysis of Trials of Partial Breast Irradiation., Int J Radiat Oncol Biol Phys, 2023. 115 (1)(1): p. 60-72., https://pubmed.ncbi.nlm.nih.gov/36155214/
814. Coles, CE, Griffin, CL, Kirby, AM, Titley, J, Agrawal, RK, Alhasso, A, et.al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial., Lancet, 2017. 390 (10099)(10099): p. 1048-1060., https://pubmed.ncbi.nlm.nih.gov/28779963/
815. Meattini, I, Marrazzo, L, Saieva, C, Desideri, I, Scotti, V, Simontacchi, G, et.al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial., J Clin Oncol, 2020. 38 (35)(35): p. 4175-4183., https://pubmed.ncbi.nlm.nih.gov/32840419/
816. Offersen, BV, Alsner, J, Nielsen, HM, Jakobsen, EH, Nielsen, MH, Stenbygaard, L, et.al. Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial., J Clin Oncol, 2022. 40 (36)(36): p. 4189-4197., https://pubmed.ncbi.nlm.nih.gov/35930754/
817. Strnad, V, Polgár, C, Ott, OJ, Hildebrandt, G, Kauer-Dorner, D, Knauerhase, H, et.al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial., Lancet Oncol, 2023. 24 (3)(3): p. 262-272., https://pubmed.ncbi.nlm.nih.gov/36738756/
818. Shaitelman, SF, Anderson, BM, Arthur, DW, Bazan, JG, Bellon, JR, Bradfield, L, et.al. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline., Pract Radiat Oncol, 2024. 14 (2)(2): p. 112-132., https://pubmed.ncbi.nlm.nih.gov/37977261/
819. Anderson, B, Arthur, D, Hannoun-Levi, JM, Kamrava, M, Khan, A, Kuske, R, et.al. Partial breast irradiation: An updated consensus statement from the American brachytherapy society., Brachytherapy, 2022. 21 (6)(6): p. 726-747., https://pubmed.ncbi.nlm.nih.gov/36117086/
820. Vaidya, JS, Bulsara, M, Baum, M, Wenz, F, Massarut, S, Pigorsch, S, et.al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial., BMJ, 2020. 370 (): p. m2836., https://pubmed.ncbi.nlm.nih.gov/32816842/
821. Vaidya, JS, Bulsara, M, Saunders, C, Flyger, H, Tobias, JS, Corica, T, et.al. Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer., JAMA Oncol, 2020. 6 (7)(7): p. e200249., https://pubmed.ncbi.nlm.nih.gov/32239210/
822. Orecchia, R, Veronesi, U, Maisonneuve, P, Galimberti, VE, Lazzari, R, Veronesi, P, et.al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial., Lancet Oncol, 2021. 22 (5)(5): p. 597-608., https://pubmed.ncbi.nlm.nih.gov/33845035/
823. Shumway, DA, Corbin, KS, Farah, MH, Viola, KE, Nayfeh, T, Saadi, S, et.al. Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis., J Natl Cancer Inst, 2023. 115 (9)(9): p. 1011-1019., https://pubmed.ncbi.nlm.nih.gov/37289549/
824. Polgár, C, Major, T, Takácsi-Nagy, Z, Fodor, J, Breast-Conserving Surgery Followed by Partial or Whole Breast Irradiation: Twenty-Year Results of a Phase 3 Clinical Study., Int J Radiat Oncol Biol Phys, 2021. 109 (4)(4): p. 998-1006., https://pubmed.ncbi.nlm.nih.gov/33186620/
825. Olivotto, IA, Whelan, TJ, Parpia, S, Kim, DH, Berrang, T, Truong, PT, et.al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy., J Clin Oncol, 2013. 31 (32)(32): p. 4038-45., https://pubmed.ncbi.nlm.nih.gov/23835717/
826. McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., et.al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials, Lancet, 2014. 383(9935): p. 2127-35., https://www.ncbi.nlm.nih.gov/pubmed/24656685
827. Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., et.al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 2016. 14(3): p. 324-54., https://www.ncbi.nlm.nih.gov/pubmed/26957618
828. Wang, H., Kong, L., Zhang, C., Chen, D., Zhu, H., Yu, J., Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study, Oncotarget, 2016. 7(46): p. 75492-75502., https://www.ncbi.nlm.nih.gov/pubmed/27690343
829. Elmore, Leisha, Deshpande, Anjali, Daly, MacKenzie, Margenthaler, Julie A, Postmastectomy radiation therapy in T3 node-negative breast cancer, Journal of Surgical Research, 2015. 199(1): p. 90-96., https://www.ncbi.nlm.nih.gov/pubmed/25976852
830. Francis, S. R., Frandsen, J., Kokeny, K. E., Gaffney, D. K., Poppe, M. M., Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers, Breast, 2017. 32: p. 156-161., https://www.ncbi.nlm.nih.gov/pubmed/28193571
831. Karlsson, P., Cole, B. F., Chua, B. H., Price, K. N., Lindtner, J., Collins, J. P., et.al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report, Ann Oncol, 2012. 23(11): p. 2852-8., https://www.ncbi.nlm.nih.gov/pubmed/22776708
832. Kyndi, Marianne, Overgaard, Marie, Nielsen, Hanne M, Sørensen, Flemming B, Knudsen, Helle, Overgaard, Jens, High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c, Radiotherapy and Oncology, 2009. 90(1): p. 74-79., https://pubmed.ncbi.nlm.nih.gov/18471914/
833. Nagao, T., Kinoshita, T., Tamura, N., Hojo, T., Morota, M., Kagami, Y., Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy, Int J Clin Oncol, 2013. 18(1): p. 54-61., https://www.ncbi.nlm.nih.gov/pubmed/22068463
834. Nielsen, H. M., Overgaard, M., Grau, C., Jensen, A. R., Overgaard, J., Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies, J Clin Oncol, 2006. 24(15): p. 2268-75., https://www.ncbi.nlm.nih.gov/pubmed/16618947
835. Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., et.al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update, J Clin Oncol, 2016. 34(36): p. 4431-4442., https://www.ncbi.nlm.nih.gov/pubmed/27646947
836. Wang, H., Zhang, C., Kong, L., Zhu, H., Yu, J., Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes: A population-based study, Medicine (Baltimore), 2017. 96(4): p. e5998., https://www.ncbi.nlm.nih.gov/pubmed/28121956
837. Headon, Hannah, Kasem, Abdul, Almukbel, Reham, Mokbel, Kefah, Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary lymph nodes: A systematic review and meta-analysis of the current literature, Molecular and Clinical Oncology, 2016. 5(4): p. 429-436., https://www.ncbi.nlm.nih.gov/pubmed/27699038
838. Valli, M. C., Controversies in loco-regional treatment: post-mastectomy radiation for pT2-pT3N0 breast cancer arguments in favour, Crit Rev Oncol Hematol, 2012. 84 Suppl 1: p. e70-4., https://www.ncbi.nlm.nih.gov/pubmed/21134765
839. Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., et.al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial, N Engl J Med, 1997. 337(14): p. 949-55., https://www.ncbi.nlm.nih.gov/pubmed/9395428
840. Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., et.al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial, Lancet, 1999. 353(9165): p. 1641-8., https://www.ncbi.nlm.nih.gov/pubmed/10335782
841. Taghian, AG, Jeong, JH, Mamounas, EP, Parda, DS, Deutsch, M, Costantino, JP, et.al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials., J Clin Oncol, 2006. 24 (24)(24): p. 3927-32., https://pubmed.ncbi.nlm.nih.gov/16921044/
842. Taghian, A, Jeong, JH, Mamounas, E, Anderson, S, Bryant, J, Deutsch, M, et.al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials., J Clin Oncol, 2004. 22 (21)(21): p. 4247-54., https://pubmed.ncbi.nlm.nih.gov/15452182/
843. Rusthoven, C. G., Rabinovitch, R. A., Jones, B. L., Koshy, M., Amini, A., Yeh, N., et.al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis, Ann Oncol, 2016. 27(5): p. 818-27., https://www.ncbi.nlm.nih.gov/pubmed/26861597
844. Mamounas, E. P., Anderson, S. J., Dignam, J. J., Bear, H. D., Julian, T. B., Geyer, C. E., Jr., et.al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27, J Clin Oncol, 2012. 30(32): p. 3960-6., https://www.ncbi.nlm.nih.gov/pubmed/23032615
845. Kishan, A. U., McCloskey, S. A., Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data, Ther Adv Med Oncol, 2016. 8(1): p. 85-97., https://www.ncbi.nlm.nih.gov/pubmed/26753007
846. Kantor, O., Pesce, C., Singh, P., Miller, M., Tseng, J., Wang, C. H., et.al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy, J Surg Oncol, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28083910
847. Krug, D, Baumann, R, Budach, W, Dunst, J, Feyer, P, Fietkau, R, et.al. Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review., Strahlenther Onkol, 2018. 194 (7)(7): p. 607-618., https://pubmed.ncbi.nlm.nih.gov/29383405/
848. Nikyar, N, Tegnelius, E, Valachis, A, Adjuvant locoregional radiation therapy in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy: A systematic review and meta-analysis., Clin Transl Radiat Oncol, 2022. 33 (): p. 45-52., https://pubmed.ncbi.nlm.nih.gov/35036587/
849. Wang, K, Jin, X, Wang, W, Yu, X, Huang, J, The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis., BMC Cancer, 2021. 21 (1)(1): p. 728., https://pubmed.ncbi.nlm.nih.gov/34172014/
850. de Wild, SR, de Munck, L, Simons, JM, Verloop, J, van Dalen, T, Elkhuizen, PHM, et.al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study., Lancet Oncol, 2022. 23 (9)(9): p. 1201-1210., https://pubmed.ncbi.nlm.nih.gov/35952707/
851. Krug, D, Baumann, R, Budach, W, Dunst, J, Feyer, P, Fietkau, R, et.al. Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment., Strahlenther Onkol, 2018. 194 (9)(9): p. 797-805., https://pubmed.ncbi.nlm.nih.gov/29974132/
852. McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., et.al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy, Int J Radiat Oncol Biol Phys, 2007. 68(4): p. 1004-9., https://www.ncbi.nlm.nih.gov/pubmed/17418973
853. Nagar, H., Mittendorf, E. A., Strom, E. A., Perkins, G. H., Oh, J. L., Tereffe, W., et.al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer, Int J Radiat Oncol Biol Phys, 2011. 81(3): p. 782-7., https://www.ncbi.nlm.nih.gov/pubmed/21885207
854. Nagar, H., Boothe, D., Ginter, P. S., Sison, C., Vahdat, L., Shin, S., et.al. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy, Clin Breast Cancer, 2015. 15(2): p. 128-34., https://www.ncbi.nlm.nih.gov/pubmed/25459070
855. Le Scodan, R., Selz, J., Stevens, D., Bollet, M. A., de la Lande, B., Daveau, C., et.al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy, Int J Radiat Oncol Biol Phys, 2012. 82(1): p. e1-7., https://www.ncbi.nlm.nih.gov/pubmed/21377284
856. Shim, S. J., Park, W., Huh, S. J., Choi, D. H., Shin, K. H., Lee, N. K., et.al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05), Int J Radiat Oncol Biol Phys, 2014. 88(1): p. 65-72., https://www.ncbi.nlm.nih.gov/pubmed/24161425
857. Eleftherios Mamounas, Hanna Bandos, Julia White, Thomas Julian, Atif Khan, Simona Shaitelman, Mylin Torres, Frank Vicini, Patricia Ganz, Susan McCloskey, Nilendu Gupta, X. Allen Li, Peter Lucas, Nadeem Abu-Rustum, Saumil Gandhi, Rahul Tendulkar, Robert Coleman, Keiichi Fujiwara, Samantha Seaward, William Irvin, Kristin Higgins, Robert Mutter, Jean-Francois Boileau, Andrew Muskovitz, Reshma Jagsi, Anna Weiss, Curran Walter, Norman Wolmark, Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304ACR; Cancer Res 2024, 2023., https://doi.org/10.1158/1538-7445.sabcs23-gs02-07
858. Selz, J., Le Scodan, R., Menard, J., Hennequin, C., Quero, L., [Indication of radiotherapy after neoadjuvant chemotherapy in breast cancer], Cancer Radiother, 2014. 18(3): p. 229-34., https://www.ncbi.nlm.nih.gov/pubmed/24819247
859. Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Hortobagyi, G. N., et.al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy, Int J Radiat Oncol Biol Phys, 2005. 62(2): p. 351-7., https://www.ncbi.nlm.nih.gov/pubmed/15890574
860. Fowble, B. L., Einck, J. P., Kim, D. N., McCloskey, S., Mayadev, J., Yashar, C., et.al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer, Int J Radiat Oncol Biol Phys, 2012. 83(2): p. 494-503., https://www.ncbi.nlm.nih.gov/pubmed/22579377
861. Bernier, J., Post-mastectomy radiotherapy after neodjuvant chemotherapy in breast cancer patients: A review, Crit Rev Oncol Hematol, 2015. 93(3): p. 180-9., https://www.ncbi.nlm.nih.gov/pubmed/25465740
862. Rueth, N. M., Lin, H. Y., Bedrosian, I., Shaitelman, S. F., Ueno, N. T., Shen, Y., et.al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database, J Clin Oncol, 2014. 32(19): p. 2018-24., https://www.ncbi.nlm.nih.gov/pubmed/24888808
863. van Uden, D. J., Bretveld, R., Siesling, S., de Wilt, J. H., Blanken-Peeters, C. F., Inflammatory breast cancer in the Netherlands; improved survival over the last decades, Breast Cancer Res Treat, 2017. 162(2): p. 365-374., https://www.ncbi.nlm.nih.gov/pubmed/28138891
864. Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., et.al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy, Int J Radiat Oncol Biol Phys, 2013. 86(5): p. 860-6., https://www.ncbi.nlm.nih.gov/pubmed/23664327
865. Budach, W., Bolke, E., Kammers, K., Gerber, P. A., Nestle-Kramling, C., Matuschek, C., Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update, Radiat Oncol, 2015. 10: p. 258., https://www.ncbi.nlm.nih.gov/pubmed/26691175
866. Kim, YB, Byun, HK, Kim, DY, Ahn, SJ, Lee, HS, Park, W, et.al. Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial., JAMA Oncol, 2022. 8 (1)(1): p. 96-105., https://pubmed.ncbi.nlm.nih.gov/34695841/
867. Poortmans, PM, Weltens, C, Fortpied, C, Kirkove, C, Peignaux-Casasnovas, K, Budach, V, et.al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial., Lancet Oncol, 2020. 21 (12)(12): p. 1602-1610., https://pubmed.ncbi.nlm.nih.gov/33152277/
868. Thorsen, LBJ, Overgaard, J, Matthiessen, LW, Berg, M, Stenbygaard, L, Pedersen, AN, et.al. Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study., J Clin Oncol, 2022. 40 (36)(36): p. 4198-4206., https://pubmed.ncbi.nlm.nih.gov/35394824/
869. Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., et.al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology, J Clin Oncol, 2001. 19(5): p. 1539-69., https://www.ncbi.nlm.nih.gov/pubmed/11230499
870. Yates, L., Kirby, A., Crichton, S., Gillett, C., Cane, P., Fentiman, I., et.al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes, Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 2093-103., https://www.ncbi.nlm.nih.gov/pubmed/21530101
871. Poortmans, Philip M, Collette, Sandra, Kirkove, Carine, Van Limbergen, Erik, Budach, Volker, Struikmans, Henk, et.al. Internal mammary and medial supraclavicular irradiation in breast cancer, New England Journal of Medicine, 2015. 373(4): p. 317-327., https://www.ncbi.nlm.nih.gov/pubmed/26200978
872. Thorsen, L. B., Offersen, B. V., Dano, H., Berg, M., Jensen, I., Pedersen, A. N., et.al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer, J Clin Oncol, 2016. 34(4): p. 314-20., https://www.ncbi.nlm.nih.gov/pubmed/26598752
873. Whelan, Timothy J, Olivotto, Ivo A, Parulekar, Wendy R, Ackerman, Ida, Chua, Boon H, Nabid, Abdenour, et.al. Regional nodal irradiation in early-stage breast cancer, New England Journal of Medicine, 2015. 373(4): p. 307-316., https://pubmed.ncbi.nlm.nih.gov/26200977/
874. Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., et.al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy, Int J Radiat Oncol Biol Phys, 2013. 86(5): p. 860-6., https://www.ncbi.nlm.nih.gov/pubmed/23664327
875. Budach, W., Bolke, E., Kammers, K., Gerber, P. A., Nestle-Kramling, C., Matuschek, C., Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update, Radiat Oncol, 2015. 10: p. 258., https://www.ncbi.nlm.nih.gov/pubmed/26691175
876. Korzets, Yasmin, Levitas, Dina, Grubstein, Ahuva, Corn, Benjamin, Amir, Eitan, Goldvaser, Hadar, Efficacy and Safety of the Addition of Internal Mammary Irradiation to Standard Adjuvant Radiation in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis, 2022/09/17. 29: p. 6657 - 6673., https://pubmed.ncbi.nlm.nih.gov/36135092/
877. Jia, Sicong, Liu, Zhikun, Zhang, Jun, Zhao, Chenguang, Zhu, Longyu, Kong, Jie, et.al. Can internal mammary lymph nodes irradiation bring survival benefits for breast cancer patients? A systematic review and meta-analysis of 12,705 patients in 12 studies, 2021/02/23. 16:, https://pubmed.ncbi.nlm.nih.gov/33622345/
878. Caussa, L., Kirova, Y. M., Gault, N., Pierga, J. Y., Savignoni, A., Campana, F., et.al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study, Eur J Cancer, 2011. 47(1): p. 65-73., https://www.ncbi.nlm.nih.gov/pubmed/20843680
879. Shaffer, R., Tyldesley, S., Rolles, M., Chia, S., Mohamed, I., Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study, Radiother Oncol, 2009. 90(1): p. 122-6., https://www.ncbi.nlm.nih.gov/pubmed/18976826
880. Thorsen, L. B., Thomsen, M. S., Berg, M., Jensen, I., Josipovic, M., Overgaard, M., et.al. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects, Acta Oncol, 2014. 53(8): p. 1027-34., https://www.ncbi.nlm.nih.gov/pubmed/24957557
881. Popescu, C. C., Olivotto, I. A., Beckham, W. A., Ansbacher, W., Zavgorodni, S., Shaffer, R., et.al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes, Int J Radiat Oncol Biol Phys, 2010. 76(1): p. 287-95., https://www.ncbi.nlm.nih.gov/pubmed/19775832
882. Hjelstuen, Mari HB, Mjaaland, Ingvil, Vikström, Johan, Dybvik, Kjell Ivar, Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular-and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk, Acta Oncologica, 2012. 51(3): p. 333-344., https://pubmed.ncbi.nlm.nih.gov/22171587/
883. Bartels, SAL, Donker, M, Poncet, C, Sauvé, N, Straver, ME, van de Velde, CJH, et.al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial., J Clin Oncol, 2023. 41 (12)(12): p. 2159-2165., https://pubmed.ncbi.nlm.nih.gov/36383926/
884. Sávolt, Á, Péley, G, Polgár, C, Udvarhelyi, N, Rubovszky, G, Kovács, E, et.al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial., Eur J Surg Oncol, 2017. 43 (4)(4): p. 672-679., https://pubmed.ncbi.nlm.nih.gov/28139362/
885. Jagsi, R., Chadha, M., Moni, J., Ballman, K., Laurie, F., Buchholz, T. A., et.al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial, J Clin Oncol, 2014. 32(32): p. 3600-6., https://www.ncbi.nlm.nih.gov/pubmed/25135994
886. Ellis, I. O., Al-Sam, S., Anderson, N., Carder, P., Deb, R., Girling, A., et.al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. G 148 LRThe Royal College of Pathologists, 2016. p. 1-160., https://www.rcpath.org/static/693db661-0592-4d7e-9644357fbfa00a76/G148_BreastDataset-lowres-Jun16.pdf
887. Schmitt, M, Pin, Y, Pflumio, C, Mathelin, C, Pivot, X, Noel, G, Incidental axillary dose delivery to axillary lymph node levels I-III by different techniques of whole-breast irradiation: a systematic literature review., Strahlenther Onkol, 2021. 197 (9)(9): p. 820-828., https://pubmed.ncbi.nlm.nih.gov/34292348/
888. Offersen, BV, Boersma, LJ, Kirkove, C, Hol, S, Aznar, MC, Biete Sola, A, et.al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer., Radiother Oncol, 2015. 114 (1)(1): p. 3-10., https://pubmed.ncbi.nlm.nih.gov/25630428/
889. Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., et.al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1, Radiother Oncol, 2016. 118(1): p. 205-8., https://www.ncbi.nlm.nih.gov/pubmed/26791404
890. Banys-Paluchowski, M, Thill, M, Kühn, T, Ditsch, N, Heil, J, Wöckel, A, et.al. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022., Geburtshilfe Frauenheilkd, 2022. 82 (10)(10): p. 1031-1043., https://pubmed.ncbi.nlm.nih.gov/36186147/
891. Alkner, S, Wieslander, E, Lundstedt, D, Berg, M, Kristensen, I, Andersson, Y, et.al. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial., Radiother Oncol, 2024. 197 (): p. 110372., https://pubmed.ncbi.nlm.nih.gov/38866204/
892. Algara, M, Rodríguez, E, Martínez-Arcelus, FJ, Salinas, J, Sanz, X, Beato, I, et.al. OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized clinical trial., Radiother Oncol, 2022. 176 (): p. 76-82., https://pubmed.ncbi.nlm.nih.gov/36210628/
893. Offersen, B., Alsner, J., Nielsen, H.M., Bechmann, T., Nielsen, M.H., Mjaaland, Ingvil, et.al. OC-0102 DBCG phase III randomized trial of hypo- vs standard fractionated RT in 2879 pN+ breast cancer pts, 2022/05/01. 170: p. S76 - S77., https://doi.org/10.1016/S0167-8140(22)02478-1
894. Karamouza, E., Kirova, Youlia, Racadot, S., Benchalal, M., Clavier, J-B, Brunaud, C., et.al. OC-0758 HypoG01:UNICANCER phase 3 trial of locoregional hypo vs normo fractionated RT in early breast cancer, 2023/05/01. 182: p. S625 - S626.
895. Haviland, JS, Mannino, M, Griffin, C, Porta, N, Sydenham, M, Bliss, JM, et.al. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials., Radiother Oncol, 2018. 126 (1)(1): p. 155-162., https://pubmed.ncbi.nlm.nih.gov/29153463/
896. Bellefqih, S, Elmajjaoui, S, Aarab, J, Khalil, J, Afif, M, Lachgar, A, et.al. Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer., Int J Radiat Oncol Biol Phys, 2017. 97 (3)(3): p. 563-570., https://pubmed.ncbi.nlm.nih.gov/28126305/
897. Bartelink, H., Rubens, R. D., van der Schueren, E., Sylvester, R., Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial, J Clin Oncol, 1997. 15(1): p. 207-15., https://www.ncbi.nlm.nih.gov/pubmed/8996144
898. Scotti, V., Desideri, I., Meattini, I., Di Cataldo, V., Cecchini, S., Petrucci, A., et.al. Management of inflammatory breast cancer: focus on radiotherapy with an evidence-based approach, Cancer Treat Rev, 2013. 39(2): p. 119-24., https://www.ncbi.nlm.nih.gov/pubmed/22564719
899. Aebi, S, Karlsson, P, Wapnir, IL, Locally advanced breast cancer., Breast, 2022. 62 Suppl 1 (Suppl 1)(Suppl 1): p. S58-S62., https://pubmed.ncbi.nlm.nih.gov/34930650/
900. Gaui, MF, Amorim, G, Arcuri, RA, Pereira, G, Moreira, D, Djahjah, C, et.al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer., Am J Clin Oncol, 2007. 30 (1)(1): p. 78-81., https://pubmed.ncbi.nlm.nih.gov/17278899/
901. Woodward, WA, Fang, P, Arriaga, L, Gao, H, Cohen, EN, Reuben, JM, et.al. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer., Int J Radiat Oncol Biol Phys, 2017. 99 (4)(4): p. 777-783., https://pubmed.ncbi.nlm.nih.gov/28843370/
902. Jagsi, R, Mason, G, Overmoyer, BA, Woodward, WA, Badve, S, Schneider, RJ, et.al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research., Breast Cancer Res Treat, 2022. 192 (2)(2): p. 235-243., https://pubmed.ncbi.nlm.nih.gov/34973083/
903. McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., et.al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy, Int J Radiat Oncol Biol Phys, 2007. 68(4): p. 1004-9., https://www.ncbi.nlm.nih.gov/pubmed/17418973
904. Nagar, H., Mittendorf, E. A., Strom, E. A., Perkins, G. H., Oh, J. L., Tereffe, W., et.al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer, Int J Radiat Oncol Biol Phys, 2011. 81(3): p. 782-7., https://www.ncbi.nlm.nih.gov/pubmed/21885207
905. Nagar, H., Boothe, D., Ginter, P. S., Sison, C., Vahdat, L., Shin, S., et.al. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy, Clin Breast Cancer, 2015. 15(2): p. 128-34., https://www.ncbi.nlm.nih.gov/pubmed/25459070
906. Ahmed, M, Jozsa, F, Douek, M, A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer., Ecancermedicalscience, 2021. 15 (): p. 1175., https://pubmed.ncbi.nlm.nih.gov/33680089/
907. Corradini, S, Krug, D, Meattini, I, Matuschek, C, Bölke, E, Francolini, G, et.al. Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature., Crit Rev Oncol Hematol, 2019. 141 (): p. 102-111., https://pubmed.ncbi.nlm.nih.gov/31272045/
908. Bellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., et.al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial, J Clin Oncol, 2005. 23(9): p. 1934-40., https://www.ncbi.nlm.nih.gov/pubmed/15774786
909. Hickey, B. E., Francis, D., Lehman, M. H., Sequencing of chemotherapy and radiation therapy for early breast cancer, Cochrane Database Syst Rev, 2006. p. Cd005212., https://www.ncbi.nlm.nih.gov/pubmed/23633328
910. Hickey, B. E., Francis, D. P., Lehman, M., Sequencing of chemotherapy and radiotherapy for early breast cancer, Cochrane Database Syst Rev, 2013. p. Cd005212., https://www.ncbi.nlm.nih.gov/pubmed/17054248
911. Pinnaro, P., Rambone, R., Giordano, C., Giannarelli, D., Strigari, L., Arcangeli, G., Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer, Am J Clin Oncol, 2011. 34(3): p. 238-44., https://www.ncbi.nlm.nih.gov/pubmed/20805741
912. Chen, Z., King, W., Pearcey, R., Kerba, M., Mackillop, W. J., The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature, Radiother Oncol, 2008. 87(1): p. 3-16., https://www.ncbi.nlm.nih.gov/pubmed/18160158
913. Huang, J., Barbera, L., Brouwers, M., Browman, G., Mackillop, W. J., Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review, J Clin Oncol, 2003. 21(3): p. 555-63., https://www.ncbi.nlm.nih.gov/pubmed/12560449
914. Li, Y. F., Chang, L., Li, W. H., Xiao, M. Y., Wang, Y., He, W. J., et.al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis, Breast, 2016. 27: p. 93-8., https://www.ncbi.nlm.nih.gov/pubmed/27054754
915. Tsoutsou, PG, Belkacemi, Y, Gligorov, J, Kuten, A, Boussen, H, Bese, N, et.al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider., Oncologist, 2010. 15 (11)(11): p. 1169-78., https://pubmed.ncbi.nlm.nih.gov/21041378/
916. Karlsson, P, Cole, BF, Colleoni, M, Roncadin, M, Chua, BH, Murray, E, et.al. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy., Int J Radiat Oncol Biol Phys, 2011. 80 (2)(2): p. 398-402., https://pubmed.ncbi.nlm.nih.gov/20729007/
917. Winzer, KJ, Sauerbrei, W, Braun, M, Liersch, T, Dunst, J, Guski, H, et.al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence., Eur J Cancer, 2010. 46 (1)(1): p. 95-101., https://pubmed.ncbi.nlm.nih.gov/19879131/
918. Azria, D, Belkacemi, Y, Romieu, G, Gourgou, S, Gutowski, M, Zaman, K, et.al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial., Lancet Oncol, 2010. 11 (3)(3): p. 258-65., https://pubmed.ncbi.nlm.nih.gov/20138810/
919. Bourgier, C, Kerns, S, Gourgou, S, Lemanski, C, Gutowski, M, Fenoglietto, P, et.al. Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial., Ann Oncol, 2016. 27 (3)(3): p. 474-80., https://pubmed.ncbi.nlm.nih.gov/26681684/
920. Meattini, I, Becherini, C, Caini, S, Coles, CE, Cortes, J, Curigliano, G, et.al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations., Lancet Oncol, 2024. 25 (2)(2): p. e73-e83., https://pubmed.ncbi.nlm.nih.gov/38301705/
921. Matuschek, Christiane, Bölke, Edwin, Haussmann, Jan, Mohrmann, Svjetlana, Nestle-Krämling, Carolin, Gerber, Peter Arne, et.al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials, 2017. 12(1): p. 60., https://doi.org/10.1186/s13014-017-0796-x
922. McGee, S.F., Mazzarello, Sasha, Caudrelier, Jean-Michel, Lima, M.A.G., Hutton, Brian, Sienkiewicz, M., et.al. Optimal Sequence of Adjuvant Endocrine and Radiation Therapy in Early-Stage Breast Cancer – A Systematic Review, 2018/06/01. 69:, https://pubmed.ncbi.nlm.nih.gov/30014951/
923. Bachir, B, Anouti, S, Abi Jaoude, J, Kayali, M, Tfayli, A, de Azambuja, E, et.al. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab., Int J Radiat Oncol Biol Phys, 2022. 113 (1)(1): p. 135-142., https://pubmed.ncbi.nlm.nih.gov/34986381/
924. Belkacémi, Y, Gligorov, J, Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge"., Radiother Oncol, 2010. 94 (1)(1): p. 119-20; author reply 120-1., https://pubmed.ncbi.nlm.nih.gov/19410315/
925. Belkacémi, Y, Gligorov, J, Ozsahin, M, Marsiglia, H, De Lafontan, B, Laharie-Mineur, H, et.al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study., Ann Oncol, 2008. 19 (6)(6): p. 1110-6., https://pubmed.ncbi.nlm.nih.gov/18344537/
926. Jacob, J, Belin, L, Pierga, JY, Gobillion, A, Vincent-Salomon, A, Dendale, R, et.al. Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study., Breast Cancer Res Treat, 2014. 148 (2)(2): p. 345-53., https://pubmed.ncbi.nlm.nih.gov/25318926/
927. Caussa, L, Kirova, YM, Gault, N, Pierga, JY, Savignoni, A, Campana, F, et.al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study., Eur J Cancer, 2011. 47 (1)(1): p. 65-73., https://pubmed.ncbi.nlm.nih.gov/20843680/
928. Aboudaram, A, Loap, P, Loirat, D, Dhia, SB, Cao, K, Fourquet, A, et.al. Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression., Cancers (Basel), 2021. 13 (19)(19):, https://pubmed.ncbi.nlm.nih.gov/34638275/
929. de Azambuja, E, Agostinetto, E, Procter, M, Eiger, D, Pondé, N, Guillaume, S, et.al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial., ESMO Open, 2023. 8 (1)(1): p. 100772., https://pubmed.ncbi.nlm.nih.gov/36681013/
930. von Minckwitz, G, Procter, M, de Azambuja, E, Zardavas, D, Benyunes, M, Viale, G, et.al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer., N Engl J Med, 2017. 377 (2)(2): p. 122-131., https://pubmed.ncbi.nlm.nih.gov/28581356/
931. von Minckwitz, G, Huang, CS, Mano, MS, Loibl, S, Mamounas, EP, Untch, M, et.al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer., N Engl J Med, 2019. 380 (7)(7): p. 617-628., https://pubmed.ncbi.nlm.nih.gov/30516102/
932. Bellon, JR, Tayob, N, Yang, DD, Tralins, J, Dang, CT, Isakoff, SJ, et.al. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer., Int J Radiat Oncol Biol Phys, 2022. 113 (1)(1): p. 117-124., https://pubmed.ncbi.nlm.nih.gov/34990776/
933. Salvestrini, V, Kim, K, Caini, S, Alkner, S, Ekholm, M, Skyttä, T, et.al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis., Radiother Oncol, 2023. 186 (): p. 109805., https://pubmed.ncbi.nlm.nih.gov/37437610/
934. Piroth, MD, Krug, D, Sedlmayer, F, Duma, MN, Baumann, R, Budach, W, et.al. Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?, Strahlenther Onkol, 2021. 197 (1)(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/32737515/
935. McArthur, Heather, Cortes, Javier, Dent, Rebecca, O’Shaughnessy, Joyce, Pusztai, Lajos, Küemmel, Sherko, et.al. Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study, 2023/03/01. 83: p. PD3 - 01.
936. Schmid, P, Cortes, J, Dent, R, Pusztai, L, McArthur, H, Kümmel, S, et.al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer., N Engl J Med, 2022. 386 (6)(6): p. 556-567., https://pubmed.ncbi.nlm.nih.gov/35139274/
937. Becherini, C, Visani, L, Caini, S, Bhattacharya, IS, Kirby, AM, Nader Marta, G, et.al. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis., Cancer Treat Rev, 2023. 119 (): p. 102586., https://pubmed.ncbi.nlm.nih.gov/37336117/
938. Balduzzi, A., Leonardi, M. C., Cardillo, A., Orecchia, R., Dellapasqua, S., Iorfida, M., et.al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy, Cancer Treat Rev, 2010. 36(6): p. 443-50., https://www.ncbi.nlm.nih.gov/pubmed/20304562
939. Benchalal, M., Le Prise, E., de Lafontan, B., Berton-Rigaud, D., Belkacemi, Y., Romestaing, P., et.al. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group, Cancer, 2005. 104(2): p. 240-50., https://www.ncbi.nlm.nih.gov/pubmed/15948160
940. Azria, D., Belkacemi, Y., Romieu, G., Gourgou, S., Gutowski, M., Zaman, K., et.al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial, Lancet Oncol, 2010. 11(3): p. 258-65., https://www.ncbi.nlm.nih.gov/pubmed/20138810
941. Bourgier, C., Kerns, S., Gourgou, S., Lemanski, C., Gutowski, M., Fenoglietto, P., et.al. Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial, Ann Oncol, 2016. 27(3): p. 474-80., https://www.ncbi.nlm.nih.gov/pubmed/26681684
942. Ishitobi, M., Komoike, Y., Motomura, K., Koyama, H., Nishiyama, K., Inaji, H., Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer, Anticancer Res, 2009. 29(11): p. 4791-4., https://www.ncbi.nlm.nih.gov/pubmed/20032437
943. Ishitobi, M., Nakahara, S., Komoike, Y., Motomura, K., Koyama, H., Inaji, H., Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy, Anticancer Res, 2011. 31(1): p. 367-71., https://www.ncbi.nlm.nih.gov/pubmed/21273625
944. Ishitobi, M., Shiba, M., Nakayama, T., Motomura, K., Koyama, H., Nishiyama, K., et.al. Treatment sequence of aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients, Anticancer Res, 2014. 34(8): p. 4311-4., https://www.ncbi.nlm.nih.gov/pubmed/25075064
945. Tsoutsou, P. G., Belkacemi, Y., Gligorov, J., Kuten, A., Boussen, H., Bese, N., et.al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider, Oncologist, 2010. 15(11): p. 1169-78., https://www.ncbi.nlm.nih.gov/pubmed/21041378
946. Schmid, P, Cortes, J, Pusztai, L, McArthur, H, Kümmel, S, Bergh, J, et.al. Pembrolizumab for Early Triple-Negative Breast Cancer., N Engl J Med, 2020. 382 (9)(9): p. 810-821., https://pubmed.ncbi.nlm.nih.gov/32101663/
947. Gnant, M, Dueck, AC, Frantal, S, Martin, M, Burstein, HJ, Greil, R, et.al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)., J Clin Oncol, 2022. 40 (3)(3): p. 282-293., https://pubmed.ncbi.nlm.nih.gov/34874182/
948. Loibl, S, Marmé, F, Martin, M, Untch, M, Bonnefoi, H, Kim, SB, et.al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial., J Clin Oncol, 2021. 39 (14)(14): p. 1518-1530., https://pubmed.ncbi.nlm.nih.gov/33793299/
949. Loap, P, Loirat, D, Berger, F, Rodrigues, M, Bazire, L, Pierga, JY, et.al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial., JAMA Oncol, 2022. 8 (12)(12): p. 1802-1808., https://pubmed.ncbi.nlm.nih.gov/36301572/
950. Jagsi, R, Griffith, KA, Bellon, JR, Woodward, WA, Horton, JK, Ho, A, et.al. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study., J Clin Oncol, 2018. 36 (13)(13): p. 1317-1322., https://pubmed.ncbi.nlm.nih.gov/29558281/
951. Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., et.al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline, J Clin Oncol, 2016. 34(6): p. 611-35., https://www.ncbi.nlm.nih.gov/pubmed/26644543
952. Grunfeld, E., Dhesy-Thind, S., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update), Cmaj, 2005. 172(10): p. 1319-20., https://www.ncbi.nlm.nih.gov/pubmed/15883407
953. Hauner, D., Janni, W., Rack, B., Hauner, H., The effect of overweight and nutrition on prognosis in breast cancer, Dtsch Arztebl Int, 2011. 108(47): p. 795-801., https://www.ncbi.nlm.nih.gov/pubmed/22190993
954. Rijnsburger, A. J., Obdeijn, I. M., Kaas, R., Tilanus-Linthorst, M. M., Boetes, C., Loo, C. E., et.al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study, Journal of Clinical Oncology, 2010. 28(36): p. 5265-73., https://www.ncbi.nlm.nih.gov/pubmed/21079137
955. Voskuil, D. W., van Nes, J. G., Junggeburt, J. M., van de Velde, C. J., van Leeuwen, F. E., de Haes, J. C., Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients, Ann Oncol, 2010. 21(10): p. 2094-101., https://www.ncbi.nlm.nih.gov/pubmed/20357033
956. Rock, C. L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., et.al. Nutrition and physical activity guidelines for cancer survivors, CA Cancer J Clin, 2012. 62(4): p. 243-74., https://www.ncbi.nlm.nih.gov/pubmed/22539238
957. Campbell, KL, Winters-Stone, KM, Wiskemann, J, May, AM, Schwartz, AL, Courneya, KS, et.al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable., Med Sci Sports Exerc, 2019. 51 (11)(11): p. 2375-2390., https://pubmed.ncbi.nlm.nih.gov/31626055/
958. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., Thun, M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 2003. 348(17): p. 1625-38., https://www.ncbi.nlm.nih.gov/pubmed/12711737
959. Ewertz, M., Jensen, M. B., Gunnarsdottir, K. A., Hojris, I., Jakobsen, E. H., Nielsen, D., et.al. Effect of obesity on prognosis after early-stage breast cancer, J Clin Oncol, 2011. 29(1): p. 25-31., https://www.ncbi.nlm.nih.gov/pubmed/21115856
960. Friedenreich, C. M., Gregory, J., Kopciuk, K. A., Mackey, J. R., Courneya, K. S., Prospective cohort study of lifetime physical activity and breast cancer survival, Int J Cancer, 2009. 124(8): p. 1954-62., https://www.ncbi.nlm.nih.gov/pubmed/19123472
961. Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., et.al. NCCN Task Force Report: Bone Health In Cancer Care, J Natl Compr Canc Netw, 2013. 11 Suppl 3: p. S1-50; quiz S51., https://www.ncbi.nlm.nih.gov/pubmed/23997241
962. Underwood, J. M., Townsend, J. S., Stewart, S. L., Buchannan, N., Ekwueme, D. U., Hawkins, N. A., et.al. Surveillance of demographic characteristics and health behaviors among adult cancer survivors--Behavioral Risk Factor Surveillance System, United States, 2009, MMWR Surveill Summ, 2012. 61(1): p. 1-23., https://www.ncbi.nlm.nih.gov/pubmed/22258477
963. Ballard-Barbash, R., Friedenreich, C. M., Courneya, K. S., Siddiqi, S. M., McTiernan, A., Alfano, C. M., Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review, J Natl Cancer Inst, 2012. 104(11): p. 815-40., https://www.ncbi.nlm.nih.gov/pubmed/22570317
964. Forbes, C. C., Blanchard, C. M., Mummery, W. K., Courneya, K., Prevalence and correlates of strength exercise among breast, prostate, and colorectal cancer survivors, Oncol Nurs Forum, 2015. 42(2): p. 118-27., https://www.ncbi.nlm.nih.gov/pubmed/25806879
965. Baumann, FT, Jensen, W, Berling-Ernst, A, Theurich, S, Leitzmann, M, Götte, M, Exercise Therapy in Oncology—the Impact on Quality of Life and Side Effects., Dtsch Arztebl Int, 2024. 121 (10)(10): p. 331-337., https://pubmed.ncbi.nlm.nih.gov/38509786/
966. Cheema, B. S., Kilbreath, S. L., Fahey, P. P., Delaney, G. P., Atlantis, E., Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis, Breast Cancer Res Treat, 2014. 148(2): p. 249-68., https://www.ncbi.nlm.nih.gov/pubmed/25324019
967. Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., et.al. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy, Br J Cancer, 2014. 111(9): p. 1718-25., https://www.ncbi.nlm.nih.gov/pubmed/25144625
968. Irwin, M. L., Cartmel, B., Gross, C. P., Ercolano, E., Li, F., Yao, X., et.al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors, J Clin Oncol, 2015. 33(10): p. 1104-11., https://www.ncbi.nlm.nih.gov/pubmed/25452437
969. Steindorf, K., Schmidt, M. E., Klassen, O., Ulrich, C. M., Oelmann, J., Habermann, N., et.al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life, Ann Oncol, 2014. 25(11): p. 2237-43., https://www.ncbi.nlm.nih.gov/pubmed/25096607
970. De Groef, A., Van Kampen, M., Dieltjens, E., Christiaens, M. R., Neven, P., Geraerts, I., et.al. Effectiveness of postoperative physical therapy for upper-limb impairments after breast cancer treatment: a systematic review, Arch Phys Med Rehabil, 2015. 96(6): p. 1140-53., https://www.ncbi.nlm.nih.gov/pubmed/25595999
971. Loh, S. Y., Musa, A. N., Methods to improve rehabilitation of patients following breast cancer surgery: a review of systematic reviews, Breast Cancer (Dove Med Press), 2015. 7: p. 81-98., https://www.ncbi.nlm.nih.gov/pubmed/25792854
972. Crew, K. D., Capodice, J. L., Greenlee, H., Brafman, L., Fuentes, D., Awad, D., et.al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer, J Clin Oncol, 2010. 28(7): p. 1154-60., https://www.ncbi.nlm.nih.gov/pubmed/20100963
973. Mishra, S. I., Scherer, R. W., Geigle, P. M., Berlanstein, D. R., Topaloglu, O., Gotay, C. C., et.al. Exercise interventions on health-related quality of life for cancer survivors, Cochrane Database Syst Rev, 2012. p. Cd007566., https://www.ncbi.nlm.nih.gov/pubmed/22895961
974. Keilani, M., Hasenoehrl, T., Neubauer, M., Crevenna, R., Resistance exercise and secondary lymphedema in breast cancer survivors-a systematic review, Support Care Cancer, 2016. 24(4): p. 1907-16., https://www.ncbi.nlm.nih.gov/pubmed/26715294
975. Nelson, N. L., Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic Review, J Strength Cond Res, 2016. 30(9): p. 2656-65., https://www.ncbi.nlm.nih.gov/pubmed/26840439
976. Bok, S. K., Jeon, Y., Hwang, P. S., Ultrasonographic Evaluation of the Effects of Progressive Resistive Exercise in Breast Cancer-Related Lymphedema, Lymphat Res Biol, 2016. 14(1): p. 18-24., https://www.ncbi.nlm.nih.gov/pubmed/26824517
977. Letellier, M. E., Towers, A., Shimony, A., Tidhar, D., Breast cancer-related lymphedema: a randomized controlled pilot and feasibility study, Am J Phys Med Rehabil, 2014. 93(9): p. 751-9; quiz 760-1., https://www.ncbi.nlm.nih.gov/pubmed/24743455
978. Cormie, P., Galvao, D. A., Spry, N., Newton, R. U., Neither heavy nor light load resistance exercise acutely exacerbates lymphedema in breast cancer survivor, Integr Cancer Ther, 2013. 12(5): p. 423-32., https://www.ncbi.nlm.nih.gov/pubmed/23439658
979. Cormie, P., Pumpa, K., Galvao, D. A., Turner, E., Spry, N., Saunders, C., et.al. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial, J Cancer Surviv, 2013. 7(3): p. 413-24., https://www.ncbi.nlm.nih.gov/pubmed/23604998
980. Lin, Y, Wu, C, He, C, Yan, J, Chen, Y, Gao, L, et.al. Effectiveness of three exercise programs and intensive follow-up in improving quality of life, pain, and lymphedema among breast cancer survivors: a randomized, controlled 6-month trial., Support Care Cancer, 2022. 31 (1)(1): p. 9., https://pubmed.ncbi.nlm.nih.gov/36512157/
981. Oliveira, MMF, Gurgel, MSC, Amorim, BJ, Ramos, CD, Derchain, S, Furlan-Santos, N, et.al. Long term effects of manual lymphatic drainage and active exercises on physical morbidities, lymphoscintigraphy parameters and lymphedema formation in patients operated due to breast cancer: A clinical trial., PLoS One, 2018. 13 (1)(1): p. e0189176., https://pubmed.ncbi.nlm.nih.gov/29304140/
982. Global, B. M. I. Mortality Collaboration, Di Angelantonio, E., Bhupathiraju Sh, N., Wormser, D., Gao, P., Kaptoge, S., et.al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet, 2016. 388(10046): p. 776-86., https://www.ncbi.nlm.nih.gov/pubmed/27423262
983. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., Straif, K., Body Fatness and Cancer--Viewpoint of the IARC Working Group, N Engl J Med, 2016. 375(8): p. 794-8., https://www.ncbi.nlm.nih.gov/pubmed/27557308
984. Arnold, M., Pandeya, N., Byrnes, G., Renehan, A. G., Stevens, G. A., Ezzati, M., et.al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study, Lancet Oncol, 2015. 16(1): p. 36-46., https://www.ncbi.nlm.nih.gov/pubmed/25467404
985. Chan, D. S., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., et.al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies, Ann Oncol, 2014. 25(10): p. 1901-14., https://www.ncbi.nlm.nih.gov/pubmed/24769692
986. Reeves, M. M., Terranova, C. O., Eakin, E. G., Demark-Wahnefried, W., Weight loss intervention trials in women with breast cancer: a systematic review, Obes Rev, 2014. 15(9): p. 749-68., https://www.ncbi.nlm.nih.gov/pubmed/24891269
987. Demark-Wahnefried, W., Colditz, G. A., Rock, C. L., Sedjo, R. L., Liu, J., Wolin, K. Y., et.al. Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors, Breast Cancer Res Treat, 2015. 154(2): p. 329-37., https://www.ncbi.nlm.nih.gov/pubmed/26518022
988. Batsis, J. A., Gill, L. E., Masutani, R. K., Adachi-Mejia, A. M., Blunt, H. B., Bagley, P. J., et.al. Weight Loss Interventions in Older Adults with Obesity: A Systematic Review of Randomized Controlled Trials Since 2005, J Am Geriatr Soc, 2017. 65(2): p. 257-268., https://www.ncbi.nlm.nih.gov/pubmed/27641543
989. Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., et.al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study, J Natl Cancer Inst, 2006. 98(24): p. 1767-76., https://www.ncbi.nlm.nih.gov/pubmed/17179478
990. Pierce, J. P., Natarajan, L., Caan, B. J., Parker, B. A., Greenberg, E. R., Flatt, S. W., et.al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial, Jama, 2007. 298(3): p. 289-98., https://www.ncbi.nlm.nih.gov/pubmed/17635889
991. Toledo, E., Salas-Salvado, J., Donat-Vargas, C., Buil-Cosiales, P., Estruch, R., Ros, E., et.al. Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial, JAMA Intern Med, 2015. 175(11): p. 1752-60., https://www.ncbi.nlm.nih.gov/pubmed/26365989
992. Aune, D., Chan, D. S., Greenwood, D. C., Vieira, A. R., Rosenblatt, D. A., Vieira, R., et.al. Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies, Ann Oncol, 2012. 23(6): p. 1394-402., https://www.ncbi.nlm.nih.gov/pubmed/22234738
993. Guo, J., Wei, W., Zhan, L., Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies, Breast Cancer Res Treat, 2015. 151(1): p. 191-8., https://www.ncbi.nlm.nih.gov/pubmed/25893586
994. Dong, J. Y., Zhang, L., He, K., Qin, L. Q., Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies, Breast Cancer Res Treat, 2011. 127(1): p. 23-31., https://www.ncbi.nlm.nih.gov/pubmed/21442197
995. Oberritter, H, Schäbethal, K, von Ruesten, A, Boeing, H, The DGE nutrition circle—Presentation and basis of the food-related recommendations from the German Nutrition Society (DGE), Ernaehrungs Umschau international, 2013. 60(2): p. 24-29., https://www.ernaehrungs-umschau.de/fileadmin/Ernaehrungs-Umschau/pdfs/pdf_2013/02_13/EU02_2013_M076_M081___Eng024_Eng029.qxd.pdf
996. Wang, K, Li, F, Zhang, X, Li, Z, Li, H, Smoking increases risks of all-cause and breast cancer specific mortality in breast cancer individuals: a dose-response meta-analysis of prospective cohort studies involving 39725 breast cancer cases., Oncotarget, 2016. 7 (50)(50): p. 83134-83147., https://pubmed.ncbi.nlm.nih.gov/27863414/
997. Berube, S., Lemieux, J., Moore, L., Maunsell, E., Brisson, J., Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis, Breast Cancer Res, 2014. 16(2): p. R42., https://www.ncbi.nlm.nih.gov/pubmed/24745601
998. Nechuta, S., Chen, W. Y., Cai, H., Poole, E. M., Kwan, M. L., Flatt, S. W., et.al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis, Int J Cancer, 2016. 138(9): p. 2088-97., https://www.ncbi.nlm.nih.gov/pubmed/26606746
999. Kwan, ML, Kushi, LH, Weltzien, E, Tam, EK, Castillo, A, Sweeney, C, et.al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study., J Clin Oncol, 2010. 28 (29)(29): p. 4410-6., https://pubmed.ncbi.nlm.nih.gov/20805458/
1000. Nomura, T, Kawai, M, Fukuma, Y, Koike, Y, Ozaki, S, Iwasaki, M, et.al. Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition., Breast Cancer, 2023. 30 (4)(4): p. 519-530., https://pubmed.ncbi.nlm.nih.gov/37029889/
1001. Sun, Q, Xie, W, Wang, Y, Chong, F, Song, M, Li, T, et.al. Alcohol Consumption by Beverage Type and Risk of Breast Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies., Alcohol Alcohol, 2020. 55 (3)(3): p. 246-253., https://pubmed.ncbi.nlm.nih.gov/32090238/
1002. Simapivapan, P, Boltong, A, Hodge, A, To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review., Cancer Treat Rev, 2016. 50 (): p. 155-167., https://pubmed.ncbi.nlm.nih.gov/27693930/
1003. Chen, JY, Zhu, HC, Guo, Q, Shu, Z, Bao, XH, Sun, F, et.al. Dose-Dependent Associations between Wine Drinking and Breast Cancer Risk - Meta-Analysis Findings., Asian Pac J Cancer Prev, 2016. 17 (3)(3): p. 1221-33., https://pubmed.ncbi.nlm.nih.gov/27039752/
1004. Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B., Senn, H. J., et.al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 2011. 22(8): p. 1736-47., https://www.ncbi.nlm.nih.gov/pubmed/21709140
1005. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials., Lancet, 2019. 393 (10179)(10179): p. 1440-1452., https://pubmed.ncbi.nlm.nih.gov/30739743/
1006. Kerr, AJ, Dodwell, D, McGale, P, Holt, F, Duane, F, Mannu, G, et.al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality., Cancer Treat Rev, 2022. 105 (): p. 102375., https://pubmed.ncbi.nlm.nih.gov/35367784/
1007. Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., et.al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update, J Clin Oncol, 2006. 24(12): p. 1940-9., https://www.ncbi.nlm.nih.gov/pubmed/16622270
1008. Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., et.al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 2011. 378(9793): p. 771-84., https://www.ncbi.nlm.nih.gov/pubmed/21802721
1009. Fisher, B., Dignam, J., Wolmark, N., DeCillis, A., Emir, B., Wickerham, D. L., et.al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J Natl Cancer Inst, 1997. 89(22): p. 1673-82., https://www.ncbi.nlm.nih.gov/pubmed/9390536
1010. Thuerlimann, B, Price, KN, Castiglione, M, Coates, AS, Goldhirsch, A, Gelber, RD, et.al. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93, The Breast, 2001. 10: p. 130-138.
1011. Blamey, R. W., Bates, T., Chetty, U., Duffy, S. W., Ellis, I. O., George, D., et.al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial, Eur J Cancer, 2013. 49(10): p. 2294-302., https://www.ncbi.nlm.nih.gov/pubmed/23523089
1012. Tamoxifen for early breast cancer., Cochrane Database Syst Rev, 2001. (1)(1): p. CD000486., https://pubmed.ncbi.nlm.nih.gov/11279694/
1013. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials., Lancet, 2015. 386 (10001)(10001): p. 1341-1352., https://pubmed.ncbi.nlm.nih.gov/26211827/
1014. Pan, H, Gray, R, Braybrooke, J, Davies, C, Taylor, C, McGale, P, et.al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years., N Engl J Med, 2017. 377 (19)(19): p. 1836-1846., https://pubmed.ncbi.nlm.nih.gov/29117498/
1015. Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, et.al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial., Lancet, 2013. 381 (9869)(9869): p. 805-16., https://pubmed.ncbi.nlm.nih.gov/23219286/
1016. Goss, PE, Ingle, JN, Pater, JL, Martino, S, Robert, NJ, Muss, HB, et.al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen., J Clin Oncol, 2008. 26 (12)(12): p. 1948-55., https://pubmed.ncbi.nlm.nih.gov/18332475/
1017. Gnant, M, Fitzal, F, Rinnerthaler, G, Steger, GG, Greil-Ressler, S, Balic, M, et.al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer., N Engl J Med, 2021. 385 (5)(5): p. 395-405., https://pubmed.ncbi.nlm.nih.gov/34320285/
1018. Blok, EJ, Kroep, JR, Meershoek-Klein Kranenbarg, E, Duijm-de Carpentier, M, Putter, H, van den Bosch, J, et.al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)., J Natl Cancer Inst, 2018. 110 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/28922787/
1019. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials., Lancet Oncol, 2022. 23 (3)(3): p. 382-392., https://pubmed.ncbi.nlm.nih.gov/35123662/
1020. Johansson, A, Dar, H, van 't Veer, LJ, Tobin, NP, Perez-Tenorio, G, Nordenskjöld, A, et.al. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial., J Clin Oncol, 2022. 40 (35)(35): p. 4071-4082., https://pubmed.ncbi.nlm.nih.gov/35862873/
1021. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials., Lancet Oncol, 2022. 23 (3)(3): p. 382-392., https://pubmed.ncbi.nlm.nih.gov/35123662/
1022. Pagani, O, Walley, BA, Fleming, GF, Colleoni, M, Láng, I, Gomez, HL, et.al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials., J Clin Oncol, 2023. 41 (7)(7): p. 1376-1382., https://pubmed.ncbi.nlm.nih.gov/36521078/
1023. Baek, SY, Noh, WC, Ahn, SH, Kim, HA, Ryu, JM, Kim, SI, et.al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial., J Clin Oncol, 2023. 41 (31)(31): p. 4864-4871., https://pubmed.ncbi.nlm.nih.gov/37607321/
1024. Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Knauer, M, Moik, M, et.al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12., Ann Oncol, 2015. 26 (2)(2): p. 313-20., https://pubmed.ncbi.nlm.nih.gov/25403582/
1025. Eisen, Andrea, Fletcher, Glenn G, Gandhi, Sonal, Mates, Mihaela, Freedman, Orit C, Dent, Susan F, et.al. Optimal Systemic Therapy for Early Female Breast Cancer, Evidence-based series, 2014. p. 1-21.
1026. Pistilli, B, Lohrisch, C, Sheade, J, Fleming, GF, Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer., Am Soc Clin Oncol Educ Book, 2022. 42 (): p. 1-13., https://pubmed.ncbi.nlm.nih.gov/35623026/
1027. Dannehl, Dominik, Engler, Tobias, Dijkstra, Tjeerd, Gutsfeld, Raphael, von Au, Alexandra, Hahn, Markus, et.al. Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis.Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 551 - 551., https://doi.org/10.1200/JCO.2023.41.16_suppl.551
1028. Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., et.al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry, J Clin Oncol, 2012. 30(7): p. 729-34., https://www.ncbi.nlm.nih.gov/pubmed/22291085
1029. Denkert, C, Huober, J, Loibl, S, Prinzler, J, Kronenwett, R, Darb-Esfahani, S, et.al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer., Breast Cancer Res, 2013. 15 (1)(1): p. R11., https://pubmed.ncbi.nlm.nih.gov/23391338/
1030. Raghav, KP, Hernandez-Aya, LF, Lei, X, Chavez-Macgregor, M, Meric-Bernstam, F, Buchholz, TA, et.al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers., Cancer, 2012. 118 (6)(6): p. 1498-506., https://pubmed.ncbi.nlm.nih.gov/21837669/
1031. Yi, M, Huo, L, Koenig, KB, Mittendorf, EA, Meric-Bernstam, F, Kuerer, HM, et.al. Which threshold for ER positivity? a retrospective study based on 9639 patients., Ann Oncol, 2014. 25 (5)(5): p. 1004-11., https://pubmed.ncbi.nlm.nih.gov/24562447/
1032. Bouchard-Fortier, A, Provencher, L, Blanchette, C, Diorio, C, Prognostic and predictive value of low estrogen receptor expression in breast cancer., Curr Oncol, 2017. 24 (2)(2): p. e106-e114., https://pubmed.ncbi.nlm.nih.gov/28490933/
1033. Gluz, Oleg, Christgen, Matthias, Kuemmel, Sherko, zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, et.al. Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.Wolters Kluwer, Journal of Clinical Oncology 40(16_suppl): p. 536 - 536., https://doi.org/10.1200/JCO.2022.40.16_suppl.536
1034. Choong, Grace Mei Yee, Hoskin, Tanya L., Boughey, Judy Caroline, Ingle, James N., Goetz, Matthew P., The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.Wolters Kluwer, Journal of Clinical Oncology, 2024. 42(16_suppl): p. 513 - 513., https://doi.org/10.1200/JCO.2024.42.16_suppl.513
1035. Madigan, LI, Dinh, P, Graham, JD, Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines., Breast Cancer Res, 2020. 22 (1)(1): p. 77., https://pubmed.ncbi.nlm.nih.gov/32690069/
1036. Martins-Branco, D, Nader-Marta, G, Molinelli, C, Ameye, L, Paesmans, M, Ignatiadis, M, et.al. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis., Eur J Cancer, 2023. 194 (): p. 113358., https://pubmed.ncbi.nlm.nih.gov/37857118/
1037. Bui, KT, Willson, ML, Goel, S, Beith, J, Goodwin, A, Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer., Cochrane Database Syst Rev, 2020. 3 (3)(3): p. CD013538., https://pubmed.ncbi.nlm.nih.gov/32141074/
1038. Qian, X, Li, Z, Ruan, G, Tu, C, Ding, W, Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials., Breast Cancer Res Treat, 2020. 179 (2)(2): p. 275-285., https://pubmed.ncbi.nlm.nih.gov/31606823/
1039. Leitlinienprogramm Onkologie, Evidenzaufbereitung der AMNOG-Daten zu medikamentösen Therapien beim frühen Mammakarzinom, Evidenzbericht zu Version 5 der S3-Leitlinie Mammakarzinom, 2025., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
1040. Slamon, D, Lipatov, O, Nowecki, Z, McAndrew, N, Kukielka-Budny, B, Stroyakovskiy, D, et.al. Ribociclib plus Endocrine Therapy in Early Breast Cancer., N Engl J Med, 2024. 390 (12)(12): p. 1080-1091., https://pubmed.ncbi.nlm.nih.gov/38507751/
1041. Desmedt, C., Turner, N., Arteaga, C., Sasano, H., Graff, S.L., Loi, S., et.al. 3MO Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchEElsevier, ESMO Open, 2024. 9:, https://doi.org/10.1016/j.esmoop.2024.103013
1042. Mason, SR, Willson, ML, Egger, SJ, Beith, J, Dear, RF, Goodwin, A, Platinum-based chemotherapy for early triple-negative breast cancer., Cochrane Database Syst Rev, 2023. 9 (9)(9): p. CD014805., https://pubmed.ncbi.nlm.nih.gov/37681577/
1043. Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos, Freedman, Rachel, Waks, Adrienne, Martínez-Sáez, Olga, et.al. Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study., 2023/06/01. 41: p. 510 - 510.
1044. Pusztai, L, Denkert, C, O'Shaughnessy, J, Cortes, J, Dent, R, McArthur, H, et.al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522., Ann Oncol, 2024. 35 (5)(5): p. 429-436., https://pubmed.ncbi.nlm.nih.gov/38369015/
1045. Schmid, P, Cortes, J, Dent, R, McArthur, H, Pusztai, L, Kümmel, S, et.al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer., N Engl J Med, 2024. 391 (21)(21): p. 1981-1991., https://pubmed.ncbi.nlm.nih.gov/39282906/
1046. van Mackelenbergh, MT, Seither, F, Möbus, V, O'Shaughnessy, J, Martin, M, Joensuu, H, et.al. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients., Eur J Cancer, 2022. 166 (): p. 185-201., https://pubmed.ncbi.nlm.nih.gov/35305453/
1047. Masuda, N, Lee, SJ, Ohtani, S, Im, YH, Lee, ES, Yokota, I, et.al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy., N Engl J Med, 2017. 376 (22)(22): p. 2147-2159., https://pubmed.ncbi.nlm.nih.gov/28564564/
1048. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials., Lancet Oncol, 2021. 22 (8)(8): p. 1139-1150., https://pubmed.ncbi.nlm.nih.gov/34339645/
1049. Petrelli, Fausto, Barni, Sandro, Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better, Medical Oncology, 2012. 29(2): p. 503-510., https://www.ncbi.nlm.nih.gov/pubmed/21400217
1050. Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., et.al. Trastuzumab containing regimens for early breast cancer, Cochrane Database Syst Rev, 2012. p. Cd006243., https://www.ncbi.nlm.nih.gov/pubmed/22513938
1051. Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., et.al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 2009. 27(34): p. 5700-6., https://www.ncbi.nlm.nih.gov/pubmed/19884543
1052. Banerjee, S., Smith, I. E., Management of small HER2-positive breast cancers, Lancet Oncol, 2010. 11(12): p. 1193-9., https://www.ncbi.nlm.nih.gov/pubmed/21126688
1053. Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., et.al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer, J Clin Oncol, 2009. 27(34): p. 5693-9., https://www.ncbi.nlm.nih.gov/pubmed/19884553
1054. Horio, Akiyo, Fujita, Takashi, Hayashi, Hironori, Hattori, Masaya, Kondou, Naoto, Yamada, Mai, et.al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers, International journal of clinical oncology, 2012. 17(2): p. 131-136., https://pubmed.ncbi.nlm.nih.gov/21681642/
1055. Kelly, C. M., Pritchard, K. I., Trudeau, M., Andreopoulou, E., Hess, K., Pusztai, L., Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?, Ann Oncol, 2011. 22(11): p. 2387-93., https://www.ncbi.nlm.nih.gov/pubmed/21406473
1056. McArthur, H. L., Mahoney, K. M., Morris, P. G., Patil, S., Jacks, L. M., Howard, J., et.al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer, Cancer, 2011. 117(24): p. 5461-8., https://www.ncbi.nlm.nih.gov/pubmed/21681735
1057. Rodrigues, M. J., Wassermann, J., Albiges, L., Brain, E., Delaloge, S., Stevens, D., et.al. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas, J Clin Oncol, 2010. 28(28): p. e541-2., https://www.ncbi.nlm.nih.gov/pubmed/20660834
1058. Theriault, R. L., Litton, J. K., Mittendorf, E. A., Chen, H., Meric-Bernstam, F., Chavez-Macgregor, M., et.al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype, Clin Breast Cancer, 2011. 11(5): p. 325-31., https://www.ncbi.nlm.nih.gov/pubmed/21764391
1059. Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., et.al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial, Ann Oncol, 2008. 19(6): p. 1090-6., https://www.ncbi.nlm.nih.gov/pubmed/18296421
1060. Zhou, Q., Yin, W., Du, Y., Lu, J., For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures, PLoS One, 2014. 9(1): p. e83646., https://www.ncbi.nlm.nih.gov/pubmed/24392090
1061. Tolaney, SM, Tarantino, P, Graham, N, Tayob, N, Parè, L, Villacampa, G, et.al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial., Lancet Oncol, 2023. 24 (3)(3): p. 273-285., https://pubmed.ncbi.nlm.nih.gov/36858723/
1062. Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., et.al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 2015. 372(2): p. 134-41., https://www.ncbi.nlm.nih.gov/pubmed/25564897
1063. Cortazar, P, Zhang, L, Untch, M, Mehta, K, Costantino, JP, Wolmark, N, et.al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis., Lancet, 2014. 384 (9938)(9938): p. 164-72., https://pubmed.ncbi.nlm.nih.gov/24529560/
1064. Chen, S, Liang, Y, Feng, Z, Wang, M, Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis., BMC Cancer, 2019. 19 (1)(1): p. 973., https://pubmed.ncbi.nlm.nih.gov/31638935/
1065. Piccart, M, Procter, M, Fumagalli, D, de Azambuja, E, Clark, E, Ewer, MS, et.al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up., J Clin Oncol, 2021. 39 (13)(13): p. 1448-1457., https://pubmed.ncbi.nlm.nih.gov/33539215/
1066. Loibl, S, Jassem, J, Sonnenblick, A, Parlier, D, Winer, E, Bergh, J, et.al. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update., J Clin Oncol, 2024. 42 (31)(31): p. 3643-3651., https://pubmed.ncbi.nlm.nih.gov/39259927/
1067. Schneeweiss, A, Chia, S, Hickish, T, Harvey, V, Eniu, A, Hegg, R, et.al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Annals of oncology, 2013. 24(9): p. 2278-2284., https://www.ncbi.nlm.nih.gov/pubmed/23704196
1068. Schneeweiss, A, Chia, S, Hickish, T, Harvey, V, Eniu, A, Waldron-Lynch, M, et.al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer., Eur J Cancer, 2018. 89 (): p. 27-35., https://pubmed.ncbi.nlm.nih.gov/29223479/
1069. van Ramshorst, MS, van der Voort, A, van Werkhoven, ED, Mandjes, IA, Kemper, I, Dezentjé, VO, et.al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2018. 19 (12)(12): p. 1630-1640., https://pubmed.ncbi.nlm.nih.gov/30413379/
1070. van Ramshorst, MS, van Werkhoven, E, Honkoop, AH, Dezentjé, VO, Oving, IM, Mandjes, IA, et.al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study., Breast, 2016. 29 (): p. 153-9., https://pubmed.ncbi.nlm.nih.gov/27498129/
1071. van der Voort, A, van Ramshorst, MS, van Werkhoven, ED, Mandjes, IA, Kemper, I, Vulink, AJ, et.al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial., JAMA Oncol, 2021. 7 (7)(7): p. 978-984., https://pubmed.ncbi.nlm.nih.gov/34014249/
1072. Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., et.al. Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 2011. 365(14): p. 1273-83., https://www.ncbi.nlm.nih.gov/pubmed/21991949
1073. Geyer, CE, Untch, M, Huang, CS, Mano, MS, Mamounas, EP, Wolmark, N, et.al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer., N Engl J Med, 2025. 392 (3)(3): p. 249-257., https://pubmed.ncbi.nlm.nih.gov/39813643/
1074. Martin, M, Holmes, FA, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, et.al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2017. 18 (12)(12): p. 1688-1700., https://pubmed.ncbi.nlm.nih.gov/29146401/
1075. Holmes, FA, Moy, B, Delaloge, S, Chia, SKL, Ejlertsen, B, Mansi, J, et.al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial., Eur J Cancer, 2023. 184 (): p. 48-59., https://pubmed.ncbi.nlm.nih.gov/36898233/
1076. Pfeilschifter, J., Diel, I. J., Osteoporosis due to cancer treatment: pathogenesis and management, J Clin Oncol, 2000. 18(7): p. 1570-93., https://www.ncbi.nlm.nih.gov/pubmed/10735906
1077. Lee, YK, Lee, EG, Kim, HY, Lee, Y, Lee, SM, Suh, DC, et.al. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis., J Korean Med Sci, 2020. 35 (46)(46): p. e403., https://pubmed.ncbi.nlm.nih.gov/33258332/
1078. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., et.al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 2009. 360(7): p. 679-91., https://www.ncbi.nlm.nih.gov/pubmed/19213681
1079. Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., et.al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, Lancet Oncol, 2011. 12(7): p. 631-41., https://www.ncbi.nlm.nih.gov/pubmed/21641868
1080. Hadji, P., Kauka, A., Ziller, M., Birkholz, K., Baier, M., Muth, M., et.al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study, Osteoporos Int, 2014. 25(4): p. 1369-78., https://www.ncbi.nlm.nih.gov/pubmed/24504100
1081. Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., et.al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2015. 386(9992): p. 433-43., https://www.ncbi.nlm.nih.gov/pubmed/26040499
1082. Kalder, M., Hans, D., Kyvernitakis, I., Lamy, O., Bauer, M., Hadji, P., Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer, J Clin Densitom, 2014. 17(1): p. 66-71., https://www.ncbi.nlm.nih.gov/pubmed/23562130
1083. Hadji, P., Asmar, L., van Nes, J. G., Menschik, T., Hasenburg, A., Kuck, J., et.al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies, J Cancer Res Clin Oncol, 2011. 137(6): p. 1015-25., https://www.ncbi.nlm.nih.gov/pubmed/21170551
1084. Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thurlimann, B., et.al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial, Ann Oncol, 2009. 20(9): p. 1489-98., https://www.ncbi.nlm.nih.gov/pubmed/19474112
1085. Tseng, OL, Spinelli, JJ, Gotay, CC, Ho, WY, McBride, ML, Dawes, MG, Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis., Ther Adv Musculoskelet Dis, 2018. 10 (4)(4): p. 71-90., https://pubmed.ncbi.nlm.nih.gov/29619093/
1086. Goldvaser, H, Barnes, TA, Šeruga, B, Cescon, DW, Ocaña, A, Ribnikar, D, et.al. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis., J Natl Cancer Inst, 2018. 110 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/28922781/
1087. DVO, S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50.Lebensjahr, 2023., https://register.awmf.org/de/leitlinien/detail/183-001
1088. Greep, N. C., Giuliano, A. E., Hansen, N. M., Taketani, T., Wang, H. J., Singer, F. R., The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer, Am J Med, 2003. 114(8): p. 653-9., https://www.ncbi.nlm.nih.gov/pubmed/12798453
1089. Hadji, P., Ziller, M., Maskow, C., Albert, U., Kalder, M., The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer, Eur J Cancer, 2009. 45(18): p. 3205-12., https://www.ncbi.nlm.nih.gov/pubmed/19850468
1090. Coleman, R., Cameron, D., Dodwell, D., Bell, R., Wilson, C., Rathbone, E., et.al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial, Lancet Oncol, 2014. 15(9): p. 997-1006., https://www.ncbi.nlm.nih.gov/pubmed/25035292
1091. Col, N. F., Hirota, L. K., Orr, R. K., Erban, J. K., Wong, J. B., Lau, J., Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk, J Clin Oncol, 2001. 19(8): p. 2357-63., https://www.ncbi.nlm.nih.gov/pubmed/11304788
1092. Col, N. F., Hirota, L. K., Orr, R. K., Erban, J. K., Wong, J. B., Lau, J., Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk, J Clin Oncol, 2001. 19(8): p. 2357-63., https://www.ncbi.nlm.nih.gov/pubmed/11304788
1093. Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., et.al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2015. 386(9992): p. 433-43., https://www.ncbi.nlm.nih.gov/pubmed/26040499
1094. Mei, M, Xiang, Z, Yang, J, Xiang, R, Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials., Curr Probl Cancer, 2020. 44 (2)(2): p. 100507., https://pubmed.ncbi.nlm.nih.gov/31732237/
1095. Pantel, K., Alix-Panabieres, C., Riethdorf, S., Cancer micrometastases, Nat Rev Clin Oncol, 2009. 6(6): p. 339-51., https://www.ncbi.nlm.nih.gov/pubmed/19399023
1096. Wilson, C., Holen, I., Coleman, R. E., Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates, Cancer Treat Rev, 2012. 38(7): p. 877-89., https://www.ncbi.nlm.nih.gov/pubmed/22398187
1097. Domschke, C., Diel, I. J., Englert, S., Kalteisen, S., Mayer, L., Rom, J., et.al. Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study, Ann Surg Oncol, 2013. 20(6): p. 1865-71., https://www.ncbi.nlm.nih.gov/pubmed/23263703
1098. Banys, M., Solomayer, E. F., Gebauer, G., Janni, W., Krawczyk, N., Lueck, H. J., et.al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial, BMC Cancer, 2013. 13: p. 480., https://www.ncbi.nlm.nih.gov/pubmed/24128322
1099. de Groot, AF, Appelman-Dijkstra, NM, van der Burg, SH, Kroep, JR, The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review., Cancer Treat Rev, 2018. 62 (): p. 18-28., https://pubmed.ncbi.nlm.nih.gov/29154022/
1100. Wang, SF, Lin, YS, Yeh, WY, Chang, YL, Chiang, CE, Chen, CH, et.al. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis., J Clin Endocrinol Metab, 2023. 108 (11)(11): p. e1433-e1447., https://pubmed.ncbi.nlm.nih.gov/37170778/
1101. Coleman, R., Powles, T., Paterson, A., Gnant, M., Anderson, S., Diel, I., et.al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 2015. 386(10001): p. 1353-61., https://www.ncbi.nlm.nih.gov/pubmed/26211824
1102. Liu, Y, Zhao, S, Zhang, Y, Onwuka, JU, Zhang, Q, Liu, X, Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies., Aging (Albany NY), 2021. 13 (15)(15): p. 19835-19866., https://pubmed.ncbi.nlm.nih.gov/34375305/
1103. Ben-Aharon, I., Vidal, L., Rizel, S., Yerushalmi, R., Shpilberg, O., Sulkes, A., et.al. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis, PLoS One, 2013. 8(8): p. e70044., https://www.ncbi.nlm.nih.gov/pubmed/23990894
1104. Eisen, A, Somerfield, MR, Accordino, MK, Blanchette, PS, Clemons, MJ, Dhesy-Thind, S, et.al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update., J Clin Oncol, 2022. 40 (7)(7): p. 787-800., https://pubmed.ncbi.nlm.nih.gov/35041467/
1105. Coleman, R., Body, J. J., Aapro, M., Hadji, P., Herrstedt, J., Bone health in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 2014. 25 Suppl 3: p. iii124-37., https://www.ncbi.nlm.nih.gov/pubmed/24782453
1106. Wong, Matthew HF, Stockler, Martin R, Pavlakis, Nick, Bisphosphonates and other bone agents for breast cancer, The Cochrane Library, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22336790
1107. Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., et.al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, 2012. 48(16): p. 3082-92., https://www.ncbi.nlm.nih.gov/pubmed/22975218
1108. Ibrahim, MFK, Mazzarello, S, Shorr, R, Vandermeer, L, Jacobs, C, Hilton, J, et.al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis, Annals of Oncology, 2015. 26(11): p. 2205-2213., https://pubmed.ncbi.nlm.nih.gov/26122727/
1109. Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., et.al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 2010. 28(35): p. 5132-9., https://www.ncbi.nlm.nih.gov/pubmed/21060033
1110. Grötz, KA, Piesold, JU, Al-Nawas, B, Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen, AWMF online, 2012. 4: p. 2012.
1111. Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., et.al. Breast-cancer adjuvant therapy with zoledronic acid, N Engl J Med, 2011. 365(15): p. 1396-405., https://www.ncbi.nlm.nih.gov/pubmed/21995387
1112. Jackson, C, Freeman, ALJ, Szlamka, Z, Spiegelhalter, DJ, The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis., PLoS One, 2021. 16 (2)(2): p. e0246441., https://pubmed.ncbi.nlm.nih.gov/33544765/
1113. Eik Schiegnitz, Bilal Al-Nawas, Sebastian Hoefert, Sven Otto, Christoph Pautke, Oliver Ristow, Pit Voss, Knut A. Grötz, Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ), 2018., https://register.awmf.org/assets/guidelines/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12.pdf
1114. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998. 351(9114): p. 1451-67., https://www.ncbi.nlm.nih.gov/pubmed/9605801
1115. Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., Wilson, K. S., Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy, Int J Radiat Oncol Biol Phys, 2000. 46(2): p. 355-62., https://www.ncbi.nlm.nih.gov/pubmed/10661342
1116. Huang, E., Buchholz, T. A., Meric, F., Krishnamurthy, S., Mirza, N. Q., Ames, F. C., et.al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences, Cancer, 2002. 95(10): p. 2059-67., https://www.ncbi.nlm.nih.gov/pubmed/12412158
1117. Newman, L. A., Kuerer, H. M., Hunt, K. K., Kroll, S. S., Ames, F. C., Ross, M. I., et.al. Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction, Ann Surg Oncol, 1998. 5(7): p. 620-6., https://www.ncbi.nlm.nih.gov/pubmed/9831111
1118. Taylor, M. E., Perez, C. A., Halverson, K. J., Kuske, R. R., Philpott, G. W., Garcia, D. M., et.al. Factors influencing cosmetic results after conservation therapy for breast cancer, Int J Radiat Oncol Biol Phys, 1995. 31(4): p. 753-64., https://www.ncbi.nlm.nih.gov/pubmed/7860386
1119. Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., Goodman, R. L., The results of radiation therapy for isolated local regional recurrence after mastectomy, Int J Radiat Oncol Biol Phys, 1991. 21(2): p. 299-310., https://www.ncbi.nlm.nih.gov/pubmed/2061107
1120. Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., Fineberg, B., Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis, Int J Radiat Oncol Biol Phys, 1992. 23(2): p. 285-91., https://www.ncbi.nlm.nih.gov/pubmed/1587748
1121. Moy, L., Newell, M. S., Mahoney, M. C., Bailey, L., Barke, L. D., Carkaci, S., et.al. ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women, J Am Coll Radiol, 2014. 11(12 Pt A): p. 1160-8., https://www.ncbi.nlm.nih.gov/pubmed/25444069
1122. Shah, C., Ahlawat, S., Khan, A., Tendulkar, R. D., Wazer, D. E., Shah, S. S., et.al. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy, Am J Clin Oncol, 2016. 39(3): p. 314-9., https://www.ncbi.nlm.nih.gov/pubmed/27203824
1123. Moy, L., Newell, M. S., Mahoney, M. C., Bailey, L., Barke, L. D., Carkaci, S., et.al. ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women, J Am Coll Radiol, 2014. 11(12 Pt A): p. 1160-8., https://www.ncbi.nlm.nih.gov/pubmed/25444069
1124. Shah, C., Ahlawat, S., Khan, A., Tendulkar, R. D., Wazer, D. E., Shah, S. S., et.al. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy, Am J Clin Oncol, 2016. 39(3): p. 314-9., https://www.ncbi.nlm.nih.gov/pubmed/27203824
1125. Moossdorff, M., van Roozendaal, L. M., Strobbe, L. J., Aebi, S., Cameron, D. A., Dixon, J. M., et.al. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research, J Natl Cancer Inst, 2014. 106(12):, https://www.ncbi.nlm.nih.gov/pubmed/25381395
1126. Witteveen, Annemieke, Kwast, Annemiek BG, Sonke, Gabe S, IJzerman, Maarten J, Siesling, Sabine, Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval, PloS one, 2015. 10(4): p. e0120832., https://www.ncbi.nlm.nih.gov/pubmed/25861031
1127. Houssami, N, Ciatto, S, Martinelli, F, Bonardi, R, Duffy, SW, Early detection of second breast cancers improves prognosis in breast cancer survivors, Annals of oncology, 2009. 20(9): p. 1505-1510., https://www.ncbi.nlm.nih.gov/pubmed/19297316
1128. Lu, W. L., Jansen, L., Post, W. J., Bonnema, J., Van de Velde, J. C., De Bock, G. H., Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis, Breast Cancer Res Treat, 2009. 114(3): p. 403-12., https://www.ncbi.nlm.nih.gov/pubmed/18421576
1129. Houssami, N., Abraham, L. A., Miglioretti, D. L., Sickles, E. A., Kerlikowske, K., Buist, D. S., et.al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer, Jama, 2011. 305(8): p. 790-9., https://www.ncbi.nlm.nih.gov/pubmed/21343578
1130. Robertson, C., Ragupathy, S. K., Boachie, C., Fraser, C., Heys, S. D., Maclennan, G., et.al. Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer: a systematic review, Eur Radiol, 2011. 21(12): p. 2484-91., https://www.ncbi.nlm.nih.gov/pubmed/21833567
1131. Robertson, C., Arcot Ragupathy, S. K., Boachie, C., Dixon, J. M., Fraser, C., Hernandez, R., et.al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation, Health Technol Assess, 2011. 15(34): p. v-vi, 1-322., https://www.ncbi.nlm.nih.gov/pubmed/21951942
1132. Hölzel, Dieter, Engel, Jutta, Schmidt, Michael, Sauer, Hansjörg, Modell zur primären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung, Strahlentherapie und Onkologie, 2001. 177(1): p. 10-24., https://pubmed.ncbi.nlm.nih.gov/11200108/
1133. Veronesi, Umberto, Marubini, Ettore, Del Vecchio, Marcella, Manzari, Antonia, Andreola, Salvatore, Greco, Marco, et.al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events, Journal of the National Cancer Institute, 1995. 87(1): p. 19-27., https://www.ncbi.nlm.nih.gov/pubmed/7666458
1134. Walstra, CJEF, Schipper, RJ, Poodt, IGM, van Riet, YE, Voogd, AC, van der Sangen, MJC, et.al. Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review., Eur J Surg Oncol, 2019. 45 (8)(8): p. 1317-1327., https://pubmed.ncbi.nlm.nih.gov/30795956/
1135. Montagne, L, Hannoun, A, Hannoun-Levi, JM, Second conservative treatment for second ipsilateral breast tumor event: A systematic review of the different re-irradiation techniques., Breast, 2020. 49 (): p. 274-280., https://pubmed.ncbi.nlm.nih.gov/31945697/
1136. Ge, I, Erbes, T, Juhasz-Böss, I, Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence: a systematic review of the literature., Arch Gynecol Obstet, 2022. 306 (4)(4): p. 943-957., https://pubmed.ncbi.nlm.nih.gov/35122159/
1137. Deutsch, M., Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation, Int J Radiat Oncol Biol Phys, 2002. 53(3): p. 687-91., https://www.ncbi.nlm.nih.gov/pubmed/12062613
1138. Haffty, B. G., Reiss, M., Beinfield, M., Fischer, D., Ward, B., McKhann, C., Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse, J Clin Oncol, 1996. 14(1): p. 52-7., https://www.ncbi.nlm.nih.gov/pubmed/8558220
1139. Kurtz, J. M., Jacquemier, J., Amalric, R., Brandone, H., Ayme, Y., Hans, D., et.al. Is breast conservation after local recurrence feasible?, Eur J Cancer, 1991. 27(3): p. 240-4., https://www.ncbi.nlm.nih.gov/pubmed/1827303
1140. Whelan, T., Clark, R., Roberts, R., Levine, M., Foster, G., Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group, Int J Radiat Oncol Biol Phys, 1994. 30(1): p. 11-6., https://www.ncbi.nlm.nih.gov/pubmed/8083103
1141. Jobsen, J. J., van der Palen, J., Meerwaldt, J. H., The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy, Eur J Cancer, 2001. 37(15): p. 1820-7., https://www.ncbi.nlm.nih.gov/pubmed/11576834
1142. Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., Haffty, B. G., Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation, Int J Radiat Oncol Biol Phys, 2005. 63(3): p. 845-51., https://www.ncbi.nlm.nih.gov/pubmed/16199315
1143. van der Sangen, M. J., van de Poll-Franse, L. V., Roumen, R. M., Rutten, H. J., Coebergh, J. W., Vreugdenhil, G., et.al. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma, Eur J Surg Oncol, 2006. 32(1): p. 34-8., https://www.ncbi.nlm.nih.gov/pubmed/16305821
1144. Maulard, C., Housset, M., Brunel, P., Delanian, S., Taurelle, R., Baillet, F., Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer, Am J Clin Oncol, 1995. 18(4): p. 348-52., https://www.ncbi.nlm.nih.gov/pubmed/7625378
1145. Newman, L. A., Kuerer, H. M., Advances in breast conservation therapy, J Clin Oncol, 2005. 23(8): p. 1685-97., https://www.ncbi.nlm.nih.gov/pubmed/15755977
1146. Resch, A., Fellner, C., Mock, U., Handl-Zeller, L., Biber, E., Seitz, W., et.al. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy-- a second chance to preserve the breast, Radiology, 2002. 225(3): p. 713-8., https://www.ncbi.nlm.nih.gov/pubmed/12461250
1147. Dunst, J., Steil, B., Furch, S., Fach, A., Lautenschlager, C., Diestelhorst, A., et.al. Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy, Strahlenther Onkol, 2001. 177(10): p. 504-10., https://www.ncbi.nlm.nih.gov/pubmed/11680014
1148. Engel, J., Eckel, R., Aydemir, U., Aydemir, S., Kerr, J., Schlesinger-Raab, A., et.al. Determinants and prognoses of locoregional and distant progression in breast cancer, Int J Radiat Oncol Biol Phys, 2003. 55(5): p. 1186-95., https://www.ncbi.nlm.nih.gov/pubmed/12654426
1149. Perez, Carlos A, Taylor, ME, Bradley, J, Mansur, D, Sanchez-Aragon, MM, Breast: Stage T1 and T2 tumors, Principles and practice of radiation oncology, 1992. 4: p. 1331-1501.
1150. Feigenberg, S. J., Price Mendenhall, N., Benda, R. K., Morris, C. G., Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using electrons, Int J Radiat Oncol Biol Phys, 2003. 56(3): p. 716-25., https://www.ncbi.nlm.nih.gov/pubmed/12788177
1151. Moran, M. S., Haffty, B. G., Local-regional breast cancer recurrence: prognostic groups based on patterns of failure, Breast J, 2002. 8(2): p. 81-7., https://www.ncbi.nlm.nih.gov/pubmed/11896752
1152. Schmoor, C., Sauerbrei, W., Bastert, G., Schumacher, M., Role of isolated locoregional recurrence of breast cancer: results of four prospective studies, J Clin Oncol, 2000. 18(8): p. 1696-708., https://www.ncbi.nlm.nih.gov/pubmed/10764430
1153. Wapnir, I. L., Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., et.al. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer, Ann Surg Oncol, 2008. 15(11): p. 3227-31., https://www.ncbi.nlm.nih.gov/pubmed/18784962
1154. Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., et.al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research, J Clin Oncol, 1994. 12(10): p. 2071-7., https://www.ncbi.nlm.nih.gov/pubmed/7931476
1155. Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O., Kennecke, H., Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, 2010. 28(10): p. 1684-91., https://www.ncbi.nlm.nih.gov/pubmed/20194857
1156. Metzger-Filho, O., Sun, Z., Viale, G., Price, K. N., Crivellari, D., Snyder, R. D., et.al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX, J Clin Oncol, 2013. 31(25): p. 3083-90., https://www.ncbi.nlm.nih.gov/pubmed/23897954
1157. Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., et.al. Locoregional recurrence after mastectomy: incidence and outcomes, J Am Coll Surg, 2006. 203(4): p. 469-74., https://www.ncbi.nlm.nih.gov/pubmed/17000389
1158. van der Pol, C. C., van Geel, A. N., Menke-Pluymers, M. B., Schmitz, P. I., Lans, T. E., Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence, Ann Surg Oncol, 2009. 16(12): p. 3414-21., https://www.ncbi.nlm.nih.gov/pubmed/19672659
1159. Aberizk, W. J., Silver, B., Henderson, I. C., Cady, B., Harris, J. R., The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy, Cancer, 1986. 58(6): p. 1214-8., https://www.ncbi.nlm.nih.gov/pubmed/3742446
1160. van Dongen, J. A., Bartelink, H., Fentiman, I. S., Lerut, T., Mignolet, F., Olthuis, G., et.al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer, Eur J Cancer, 1992. 28a(4-5): p. 801-5., https://www.ncbi.nlm.nih.gov/pubmed/1524898
1161. Rapiti, E., Verkooijen, H. M., Vlastos, G., Fioretta, G., Neyroud-Caspar, I., Sappino, A. P., et.al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis, J Clin Oncol, 2006. 24(18): p. 2743-9., https://www.ncbi.nlm.nih.gov/pubmed/16702580
1162. Haffty, B. G., Fischer, D., Beinfield, M., McKhann, C., Prognosis following local recurrence in the conservatively treated breast cancer patient, Int J Radiat Oncol Biol Phys, 1991. 21(2): p. 293-8., https://www.ncbi.nlm.nih.gov/pubmed/2061106
1163. Andersson, Y., de Boniface, J., Jonsson, P. E., Ingvar, C., Liljegren, G., Bergkvist, L., et.al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer, Br J Surg, 2012. 99(2): p. 226-31., https://www.ncbi.nlm.nih.gov/pubmed/22180063
1164. Newman, L. A., Hunt, K. K., Buchholz, T., Kuerer, H. M., Vlastos, G., Mirza, N., et.al. Presentation, management and outcome of axillary recurrence from breast cancer, Am J Surg, 2000. 180(4): p. 252-6., https://www.ncbi.nlm.nih.gov/pubmed/11113430
1165. Feyerabend, T., Wiedemann, G. J., Jager, B., Vesely, H., Mahlmann, B., Richter, E., Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease, Int J Radiat Oncol Biol Phys, 2001. 49(5): p. 1317-25., https://www.ncbi.nlm.nih.gov/pubmed/11286840
1166. Sherar, M., Liu, F. F., Pintilie, M., Levin, W., Hunt, J., Hill, R., et.al. Relationship between thermal dose and outcome in thermoradiotherapy treatments for superficial recurrences of breast cancer: data from a phase III trial, Int J Radiat Oncol Biol Phys, 1997. 39(2): p. 371-80., https://www.ncbi.nlm.nih.gov/pubmed/9308941
1167. van der Zee, J., van der Holt, B., Rietveld, P. J., Helle, P. A., Wijnmaalen, A. J., van Putten, W. L., et.al. Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation, Br J Cancer, 1999. 79(3-4): p. 483-90., https://www.ncbi.nlm.nih.gov/pubmed/10027317
1168. Vernon, C. C., Hand, J. W., Field, S. B., Machin, D., Whaley, J. B., van der Zee, J., et.al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group, Int J Radiat Oncol Biol Phys, 1996. 35(4): p. 731-44., https://www.ncbi.nlm.nih.gov/pubmed/8690639
1169. Waeber, M., Castiglione-Gertsch, M., Dietrich, D., Thurlimann, B., Goldhirsch, A., Brunner, K. W., et.al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation, Ann Oncol, 2003. 14(8): p. 1215-21., https://www.ncbi.nlm.nih.gov/pubmed/12881382
1170. Yarbro, J. W., Page, D. L., Fielding, L. P., Partridge, E. E., Murphy, G. P., American Joint Committee on Cancer prognostic factors consensus conference, Cancer, 1999. 86(11): p. 2436-46., https://www.ncbi.nlm.nih.gov/pubmed/10590388
1171. Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., Martin, M., et.al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial, Lancet Oncol, 2014. 15(2): p. 156-63., https://www.ncbi.nlm.nih.gov/pubmed/24439313
1172. Wapnir, IL, Price, KN, Anderson, SJ, Robidoux, A, Martín, M, Nortier, JWR, et.al. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial., J Clin Oncol, 2018. 36 (11)(11): p. 1073-1079., https://pubmed.ncbi.nlm.nih.gov/29443653/
1173. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus, E., Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2012. 23 Suppl 7: p. vii11-9., https://www.ncbi.nlm.nih.gov/pubmed/22997442
1174. McCormick, B., Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences, J Natl Compr Canc Netw, 2007. 5(3): p. 345-8., https://www.ncbi.nlm.nih.gov/pubmed/17439763
1175. Nederland., Nationaal Borstkanker Overleg, Richtlijn Mammacarcinoom (Niederländische Leitlinie)., 2011.
1176. Cardoso, F, Paluch-Shimon, S, Senkus, E, Curigliano, G, Aapro, MS, André, F, et.al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)., Ann Oncol, 2020. 31 (12)(12): p. 1623-1649., https://pubmed.ncbi.nlm.nih.gov/32979513/
1177. Gradishar, WJ, Moran, MS, Abraham, J, Aft, R, Agnese, D, Allison, KH, et.al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2022. 20 (6)(6): p. 691-722., https://pubmed.ncbi.nlm.nih.gov/35714673/
1178. Thill, M, Kolberg-Liedtke, C, Albert, US, Banys-Paluchowski, M, Bauerfeind, I, Blohmer, JU, et.al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023., Breast Care (Basel), 2023. 18 (4)(4): p. 306-315., https://pubmed.ncbi.nlm.nih.gov/37900553/
1179. Caswell-Jin, JL, Sun, LP, Munoz, D, Lu, Y, Li, Y, Huang, H, et.al. Analysis of Breast Cancer Mortality in the US-1975 to 2019., JAMA, 2024. 331 (3)(3): p. 233-241., https://pubmed.ncbi.nlm.nih.gov/38227031/
1180. Weide, R, Feiten, S, Waßmann, C, Rendenbach, B, Braun, U, Burkhard, O, et.al. Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care., Cancers (Basel), 2024. 16 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/38610931/
1181. Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., et.al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 2014. 32(19): p. 2078-99., https://www.ncbi.nlm.nih.gov/pubmed/24799465
1182. Balduzzi, S., Mantarro, S., Guarneri, V., Tagliabue, L., Pistotti, V., Moja, L., et.al. Trastuzumab-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2014. p. Cd006242., https://www.ncbi.nlm.nih.gov/pubmed/24919460
1183. Xie, BJ, Zhu, LN, Ma, C, Li, JB, Dong, L, Zhu, ZN, et.al. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer., Breast Cancer, 2020. 27 (2)(2): p. 186-196., https://pubmed.ncbi.nlm.nih.gov/31529262/
1184. Leitlinienprogramm Onkologie, Evidenzaufbereitung der AMNOG-Daten zu medikamentösen Therapien beim metastasierten Mammakarzinom, Evidenzbericht zu Version 5 der S3-Leitlinie Mammakarzinom, 2024., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
1185. André, F, Hee Park, Y, Kim, SB, Takano, T, Im, SA, Borges, G, et.al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial., Lancet, 2023. 401 (10390)(10390): p. 1773-1785., https://pubmed.ncbi.nlm.nih.gov/37086745/
1186. Murthy, RK, Loi, S, Okines, A, Paplomata, E, Hamilton, E, Hurvitz, SA, et.al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer., N Engl J Med, 2020. 382 (7)(7): p. 597-609., https://pubmed.ncbi.nlm.nih.gov/31825569/
1187. Omarini, C, Piacentini, F, Sperduti, I, Cerma, K, Barbolini, M, Canino, F, et.al. T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis., BMC Cancer, 2022. 22 (1)(1): p. 623., https://pubmed.ncbi.nlm.nih.gov/35672679/
1188. DeBusk, K, Abeysinghe, S, Vickers, A, Nangia, A, Bell, J, Ike, C, et.al. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis., Future Oncol, 2021. 17 (33)(33): p. 4635-4647., https://pubmed.ncbi.nlm.nih.gov/34463120/
1189. Martin Huertas, R, Fernández Abad, M, Corral de la Fuente, E, Serrano Domingo, JJ, Martínez Jáñez, N, Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence., Clin Breast Cancer, 2021. 21 (5)(5): p. 391-398., https://pubmed.ncbi.nlm.nih.gov/33549470/
1190. Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, et.al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2., N Engl J Med, 2001. 344 (11)(11): p. 783-92., https://pubmed.ncbi.nlm.nih.gov/11248153/
1191. Baselga, J, Cortés, J, Kim, SB, Im, SA, Hegg, R, Im, YH, et.al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N Engl J Med, 2012. 366 (2)(2): p. 109-19., https://pubmed.ncbi.nlm.nih.gov/22149875/
1192. Swain, SM, Baselga, J, Kim, SB, Ro, J, Semiglazov, V, Campone, M, et.al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N Engl J Med, 2015. 372 (8)(8): p. 724-34., https://pubmed.ncbi.nlm.nih.gov/25693012/
1193. Modi, S, Saura, C, Yamashita, T, Park, YH, Kim, SB, Tamura, K, et.al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer., N Engl J Med, 2020. 382 (7)(7): p. 610-621., https://pubmed.ncbi.nlm.nih.gov/31825192/
1194. Cortés, J, Kim, SB, Chung, WP, Im, SA, Park, YH, Hegg, R, et.al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer., N Engl J Med, 2022. 386 (12)(12): p. 1143-1154., https://pubmed.ncbi.nlm.nih.gov/35320644/
1195. Harbeck, N, Ciruelos, E, Jerusalem, G, Müller, V, Niikura, N, Viale, G, et.al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial., Nat Med, 2024. 30 (12)(12): p. 3717-3727., https://pubmed.ncbi.nlm.nih.gov/39271844/
1196. Lin, NU, Borges, V, Anders, C, Murthy, RK, Paplomata, E, Hamilton, E, et.al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial., J Clin Oncol, 2020. 38 (23)(23): p. 2610-2619., https://pubmed.ncbi.nlm.nih.gov/32468955/
1197. Verma, S, Miles, D, Gianni, L, Krop, IE, Welslau, M, Baselga, J, et.al. Trastuzumab emtansine for HER2-positive advanced breast cancer., N Engl J Med, 2012. 367 (19)(19): p. 1783-91., https://pubmed.ncbi.nlm.nih.gov/23020162/
1198. Díaz-Rodríguez, E, Gandullo-Sánchez, L, Ocaña, A, Pandiella, A, Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs., Cancers (Basel), 2021. 14 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/35008318/
1199. Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., Simes, J., Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev, 2005. p. Cd003372., https://www.ncbi.nlm.nih.gov/pubmed/15846660
1200. Sledge, G. W., Jr., Hu, P., Falkson, G., Tormey, D., Abeloff, M., Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study, J Clin Oncol, 2000. 18(2): p. 262-6., https://www.ncbi.nlm.nih.gov/pubmed/10637238
1201. Schettini, F, Giudici, F, Giuliano, M, Cristofanilli, M, Arpino, G, Del Mastro, L, et.al. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis., J Natl Cancer Inst, 2020. 112 (11)(11): p. 1089-1097., https://pubmed.ncbi.nlm.nih.gov/32407488/
1202. Li, J, Huo, X, Zhao, F, Ren, D, Ahmad, R, Yuan, X, et.al. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis., JAMA Netw Open, 2020. 3 (10)(10): p. e2020312., https://pubmed.ncbi.nlm.nih.gov/33048129/
1203. Park, YH, Kim, TY, Kim, GM, Kang, SY, Park, IH, Kim, JH, et.al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial., Lancet Oncol, 2019. 20 (12)(12): p. 1750-1759., https://pubmed.ncbi.nlm.nih.gov/31668850/
1204. Lee, S, Im, SA, Kim, GM, Jung, KH, Kang, SY, Park, IH, et.al. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)., Cancers (Basel), 2020. 12 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/33167305/
1205. Gao, JJ, Cheng, J, Bloomquist, E, Sanchez, J, Wedam, SB, Singh, H, et.al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis., Lancet Oncol, 2020. 21 (2)(2): p. 250-260., https://pubmed.ncbi.nlm.nih.gov/31859246/
1206. Lu, YS, Mahidin, EIBM, Azim, H, Eralp, Y, Yap, YS, Im, SA, et.al. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer., J Clin Oncol, 2024. 42 (23)(23): p. 2812-2821., https://pubmed.ncbi.nlm.nih.gov/38771995/
1207. Arpino, G, de la Haba Rodríguez, J, Ferrero, JM, De Placido, S, Osborne, CK, Klingbiel, D, et.al. Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis., Clin Cancer Res, 2023. 29 (8)(8): p. 1468-1476., https://pubmed.ncbi.nlm.nih.gov/36716289/
1208. Sledge, G W, Toi, M, Neven, P, Sohn, J, Inoue, K, Pivot, X, et.al. LBA6_PRMONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer, Annals of Oncology, 2019. 30(Supplement_5):, https://doi.org/10.1093/annonc/mdz394.006
1209. Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., et.al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer, N Engl J Med, 2018. 379(20): p. 1926-1936., https://www.ncbi.nlm.nih.gov/pubmed/30345905
1210. Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., et.al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer, N Engl J Med, 2019. 381(4): p. 307-316., https://pubmed.ncbi.nlm.nih.gov/31166679/
1211. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Bericht Nr. 781 - Ribociclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Addendum zum Auftrag A19-06, 2019., https://www.g-ba.de/downloads/92-975-3033/2019-07-04_Addendum_Ribociclib-Aromatasehemmer_D-430.pdf
1212. Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., et.al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy, J Clin Oncol, 2017. 35(25): p. 2875-2884., https://www.ncbi.nlm.nih.gov/pubmed/28580882
1213. Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et.al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, 2015. 373(3): p. 209-19., https://www.ncbi.nlm.nih.gov/pubmed/26030518
1214. Tripathy, D., Im, S. A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., et.al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial, Lancet Oncol, 2018. 19(7): p. 904-915., https://pubmed.ncbi.nlm.nih.gov/29804902/
1215. Osoba, D., Rodrigues, G., Myles, J., Zee, B., Pater, J., Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 1998. 16(1): p. 139-44., https://pubmed.ncbi.nlm.nih.gov/9440735/
1216. Gemeinsamer Bundesausschuss (G-BA), Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V - Crizotinib (neues Anwendungsgebiet), 2016., https://www.g-ba.de/downloads/40-268-3830/2016-06-16_AM-Rl-XII_Crizotinib_nAWG_D-205_TrG.pdf?
1217. Kappel, C, Elliott, MJ, Kumar, V, Nadler, MB, Desnoyers, A, Amir, E, Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer., Sci Rep, 2024. 14 (1)(1): p. 3129., https://pubmed.ncbi.nlm.nih.gov/38326452/
1218. Cazzaniga, M. E., Danesi, R., Girmenia, C., Invernizzi, P., Elvevi, A., Uguccioni, M., Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success, Breast Cancer Res Treat, 2019. 176(3): p. 483-494., https://pubmed.ncbi.nlm.nih.gov/31065872/
1219. Taylor, C. W., Green, S., Dalton, W. S., Martino, S., Rector, D., Ingle, J. N., et.al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study, J Clin Oncol, 1998. 16(3): p. 994-9., https://www.ncbi.nlm.nih.gov/pubmed/9508182
1220. Loibl, S, Turner, NC, Ro, J, Cristofanilli, M, Iwata, H, Im, SA, Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3, J Clin Oncol, 2016. 34(suppl): p. abstr 524.
1221. Burstein, HJ, Somerfield, MR, Barton, DL, Dorris, A, Fallowfield, LJ, Jain, D, et.al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update., J Clin Oncol, 2021. 39 (35)(35): p. 3959-3977., https://pubmed.ncbi.nlm.nih.gov/34324367/
1222. Harbeck, N, Bartlett, M, Spurden, D, Hooper, B, Zhan, L, Rosta, E, et.al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies., Future Oncol, 2021. 17 (16)(16): p. 2107-2122., https://pubmed.ncbi.nlm.nih.gov/33663223/
1223. Tian, Q, Gao, H, Zhou, Y, Yang, J, Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials., Eur Rev Med Pharmacol Sci, 2021. 25 (23)(23): p. 7252-7267., https://pubmed.ncbi.nlm.nih.gov/34919224/
1224. Hortobagyi, GN, Stemmer, SM, Burris, HA, Yap, YS, Sonke, GS, Hart, L, et.al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer., N Engl J Med, 2022. 386 (10)(10): p. 942-950., https://pubmed.ncbi.nlm.nih.gov/35263519/
1225. Slamon, DJ, Neven, P, Chia, S, Jerusalem, G, De Laurentiis, M, Im, S, et.al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival., Ann Oncol, 2021. 32 (8)(8): p. 1015-1024., https://pubmed.ncbi.nlm.nih.gov/34102253/
1226. Slamon, DJ, Diéras, V, Rugo, HS, Harbeck, N, Im, SA, Gelmon, KA, et.al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer., J Clin Oncol, 2024. 42 (9)(9): p. 994-1000., https://pubmed.ncbi.nlm.nih.gov/38252901/
1227. Goetz, MP, Toi, M, Huober, J, Sohn, J, Trédan, O, Park, IH, et.al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3., Ann Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38729566/
1228. Rugo, HS, Layman, RM, Lynce, F, Liu, X, Li, B, McRoy, L, et.al. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting., ESMO Open, 2025. 10 (1)(1): p. 104103., https://pubmed.ncbi.nlm.nih.gov/39754979/
1229. Thill, M, Zahn, MO, Welt, A, Nusch, A, Zaiss, M, Engelken, K, et.al. Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry., Int J Cancer, 2025. 156 (9)(9): p. 1770-1782., https://pubmed.ncbi.nlm.nih.gov/39707595/
1230. Johnston, Stephen, Martin, Miguel, Di Leo, Angelo, Im, Seock-Ah, Awada, Ahmad, Forrester, Tammy, et.al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer, npj Breast Cancer, 2019. 5(1): p. 5., https://doi.org/10.1038/s41523-018-0097-z
1231. Pfizer Pharma GmbH, Palbociclib (IBRANCE®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4 A, 2016., https://www.g-ba.de/downloads/92-975-1744/2016-11-22_Palbociclib_Modul4A.pdf
1232. Novartis Pharma GmbH, Ribociclib (Kisqali®) - Dossier zur Nutzenbewertung gemäß § 35a SGB V. Modul 4, 2017., https://www.g-ba.de/downloads/92-975-2078/2017-08-29_Modul4_Ribociclib.pdf
1233. Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., et.al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3, J Clin Oncol, 2018. 36(24): p. 2465-2472., https://pubmed.ncbi.nlm.nih.gov/29860922/
1234. Sledge, GW, Toi, M, Neven, P, Sohn, J, Inoue, K, Pivot, X, et.al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial., JAMA Oncol, 2020. 6 (1)(1): p. 116-124., https://pubmed.ncbi.nlm.nih.gov/31563959/
1235. Slamon, Dennis J., Neven, Patrick, Chia, Stephen, Fasching, Peter A., De Laurentiis, Michelino, Im, Seock-Ah, et.al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer, New England Journal of Medicine, 2019., https://doi.org/10.1056/NEJMoa1911149
1236. Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., et.al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med, 2015. 373(3): p. 209-19., https://pubmed.ncbi.nlm.nih.gov/26030518/
1237. Sonke, GS, van Ommen-Nijhof, A, Wortelboer, N, van der Noort, V, Swinkels, ACP, Blommestein, HM, et.al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer., Nature, 2024. 636 (8042)(8042): p. 474-480., https://pubmed.ncbi.nlm.nih.gov/39604725/
1238. Gibson, L., Lawrence, D., Dawson, C., Bliss, J., Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women, Cochrane Database Syst Rev, 2009. p. Cd003370., https://www.ncbi.nlm.nih.gov/pubmed/19821307
1239. Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., et.al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3), Ann Oncol, 1998. 9(6): p. 639-45., https://www.ncbi.nlm.nih.gov/pubmed/9681078
1240. Robertson, J. F., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., et.al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials, Cancer, 2003. 98(2): p. 229-38., https://www.ncbi.nlm.nih.gov/pubmed/12872340
1241. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., et.al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 2005. 97(17): p. 1262-71., https://www.ncbi.nlm.nih.gov/pubmed/16145047
1242. Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., et.al. Palbociclib and Letrozole in Advanced Breast Cancer, N Engl J Med, 2016. 375(20): p. 1925-1936., https://www.ncbi.nlm.nih.gov/pubmed/27959613
1243. Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., et.al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 2015. 16(1): p. 25-35., https://www.ncbi.nlm.nih.gov/pubmed/25524798
1244. Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., et.al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, 2016. 17(4): p. 425-39., https://www.ncbi.nlm.nih.gov/pubmed/26947331
1245. Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., Andre, F., et.al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 2016. 27(6): p. 1047-54., https://www.ncbi.nlm.nih.gov/pubmed/27029704
1246. Bell, T., Crown, J. P., Lang, I., Bhattacharyya, H., Zanotti, G., Randolph, S., et.al. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment, Curr Med Res Opin, 2016. 32(5): p. 959-65., https://www.ncbi.nlm.nih.gov/pubmed/26894413
1247. Finn, R. S., Crown, J. P., Ettl, J., Schmidt, M., Bondarenko, I. M., Lang, I., et.al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18, Breast Cancer Res, 2016. 18(1): p. 67., https://www.ncbi.nlm.nih.gov/pubmed/27349747
1248. Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., et.al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3), Oncologist, 2016. 21(10): p. 1165-1175., https://www.ncbi.nlm.nih.gov/pubmed/27368881
1249. Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., et.al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer, N Engl J Med, 2016. 375(18): p. 1738-1748., https://www.ncbi.nlm.nih.gov/pubmed/27717303
1250. Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., et.al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 2012. 366(6): p. 520-9., https://pubmed.ncbi.nlm.nih.gov/22149876/
1251. Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., et.al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger, Ann Oncol, 2014. 25(12): p. 2357-62., https://www.ncbi.nlm.nih.gov/pubmed/25231953
1252. Turner, NC, Im, SA, Saura, C, Juric, D, Loibl, S, Kalinsky, K, et.al. Inavolisib-Based Therapy in , N Engl J Med, 2024. 391 (17)(17): p. 1584-1596., https://pubmed.ncbi.nlm.nih.gov/39476340/
1253. Jhaveri, KL, Im, SA, Saura, C, Loibl, S, Kalinsky, K, Schmid, P, et.al. Overall Survival with Inavolisib in , N Engl J Med, 2025. 393 (2)(2): p. 151-161., https://pubmed.ncbi.nlm.nih.gov/40454641/
1254. Bidard, FC, Kaklamani, VG, Neven, P, Streich, G, Montero, AJ, Forget, F, et.al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial., J Clin Oncol, 2022. 40 (28)(28): p. 3246-3256., https://pubmed.ncbi.nlm.nih.gov/35584336/
1255. Turner, NC, Oliveira, M, Howell, SJ, Dalenc, F, Cortes, J, Gomez Moreno, HL, et.al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer., N Engl J Med, 2023. 388 (22)(22): p. 2058-2070., https://pubmed.ncbi.nlm.nih.gov/37256976/
1256. Johnston, SR, New strategies in estrogen receptor-positive breast cancer., Clin Cancer Res, 2010. 16 (7)(7): p. 1979-87., https://pubmed.ncbi.nlm.nih.gov/20332324/
1257. André, F, Ciruelos, E, Rubovszky, G, Campone, M, Loibl, S, Rugo, HS, et.al. Alpelisib for , N Engl J Med, 2019. 380 (20)(20): p. 1929-1940., https://pubmed.ncbi.nlm.nih.gov/31091374/
1258. André, F, Ciruelos, EM, Juric, D, Loibl, S, Campone, M, Mayer, IA, et.al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1., Ann Oncol, 2021. 32 (2)(2): p. 208-217., https://pubmed.ncbi.nlm.nih.gov/33246021/
1259. Ditsch, N, Untch, M, Kolberg-Liedtke, C, Jackisch, C, Krug, D, Friedrich, M, et.al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020., Breast Care (Basel), 2020. 15 (3)(3): p. 294-309., https://pubmed.ncbi.nlm.nih.gov/32774225/
1260. Condorelli, R, Mosele, F, Verret, B, Bachelot, T, Bedard, PL, Cortes, J, et.al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)., Ann Oncol, 2019. 30 (3)(3): p. 365-373., https://pubmed.ncbi.nlm.nih.gov/30715161/
1261. Brett, JO, Spring, LM, Bardia, A, Wander, SA, ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer., Breast Cancer Res, 2021. 23 (1)(1): p. 85., https://pubmed.ncbi.nlm.nih.gov/34392831/
1262. Fribbens, C, O'Leary, B, Kilburn, L, Hrebien, S, Garcia-Murillas, I, Beaney, M, et.al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer., J Clin Oncol, 2016. 34 (25)(25): p. 2961-8., https://pubmed.ncbi.nlm.nih.gov/27269946/
1263. Turner, NC, Swift, C, Kilburn, L, Fribbens, C, Beaney, M, Garcia-Murillas, I, et.al. None, Clin Cancer Res, 2020. 26 (19)(19): p. 5172-5177., https://pubmed.ncbi.nlm.nih.gov/32546646/
1264. Modi, S, Jacot, W, Yamashita, T, Sohn, J, Vidal, M, Tokunaga, E, et.al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer., N Engl J Med, 2022. 387 (1)(1): p. 9-20., https://pubmed.ncbi.nlm.nih.gov/35665782/
1265. Bardia, A, Hu, X, Dent, R, Yonemori, K, Barrios, CH, O'Shaughnessy, JA, et.al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer., N Engl J Med, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39282896/
1266. Rugo, HS, Bardia, A, Marmé, F, Cortés, J, Schmid, P, Loirat, D, et.al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial., Lancet, 2023. 402 (10411)(10411): p. 1423-1433., https://pubmed.ncbi.nlm.nih.gov/37633306/
1267. Pavone, G, Motta, L, Martorana, F, Motta, G, Vigneri, P, A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors., Molecules, 2021. 26 (23)(23):, https://pubmed.ncbi.nlm.nih.gov/34885875/
1268. Rugo, HS, Bardia, A, Marmé, F, Cortes, J, Schmid, P, Loirat, D, et.al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer., J Clin Oncol, 2022. 40 (29)(29): p. 3365-3376., https://pubmed.ncbi.nlm.nih.gov/36027558/
1269. Bardia, A, Jhaveri, K, Im, SA, Pernas, S, De Laurentiis, M, Wang, S, et.al. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01., J Clin Oncol, 2025. 43 (3)(3): p. 285-296., https://pubmed.ncbi.nlm.nih.gov/39265124/
1270. Robson, M, Im, SA, Senkus, E, Xu, B, Domchek, SM, Masuda, N, et.al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med, 2017. 377 (6)(6): p. 523-533., https://pubmed.ncbi.nlm.nih.gov/28578601/
1271. Robson, ME, Tung, N, Conte, P, Im, SA, Senkus, E, Xu, B, et.al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer., Ann Oncol, 2019. 30 (4)(4): p. 558-566., https://pubmed.ncbi.nlm.nih.gov/30689707/
1272. Litton, JK, Rugo, HS, Ettl, J, Hurvitz, SA, Gonçalves, A, Lee, KH, et.al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation., N Engl J Med, 2018. 379 (8)(8): p. 753-763., https://pubmed.ncbi.nlm.nih.gov/30110579/
1273. Yan, F, Jiang, Q, He, M, Shen, P, PARP inhibitor treatment of advanced breast cancer beyond the , Future Oncol, 2021. 17 (18)(18): p. 2381-2393., https://pubmed.ncbi.nlm.nih.gov/33784822/
1274. Zhang, M, Yu, X, Wang, J, Li, Y, Cao, L, Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for , J Cancer Res Ther, 2021. 17 (7)(7): p. 1672-1678., https://pubmed.ncbi.nlm.nih.gov/35381738/
1275. Farmer, H, McCabe, N, Lord, CJ, Tutt, AN, Johnson, DA, Richardson, TB, et.al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy., Nature, 2005. 434 (7035)(7035): p. 917-21., https://pubmed.ncbi.nlm.nih.gov/15829967/
1276. Basham, VM, Lipscombe, JM, Ward, JM, Gayther, SA, Ponder, BA, Easton, DF, et.al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer., Breast Cancer Res, 2002. 4 (1)(1): p. R2., https://pubmed.ncbi.nlm.nih.gov/11879560/
1277. Bryant, HE, Schultz, N, Thomas, HD, Parker, KM, Flower, D, Lopez, E, et.al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase., Nature, 2005. 434 (7035)(7035): p. 913-7., https://pubmed.ncbi.nlm.nih.gov/15829966/
1278. McCabe, N, Turner, NC, Lord, CJ, Kluzek, K, Bialkowska, A, Swift, S, et.al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition., Cancer Res, 2006. 66 (16)(16): p. 8109-15., https://pubmed.ncbi.nlm.nih.gov/16912188/
1279. Ashworth, A, A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair., J Clin Oncol, 2008. 26 (22)(22): p. 3785-90., https://pubmed.ncbi.nlm.nih.gov/18591545/
1280. Robson, M, Ruddy, KJ, Im, SA, Senkus, E, Xu, B, Domchek, SM, et.al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial., Eur J Cancer, 2019. 120 (): p. 20-30., https://pubmed.ncbi.nlm.nih.gov/31446213/
1281. Rugo, HS, Ettl, J, Hurvitz, SA, Gonçalves, A, Lee, KH, Fehrenbacher, L, et.al. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy., JNCI Cancer Spectr, 2020. 4 (1)(1): p. pkz085., https://pubmed.ncbi.nlm.nih.gov/32337496/
1282. Cortes, J, Rugo, HS, Cescon, DW, Im, SA, Yusof, MM, Gallardo, C, et.al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer., N Engl J Med, 2022. 387 (3)(3): p. 217-226., https://pubmed.ncbi.nlm.nih.gov/35857659/
1283. Cortes, J, Cescon, DW, Rugo, HS, Nowecki, Z, Im, SA, Yusof, MM, et.al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial., Lancet, 2020. 396 (10265)(10265): p. 1817-1828., https://pubmed.ncbi.nlm.nih.gov/33278935/
1284. Schmid, P, Rugo, HS, Adams, S, Schneeweiss, A, Barrios, CH, Iwata, H, et.al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2020. 21 (1)(1): p. 44-59., https://pubmed.ncbi.nlm.nih.gov/31786121/
1285. Huo, X, Shen, G, Liu, Z, Liang, Y, Li, J, Zhao, F, et.al. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials., Crit Rev Oncol Hematol, 2021. 168 (): p. 103530., https://pubmed.ncbi.nlm.nih.gov/34801695/
1286. Narang, P, Chen, M, Sharma, AA, Anderson, KS, Wilson, MA, The neoepitope landscape of breast cancer: implications for immunotherapy., BMC Cancer, 2019. 19 (1)(1): p. 200., https://pubmed.ncbi.nlm.nih.gov/30832597/
1287. Adams, S, Gray, RJ, Demaria, S, Goldstein, L, Perez, EA, Shulman, LN, et.al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199., J Clin Oncol, 2014. 32 (27)(27): p. 2959-66., https://pubmed.ncbi.nlm.nih.gov/25071121/
1288. Denkert, C, Loibl, S, Noske, A, Roller, M, Müller, BM, Komor, M, et.al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer., J Clin Oncol, 2010. 28 (1)(1): p. 105-13., https://pubmed.ncbi.nlm.nih.gov/19917869/
1289. Denkert, C, von Minckwitz, G, Brase, JC, Sinn, BV, Gade, S, Kronenwett, R, et.al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers., J Clin Oncol, 2015. 33 (9)(9): p. 983-91., https://pubmed.ncbi.nlm.nih.gov/25534375/
1290. Schmidt, M, Weyer-Elberich, V, Hengstler, JG, Heimes, AS, Almstedt, K, Gerhold-Ay, A, et.al. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population., Breast Cancer Res, 2018. 20 (1)(1): p. 15., https://pubmed.ncbi.nlm.nih.gov/29482642/
1291. Schmidt, M, Heimes, AS, Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice., Cancers (Basel), 2021. 13 (19)(19):, https://pubmed.ncbi.nlm.nih.gov/34638367/
1292. Emens, LA, Breast Cancer Immunotherapy: Facts and Hopes., Clin Cancer Res, 2018. 24 (3)(3): p. 511-520., https://pubmed.ncbi.nlm.nih.gov/28801472/
1293. Chen, DS, Mellman, I, Oncology meets immunology: the cancer-immunity cycle., Immunity, 2013. 39 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/23890059/
1294. Ribas, A, Releasing the Brakes on Cancer Immunotherapy., N Engl J Med, 2015. 373 (16)(16): p. 1490-2., https://pubmed.ncbi.nlm.nih.gov/26348216/
1295. Bardia, A, Mayer, IA, Vahdat, LT, Tolaney, SM, Isakoff, SJ, Diamond, JR, et.al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer., N Engl J Med, 2019. 380 (8)(8): p. 741-751., https://pubmed.ncbi.nlm.nih.gov/30786188/
1296. Bardia, A, Hurvitz, SA, Tolaney, SM, Loirat, D, Punie, K, Oliveira, M, et.al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer., N Engl J Med, 2021. 384 (16)(16): p. 1529-1541., https://pubmed.ncbi.nlm.nih.gov/33882206/
1297. Li, CH, Karantza, V, Aktan, G, Lala, M, Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review., Breast Cancer Res, 2019. 21 (1)(1): p. 143., https://pubmed.ncbi.nlm.nih.gov/31842957/
1298. Huang, M, Haiderali, A, Fox, GE, Frederickson, A, Cortes, J, Fasching, PA, et.al. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review., Pharmacoeconomics, 2022. 40 (5)(5): p. 519-558., https://pubmed.ncbi.nlm.nih.gov/35112331/
1299. Bardia, Aditya Hurvitz, Sara A Tolaney, Sara M Loirat, Delphine Punie, Kevin Oliveira, Mafalda Brufsky, Adam Sardesai, Sagar D Kalinsky, Kevin Zelnak, Amelia B Weaver, Robert Traina, Tiffany Dalenc, Florence Aftimos, Philippe Lynce, Filipa Diab, Sami Cortés, Javier O'Shaughnessy, Joyce Diéras, Véronique Ferrario, Cristiano Schmid, Peter Carey, Lisa A Gianni, Luca Piccart, Martine J Loibl, Sibylle Goldenberg, David M Hong, Quan Olivo, Martin S Itri, Loretta M Rugo, Hope S ASCENT Clinical Trial Investigators, Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer., 2021. 384(16): p. 1529-1541., https://pubmed.ncbi.nlm.nih.gov/33882206
1300. Dear, R. F., McGeechan, K., Jenkins, M. C., Barratt, A., Tattersall, M. H., Wilcken, N., Combination versus sequential single agent chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev, 2013. p. Cd008792., https://www.ncbi.nlm.nih.gov/pubmed/24347031
1301. Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., et.al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193), J Clin Oncol, 2003. 21(4): p. 588-92., https://www.ncbi.nlm.nih.gov/pubmed/12586793
1302. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., et.al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 2007. 357(26): p. 2666-76., https://www.ncbi.nlm.nih.gov/pubmed/18160686
1303. Gray, R., Bhattacharya, S., Bowden, C., Miller, K., Comis, R. L., Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J Clin Oncol, 2009. 27(30): p. 4966-72., https://www.ncbi.nlm.nih.gov/pubmed/19720913
1304. Robert, Nicholas J, Diéras, Véronique, Glaspy, John, Brufsky, Adam M, Bondarenko, Igor, Lipatov, Oleg N, et.al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer, Journal of Clinical Oncology, 2011. 29(10): p. 1252-1260., https://pubmed.ncbi.nlm.nih.gov/21383283/
1305. Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C. C., Koehler, A., et.al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial, Breast Cancer Res Treat, 2016. 156(1): p. 97-107., https://www.ncbi.nlm.nih.gov/pubmed/26927446
1306. Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., et.al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial, Lancet Oncol, 2013. 14(2): p. 125-33., https://www.ncbi.nlm.nih.gov/pubmed/23312888
1307. Zielinski, C., Lang, I., Inbar, M., Kahan, Z., Greil, R., Beslija, S., et.al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial, Lancet Oncol, 2016. 17(9): p. 1230-9., https://pubmed.ncbi.nlm.nih.gov/27501767/
1308. Puglisi, F, Rea, D, Kroes, MA, Pronzato, P, Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review., Cancer Treat Rev, 2016. 43 (): p. 36-49., https://pubmed.ncbi.nlm.nih.gov/26827691/
1309. Tanni, KA, Truong, CB, Johnson, BS, Qian, J, Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis., Crit Rev Oncol Hematol, 2021. 163 (): p. 103375., https://pubmed.ncbi.nlm.nih.gov/34087344/
1310. Ghersi, D., Willson, M. L., Chan, M. M., Simes, J., Donoghue, E., Wilcken, N., Taxane-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev, 2015. p. Cd003366., https://www.ncbi.nlm.nih.gov/pubmed/26058962
1311. Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C. H., et.al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol, 2016., https://www.ncbi.nlm.nih.gov/pubmed/28177437
1312. Heindel, Walter, Gübitz, Raphael, Vieth, Volker, Weckesser, Matthias, Schober, Otmar, Schäfers, Michael, The diagnostic imaging of bone metastases, Deutsches Ärzteblatt International, 2014. 111(44): p. 741., https://www.ncbi.nlm.nih.gov/pubmed/25412631
1313. Chow, E, Zeng, L, Salvo, N, Dennis, K, Tsao, M, Lutz, S, Update on the systematic review of palliative radiotherapy trials for bone metastases, Clinical oncology, 2012. 24(2): p. 112-124., https://www.ncbi.nlm.nih.gov/pubmed/22130630
1314. Chow, Edward, van der Linden, Yvette M, Roos, Daniel, Hartsell, William F, Hoskin, Peter, Wu, Jackson SY, et.al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial, The Lancet Oncology, 2014. 15(2): p. 164-171., https://www.ncbi.nlm.nih.gov/pubmed/24369114
1315. Lutz, Stephen, Berk, Lawrence, Chang, Eric, Chow, Edward, Hahn, Carol, Hoskin, Peter, et.al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, International Journal of Radiation Oncology* Biology* Physics, 2011. 79(4): p. 965-976., https://www.ncbi.nlm.nih.gov/pubmed/21277118
1316. Roque, I. Figuls M., Martinez-Zapata, M. J., Scott-Brown, M., Alonso-Coello, P., Radioisotopes for metastatic bone pain, Cochrane Database Syst Rev, 2011. p. Cd003347., https://www.ncbi.nlm.nih.gov/pubmed/21735393
1317. Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366(9486): p. 643-8., https://www.ncbi.nlm.nih.gov/pubmed/16112300
1318. Leithner, Andreas, Maurer-Ertl, Werner, Windhager, Reinhard, Biopsy of bone and soft tissue tumours: hints and hazards, Treatment of bone and soft tissue sarcomas, 2009. p. 3-10., https://www.ncbi.nlm.nih.gov/pubmed/19230530
1319. Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schechtman, K., Tillman, J. B., et.al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial, Lancet Oncol, 2011. 12(3): p. 225-35., https://www.ncbi.nlm.nih.gov/pubmed/21333599
1320. Eck, J. C., Nachtigall, D., Humphreys, S. C., Hodges, S. D., Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature, Spine J, 2008. 8(3): p. 488-97., https://www.ncbi.nlm.nih.gov/pubmed/17588820
1321. Vogelbaum, MA, Brown, PD, Messersmith, H, Brastianos, PK, Burri, S, Cahill, D, et.al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline., J Clin Oncol, 2022. 40 (5)(5): p. 492-516., https://pubmed.ncbi.nlm.nih.gov/34932393/
1322. Kalkanis, S. N., Kondziolka, D., Gaspar, L. E., Burri, S. H., Asher, A. L., Cobbs, C. S., et.al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 2010. 96(1): p. 33-43., https://www.ncbi.nlm.nih.gov/pubmed/19960230
1323. Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et.al. A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 1990. 322(8): p. 494-500., https://www.ncbi.nlm.nih.gov/pubmed/2405271
1324. Vecht, Charles J, Haaxma‐Reiche, Hanny, Noordijk, Evert M, Padberg, George W, Voormolen, Joan HC, Hoekstra, Foppe H, et.al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery, Annals of neurology, 1993. 33(6): p. 583-590., https://www.ncbi.nlm.nih.gov/pubmed/8498838
1325. Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., et.al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial, Jama, 1998. 280(17): p. 1485-9., https://www.ncbi.nlm.nih.gov/pubmed/9809728
1326. Kondziolka, D., Patel, A., Lunsford, L. D., Kassam, A., Flickinger, J. C., Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases, Int J Radiat Oncol Biol Phys, 1999. 45(2): p. 427-34., https://www.ncbi.nlm.nih.gov/pubmed/10487566
1327. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et.al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 2004. 363(9422): p. 1665-72., https://www.ncbi.nlm.nih.gov/pubmed/15158627
1328. Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et.al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, Jama, 2006. 295(21): p. 2483-91., https://www.ncbi.nlm.nih.gov/pubmed/16757720
1329. Chang, Eric L, Wefel, Jeffrey S, Hess, Kenneth R, Allen, Pamela K, Lang, Frederick F, Kornguth, David G, et.al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, The lancet oncology, 2009. 10(11): p. 1037-1044., https://www.ncbi.nlm.nih.gov/pubmed/19801201
1330. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et.al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 2011. 29(2): p. 134-41., https://www.ncbi.nlm.nih.gov/pubmed/21041710
1331. Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., et.al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial, Jama, 2016. 316(4): p. 401-9., https://www.ncbi.nlm.nih.gov/pubmed/27458945
1332. Lin, N. U., Bellon, J. R., Winer, E. P., CNS metastases in breast cancer, J Clin Oncol, 2004. 22(17): p. 3608-17., https://www.ncbi.nlm.nih.gov/pubmed/15337811
1333. Leone, J. P., Leone, B. A., Breast cancer brain metastases: the last frontier, Exp Hematol Oncol, 2015. 4: p. 33., https://www.ncbi.nlm.nih.gov/pubmed/26605131
1334. Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., et.al. Metastatic breast cancer subtypes and central nervous system metastases, Breast, 2014. 23(5): p. 623-8., https://www.ncbi.nlm.nih.gov/pubmed/24993072
1335. Gaspar, Laurie E, Scott, Charles, Murray, Kevin, Curran, Walter, Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases, International Journal of Radiation Oncology* Biology* Physics, 2000. 47(4): p. 1001-1006., https://www.ncbi.nlm.nih.gov/pubmed/10863071
1336. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et.al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 2012. 30(4): p. 419-25., https://www.ncbi.nlm.nih.gov/pubmed/22203767
1337. Mintz, A. H., Kestle, J., Rathbone, M. P., Gaspar, L., Hugenholtz, H., Fisher, B., et.al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis, Cancer, 1996. 78(7): p. 1470-6., https://www.ncbi.nlm.nih.gov/pubmed/8839553
1338. Rades, D., Kieckebusch, S., Haatanen, T., Lohynska, R., Dunst, J., Schild, S. E., Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis, Int J Radiat Oncol Biol Phys, 2008. 70(5): p. 1319-24., https://www.ncbi.nlm.nih.gov/pubmed/18374222
1339. Mahajan, A, Ahmed, S, McAleer, MF, Weinberg, JS, Li, J, Brown, P, et.al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial., Lancet Oncol, 2017. 18 (8)(8): p. 1040-1048., https://pubmed.ncbi.nlm.nih.gov/28687375/
1340. Brown, PD, Ballman, KV, Cerhan, JH, Anderson, SK, Carrero, XW, Whitton, AC, et.al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial., Lancet Oncol, 2017. 18 (8)(8): p. 1049-1060., https://pubmed.ncbi.nlm.nih.gov/28687377/
1341. Eitz, KA, Lo, SS, Soliman, H, Sahgal, A, Theriault, A, Pinkham, MB, et.al. Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases., JAMA Oncol, 2020. 6 (12)(12): p. 1901-1909., https://pubmed.ncbi.nlm.nih.gov/33057566/
1342. Yamamoto, Masaaki, Serizawa, Toru, Shuto, Takashi, Akabane, Atsuya, Higuchi, Yoshinori, Kawagishi, Jun, et.al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, The Lancet Oncology, 2014. 15(4): p. 387-395., https://www.ncbi.nlm.nih.gov/pubmed/24621620
1343. Brown, PD, Gondi, V, Pugh, S, Tome, WA, Wefel, JS, Armstrong, TS, et.al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001., J Clin Oncol, 2020. 38 (10)(10): p. 1019-1029., https://pubmed.ncbi.nlm.nih.gov/32058845/
1344. Ramakrishna, N, Anders, CK, Lin, NU, Morikawa, A, Temin, S, Chandarlapaty, S, et.al. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update., J Clin Oncol, 2022. 40 (23)(23): p. 2636-2655., https://pubmed.ncbi.nlm.nih.gov/35640075/
1345. Lin, NU, Murthy, RK, Abramson, V, Anders, C, Bachelot, T, Bedard, PL, et.al. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial., JAMA Oncol, 2023. 9 (2)(2): p. 197-205., https://pubmed.ncbi.nlm.nih.gov/36454580/
1346. Hurvitz, SA, Kim, SB, Chung, WP, Im, SA, Park, YH, Hegg, R, et.al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial., ESMO Open, 2024. 9 (5)(5): p. 102924., https://pubmed.ncbi.nlm.nih.gov/38796287/
1347. Bartsch, R, Berghoff, AS, Furtner, J, Marhold, M, Bergen, ES, Roider-Schur, S, et.al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial., Nat Med, 2022. 28 (9)(9): p. 1840-1847., https://pubmed.ncbi.nlm.nih.gov/35941372/
1348. Vaz Batista, M, Pérez-García, JM, Cortez, P, Garrigós, L, Fernández-Abad, M, Gion, M, et.al. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial., ESMO Open, 2024. 9 (9)(9): p. 103699., https://pubmed.ncbi.nlm.nih.gov/39255534/
1349. Le Rhun, E, Guckenberger, M, Smits, M, Dummer, R, Bachelot, T, Sahm, F, et.al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours., Ann Oncol, 2021. 32 (11)(11): p. 1332-1347., https://pubmed.ncbi.nlm.nih.gov/34364998/
1350. Tolaney, SM, Do, KT, Eder, JP, LoRusso, PM, Weekes, CD, Chandarlapaty, S, et.al. A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors., Clin Cancer Res, 2020. 26 (21)(21): p. 5588-5597., https://pubmed.ncbi.nlm.nih.gov/32694157/
1351. Morikawa, A, Jordan, L, Rozner, R, Patil, S, Boire, A, Pentsova, E, et.al. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis., Clin Breast Cancer, 2017. 17 (1)(1): p. 23-28., https://pubmed.ncbi.nlm.nih.gov/27569275/
1352. Le Rhun, E, Devos, P, Weller, J, Seystahl, K, Mo, F, Compter, A, et.al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors., Neuro Oncol, 2021. 23 (7)(7): p. 1100-1112., https://pubmed.ncbi.nlm.nih.gov/33367859/
1353. Stringer-Reasor, Erica, O'Brien, Barbara, Topletz-Erickson, Ariel, White, Jason, Lobbous, Mina, Riley, Kristen, et.al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer., 2021/05/20. 39: p. 1044 - 1044.
1354. Tolaney, SM, Sahebjam, S, Le Rhun, E, Bachelot, T, Kabos, P, Awada, A, et.al. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer., Clin Cancer Res, 2020. 26 (20)(20): p. 5310-5319., https://pubmed.ncbi.nlm.nih.gov/32694159/
1355. Murthy, Rashmi K, O'Brien, Barbara, Berry, Donald A, Singareeka-Raghavendra, Akshara, Monroe, Maria Gule, Johnson, Jason, et.al. Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study, 2022. 82(4_Supplement): p. PD4-02 - PD4-02., https://doi.org/10.1158/1538-7445.SABCS21-PD4-02
1356. Alder, L, Trapani, D, Bradbury, C, Van Swearingen, AED, Tolaney, SM, Khasraw, M, et.al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan., NPJ Breast Cancer, 2023. 9 (1)(1): p. 19., https://pubmed.ncbi.nlm.nih.gov/36997605/
1357. Niikura, N, Yamanaka, T, Nomura, H, Shiraishi, K, Kusama, H, Yamamoto, M, et.al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)., NPJ Breast Cancer, 2023. 9 (1)(1): p. 82., https://pubmed.ncbi.nlm.nih.gov/37821514/
1358. Vaz Batista, M, Pérez-García, JM, Garrigós, L, García-Sáenz, JÁ, Cortez, P, Racca, F, et.al. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis., Med, 2025. 6 (1)(1): p. 100502., https://pubmed.ncbi.nlm.nih.gov/39265579/
1359. Zagouri, F, Sergentanis, TN, Bartsch, R, Berghoff, AS, Chrysikos, D, de Azambuja, E, et.al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis., Breast Cancer Res Treat, 2013. 139 (1)(1): p. 13-22., https://pubmed.ncbi.nlm.nih.gov/23588955/
1360. Bonneau, C, Paintaud, G, Trédan, O, Dubot, C, Desvignes, C, Dieras, V, et.al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis., Eur J Cancer, 2018. 95 (): p. 75-84., https://pubmed.ncbi.nlm.nih.gov/29635147/
1361. Kumthekar, PU, Avram, MJ, Lassman, AB, Lin, NU, Lee, E, Grimm, SA, et.al. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics., Neuro Oncol, 2023. 25 (3)(3): p. 557-565., https://pubmed.ncbi.nlm.nih.gov/35948282/
1362. Boogerd, Willem, Van den Bent, MJ, Koehler, PJ, Heimans, JJ, Van der Sande, JJ, Aaronson, NK, et.al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study, European Journal of Cancer, 2004. 40(18): p. 2726-2733., https://www.ncbi.nlm.nih.gov/pubmed/15571954
1363. Le Rhun, E, Wallet, J, Mailliez, A, Le Deley, MC, Rodrigues, I, Boulanger, T, et.al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer., Neuro Oncol, 2020. 22 (4)(4): p. 524-538., https://pubmed.ncbi.nlm.nih.gov/31637444/
1364. Méndez Romero, A, Schillemans, W, van Os, R, Koppe, F, Haasbeek, CJ, Hendriksen, EM, et.al. The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases., Int J Radiat Oncol Biol Phys, 2021. 109 (5)(5): p. 1377-1386., https://pubmed.ncbi.nlm.nih.gov/33451857/
1365. Stera, S, Miebach, G, Buergy, D, Dreher, C, Lohr, F, Wurster, S, et.al. Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort., Radiother Oncol, 2021. 158 (): p. 230-236., https://pubmed.ncbi.nlm.nih.gov/33667585/
1366. Scorsetti, M, Comito, T, Clerici, E, Franzese, C, Tozzi, A, Iftode, C, et.al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up., Radiat Oncol, 2018. 13 (1)(1): p. 234., https://pubmed.ncbi.nlm.nih.gov/30477560/
1367. Wieners, G, Mohnike, K, Peters, N, Bischoff, J, Kleine-Tebbe, A, Seidensticker, R, et.al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study., Radiother Oncol, 2011. 100 (2)(2): p. 314-9., https://pubmed.ncbi.nlm.nih.gov/21497930/
1368. Onal, C, Guler, OC, Yildirim, BA, Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy., Breast, 2018. 42 (): p. 150-156., https://pubmed.ncbi.nlm.nih.gov/30296648/
1369. Scorsetti, M, Franceschini, D, De Rose, F, Comito, T, Franzese, C, Masci, G, et.al. The role of SBRT in oligometastatic patients with liver metastases from breast cancer., Rep Pract Oncol Radiother, 2017. 22 (2)(2): p. 163-169., https://pubmed.ncbi.nlm.nih.gov/28490988/
1370. Andratschke, N, Alheid, H, Allgäuer, M, Becker, G, Blanck, O, Boda-Heggemann, J, et.al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases., BMC Cancer, 2018. 18 (1)(1): p. 283., https://pubmed.ncbi.nlm.nih.gov/29534687/
1371. Franceschini, D, Comito, T, Di Gallo, A, Vernier, V, Marzo, MA, Di Cristina, L, et.al. Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial., Curr Oncol, 2022. 29 (10)(10): p. 7858-7867., https://pubmed.ncbi.nlm.nih.gov/36290898/
1372. Viani, GA, Gouveia, AG, Louie, AV, Korzeniowski, M, Pavoni, JF, Hamamura, AC, et.al. Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis., Radiother Oncol, 2021. 164 (): p. 245-250., https://pubmed.ncbi.nlm.nih.gov/34624408/
1373. Milano, MT, Katz, AW, Zhang, H, Huggins, CF, Aujla, KS, Okunieff, P, Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade., Radiother Oncol, 2019. 131 (): p. 45-51., https://pubmed.ncbi.nlm.nih.gov/30773186/
1374. Trovo, M, Furlan, C, Polesel, J, Fiorica, F, Arcangeli, S, Giaj-Levra, N, et.al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial., Radiother Oncol, 2018. 126 (1)(1): p. 177-180., https://pubmed.ncbi.nlm.nih.gov/28943046/
1375. Wang, M., Zhang, J., Ji, S., Shao, G., Zhao, K., Wang, Z., et.al. Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review, Breast, 2017. 36: p. 25-30., https://www.ncbi.nlm.nih.gov/pubmed/28915408
1376. Gordon, A. C., Gradishar, W. J., Kaklamani, V. G., Thuluvath, A. J., Ryu, R. K., Sato, K. T., et.al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy, J Vasc Interv Radiol, 2014. 25(10): p. 1523-32, 1532.e1-2., https://www.ncbi.nlm.nih.gov/pubmed/25156827
1377. Franceschini, D, Franzese, C, Comito, T, Ilieva, MB, Spoto, R, Marzo, AM, et.al. Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer., Radiother Oncol, 2024. 195 (): p. 110240., https://pubmed.ncbi.nlm.nih.gov/38522597/
1378. Caralt, M., Bilbao, I., Cortes, J., Escartin, A., Lazaro, J. L., Dopazo, C., et.al. Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer, Ann Surg Oncol, 2008. 15(10): p. 2804-10., https://www.ncbi.nlm.nih.gov/pubmed/18670821
1379. Chua, T. C., Saxena, A., Liauw, W., Chu, F., Morris, D. L., Hepatic resection for metastatic breast cancer: a systematic review, Eur J Cancer, 2011. 47(15): p. 2282-90., https://www.ncbi.nlm.nih.gov/pubmed/21741832
1380. Groeschl, Ryan T, Nachmany, Ido, Steel, Jennifer L, Reddy, Srinevas K, Glazer, Evan S, De Jong, Mechteld C, et.al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis, Journal of the American College of Surgeons, 2012. 214(5): p. 769-777., https://www.ncbi.nlm.nih.gov/pubmed/22425166
1381. Hoffmann, Katrin, Franz, Clemens, Hinz, Ulf, Schirmacher, Peter, Herfarth, Christian, Eichbaum, Michael, et.al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors, Annals of surgical oncology, 2010. 17(6): p. 1546-1554., https://www.ncbi.nlm.nih.gov/pubmed/20143267
1382. Clive, A. O., Jones, H. E., Bhatnagar, R., Preston, N. J., Maskell, N., Interventions for the management of malignant pleural effusions: a network meta-analysis, Cochrane Database Syst Rev, 2016. p. Cd010529., https://www.ncbi.nlm.nih.gov/pubmed/27155783
1383. Leonard, R., Hardy, J., van Tienhoven, G., Houston, S., Simmonds, P., David, M., et.al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer, J Clin Oncol, 2001. 19(21): p. 4150-9., https://www.ncbi.nlm.nih.gov/pubmed/11689583
1384. Spratt, D. E., Gordon Spratt, E. A., Wu, S., DeRosa, A., Lee, N. Y., Lacouture, M. E., et.al. Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis, J Clin Oncol, 2014. 32(28): p. 3144-55., https://www.ncbi.nlm.nih.gov/pubmed/25154827
1385. Adderley, U. J., Holt, I. G., Topical agents and dressings for fungating wounds, Cochrane Database Syst Rev, 2014. p. Cd003948., https://www.ncbi.nlm.nih.gov/pubmed/24832784
1386. Cabula, C., Campana, L. G., Grilz, G., Galuppo, S., Bussone, R., De Meo, L., et.al. Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis, Ann Surg Oncol, 2015. 22 Suppl 3: p. S442-50., https://www.ncbi.nlm.nih.gov/pubmed/26242370
1387. Campana, L. G., Galuppo, S., Valpione, S., Brunello, A., Ghiotto, C., Ongaro, A., et.al. Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations, J Cancer Res Clin Oncol, 2014. 140(9): p. 1557-65., https://www.ncbi.nlm.nih.gov/pubmed/24793549
1388. Matthiessen, L. W., Johannesen, H. H., Hendel, H. W., Moss, T., Kamby, C., Gehl, J., Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial, Acta Oncol, 2012. 51(6): p. 713-21., https://www.ncbi.nlm.nih.gov/pubmed/22731832
1389. Jarvis, Virginia, The range and role of palliative interventions for locally advanced breast cancer, Current opinion in supportive and palliative care, 2014. 8(1): p. 70-76., https://www.ncbi.nlm.nih.gov/pubmed/24407016
1390. Lund-Nielsen, B., Adamsen, L., Kolmos, H. J., Rorth, M., Tolver, A., Gottrup, F., The effect of honey-coated bandages compared with silver-coated bandages on treatment of malignant wounds-a randomized study, Wound Repair Regen, 2011. 19(6): p. 664-70., https://www.ncbi.nlm.nih.gov/pubmed/22092836
1391. Jull, Andrew B, Cullum, Nicky, Dumville, Jo C, Westby, Maggie J, Deshpande, Sohan, Walker, Natalie, Honey as a topical treatment for wounds, The Cochrane Library, 2015., https://pubmed.ncbi.nlm.nih.gov/25742878/
1392. Tryfonidis, K., Senkus, E., Cardoso, M. J., Cardoso, F., Management of locally advanced breast cancer-perspectives and future directions, Nat Rev Clin Oncol, 2015. 12(3): p. 147-62., https://www.ncbi.nlm.nih.gov/pubmed/25668732
1393. Aranda, S., Schofield, P., Weih, L., Milne, D., Yates, P., Faulkner, R., Meeting the support and information needs of women with advanced breast cancer: a randomised controlled trial, Br J Cancer, 2006. 95(6): p. 667-73., https://www.ncbi.nlm.nih.gov/pubmed/16967054
1394. Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et.al. Communication styles in the cancer consultation: preferences for a patient-centred approach, Psychooncology, 2000. 9(2): p. 147-56., https://www.ncbi.nlm.nih.gov/pubmed/10767752
1395. Pistrang, N., Barker, C., The partner relationship in psychological response to breast cancer, Soc Sci Med, 1995. 40(6): p. 789-97., https://www.ncbi.nlm.nih.gov/pubmed/7747213
1396. Goedendorp, M. M., Gielissen, M. F., Verhagen, C. A., Bleijenberg, G., Psychosocial interventions for reducing fatigue during cancer treatment in adults, Cochrane Database Syst Rev, 2009. p. CD006953., https://www.ncbi.nlm.nih.gov/pubmed/19160308
1397. Lindor, N. M., Goldgar, D. E., Tavtigian, S. V., Plon, S. E., Couch, F. J., BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management, Oncologist, 2013. 18(5): p. 518-24., https://www.ncbi.nlm.nih.gov/pubmed/23615697
1398. Heemskerk-Gerritsen, B. A., Menke-Pluijmers, M. B., Jager, A., Tilanus-Linthorst, M. M., Koppert, L. B., Obdeijn, I. M., et.al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis, Ann Oncol, 2013. 24(8): p. 2029-35., https://www.ncbi.nlm.nih.gov/pubmed/23576707
1399. Marten-Mittag, B, Book, K, Buchhold, B, Dinkel, A, Gründobler, B, Henrich, G, et.al. The Basic Documentation for Psycho-Oncology Short Form (PO-Bado SF)--an expert rating scale for distress screening: development and psychometric properties., Psychooncology, 2015. 24 (6)(6): p. 653-60., https://pubmed.ncbi.nlm.nih.gov/25346529/
1400. Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Kuffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis, J Clin Oncol, 2013. 31(6): p. 782-93., https://www.ncbi.nlm.nih.gov/pubmed/23319686
1401. Rapp, M, Schipmann, S, Hoffmann, K, Wiewrodt, R, Steiger, HJ, Kamp, M, et.al. Impact of distress screening algorithm for psycho-oncological needs in neurosurgical patients., Oncotarget, 2018. 9 (60)(60): p. 31650-31663., https://pubmed.ncbi.nlm.nih.gov/30167085/
1402. Friedrich, M, Nowe, E, Hofmeister, D, Kuhnt, S, Leuteritz, K, Sender, A, et.al. Psychometric properties of the fatigue questionnaire EORTC QLQ-FA12 and proposal of a cut-off value for young adults with cancer., Health Qual Life Outcomes, 2018. 16 (1)(1): p. 125., https://pubmed.ncbi.nlm.nih.gov/29903021/
1403. Klingenstein, A, Samel, C, Garip-Kuebler, A, Miller, C, Liegl, RG, Priglinger, SG, et.al. The national comprehensive cancer network distress thermometer as a screening tool for the evaluation of quality of life in uveal melanoma patients., Acta Ophthalmol, 2020. 98 (3)(3): p. e381-e387., https://pubmed.ncbi.nlm.nih.gov/31654488 /
1404. Tilkorn, M, Mawick, R, Sommerfeld, S, Strittmatter, G, [Quality of life of patients with malignant facial and skin tumors--development of a questionnaire and initial findings of a study]., Rehabilitation (Stuttg), 1990. 29 (2)(2): p. 134-9., https://pubmed.ncbi.nlm.nih.gov/2367741 /
1405. Erim, Y, Beckmann, M, Gerlach, G, Kümmel, S, Oberhoff, C, Senf, W, et.al. [Screening for distress in women with breast cancer diagnosed for the first time: employment of HADS-D and PO-Bado]., Z Psychosom Med Psychother, 2009. 55 (3)(3): p. 248-62., https://pubmed.ncbi.nlm.nih.gov/19886593 /
1406. Book, K, Marten-Mittag, B, Henrich, G, Dinkel, A, Scheddel, P, Sehlen, S, et.al. Distress screening in oncology-evaluation of the Questionnaire on Distress in Cancer Patients-short form (QSC-R10) in a German sample., Psychooncology, 2011. 20 (3)(3): p. 287-93., https://pubmed.ncbi.nlm.nih.gov/20669340 /
1407. Wüller, J, Küttner, S, Foldenauer, AC, Rolke, R, Pastrana, T, Accuracy of the Distress Thermometer for home care patients with palliative care needs in Germany., Palliat Support Care, 2017. 15 (3)(3): p. 288-294., https://pubmed.ncbi.nlm.nih.gov/27666282 /
1408. Hartung, TJ, Friedrich, M, Johansen, C, Wittchen, HU, Faller, H, Koch, U, et.al. The Hospital Anxiety and Depression Scale (HADS) and the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression in patients with cancer., Cancer, 2017. 123 (21)(21): p. 4236-4243., https://pubmed.ncbi.nlm.nih.gov/28654189 /
1409. Renovanz, M, Soebianto, S, Tsakmaklis, H, Keric, N, Nadji-Ohl, M, Beutel, M, et.al. Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4)., Support Care Cancer, 2019. 27 (12)(12): p. 4469-4477., https://pubmed.ncbi.nlm.nih.gov/30904948 /
1410. Rumpold, G, Augustin, M, Zschocke, I, Strittmatter, G, Söllner, W, [The validity of the Hornheide questionnaire for psychosocial support in skin tumor patients: a survey in an Austrian and German outpatient population with melanoma]., Psychother Psychosom Med Psychol, 2001. 51 (1)(1): p. 25-33., https://pubmed.ncbi.nlm.nih.gov/11227322 /
1411. Singer, S, Kuhnt, S, Götze, H, Hauss, J, Hinz, A, Liebmann, A, et.al. Hospital anxiety and depression scale cutoff scores for cancer patients in acute care., Br J Cancer, 2009. 100 (6)(6): p. 908-12., https://pubmed.ncbi.nlm.nih.gov/19240713/
1412. Esser, P, Hartung, TJ, Friedrich, M, Johansen, C, Wittchen, HU, Faller, H, et.al. The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients., Psychooncology, 2018. 27 (6)(6): p. 1509-1516., https://pubmed.ncbi.nlm.nih.gov/29473255 /
1413. Herschbach, P, Book, K, Brandl, T, Keller, M, Marten-Mittag, B, The Basic Documentation for Psycho-Oncology (PO-Bado): an expert rating scale for the psychosocial experience of cancer patients., Onkologie, 2008. 31 (11)(11): p. 591-6., https://pubmed.ncbi.nlm.nih.gov/19145091/
1414. Herschbach P, Das subjektive Befinden von Krebskranken einheitlich beschreiben - Vorstellung der Psycho-Onkologischen Basisdokumentation (PO-Bado)Deutsches Ärzteblatt, 2004. 101: p. 799 - 802.
1415. Strittmatter G, Entwicklung und klinischer Einsatz von Screening‐ Instrumenten zur Identifikation betreuungsbedürftiger Tumorpatienten., Lebensqualitätsforschung aus medizinpsychologischer und -soziologischer Perspektive., 2000. p. 59 - 75.
1416. Strittmatter G, Indikation zur Intervention in der Psychoonkologie, in Psychosoziale Belastungen und Ermittlung der Betreuungsbedürftigkeit stationärer Hauttumorpatienten. Internationale Hochschulschriften, 1997. 228: p. 428.
1417. Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., et.al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline, J Clin Oncol, 2016. 34(6): p. 611-35., https://www.ncbi.nlm.nih.gov/pubmed/26644543
1418. Dolbeault, S., Cayrou, S., Bredart, A., Viala, A. L., Desclaux, B., Saltel, P., et.al. The effectiveness of a psycho-educational group after early-stage breast cancer treatment: results of a randomized French study, Psychooncology, 2009. 18(6): p. 647-56., https://www.ncbi.nlm.nih.gov/pubmed/19039808
1419. Bindemann, S., Soukop, M., Kaye, S. B., Randomised controlled study of relaxation training, Eur J Cancer, 1991. 27(2): p. 170-4., https://www.ncbi.nlm.nih.gov/pubmed/1827283
1420. Kissane, D. W., Grabsch, B., Clarke, D. M., Smith, G. C., Love, A. W., Bloch, S., et.al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial, Psychooncology, 2007. 16(4): p. 277-86., https://www.ncbi.nlm.nih.gov/pubmed/17385190
1421. Cohen, Miri, Fried, Georgeta, Comparing relaxation training and cognitive-behavioral group therapy for women with breast cancer, Research on Social Work Practice, 2007. 17(3): p. 313-323.
1422. Lengacher, C. A., Johnson-Mallard, V., Post-White, J., Moscoso, M. S., Jacobsen, P. B., Klein, T. W., et.al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer, Psychooncology, 2009. 18(12): p. 1261-72., https://www.ncbi.nlm.nih.gov/pubmed/19235193
1423. Nidich, S. I., Fields, J. Z., Rainforth, M. V., Pomerantz, R., Cella, D., Kristeller, J., et.al. A randomized controlled trial of the effects of transcendental meditation on quality of life in older breast cancer patients, Integr Cancer Ther, 2009. 8(3): p. 228-34., https://www.ncbi.nlm.nih.gov/pubmed/19815592
1424. Fillion, L., Gagnon, P., Leblond, F., Gelinas, C., Savard, J., Dupuis, R., et.al. A brief intervention for fatigue management in breast cancer survivors, Cancer Nurs, 2008. 31(2): p. 145-59., https://www.ncbi.nlm.nih.gov/pubmed/18490891
1425. Yoo, H. J., Ahn, S. H., Kim, S. B., Kim, W. K., Han, O. S., Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life, Support Care Cancer, 2005. 13(10): p. 826-33., https://www.ncbi.nlm.nih.gov/pubmed/15856335
1426. Baucom, D. H., Porter, L. S., Kirby, J. S., Gremore, T. M., Wiesenthal, N., Aldridge, W., et.al. A couple-based intervention for female breast cancer, Psychooncology, 2009. 18(3): p. 276-83., https://www.ncbi.nlm.nih.gov/pubmed/18702064
1427. Manne, S. L., Ostroff, J. S., Winkel, G., Fox, K., Grana, G., Miller, E., et.al. Couple-focused group intervention for women with early stage breast cancer, J Consult Clin Psychol, 2005. 73(4): p. 634-46., https://www.ncbi.nlm.nih.gov/pubmed/16173851
1428. Northouse, L., Kershaw, T., Mood, D., Schafenacker, A., Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers, Psychooncology, 2005. 14(6): p. 478-91., https://www.ncbi.nlm.nih.gov/pubmed/15599947
1429. Scott, J. L., Halford, W. K., Ward, B. G., United we stand? The effects of a couple-coping intervention on adjustment to early stage breast or gynecological cancer, J Consult Clin Psychol, 2004. 72(6): p. 1122-35., https://www.ncbi.nlm.nih.gov/pubmed/15612858
1430. Kesler, S., Hadi Hosseini, S. M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K., et.al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors, Clin Breast Cancer, 2013. 13(4): p. 299-306., https://www.ncbi.nlm.nih.gov/pubmed/23647804
1431. Ercoli, L. M., Petersen, L., Hunter, A. M., Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial, 2015. 24(11): p. 1360-7., https://www.ncbi.nlm.nih.gov/pubmed/25759235
1432. Montgomery, G. H., Kangas, M., David, D., Hallquist, M. N., Green, S., Bovbjerg, D. H., et.al. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis, Health Psychol, 2009. 28(3): p. 317-22., https://www.ncbi.nlm.nih.gov/pubmed/19450037
1433. Nelson, D. V., Friedman, L. C., Baer, P. E., Lane, M., Smith, F. E., Subtypes of psychosocial adjustment to breast cancer, J Behav Med, 1994. 17(2): p. 127-41., https://www.ncbi.nlm.nih.gov/pubmed/8035448
1434. Bradt, J., Dileo, C., Magill, L., Teague, A., Music interventions for improving psychological and physical outcomes in cancer patients, Cochrane Database Syst Rev, 2016. p. Cd006911., https://www.ncbi.nlm.nih.gov/pubmed/27524661
1435. Burns, D. S., The effect of the bonny method of guided imagery and music on the mood and life quality of cancer patients, J Music Ther, 2001. 38(1): p. 51-65., https://www.ncbi.nlm.nih.gov/pubmed/11407965
1436. Hanser, S. B., Bauer-Wu, S., Kubicek, L., Healey, M., Manola, J., Hernandez, M., et.al. Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer, J Soc Integr Oncol, 2006. 4(3): p. 116-24., https://www.ncbi.nlm.nih.gov/pubmed/19442346
1437. Puig, Ana, Lee, Sang Min, Goodwin, Linda, Sherrard, Peter AD, The efficacy of creative arts therapies to enhance emotional expression, spirituality, and psychological well-being of newly diagnosed Stage I and Stage II breast cancer patients: A preliminary study, The Arts in Psychotherapy, 2006. 33(3): p. 218-228., https://smartmove.co.in/wp-content/uploads/2020/04/The-efficacy-of-creative-arts-therapies-to-enhance-emotional-expression-spirituality-and-psychological-well-being-of-newly-diagnosed-Stage-I-and-Stage-II-breast-cancer-patients.pdf
1438. Svensk, A. C., Oster, I., Thyme, K. E., Magnusson, E., Sjodin, M., Eisemann, M., et.al. Art therapy improves experienced quality of life among women undergoing treatment for breast cancer: a randomized controlled study, Eur J Cancer Care (Engl), 2009. 18(1): p. 69-77., https://www.ncbi.nlm.nih.gov/pubmed/19473224
1439. Mehnert, A., Lehmann, C., Cao, P., Koch, U., [Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56(12): p. 462-79., https://www.ncbi.nlm.nih.gov/pubmed/17160791
1440. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 1993. 85(5): p. 365-76., https://www.ncbi.nlm.nih.gov/pubmed/8433390
1441. Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et.al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J Clin Oncol, 1993. 11(3): p. 570-9., https://www.ncbi.nlm.nih.gov/pubmed/8445433
1442. Faller, H, Schuler, M, Richard, M, Heckl, U, Weis, J, Küffner, R, Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis., J Clin Oncol, 2013. 31 (6)(6): p. 782-93., https://pubmed.ncbi.nlm.nih.gov/23319686 /
1443. Sanjida, S, McPhail, SM, Shaw, J, Couper, J, Kissane, D, Price, MA, et.al. Are psychological interventions effective on anxiety in cancer patients? A systematic review and meta-analyses., Psychooncology, 2018. 27 (9)(9): p. 2063-2076., https://pubmed.ncbi.nlm.nih.gov/29885258 /
1444. Al-Sulaiman, RJ, Bener, A, Doodson, L, Bujassoum Al Bader, S, Ghuloum, S, Lemaux, A, et.al. Exploring the effectiveness of crisis counseling and psychoeducation in relation to improving mental well-being, quality of life and treatment compliance of breast cancer patients in Qatar., Int J Womens Health, 2018. 10 (): p. 285-298., https://pubmed.ncbi.nlm.nih.gov/29922098 /
1445. Hsieh, CC, Hsiao, FH, The effects of supportive care interventions on depressive symptoms among patients with lung cancer: A metaanalysis of randomized controlled studies., Palliat Support Care, 2017. 15 (6)(6): p. 710-723., https://pubmed.ncbi.nlm.nih.gov/28508739 /
1446. Kalter, J, Verdonck-de Leeuw, IM, Sweegers, MG, Aaronson, NK, Jacobsen, PB, Newton, RU, et.al. Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs., Psychooncology, 2018. 27 (4)(4): p. 1150-1161., https://pubmed.ncbi.nlm.nih.gov/29361206 /
1447. Freeman, LW, White, R, Ratcliff, CG, Sutton, S, Stewart, M, Palmer, JL, et.al. A randomized trial comparing live and telemedicine deliveries of an imagery-based behavioral intervention for breast cancer survivors: reducing symptoms and barriers to care., Psychooncology, 2015. 24 (8)(8): p. 910-8., https://pubmed.ncbi.nlm.nih.gov/25146413 /
1448. Aminnasab, A, Mohammadi, S, Zareinezhad, M, Chatrrouz, T, Mirghafari, SB, Rahmani, S, Effectiveness of Solution-Focused Brief Therapy (SFBT) on Depression and Perceived Stress in Patients with Breast Cancer., Tanaffos, 2018. 17 (4)(4): p. 272-279., https://pubmed.ncbi.nlm.nih.gov/31143218 /
1449. Arving, C, Assmus, J, Thormodsen, I, Berntsen, S, Nordin, K, Early rehabilitation of cancer patients-An individual randomized stepped-care stress-management intervention., Psychooncology, 2019. 28 (2)(2): p. 301-308., https://pubmed.ncbi.nlm.nih.gov/30408282 /
1450. Aubin, S, Rosberger, Z, Hafez, N, Noory, MR, Perez, S, Lehmann, S, et.al. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer., J Adolesc Young Adult Oncol, 2019. 8 (2)(2): p. 172-189., https://pubmed.ncbi.nlm.nih.gov/30484730/
1451. Bao, H, Chen, Y, Li, M, Pan, L, Zheng, X, Intensive patient's care program reduces anxiety and depression as well as improves overall survival in , Transl Cancer Res, 2019. 8 (1)(1): p. 212-227., https://pubmed.ncbi.nlm.nih.gov/35116750/
1452. Conley, CC, Andersen, BL, Lemons to lemonade: Effects of a biobehavioral intervention for cancer patients on later life changes., Health Psychol, 2019. 38 (3)(3): p. 206-216., https://pubmed.ncbi.nlm.nih.gov/30762400 /
1453. Dowlatabadi, MM, Ahmadi, SM, Sorbi, MH, Beiki, O, Razavi, TK, Bidaki, R, The effectiveness of group positive psychotherapy on depression and happiness in breast cancer patients: A randomized controlled trial., Electron Physician, 2016. 8 (3)(3): p. 2175-80., https://pubmed.ncbi.nlm.nih.gov/27123227 /
1454. Esplen, MJ, Wong, J, Warner, E, Toner, B, Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial., J Clin Oncol, 2018. 36 (8)(8): p. 749-756., https://pubmed.ncbi.nlm.nih.gov/29356610 /
1455. Fernández-Rodríguez, C, González-Fernández, S, Coto-Lesmes, R, Pedrosa, I, Behavioral Activation and Acceptance and Commitment Therapy in the Treatment of Anxiety and Depression in Cancer Survivors: A Randomized Clinical Trial., Behav Modif, 2021. 45 (5)(5): p. 822-859., https://pubmed.ncbi.nlm.nih.gov/32316765 /
1456. Ho, RT, Fong, TC, Lo, PH, Ho, SM, Lee, PW, Leung, PP, et.al. Randomized controlled trial of supportive-expressive group therapy and body-mind-spirit intervention for Chinese non-metastatic breast cancer patients., Support Care Cancer, 2016. 24 (12)(12): p. 4929-4937., https://pubmed.ncbi.nlm.nih.gov/27470259 /
1457. Mohabbat-Bahar, S, Maleki-Rizi, F, Akbari, ME, Moradi-Joo, M, Effectiveness of group training based on acceptance and commitment therapy on anxiety and depression of women with breast cancer., Iran J Cancer Prev, 2015. 8 (2)(2): p. 71-6., https://pubmed.ncbi.nlm.nih.gov/25960844 /
1458. Naccarato, AM, Reis, LO, Ferreira, U, Denardi, F, Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial., Andrologia, 2016. 48 (10)(10): p. 1183-1187., https://pubmed.ncbi.nlm.nih.gov/27062069 /
1459. Peng, W, Zhang, H, Li, Z, Responses of lung cancer survivors undergoing gamma knife surgery to supportive group psychotherapy., Medicine (Baltimore), 2019. 98 (9)(9): p. e14693., https://pubmed.ncbi.nlm.nih.gov/30817604 /
1460. Ren, W, Qiu, H, Yang, Y, Zhu, X, Zhu, C, Mao, G, et.al. Randomized controlled trial of cognitive behavioural therapy for depressive and anxiety symptoms in Chinese women with breast cancer., Psychiatry Res, 2019. 271 (): p. 52-59., https://pubmed.ncbi.nlm.nih.gov/30469089/
1461. Stagl, JM, Bouchard, LC, Lechner, SC, Blomberg, BB, Gudenkauf, LM, Jutagir, DR, et.al. Long-term psychological benefits of cognitive-behavioral stress management for women with breast cancer: 11-year follow-up of a randomized controlled trial., Cancer, 2015. 121 (11)(11): p. 1873-81., https://pubmed.ncbi.nlm.nih.gov/25809235 /
1462. Tomei, C, Lebel, S, Maheu, C, Lefebvre, M, Harris, C, Examining the preliminary efficacy of an intervention for fear of cancer recurrence in female cancer survivors: a randomized controlled clinical trial pilot study., Support Care Cancer, 2018. 26 (8)(8): p. 2751-2762., https://pubmed.ncbi.nlm.nih.gov/29500582 /
1463. van der Spek, N, Vos, J, van Uden-Kraan, CF, Breitbart, W, Cuijpers, P, Holtmaat, K, et.al. Efficacy of meaning-centered group psychotherapy for cancer survivors: a randomized controlled trial., Psychol Med, 2017. 47 (11)(11): p. 1990-2001., https://pubmed.ncbi.nlm.nih.gov/28374663 /
1464. Bauereiß, N, Obermaier, S, Özünal, SE, Baumeister, H, Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials., Psychooncology, 2018. 27 (11)(11): p. 2531-2545., https://pubmed.ncbi.nlm.nih.gov/29958339 /
1465. Ye, M, Du, K, Zhou, J, Zhou, Q, Shou, M, Hu, B, et.al. A meta-analysis of the efficacy of cognitive behavior therapy on quality of life and psychological health of breast cancer survivors and patients., Psychooncology, 2018. 27 (7)(7): p. 1695-1703., https://pubmed.ncbi.nlm.nih.gov/29500842 /
1466. Cobeanu, O, David, D, Alleviation of Side Effects and Distress in Breast Cancer Patients by Cognitive-Behavioral Interventions: A Systematic Review and Meta-analysis., J Clin Psychol Med Settings, 2018. 25 (4)(4): p. 335-355., https://pubmed.ncbi.nlm.nih.gov/29480435 /
1467. Coutiño-Escamilla, L, Piña-Pozas, M, Tobías Garces, A, Gamboa-Loira, B, López-Carrillo, L, Non-pharmacological therapies for depressive symptoms in breast cancer patients: Systematic review and meta-analysis of randomized clinical trials., Breast, 2019. 44 (): p. 135-143., https://pubmed.ncbi.nlm.nih.gov/30776733 /
1468. Hall, DL, Luberto, CM, Philpotts, LL, Song, R, Park, ER, Yeh, GY, Mind-body interventions for fear of cancer recurrence: A systematic review and meta-analysis., Psychooncology, 2018. 27 (11)(11): p. 2546-2558., https://pubmed.ncbi.nlm.nih.gov/29744965 /
1469. Zhang, M, Huang, L, Feng, Z, Shao, L, Chen, L, Effects of cognitive behavioral therapy on quality of life and stress for breast cancer survivors: a meta-analysis., Minerva Med, 2017. 108 (1)(1): p. 84-93., https://pubmed.ncbi.nlm.nih.gov/27635602 /
1470. Jassim, GA, Whitford, DL, Hickey, A, Carter, B, Psychological interventions for women with non-metastatic breast cancer., Cochrane Database Syst Rev, 2015. (5)(5): p. CD008729., https://pubmed.ncbi.nlm.nih.gov/26017383/
1471. Cheung, EO, Cohn, MA, Dunn, LB, Melisko, ME, Morgan, S, Penedo, FJ, et.al. A randomized pilot trial of a positive affect skill intervention (lessons in linking affect and coping) for women with metastatic breast cancer., Psychooncology, 2017. 26 (12)(12): p. 2101-2108., https://pubmed.ncbi.nlm.nih.gov/27862646/
1472. Desautels, C, Savard, J, Ivers, H, Savard, MH, Caplette-Gingras, A, Treatment of depressive symptoms in patients with breast cancer: A randomized controlled trial comparing cognitive therapy and bright light therapy., Health Psychol, 2018. 37 (1)(1): p. 1-13., https://pubmed.ncbi.nlm.nih.gov/29172605 /
1473. Garcia, ACM, Simão-Miranda, TP, Carvalho, AMP, Elias, PCL, Pereira, MDG, Carvalho, EC, The effect of therapeutic listening on anxiety and fear among surgical patients: randomized controlled trial., Rev Lat Am Enfermagem, 2018. 26 (): p. e3027., https://pubmed.ncbi.nlm.nih.gov/30110103 /
1474. Hazard Vallerand, A, Hasenau, SM, Robinson-Lane, SG, Templin, TN, Improving Functional Status in African Americans With Cancer Pain: A Randomized Clinical Trial., Oncol Nurs Forum, 2018. 45 (2)(2): p. 260-272., https://pubmed.ncbi.nlm.nih.gov/29466352 /
1475. Kim, YH, Choi, KS, Han, K, Kim, HW, A psychological intervention programme for patients with breast cancer under chemotherapy and at a high risk of depression: A randomised clinical trial., J Clin Nurs, 2018. 27 (3-4)(3-4): p. 572-581., https://pubmed.ncbi.nlm.nih.gov/28557043 /
1476. Olesen, ML, Duun-Henriksen, AK, Hansson, H, Ottesen, B, Andersen, KK, Zoffmann, V, A person-centered intervention targeting the psychosocial needs of gynecological cancer survivors: a randomized clinical trial., J Cancer Surviv, 2016. 10 (5)(5): p. 832-41., https://pubmed.ncbi.nlm.nih.gov/26902366 /
1477. Peoples, AR, Garland, SN, Pigeon, WR, Perlis, ML, Wolf, JR, Heffner, KL, et.al. Cognitive Behavioral Therapy for Insomnia Reduces Depression in Cancer Survivors., J Clin Sleep Med, 2019. 15 (1)(1): p. 129-137., https://pubmed.ncbi.nlm.nih.gov/30621831 /
1478. Qiu, H, Ren, W, Yang, Y, Zhu, X, Mao, G, Mao, S, et.al. Effects of cognitive behavioral therapy for depression on improving insomnia and quality of life in Chinese women with breast cancer: results of a randomized, controlled, multicenter trial., Neuropsychiatr Dis Treat, 2018. 14 (): p. 2665-2673., https://pubmed.ncbi.nlm.nih.gov/30349264 /
1479. Richardson, AE, Tennant, G, Morton, RP, Broadbent, E, A Self-Regulatory Intervention for Patients with Head and Neck Cancer: Pilot Randomized Trial., Ann Behav Med, 2017. 51 (5)(5): p. 629-641., https://pubmed.ncbi.nlm.nih.gov/28244003 /
1480. Scarpa, M, Pinto, E, Saraceni, E, Cavallin, F, Parotto, M, Alfieri, R, et.al. Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy., Br J Surg, 2017. 104 (10)(10): p. 1307-1314., https://pubmed.ncbi.nlm.nih.gov/28707741 /
1481. Singer, S, Danker, H, Roick, J, Einenkel, J, Briest, S, Spieker, H, et.al. Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial., Psychooncology, 2017. 26 (10)(10): p. 1675-1683., https://pubmed.ncbi.nlm.nih.gov/28665542/
1482. Balck, Friedrich, Zschieschang, Anja, Zimmermann, Anja, Ordemann, Rainer, A randomized controlled trial of problem-solving training (PST) for hematopoietic stem cell transplant (HSCT) patients: Effects on anxiety, depression, distress, coping and painRoutledge, Journal of Psychosocial Oncology, 2019. 37(5): p. 541 - 556., https://doi.org/10.1080/07347332.2019.1624673
1483. Schneider, Gudrun, Kropff, Birgit, Unrath, Michael, Floeth, Sandra, Semjonow, Axel, Doering, Stephan, Results of a psychooncological group intervention in male cancer patients aged 60 years or older/Ergebnisse einer psychoonkologischen Gruppenintervention bei mannlichen Krebspatienten ab 60 Jahren--eine randomisierte kontrollierte Studie, 2016///. 62: p. 336+., https://link.gale.com/apps/doc/A571836404/AONE?u=anon~f3f6b20c&sid=googleScholar&xid=7fffd946
1484. Mani A, Khabir L, Mosalaei A, The Effectiveness of Group Acceptance and Commitment Psychotherapy on Psychological Well-being of Breast Cancer Patients in Shiraz, Iran., 2019. 10: p. 231 - 238.
1485. Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., et.al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, J Clin Oncol, 2006. 24(31): p. 5091-7., https://www.ncbi.nlm.nih.gov/pubmed/17033037
1486. Saphner, T., Tormey, D. C., Gray, R., Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 1996. 14(10): p. 2738-46., https://www.ncbi.nlm.nih.gov/pubmed/8874335
1487. Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del Turco, M., Distante, V., et.al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up, Jama, 1999. 281(17): p. 1586., https://www.ncbi.nlm.nih.gov/pubmed/10235147
1488. Rosselli Del Turco, M., Palli, D., Cariddi, A., Ciatto, S., Pacini, P., Distante, V., Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up, Jama, 1994. 271(20): p. 1593-7., https://www.ncbi.nlm.nih.gov/pubmed/7848404
1489. Dalberg, K., Mattsson, A., Sandelin, K., Rutqvist, L. E., Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer, Breast Cancer Res Treat, 1998. 49(1): p. 69-78., https://www.ncbi.nlm.nih.gov/pubmed/9694613
1490. Moschetti, I, Cinquini, M, Lambertini, M, Levaggi, A, Liberati, A, Follow-up strategies for women treated for early breast cancer., Cochrane Database Syst Rev, 2016. 2016 (5)(5): p. CD001768., https://pubmed.ncbi.nlm.nih.gov/27230946/
1491. Muuller, R. D., Barkhausen, J., Sauerwein, W., Langer, R., Assessment of local recurrence after breast-conserving therapy with MRI, J Comput Assist Tomogr, 1998. 22(3): p. 408-12., https://www.ncbi.nlm.nih.gov/pubmed/9606381
1492. Viehweg, P., Heinig, A., Lampe, D., Buchmann, J., Heywang-Kobrunner, S. H., Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy, Magma, 1998. 7(3): p. 141-52., https://www.ncbi.nlm.nih.gov/pubmed/10050940
1493. Kollias, J., Evans, A. J., Wilson, A. R., Ellis, I. O., Elston, C. W., Blamey, R. W., Value of contralateral surveillance mammography for primary breast cancer follow-up, World J Surg, 2000. 24(8): p. 983-7; discussion 988-9., https://www.ncbi.nlm.nih.gov/pubmed/10865045
1494. Bindemann, S., Soukop, M., Kaye, S. B., Randomised controlled study of relaxation training, Eur J Cancer, 1991. 27(2): p. 170-4., https://www.ncbi.nlm.nih.gov/pubmed/1827283
1495. Kuhl, C., Weigel, S., Schrading, S., Arand, B., Bieling, H., Konig, R., et.al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial, J Clin Oncol, 2010. 28(9): p. 1450-7., https://www.ncbi.nlm.nih.gov/pubmed/20177029
1496. Riebe, E., Gunther, K., Schulz, K., Kohler, G., Schimming, A., Schwesinger, G., et.al. Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer--diagnostic yield of palpation, mammography and ultrasonography, Ultraschall Med, 2007. 28(4): p. 394-400., https://www.ncbi.nlm.nih.gov/pubmed/17610177
1497. Wojcinski, S., Farrokh, A., Hille, U., Hirschauer, E., Schmidt, W., Hillemanns, P., et.al. Optimizing breast cancer follow-up: diagnostic value and costs of additional routine breast ultrasound, Ultrasound Med Biol, 2011. 37(2): p. 198-206., https://www.ncbi.nlm.nih.gov/pubmed/21208726
1498. Auvinen, A., Curtis, R. E., Ron, E., Risk of subsequent cancer following breast cancer in men, J Natl Cancer Inst, 2002. 94(17): p. 1330-2., https://www.ncbi.nlm.nih.gov/pubmed/12208898
1499. Brennan, M. J., Lymphedema following the surgical treatment of breast cancer: a review of pathophysiology and treatment, J Pain Symptom Manage, 1992. 7(2): p. 110-6., https://www.ncbi.nlm.nih.gov/pubmed/1573284
1500. Hayes, D. F., Clinical practice. Follow-up of patients with early breast cancer, N Engl J Med, 2007. 356(24): p. 2505-13., https://www.ncbi.nlm.nih.gov/pubmed/17568031
1501. Armer, J., Fu, M. R., Wainstock, J. M., Zagar, E., Jacobs, L. K., Lymphedema following breast cancer treatment, including sentinel lymph node biopsy, Lymphology, 2004. 37(2): p. 73-91., https://www.ncbi.nlm.nih.gov/pubmed/15328760
1502. Bani, H. A., Fasching, P. A., Lux, M. M., Rauh, C., Willner, M., Eder, I., et.al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit, Patient Educ Couns, 2007. 66(3): p. 311-8., https://www.ncbi.nlm.nih.gov/pubmed/17331692
1503. Francis, W. P., Abghari, P., Du, W., Rymal, C., Suna, M., Kosir, M. A., Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection, Am J Surg, 2006. 192(5): p. 636-9., https://www.ncbi.nlm.nih.gov/pubmed/17071198
1504. Golshan, M., Martin, W. J., Dowlatshahi, K., Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection, Am Surg, 2003. 69(3): p. 209-11; discussion 212., https://www.ncbi.nlm.nih.gov/pubmed/12678476
1505. Hamner, J. B., Fleming, M. D., Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer, Ann Surg Oncol, 2007. 14(6): p. 1904-8., https://www.ncbi.nlm.nih.gov/pubmed/17342565
1506. Harris, S. R., Hugi, M. R., Olivotto, I. A., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema, Cmaj, 2001. 164(2): p. 191-9., https://www.ncbi.nlm.nih.gov/pubmed/11332311
1507. Hayes, S., Cornish, B., Newman, B., Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up, Breast Cancer Res Treat, 2005. 89(3): p. 221-6., https://www.ncbi.nlm.nih.gov/pubmed/15754119
1508. Moseley, A. L., Carati, C. J., Piller, N. B., A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment, Ann Oncol, 2007. 18(4): p. 639-46., https://www.ncbi.nlm.nih.gov/pubmed/17018707
1509. Sanjuan, A., Vidal-Sicart, S., Zanon, G., Pahisa, J., Velasco, M., Fernandez, P. L., et.al. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients, Eur J Nucl Med Mol Imaging, 2005. 32(8): p. 932-6., https://www.ncbi.nlm.nih.gov/pubmed/15791433
1510. Torrenga, H., Fabry, H., van der Sijp, J. R., van Diest, P. J., Pijpers, R., Meijer, S., Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis, J Surg Oncol, 2004. 88(1): p. 4-7; discussion 7-8., https://www.ncbi.nlm.nih.gov/pubmed/15384064
1511. Gulliford, T., Opomu, M., Wilson, E., Hanham, I., Epstein, R., Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study, Bmj, 1997. 314(7075): p. 174-7., https://www.ncbi.nlm.nih.gov/pubmed/9022429
1512. Selby, P., Gillis, C., Haward, R., Benefits from specialised cancer care, Lancet, 1996. 348(9023): p. 313-8., https://www.ncbi.nlm.nih.gov/pubmed/8709693
1513. Clark, B., Sitzia, J., Harlow, W., Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study, Qjm, 2005. 98(5): p. 343-8., https://www.ncbi.nlm.nih.gov/pubmed/15820971
1514. Kokke, M. C., Jannink, I., Barneveld, P. C., van der Linden, J. C., Gelderman, W. A., Wissing, J. C., et.al. Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study, Eur J Surg Oncol, 2005. 31(3): p. 221-5., https://www.ncbi.nlm.nih.gov/pubmed/15780554
1515. Mansel, R. E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R. G., Dixon, J. M., et.al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial, J Natl Cancer Inst, 2006. 98(9): p. 599-609., https://www.ncbi.nlm.nih.gov/pubmed/16670385
1516. Purushotham, A. D., Upponi, S., Klevesath, M. B., Bobrow, L., Millar, K., Myles, J. P., et.al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial, J Clin Oncol, 2005. 23(19): p. 4312-21., https://www.ncbi.nlm.nih.gov/pubmed/15994144
1517. McNeely, M. L., Campbell, K., Ospina, M., Rowe, B. H., Dabbs, K., Klassen, T. P., et.al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment, Cochrane Database Syst Rev, 2010. p. Cd005211., https://www.ncbi.nlm.nih.gov/pubmed/20556760
1518. Devoogdt, N., Van Kampen, M., Geraerts, I., Coremans, T., Christiaens, M. R., Different physical treatment modalities for lymphoedema developing after axillary lymph node dissection for breast cancer: a review, Eur J Obstet Gynecol Reprod Biol, 2010. 149(1): p. 3-9., https://www.ncbi.nlm.nih.gov/pubmed/20018422
1519. Schmitz, K. H., Ahmed, R. L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, L., et.al. Weight lifting in women with breast-cancer-related lymphedema, N Engl J Med, 2009. 361(7): p. 664-73., https://www.ncbi.nlm.nih.gov/pubmed/19675330
1520. Donnelly, J., Mack, P., Donaldson, L. A., Follow-up of breast cancer: time for a new approach?, Int J Clin Pract, 2001. 55(7): p. 431-3., https://www.ncbi.nlm.nih.gov/pubmed/11594249
1521. Allen, I, Hassan, H, Sofianopoulou, E, Eccles, D, Turnbull, C, Tischkowitz, M, et.al. Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis., Breast Cancer Res, 2023. 25 (1)(1): p. 18., https://pubmed.ncbi.nlm.nih.gov/36765408/
1522. Renton, J. P., Twelves, C. J., Yuille, F. A., Follow-up in women with breast cancer: the patients' perspective, Breast, 2002. 11(3): p. 257-61., https://www.ncbi.nlm.nih.gov/pubmed/14965677
1523. Doubeni, C. A., Field, T. S., Ulcickas Yood, M., Rolnick, S. J., Quessenberry, C. P., Fouayzi, H., et.al. Patterns and predictors of mammography utilization among breast cancer survivors, Cancer, 2006. 106(11): p. 2482-8., https://www.ncbi.nlm.nih.gov/pubmed/16634097
1524. Grunfeld, E., Noorani, H., McGahan, L., Paszat, L., Coyle, D., van Walraven, C., et.al. Surveillance mammography after treatment of primary breast cancer: a systematic review, Breast, 2002. 11(3): p. 228-35., https://www.ncbi.nlm.nih.gov/pubmed/14965672
1525. Hollowell, K., Olmsted, C. L., Richardson, A. S., Pittman, H. K., Bellin, L., Tafra, L., et.al. American Society of Clinical Oncology-recommended surveillance and physician specialty among long-term breast cancer survivors, Cancer, 2010. 116(9): p. 2090-8., https://www.ncbi.nlm.nih.gov/pubmed/20198707
1526. Katz, M. L., Donohue, K. A., Alfano, C. M., Day, J. M., Herndon, J. E., 2nd, Paskett, E. D., Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804, Cancer, 2009. 115(3): p. 480-8., https://www.ncbi.nlm.nih.gov/pubmed/19133656
1527. Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., et.al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer, Breast Cancer Res Treat, 2011. 126(2): p. 529-37., https://www.ncbi.nlm.nih.gov/pubmed/20803066
1528. National Comprehensive Cancer Network, NCCN Practice Guidelines for Cancer-Related Fatigue., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 2.2024, 2024.
1529. Wu, T, Yan, F, Wei, Y, Yuan, C, Jiao, Y, Pan, Y, et.al. Effect of Exercise Therapy on Cancer-Related Fatigue in Patients With Breast Cancer: A Systematic Review and Network Meta-analysis., Am J Phys Med Rehabil, 2023. 102 (12)(12): p. 1055-1062., https://pubmed.ncbi.nlm.nih.gov/37204936/
1530. Network, National Comprehensive Cancer, NCCN GUIDELINES FOR SUPPORTIVE CARE-Cancer Related Fatigue, Version 1, 2015
1531. Onkologie, Leitlinienprogramm, Supportive Therapie bei onkologischen PatientInnen-Konsultationsfassung, LangversionDeutsche Krebsgesellschaft, D.K., AWMF, 2016.
1532. oder Chemobrain, Kognitive Dysfunktion, GMS Onkologische Rehabilitation und Sozialmedizin
1533. Ribeiro, IL, Moreira, RFC, Ferrari, AV, Alburquerque-Sendín, F, Camargo, PR, Salvini, TF, Effectiveness of early rehabilitation on range of motion, muscle strength and arm function after breast cancer surgery: a systematic review of randomized controlled trials., Clin Rehabil, 2019. 33 (12)(12): p. 1876-1886., https://pubmed.ncbi.nlm.nih.gov/31480855/
1534. Redemski, T, Hamilton, DG, Schuler, S, Liang, R, Michaleff, ZA, Rehabilitation for Women Undergoing Breast Cancer Surgery: A Systematic Review and Meta-Analysis of the Effectiveness of Early, Unrestricted Exercise Programs on Upper Limb Function., Clin Breast Cancer, 2022. 22 (7)(7): p. 650-665., https://pubmed.ncbi.nlm.nih.gov/35902321/
1535. Appelgren, M, Sackey, H, Wengström, Y, Johansson, K, Ahlgren, J, Andersson, Y, et.al. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial., Breast, 2022. 63 (): p. 16-23., https://pubmed.ncbi.nlm.nih.gov/35279508/
1536. Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., et.al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, Lancet, 2016. 387(10021): p. 866-73., https://www.ncbi.nlm.nih.gov/pubmed/26686313
1537. Janelsins, M. C., Peppone, L. J., Heckler, C. E., Kesler, S. R., Sprod, L. K., Atkins, J., et.al. YOCAS(c)(R) Yoga Reduces Self-reported Memory Difficulty in Cancer Survivors in a Nationwide Randomized Clinical Trial: Investigating Relationships Between Memory and Sleep, Integr Cancer Ther, 2016. 15(3): p. 263-71., https://www.ncbi.nlm.nih.gov/pubmed/26621521
1538. Bray, V. J., Dhillon, H. M., Bell, M. L., Kabourakis, M., Fiero, M. H., Yip, D., et.al. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy, J Clin Oncol, 2017. 35(2): p. 217-225., https://www.ncbi.nlm.nih.gov/pubmed/28056205
1539. Dos Santos, M, Hardy-Léger, I, Rigal, O, Licaj, I, Dauchy, S, Levy, C, et.al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial., Cancer, 2020. 126 (24)(24): p. 5328-5336., https://pubmed.ncbi.nlm.nih.gov/32996583/
1540. Johns, SA, Brown, LF, Beck-Coon, K, Talib, TL, Monahan, PO, Giesler, RB, et.al. Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors., Support Care Cancer, 2016. 24 (10)(10): p. 4085-96., https://pubmed.ncbi.nlm.nih.gov/27189614/
1541. Campbell, KL, Zadravec, K, Bland, KA, Chesley, E, Wolf, F, Janelsins, MC, The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials., Phys Ther, 2020. 100 (3)(3): p. 523-542., https://pubmed.ncbi.nlm.nih.gov/32065236/
1542. Radbruch, Lukas, Payne, Sheila, White Paper on standards and norms for hospice and palliative care in Europe: part 2, European journal of palliative care, 2010. 17(1): p. 22-33., https://www.researchgate.net/publication/279547069_White_paper_on_standards_and_norms_for_hospice_and_palliative_care_in_Europe_Part_1
1543. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7., https://www.ncbi.nlm.nih.gov/pubmed/22312101
1544. Radbruch, Lukas, Payne, Sheila, White paper on standards and norms for hospice and palliative care in Europe: part 1, European journal of palliative care, 2009. 16(6): p. 278-289.
1545. Douglas, C., Murtagh, F. E., Chambers, E. J., Howse, M., Ellershaw, J., Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group, Palliat Med, 2009. 23(2): p. 103-10., https://www.ncbi.nlm.nih.gov/pubmed/19273566
1546. Griffin, J. P., Koch, K. A., Nelson, J. E., Cooley, M. E., Palliative care consultation, quality-of-life measurements, and bereavement for end-of-life care in patients with lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007. 132(3 Suppl): p. 404s-422s., https://www.ncbi.nlm.nih.gov/pubmed/17873182
1547. Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 5: Palliative CareCopyright (c) World Health Organization, 2007.
1548. Supportive, Improving, Palliative Care for Adults with Cancer NICE London http://www. nice. org. ukCSGSP, 2004.
1549. NIH State-of-the-Science Conference Statement on improving end-of-life care, NIH Consens State Sci Statements, 2004. 21(3): p. 1-26., https://www.ncbi.nlm.nih.gov/pubmed/17308546
1550. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29(6): p. 755-60., https://www.ncbi.nlm.nih.gov/pubmed/21263086
1551. Levy, M. H., Adolph, M. D., Back, A., Block, S., Codada, S. N., Dalal, S., et.al. Palliative care, J Natl Compr Canc Netw, 2012. 10(10): p. 1284-309., https://www.ncbi.nlm.nih.gov/pubmed/23054879
1552. (WHO)., World Health Organization, Palliative care., 2007.
1553. Improvement., Institute for Clinical Systems, Health care guidelines: palliative care, 2009.
1554. Committee, O.G.A., Palliative Care: Recognizing Eligible Patients and Starting the Discussion., 2008.
1555. Project, N.C., Clinical Practice Guidelines for Quality Palliative Care ., 2012., http://www.nationalconsensusproject.org.
1556. Gärtner, J, Daun, M, Wolf, J, von Bergwelt-Baildon, M, Hallek, M, Early Palliative Care: Pro, but Please Be Precise!, Oncol Res Treat, 2019. 42 (1-2)(1-2): p. 11-18., https://pubmed.ncbi.nlm.nih.gov/30685764/
1557. Gaertner, J, Boehlke, C, Simone, CB, Hui, D, Early palliative care and the opioid crisis: ten pragmatic steps towards a more rational use of opioids., Ann Palliat Med, 2019. 8 (4)(4): p. 490-497., https://pubmed.ncbi.nlm.nih.gov/31431028/
1558. Gaertner, J, Wuerstlein, R, Ostgathe, C, Mallmann, P, Harbeck, N, Voltz, R, Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific Guidelines., Breast Care (Basel), 2011. 6 (3)(3): p. 240-244., https://pubmed.ncbi.nlm.nih.gov/21779232/
1559. Gaertner, J, Wuerstlein, R, Klein, U, Scheicht, D, Frechen, S, Wolf, J, et.al. Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project., Breast Care (Basel), 2011. 6 (3)(3): p. 215-220., https://pubmed.ncbi.nlm.nih.gov/21779227/
1560. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis., BMJ, 2017. 357 (): p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/
1561. Dudgeon, D., King, S., Howell, D., Green, E., Gilbert, J., Hughes, E., et.al. Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening, Psychooncology, 2012. 21(4): p. 357-64., https://www.ncbi.nlm.nih.gov/pubmed/21308858
1562. Carlson, L. E., Waller, A., Groff, S. L., Zhong, L., Bultz, B. D., Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage, Br J Cancer, 2012. 107(4): p. 617-25., https://www.ncbi.nlm.nih.gov/pubmed/22828610
1563. Simon, S. T., Higginson, I. J., Harding, R., Daveson, B. A., Gysels, M., Deliens, L., et.al. Enhancing patient-reported outcome measurement in research and practice of palliative and end-of-life care, Support Care Cancer, 2012. 20(7): p. 1573-8., https://www.ncbi.nlm.nih.gov/pubmed/22391595
1564. Network, National Comprehensive Cancer, Distress management, NCCN Clinical Practice Guidelines in Oncology, 2008.
1565. Stiel, S., Pollok, A., Elsner, F., Lindena, G., Ostgathe, C., Nauck, F., et.al. Validation of the Symptom and Problem Checklist of the German Hospice and Palliative Care Evaluation (HOPE), J Pain Symptom Manage, 2012. 43(3): p. 593-605., https://www.ncbi.nlm.nih.gov/pubmed/22071164
1566. Stiel, S., Matthes, M. E., Bertram, L., Ostgathe, C., Elsner, F., Radbruch, L., [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)], Schmerz, 2010. 24(6): p. 596-604., https://www.ncbi.nlm.nih.gov/pubmed/20882300
1567. Mehnert, Anja, Müller, Diana, Lehmann, Claudia, Koch, Uwe, Die deutsche version des NCCN distress-thermometers: empirische Prüfung eines screening-instruments zur erfassung psychosozialer belastung bei krebspatienten, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2006. 54(3): p. 213-223.
1568. Bausewein, C., Fegg, M., Radbruch, L., Nauck, F., von Mackensen, S., Borasio, G. D., et.al. Validation and clinical application of the german version of the palliative care outcome scale, J Pain Symptom Manage, 2005. 30(1): p. 51-62., https://www.ncbi.nlm.nih.gov/pubmed/16043007
1569. Gartlehner, G., Chapman, A., Strobelberger, M., Kerschner, B., Thaler, K., Griebler, U., et.al. Vergleichende Wirksamkeit und Sicherheit von alleiniger Sentinel-Lymphknoten-Biopsie oder kompletter Axilladissektion bei Sentinel-positivem Mammakarzinom: Systematische Übersichtsarbeit., 2011., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom/S3-Brustkrebs-v2012-OL-Evidenzbericht-Prof.-Gartlehner.pdf
1570. Martelli, G., Boracchi, P., De Palo, M., Pilotti, S., Oriana, S., Zucali, R., et.al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up, Ann Surg, 2005. 242(1): p. 1-6; discussion 7-9., https://www.ncbi.nlm.nih.gov/pubmed/15973094
1571. Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., Rey, P., et.al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93, J Clin Oncol, 2006. 24(3): p. 337-44., https://www.ncbi.nlm.nih.gov/pubmed/16344321
1572. Horneber, M. A., Bueschel, G., Huber, R., Linde, K., Rostock, M., Mistletoe therapy in oncology, Cochrane Database Syst Rev, 2008. p. Cd003297., https://www.ncbi.nlm.nih.gov/pubmed/18425885
1573. Kalder, M., Muller, T., Fischer, D., Muller, A., Bader, W., Beckmann, M. W., et.al. A Review of Integrative Medicine in Gynaecological Oncology, Geburtshilfe Frauenheilkd, 2016. 76(2): p. 150-155., https://www.ncbi.nlm.nih.gov/pubmed/26941447
1574. Horneber, M., Bueschel, G., Dennert, G., Less, D., Ritter, E., Zwahlen, M., How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis, Integr Cancer Ther, 2012. 11(3): p. 187-203., https://www.ncbi.nlm.nih.gov/pubmed/22019489
1575. Micke, Oliver, Bruns, Frank, Glatzel, Michael, Schönekaes, Klaus, Micke, Patrick, Mücke, Ralph, et.al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology, European Journal of Integrative Medicine, 2009. 1(1): p. 19-25.
1576. Zeller, T., Muenstedt, K., Stoll, C., Schweder, J., Senf, B., Ruckhaeberle, E., et.al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center, J Cancer Res Clin Oncol, 2013. 139(3): p. 357-65., https://www.ncbi.nlm.nih.gov/pubmed/23099993
1577. Huebner, J., Muenstedt, K., Prott, F. J., Stoll, C., Micke, O., Buentzel, J., et.al. Online survey of patients with breast cancer on complementary and alternative medicine, Breast Care (Basel), 2014. 9(1): p. 60-3., https://www.ncbi.nlm.nih.gov/pubmed/24803889
1578. Lambertini, M, Moore, HCF, Leonard, RCF, Loibl, S, Munster, P, Bruzzone, M, et.al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data., J Clin Oncol, 2018. 36 (19)(19): p. 1981-1990., https://pubmed.ncbi.nlm.nih.gov/29718793/
1579. Li, ZY, Dong, YL, Cao, XZ, Ren, SS, Zhang, Z, Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis., Menopause, 2022. 29 (9)(9): p. 1093-1100., https://pubmed.ncbi.nlm.nih.gov/35917530/
1580. Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., et.al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial, Jama, 2015. 314(24): p. 2632-40., https://www.ncbi.nlm.nih.gov/pubmed/26720025
1581. Lambertini, M, Boni, L, Michelotti, A, Magnolfi, E, Cogoni, AA, Mosconi, AM, et.al. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients., J Natl Cancer Inst, 2022. 114 (3)(3): p. 400-408., https://pubmed.ncbi.nlm.nih.gov/34850043/
1582. Moore, HCF, Unger, JM, Phillips, KA, Boyle, F, Hitre, E, Moseley, A, et.al. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230., J Natl Cancer Inst, 2019. 111 (2)(2): p. 210-213., https://pubmed.ncbi.nlm.nih.gov/30371800/
1583. Lambertini, M, Blondeaux, E, Bruzzone, M, Perachino, M, Anderson, RA, de Azambuja, E, et.al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis., J Clin Oncol, 2021. 39 (29)(29): p. 3293-3305., https://pubmed.ncbi.nlm.nih.gov/34197218/
1584. D'Ambrosio, V, Vena, F, Di Mascio, D, Faralli, I, Musacchio, L, Boccherini, C, et.al. Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis., Breast Cancer Res Treat, 2019. 178 (3)(3): p. 485-492., https://pubmed.ncbi.nlm.nih.gov/31451975/
1585. Lambertini, M, Kroman, N, Ameye, L, Cordoba, O, Pinto, A, Benedetti, G, et.al. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status., J Natl Cancer Inst, 2018. 110 (4)(4): p. 426-429., https://pubmed.ncbi.nlm.nih.gov/29087485/
1586. Partridge, AH, Niman, SM, Ruggeri, M, Peccatori, FA, Azim, HA, Colleoni, M, et.al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer., N Engl J Med, 2023. 388 (18)(18): p. 1645-1656., https://pubmed.ncbi.nlm.nih.gov/37133584/
1587. Goldrat, O., Kroman, N., Peccatori, F. A., Cordoba, O., Pistilli, B., Lidegaard, O., et.al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome, Eur J Cancer, 2015. 51(12): p. 1490-6., https://www.ncbi.nlm.nih.gov/pubmed/26070684
1588. Luke, B., Brown, M. B., Missmer, S. A., Spector, L. G., Leach, R. E., Williams, M., et.al. Assisted reproductive technology use and outcomes among women with a history of cancer, Hum Reprod, 2016. 31(1): p. 183-9., https://www.ncbi.nlm.nih.gov/pubmed/26577302
1589. Rodgers, RJ, Reid, GD, Koch, J, Deans, R, Ledger, WL, Friedlander, M, et.al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review., Hum Reprod, 2017. 32 (5)(5): p. 1033-1045., https://pubmed.ncbi.nlm.nih.gov/28333356/
1590. Ortmann, O, Schüler-Toprak, S, Kast, K, The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer., J Cancer Res Clin Oncol, 2024. 150 (9)(9): p. 417., https://pubmed.ncbi.nlm.nih.gov/39259360/
1591. Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., et.al. Treatment of breast cancer during pregnancy: an observational study, Lancet Oncol, 2012. 13(9): p. 887-96., https://www.ncbi.nlm.nih.gov/pubmed/22902483
1592. Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., et.al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients, JAMA Oncol, 2015. 1(8): p. 1145-53., https://www.ncbi.nlm.nih.gov/pubmed/26247818
1593. NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy, NTP Monogr, 2013. p. i-214., https://www.ncbi.nlm.nih.gov/pubmed/24736875
1594. Metcalfe, A, Cairncross, ZF, McMorris, CA, Friedenreich, CM, Nelson, G, Bhatti, P, et.al. Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study., J Natl Cancer Inst, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39475425/
1595. Xia, LY, Hu, QL, Zhou, Q, Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis., BMC Womens Health, 2021. 21 (1)(1): p. 169., https://pubmed.ncbi.nlm.nih.gov/33882925/
1596. Andrikopoulou, A, Apostolidou, K, Chatzinikolaou, S, Bletsa, G, Zografos, E, Dimopoulos, MA, et.al. Trastuzumab administration during pregnancy: an update., BMC Cancer, 2021. 21 (1)(1): p. 463., https://pubmed.ncbi.nlm.nih.gov/33902516/
1597. Schuurman, TN, Witteveen, PO, van der Wall, E, Passier, JLM, Huitema, ADR, Amant, F, et.al. Tamoxifen and pregnancy: an absolute contraindication?, Breast Cancer Res Treat, 2019. 175 (1)(1): p. 17-25., https://pubmed.ncbi.nlm.nih.gov/30707336/
1598. Van Calsteren, K, Verbesselt, R, Ottevanger, N, Halaska, M, Heyns, L, Van Bree, R, et.al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study., Acta Obstet Gynecol Scand, 2010. 89 (10)(10): p. 1338-45., https://pubmed.ncbi.nlm.nih.gov/20846067/
1599. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Papadimitriou, C. A., Dimopoulos, M. A., Bartsch, R., Trastuzumab administration during pregnancy: a systematic review and meta-analysis, Breast Cancer Res Treat, 2013. 137(2): p. 349-57., https://www.ncbi.nlm.nih.gov/pubmed/23242615
1600. Mehta, A, Kim, KB, Minor, DR, Case Report of a Pregnancy During Ipilimumab Therapy., J Glob Oncol, 2018. 4 (): p. 1-3., https://pubmed.ncbi.nlm.nih.gov/30241195/
1601. Bucheit, AD, Hardy, JT, Szender, JB, Glitza Oliva, IC, Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition., Melanoma Res, 2020. 30 (4)(4): p. 423-425., https://pubmed.ncbi.nlm.nih.gov/32073510/
1602. Xu, W, Moor, RJ, Walpole, ET, Atkinson, VG, Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature., Melanoma Res, 2019. 29 (3)(3): p. 333-337., https://pubmed.ncbi.nlm.nih.gov/30730328/
1603. Haiduk, J, Ziemer, M, Pregnancy in a patient with metastatic uveal melanoma treated with nivolumab., J Dtsch Dermatol Ges, 2021. 19 (5)(5): p. 762-765., https://pubmed.ncbi.nlm.nih.gov/33768686/
1604. Menzer, C, Beedgen, B, Rom, J, Duffert, CM, Volckmar, AL, Sedlaczek, O, et.al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy., Eur J Cancer, 2018. 104 (): p. 239-242., https://pubmed.ncbi.nlm.nih.gov/30454709/
1605. Burotto, M, Gormaz, JG, Samtani, S, Valls, N, Silva, R, Rojas, C, et.al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy., Semin Oncol, 2018. 45 (3)(3): p. 164-169., https://pubmed.ncbi.nlm.nih.gov/30262400/
1606. Guleria, I, Khosroshahi, A, Ansari, MJ, Habicht, A, Azuma, M, Yagita, H, et.al. A critical role for the programmed death ligand 1 in fetomaternal tolerance., J Exp Med, 2005. 202 (2)(2): p. 231-7., https://pubmed.ncbi.nlm.nih.gov/16027236/
1607. Plitnick, Lisa, Herzyk, Danuta, Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics, 2013/07/01. p. 1 - 416., https://www.researchgate.net/publication/296388849_Nonclinical_Development_of_Novel_Biologics_Biosimilars_Vaccines_and_Specialty_Biologics
1608. Gougis, P, Hamy, AS, Jochum, F, Bihan, K, Carbonnel, M, Salem, JE, et.al. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns., JAMA Netw Open, 2024. 7 (4)(4): p. e245625., https://pubmed.ncbi.nlm.nih.gov/38630478/
1609. Kalsi, T., Babic-Illman, G., Ross, P. J., Maisey, N. R., Hughes, S., Fields, P., et.al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people, Br J Cancer, 2015. 112(9): p. 1435-44., https://www.ncbi.nlm.nih.gov/pubmed/25871332
1610. Hall, D. E., Arya, S., Schmid, K. K., Carlson, M. A., Lavedan, P., Bailey, T. L., et.al. Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days, JAMA Surg, 2017. 152(3): p. 233-240., https://www.ncbi.nlm.nih.gov/pubmed/27902826
1611. Le Saux, O., Ripamonti, B., Bruyas, A., Bonin, O., Freyer, G., Bonnefoy, M., et.al. Optimal management of breast cancer in the elderly patient: current perspectives, Clin Interv Aging, 2015. 10: p. 157-74., https://www.ncbi.nlm.nih.gov/pubmed/25609933
1612. Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G., et.al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger, Ann Oncol, 2015. 26(2): p. 288-300., https://www.ncbi.nlm.nih.gov/pubmed/24936581
1613. Dale, W, Klepin, HD, Williams, GR, Alibhai, SMH, Bergerot, C, Brintzenhofeszoc, K, et.al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update., J Clin Oncol, 2023. 41 (26)(26): p. 4293-4312., https://pubmed.ncbi.nlm.nih.gov/37459573/
1614. Dotan, E, Walter, LC, Browner, IS, Clifton, K, Cohen, HJ, Extermann, M, et.al. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021., J Natl Compr Canc Netw, 2021. 19 (9)(9): p. 1006-1019., https://pubmed.ncbi.nlm.nih.gov/34551388/
1615. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603., https://www.ncbi.nlm.nih.gov/pubmed/25071125
1616. Clough-Gorr, K. M., Stuck, A. E., Thwin, S. S., Silliman, R. A., Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up, J Clin Oncol, 2010. 28(3): p. 380-6., https://www.ncbi.nlm.nih.gov/pubmed/20008637
1617. Mislang, A. R., Biganzoli, L., Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?, Cancers (Basel), 2015. 7(3): p. 1191-214., https://www.ncbi.nlm.nih.gov/pubmed/26151681
1618. Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., et.al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet Oncol, 2012. 13(4): p. e148-60., https://www.ncbi.nlm.nih.gov/pubmed/22469125
1619. Thavarajah, N., Menjak, I., Trudeau, M., Mehta, R., Wright, F., Leahey, A., et.al. Towards an optimal multidisciplinary approach to breast cancer treatment for older women, Can Oncol Nurs J, 2015. 25(4): p. 384-408., https://www.ncbi.nlm.nih.gov/pubmed/26897863
1620. Onkologie, Leitlinienprogramm, S3-Leitlinie Umfassendes Geriatrisches Assessment (Comprehensive Geriatric Assessment CGA) bei hospitalisierten Patientinnen und PatientenAWMF, 2024. Registernummer 084 - 003:
1621. Perrone, F., Nuzzo, F., Di Rella, F., Gravina, A., Iodice, G., Labonia, V., et.al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial, Ann Oncol, 2015. 26(4): p. 675-82., https://www.ncbi.nlm.nih.gov/pubmed/25488686
1622. Hamaker, M. E., Seynaeve, C., Wymenga, A. N., van Tinteren, H., Nortier, J. W., Maartense, E., et.al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group, Breast, 2014. 23(1): p. 81-7., https://www.ncbi.nlm.nih.gov/pubmed/24314824
1623. Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., et.al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 2011. 29(25): p. 3457-65., https://www.ncbi.nlm.nih.gov/pubmed/21810685
1624. Disalvo, D, Moth, E, Soo, WK, Garcia, MV, Blinman, P, Steer, C, et.al. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review., J Geriatr Oncol, 2023. 14 (8)(8): p. 101585., https://pubmed.ncbi.nlm.nih.gov/37573197/
1625. Hamaker, ME, Vos, AG, Smorenburg, CH, de Rooij, SE, van Munster, BC, The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer., Oncologist, 2012. 17 (11)(11): p. 1439-49., https://pubmed.ncbi.nlm.nih.gov/22941970/
1626. Uranga, C, Chien, LC, Liposits, G, Geriatric screening in older adults with cancer - A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative., J Geriatr Oncol, 2022. 13 (3)(3): p. 374-377., https://pubmed.ncbi.nlm.nih.gov/34509397/
1627. ():, https://pubmed.ncbi.nlm.nih.gov/33828260/
1628. Chuang, MH, Chen, JY, Tsai, WW, Lee, CW, Lee, MC, Tseng, WH, et.al. Impact of comprehensive geriatric assessment on the risk of adverse events in the older patients receiving anti-cancer therapy: a systematic review and meta-analysis., Age Ageing, 2022. 51 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/35776674/
1629. Mohile, SG, Mohamed, MR, Xu, H, Culakova, E, Loh, KP, Magnuson, A, et.al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study., Lancet, 2021. 398 (10314)(10314): p. 1894-1904., https://pubmed.ncbi.nlm.nih.gov/34741815/
1630. Li, D, Sun, CL, Kim, H, Soto-Perez-de-Celis, E, Chung, V, Koczywas, M, et.al. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial., JAMA Oncol, 2021. 7 (11)(11): p. e214158., https://pubmed.ncbi.nlm.nih.gov/34591080/
1631. Morgan, Jenna, Wyld, Lynda, Collins Karen, A., Reed Malcolm, W., Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus), Cochrane Database of Systematic Reviews, 2014., http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004272.pub3/abstract
1632. Christiansen, P., Bjerre, K., Ejlertsen, B., Jensen, M. B., Rasmussen, B. B., Laenkholm, A. V., et.al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark, J Natl Cancer Inst, 2011. 103(18): p. 1363-72., https://www.ncbi.nlm.nih.gov/pubmed/21881042
1633. Meattini, I, De Santis, MC, Visani, L, Scorsetti, M, Fozza, A, Meduri, B, et.al. Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial., Lancet Oncol, 2025. 26 (1)(1): p. 37-50., https://pubmed.ncbi.nlm.nih.gov/39675376/
1634. Lange, M., Heutte, N., Rigal, O., Noal, S., Kurtz, J. E., Levy, C., et.al. Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment, Oncologist, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27473044
1635. Ono, M., Ogilvie, J. M., Wilson, J. S., Green, H. J., Chambers, S. K., Ownsworth, T., et.al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer, Front Oncol, 2015. 5: p. 59., https://www.ncbi.nlm.nih.gov/pubmed/25806355
1636. Jones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., McIntyre, K. J., et.al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735, J Clin Oncol, 2009. 27(8): p. 1177-83., https://www.ncbi.nlm.nih.gov/pubmed/19204201
1637. Biganzoli, L., Aapro, M., Loibl, S., Wildiers, H., Brain, E., Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force, Cancer Treat Rev, 2016. 43: p. 19-26., https://www.ncbi.nlm.nih.gov/pubmed/26827689
1638. Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., et.al. Adjuvant chemotherapy in older women with early-stage breast cancer, N Engl J Med, 2009. 360(20): p. 2055-65., https://www.ncbi.nlm.nih.gov/pubmed/19439741
1639. Freyer, G., Campone, M., Peron, J., Facchini, T., Terret, C., Berdah, J. F., et.al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study, Crit Rev Oncol Hematol, 2011. 80(3): p. 466-73., https://www.ncbi.nlm.nih.gov/pubmed/21565521
1640. Loibl, S., von Minckwitz, G., Harbeck, N., Janni, W., Elling, D., Kaufmann, M., et.al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials, Breast Cancer Res, 2008. 10(5): p. R77., https://www.ncbi.nlm.nih.gov/pubmed/18796139
1641. Swain, S. M., Whaley, F. S., Ewer, M. S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 2003. 97(11): p. 2869-79., https://www.ncbi.nlm.nih.gov/pubmed/12767102
1642. Freedman, R. A., Seisler, D. K., Foster, J. C., Sloan, J. A., Lafky, J. M., Kimmick, G. G., et.al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511), Breast Cancer Res Treat, 2017. 161(2): p. 363-373., https://www.ncbi.nlm.nih.gov/pubmed/27866278
1643. Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H., Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer, J Clin Oncol, 2007. 25(25): p. 3808-15., https://www.ncbi.nlm.nih.gov/pubmed/17664460
1644. Robert Koch-Institut, Krebs in Deutschland für 2019/2020, 14. Ausgabe, 2023., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2023.pdf?__blob=publicationFile
1645. Cardoso, F, Bartlett, JMS, Slaets, L, van Deurzen, CHM, van Leeuwen-Stok, E, Porter, P, et.al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program., Ann Oncol, 2018. 29 (2)(2): p. 405-417., https://pubmed.ncbi.nlm.nih.gov/29092024/
1646. Deb, S., Lakhani, S. R., Ottini, L., Fox, S. B., The cancer genetics and pathology of male breast cancer, Histopathology, 2016. 68(1): p. 110-8., https://www.ncbi.nlm.nih.gov/pubmed/26768033
1647. Chamseddine, RS, Wang, C, Yin, K, Wang, J, Singh, P, Zhou, J, et.al. Penetrance of male breast cancer susceptibility genes: a systematic review., Breast Cancer Res Treat, 2022. 191 (1)(1): p. 31-38., https://pubmed.ncbi.nlm.nih.gov/34642874/
1648. Fogh, S., Kachnic, L. A., Goldberg, S. I., Taghian, A. G., Powell, S. N., Hirsch, A. E., Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation, Clin Breast Cancer, 2013. 13(5): p. 344-9., https://www.ncbi.nlm.nih.gov/pubmed/23891587
1649. Jardel, P, Vignot, S, Cutuli, B, Creisson, A, Vass, S, Barranger, E, et.al. Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review., Anticancer Res, 2018. 38 (1)(1): p. 23-31., https://pubmed.ncbi.nlm.nih.gov/29277752/
1650. Altman, AM, Kizy, S, Yuan, J, Denbo, JW, Jensen, EH, Hui, JYC, et.al. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States., Ann Surg Oncol, 2018. 25 (8)(8): p. 2296-2302., https://pubmed.ncbi.nlm.nih.gov/29907942/
1651. Davey, MG, Davey, CM, Bouz, L, Kerin, E, McFeetors, C, Lowery, AJ, et.al. Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis., Breast, 2022. 64 (): p. 41-46., https://pubmed.ncbi.nlm.nih.gov/35512428/
1652. Leone, JP, Hassett, MJ, Leone, J, Tolaney, SM, Vallejo, CT, Leone, BA, et.al. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer., Cancer, 2022. 128 (21)(21): p. 3796-3803., https://pubmed.ncbi.nlm.nih.gov/36069365/
1653. Pemmaraju, N, Munsell, MF, Hortobagyi, GN, Giordano, SH, Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects., Ann Oncol, 2012. 23 (6)(6): p. 1471-4., https://pubmed.ncbi.nlm.nih.gov/22085764/
1654. Zagouri, F, Sergentanis, TN, Azim, HA, Chrysikos, D, Dimopoulos, MA, Psaltopoulou, T, Aromatase inhibitors in male breast cancer: a pooled analysis., Breast Cancer Res Treat, 2015. 151 (1)(1): p. 141-7., https://pubmed.ncbi.nlm.nih.gov/25850534/
1655. Yadav, Siddhartha, Giridhar, Karthik, Leone, Jose, Leon-Ferre, Roberto, Ruddy, Kathryn, A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer, 2021/09/07. 10: p. BMT59.
1656. Johnston, SRD, Harbeck, N, Hegg, R, Toi, M, Martin, M, Shao, ZM, et.al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)., J Clin Oncol, 2020. 38 (34)(34): p. 3987-3998., https://pubmed.ncbi.nlm.nih.gov/32954927/
1657. Castañeda, S, Casas, A, González-Del-Alba, A, Martínez-Díaz-Guerra, G, Nogués, X, Ojeda Thies, C, et.al. Bone loss induced by cancer treatments in breast and prostate cancer patients., Clin Transl Oncol, 2022. 24 (11)(11): p. 2090-2106., https://pubmed.ncbi.nlm.nih.gov/35779210/
1658. Campone, M, De Laurentiis, M, Zamagni, C, Kudryavcev, I, Agterof, M, Brown-Glaberman, U, et.al. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial., Breast Cancer Res Treat, 2022. 193 (1)(1): p. 95-103., https://pubmed.ncbi.nlm.nih.gov/35212906/
1659. Sauder, CAM, Bateni, SB, Davidson, AJ, Nishijima, DK, Breast Conserving Surgery Compared With Mastectomy in Male Breast Cancer: A Brief Systematic Review., Clin Breast Cancer, 2020. 20 (3)(3): p. e309-e314., https://pubmed.ncbi.nlm.nih.gov/32171701/
1660. Deldar, R, Sayyed, AA, Towfighi, P, Aminpour, N, Sogunro, O, Son, JD, et.al. Postmastectomy Reconstruction in Male Breast Cancer., Breast J, 2022. 2022 (): p. 5482261., https://pubmed.ncbi.nlm.nih.gov/35711890/
1661. De La Cruz, LM, Thiruchelvam, PTR, Shivani, J, Trina, J, Blankenship, SA, Fisher, CS, Saving the Male Breast: A Systematic Literature Review of Breast-Conservation Surgery for Male Breast Cancer., Ann Surg Oncol, 2019. 26 (12)(12): p. 3939-3944., https://pubmed.ncbi.nlm.nih.gov/31250345/
1662. Hassett, MJ, Somerfield, MR, Baker, ER, Cardoso, F, Kansal, KJ, Kwait, DC, et.al. Management of Male Breast Cancer: ASCO Guideline., J Clin Oncol, 2020. 38 (16)(16): p. 1849-1863., https://pubmed.ncbi.nlm.nih.gov/32058842/
1663. Hartley, RL, Stone, JP, Temple-Oberle, C, Breast cancer in transgender patients: A systematic review. Part 1: Male to female., Eur J Surg Oncol, 2018. 44 (10)(10): p. 1455-1462., https://pubmed.ncbi.nlm.nih.gov/30087072/
1664. Joint, R, Chen, ZE, Cameron, S, Breast and reproductive cancers in the transgender population: a systematic review., BJOG, 2018. 125 (12)(12): p. 1505-1512., https://pubmed.ncbi.nlm.nih.gov/29706033/
1665. Fledderus, AC, Gout, HA, Ogilvie, AC, van Loenen, DKG, Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening., Breast, 2020. 53 (): p. 92-100., https://pubmed.ncbi.nlm.nih.gov/32679529/
1666. Stone, JP, Hartley, RL, Temple-Oberle, C, Breast cancer in transgender patients: A systematic review. Part 2: Female to Male., Eur J Surg Oncol, 2018. 44 (10)(10): p. 1463-1468., https://pubmed.ncbi.nlm.nih.gov/30037639/
1667. Corso, G, Gandini, S, D'Ecclesiis, O, Mazza, M, Magnoni, F, Veronesi, P, et.al. Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis., Eur J Cancer Prev, 2023. 32 (3)(3): p. 207-214., https://pubmed.ncbi.nlm.nih.gov/36789830/
1668. Brown, A, Lourenco, AP, Niell, BL, Cronin, B, Dibble, EH, DiNome, ML, et.al. ACR Appropriateness Criteria® Transgender Breast Cancer Screening., J Am Coll Radiol, 2021. 18 (11S)(11S): p. S502-S515., https://pubmed.ncbi.nlm.nih.gov/34794604/
1669. Coleman, E, Radix, AE, Bouman, WP, Brown, GR, de Vries, ALC, Deutsch, MB, et.al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8., Int J Transgend Health, 2022. 23 (Suppl 1)(Suppl 1): p. S1-S259., https://pubmed.ncbi.nlm.nih.gov/36238954/
1670. Alderman, A, Gutowski, K, Ahuja, A, Gray, D, ASPS clinical practice guideline summary on breast reconstruction with expanders and implants., Plast Reconstr Surg, 2014. 134 (4)(4): p. 648e-655e., https://pubmed.ncbi.nlm.nih.gov/25357060/
1671. Nahabedian, MY, Patel, K, Autologous flap breast reconstruction: Surgical algorithm and patient selection., J Surg Oncol, 2016. 113 (8)(8): p. 865-74., https://pubmed.ncbi.nlm.nih.gov/26918920/
1672. Weber, WP, Shaw, J, Pusic, A, Wyld, L, Morrow, M, King, T, et.al. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy., Breast, 2022. 63 (): p. 123-139., https://pubmed.ncbi.nlm.nih.gov/35366506/
1673. Djohan, R, Knackstedt, R, Collaboration between breast and reconstructive surgery in optimizing outcomes for women with breast cancer., Breast J, 2020. 26 (1)(1): p. 42-46., https://pubmed.ncbi.nlm.nih.gov/31876102/
1674. Alderman, AK, Hawley, ST, Waljee, J, Mujahid, M, Morrow, M, Katz, SJ, Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer., Cancer, 2008. 112 (3)(3): p. 489-94., https://pubmed.ncbi.nlm.nih.gov/18157830/
1675. de Ligt, KM, van Bommel, ACM, Schreuder, K, Maduro, JH, Vrancken Peeters, MTFD, Mureau, MAM, et.al. The effect of being informed on receiving immediate breast reconstruction in breast cancer patients., Eur J Surg Oncol, 2018. 44 (5)(5): p. 717-724., https://pubmed.ncbi.nlm.nih.gov/29452858/
1676. Dobke, MK, Yee, B, Mackert, GA, Zhu, WY, Blair, SL, The Influence of Patient Exposure to Breast Reconstruction Approaches and Education on Patient Choices in Breast Cancer Treatment., Ann Plast Surg, 2019. 83 (2)(2): p. 206-210., https://pubmed.ncbi.nlm.nih.gov/30300225/
1677. Grigor, EJM, Stein, MJ, Arnaout, A, Ghaedi, B, Cormier, N, Ramsay, T, et.al. The effect of immediate breast reconstruction on adjuvant therapy delay, locoregional recurrence, and disease-free survival., Breast J, 2021. 27 (12)(12): p. 857-862., https://pubmed.ncbi.nlm.nih.gov/34651372/
1678. Ho, D, Chan, E, Izwan, S, Ng, J, Teng, R, Swindon, D, et.al. Uptake of breast reconstruction following mastectomy: a Gold Coast experience., ANZ J Surg, 2022. 92 (11)(11): p. 3011-3016., https://pubmed.ncbi.nlm.nih.gov/35426189/
1679. Nickel, KB, Myckatyn, TM, Lee, CN, Fraser, VJ, Olsen, MA, Individualized Risk Prediction Tool for Serious Wound Complications After Mastectomy With and Without Immediate Reconstruction., Ann Surg Oncol, 2022. 29 (12)(12): p. 7751-7764., https://pubmed.ncbi.nlm.nih.gov/35831524/
1680. Shen, Z, Sun, J, Yu, Y, Chiu, C, Zhang, Z, Zhang, Y, et.al. Oncological safety and complication risks of mastectomy with or without breast reconstruction: A Bayesian analysis., J Plast Reconstr Aesthet Surg, 2021. 74 (2)(2): p. 290-299., https://pubmed.ncbi.nlm.nih.gov/33093010/
1681. Afshar-Bakshloo, M, Albers, S, Richter, C, Berninger, O, Blohmer, JU, Roehle, R, et.al. How breast cancer therapies impact body image - real-world data from a prospective cohort study collecting patient-reported outcomes., BMC Cancer, 2023. 23 (1)(1): p. 705., https://pubmed.ncbi.nlm.nih.gov/37507687/
1682. Taqi, K, Pao, JS, Chen, L, Ma, C, Zhang, M, McKevitt, E, et.al. Immediate breast reconstruction in locally advanced breast cancer: is it safe?, Breast Cancer Res Treat, 2021. 190 (2)(2): p. 175-182., https://pubmed.ncbi.nlm.nih.gov/34467443/
1683. Simon, P, Barrou, J, Cohen, M, Rua, S, Lambaudie, E, Houvenaeghel, G, Types of Mastectomies and Immediate Reconstructions for Ipsilateral Breast Local Recurrences., Front Oncol, 2020. 10 (): p. 567298., https://pubmed.ncbi.nlm.nih.gov/33363007/
1684. Delenne, S, Philip, CA, Guimont, I, Bienstman, J, Mojallal, AA, Cortet, M, Mastectomies for breast cancer: Comparison between peri-operative morbidity after simple mastectomy or after immediate breast reconstruction in a unicentric serie of 210 patients., J Gynecol Obstet Hum Reprod, 2024. 53 (1)(1): p. 102695., https://pubmed.ncbi.nlm.nih.gov/37995939/
1685. Browne, JP, Jeevan, R, Gulliver-Clarke, C, Pereira, J, Caddy, CM, van der Meulen, JHP, The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer., Cancer, 2017. 123 (18)(18): p. 3460-3467., https://pubmed.ncbi.nlm.nih.gov/28513834/
1686. Eriksen, C, Frisell, J, Wickman, M, Lidbrink, E, Krawiec, K, Sandelin, K, Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study., Breast Cancer Res Treat, 2011. 127 (2)(2): p. 439-46., https://pubmed.ncbi.nlm.nih.gov/21409394/
1687. Ryu, JM, Paik, HJ, Park, S, Yi, HW, Nam, SJ, Kim, SW, et.al. Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study., J Breast Cancer, 2017. 20 (1)(1): p. 74-81., https://pubmed.ncbi.nlm.nih.gov/28382097/
1688. O'Connell, RL, Rattay, T, Dave, RV, Trickey, A, Skillman, J, Barnes, NLP, et.al. The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study., Br J Cancer, 2019. 120 (9)(9): p. 883-895., https://pubmed.ncbi.nlm.nih.gov/30923359/
1689. Lagendijk, M, van Egdom, LSE, van Veen, FEE, Vos, EL, Mureau, MAM, van Leeuwen, N, et.al. Patient-Reported Outcome Measures May Add Value in Breast Cancer Surgery., Ann Surg Oncol, 2018. 25 (12)(12): p. 3563-3571., https://pubmed.ncbi.nlm.nih.gov/30178391/
1690. Roy, N, Downes, MH, Ibelli, T, Amakiri, UO, Li, T, Tebha, SS, et.al. The psychological impacts of post-mastectomy breast reconstruction: a systematic review., Ann Breast Surg, 2024. 8 ():, https://pubmed.ncbi.nlm.nih.gov/39100730/
1691. Yoon, AP, Qi, J, Brown, DL, Kim, HM, Hamill, JB, Erdmann-Sager, J, et.al. Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study., Breast, 2018. 37 (): p. 72-79., https://pubmed.ncbi.nlm.nih.gov/29102781/
1692. Broyles, JM, Balk, EM, Adam, GP, Cao, W, Bhuma, MR, Mehta, S, et.al. Implant-based versus Autologous Reconstruction after Mastectomy for Breast Cancer: A Systematic Review and Meta-analysis., Plast Reconstr Surg Glob Open, 2022. 10 (3)(3): p. e4180., https://pubmed.ncbi.nlm.nih.gov/35291333/
1693. Miseré, RM, van Kuijk, SM, Claassens, EL, Heuts, EM, Piatkowski, AA, van der Hulst, RR, Breast-related and body-related quality of life following autologous breast reconstruction is superior to implant-based breast reconstruction - A long-term follow-up study., Breast, 2021. 59 (): p. 176-182., https://pubmed.ncbi.nlm.nih.gov/34271290/
1694. Persichetti, P, Barone, M, Salzillo, R, Cogliandro, A, Brunetti, B, Ciarrocchi, S, et.al. Impact on Patient's Appearance Perception of Autologous and Implant Based Breast Reconstruction Following Mastectomy Using BREAST-Q., Aesthetic Plast Surg, 2022. 46 (3)(3): p. 1153-1163., https://pubmed.ncbi.nlm.nih.gov/35229192/
1695. Sadok, N, Krabbe-Timmerman, IS, Buisman, NH, van Aalst, VC, de Bock, GH, Werker, PMN, Short-Term Quality of Life after Autologous Compared with Alloplastic Breast Reconstruction: A Prospective Study., Plast Reconstr Surg, 2023. 152 (4S)(4S): p. 55S-68S., https://pubmed.ncbi.nlm.nih.gov/37036311/
1696. von Glinski, M, Holler, N, Kümmel, S, Reinisch, M, Wallner, C, Wagner, JM, et.al. Autologous vs. implant-based breast reconstruction after skin- and nipple-sparing mastectomy-A deeper insight considering surgical and patient-reported outcomes., Front Surg, 2022. 9 (): p. 903734., https://pubmed.ncbi.nlm.nih.gov/36132203/
1697. Cai, L, Momeni, A, The Impact of Reconstructive Modality and Postoperative Complications on Decision Regret and Patient-Reported Outcomes following Breast Reconstruction., Aesthetic Plast Surg, 2022. 46 (2)(2): p. 655-660., https://pubmed.ncbi.nlm.nih.gov/34845512/
1698. Gao, P, Bai, P, Kong, X, Fang, Y, Gao, J, Wang, J, Patient-Reported Outcomes and Complications Following Breast Reconstruction: A Comparison Between Biological Matrix-Assisted Direct-to-Implant and Latissimus Dorsi Flap., Front Oncol, 2022. 12 (): p. 766076., https://pubmed.ncbi.nlm.nih.gov/35155227/
1699. Nelson, JA, Shamsunder, MG, Myers, PL, Polanco, TO, Coriddi, MR, McCarthy, CM, et.al. Matched Preliminary Analysis of Patient-Reported Outcomes following Autologous and Implant-Based Breast Reconstruction., Ann Surg Oncol, 2022. 29 (8)(8): p. 5266-5275., https://pubmed.ncbi.nlm.nih.gov/35366702/
1700. Eltahir, Y, Werners, LLCH, Dreise, MM, Zeijlmans van Emmichoven, IA, Werker, PMN, de Bock, GH, Which breast is the best? Successful autologous or alloplastic breast reconstruction: patient-reported quality-of-life outcomes., Plast Reconstr Surg, 2015. 135 (1)(1): p. 43-50., https://pubmed.ncbi.nlm.nih.gov/25539295/
1701. Kouwenberg, CAE, de Ligt, KM, Kranenburg, LW, Rakhorst, H, de Leeuw, D, Siesling, S, et.al. Long-Term Health-Related Quality of Life after Four Common Surgical Treatment Options for Breast Cancer and the Effect of Complications: A Retrospective Patient-Reported Survey among 1871 Patients., Plast Reconstr Surg, 2020. 146 (1)(1): p. 1-13., https://pubmed.ncbi.nlm.nih.gov/32590633/
1702. McCarthy, CM, Mehrara, BJ, Long, T, Garcia, P, Kropf, N, Klassen, AF, et.al. Chest and upper body morbidity following immediate postmastectomy breast reconstruction., Ann Surg Oncol, 2014. 21 (1)(1): p. 107-12., https://pubmed.ncbi.nlm.nih.gov/24201740/
1703. Brito, Íris M., Fernandes, Andreia, Andresen, Carolina, Barbosa, Rui, Ribeiro, Matilde, Valença-Filipe, Rita, Patient satisfaction with breast reconstruction: how much do timing and surgical technique matter?, 2020. 43(6): p. 809 - 818., https://doi.org/10.1007/s00238-020-01663-7
1704. Tallroth, L, Velander, P, Klasson, S, A short-term comparison of expander prosthesis and DIEP flap in breast reconstructions: A prospective randomized study., J Plast Reconstr Aesthet Surg, 2021. 74 (6)(6): p. 1193-1202., https://pubmed.ncbi.nlm.nih.gov/33436336/
1705. Bachour, Y, Bargon, CA, de Blok, CJM, Ket, JCF, Ritt, MJPF, Niessen, FB, Risk factors for developing capsular contracture in women after breast implant surgery: A systematic review of the literature., J Plast Reconstr Aesthet Surg, 2018. 71 (9)(9): p. e29-e48., https://pubmed.ncbi.nlm.nih.gov/29980456/
1706. Hillard, C, Fowler, JD, Barta, R, Cunningham, B, Silicone breast implant rupture: a review., Gland Surg, 2017. 6 (2)(2): p. 163-168., https://pubmed.ncbi.nlm.nih.gov/28497020/
1707. McGuire, P, Clauw, DJ, Hammer, J, Haws, M, Adams, WP, A Practical Guide to Managing Patients With Systemic Symptoms and Breast Implants., Aesthet Surg J, 2022. 42 (4)(4): p. 397-407., https://pubmed.ncbi.nlm.nih.gov/34687293/
1708. Niraula, S, Katel, A, Barua, A, Weiss, A, Strawderman, MS, Zhang, H, et.al. A Systematic Review of Breast Implant-Associated Squamous Cell Carcinoma., Cancers (Basel), 2023. 15 (18)(18):, https://pubmed.ncbi.nlm.nih.gov/37760485/
1709. Santanelli di Pompeo, F, Clemens, MW, Atlan, M, Botti, G, Cordeiro, PG, De Jong, D, et.al. 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL., Aesthet Surg J, 2022. 42 (11)(11): p. 1262-1278., https://pubmed.ncbi.nlm.nih.gov/35639805/
1710. Santanelli di Pompeo, F, Clemens, MW, Paolini, G, Firmani, G, Panagiotakos, D, Sorotos, M, Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in the United States: A Systematic Review., Aesthet Surg J, 2023. 44 (1)(1): p. NP32-NP40., https://pubmed.ncbi.nlm.nih.gov/37616552/
1711. McCarthy, CM, Loyo-Berríos, N, Qureshi, AA, Mullen, E, Gordillo, G, Pusic, AL, et.al. Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012-2018., Plast Reconstr Surg, 2019. 143 (3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma)(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): p. 65S-73S., https://pubmed.ncbi.nlm.nih.gov/30817558/
1712. Möllhoff, N, Ehrl, D, Fuchs, B, Frank, K, Alt, V, Mayr, D, et.al. [Breast implant-associated squamous cell carcinoma: a systematic literature review]., Handchir Mikrochir Plast Chir, 2023. 55 (4)(4): p. 268-277., https://pubmed.ncbi.nlm.nih.gov/37473774/
1713. Ablatio mammae e.V., Selbstbewusst ohne Brust: Nach der Mastektomie. (n.d.), Retrieved September 10, 2024., https://amsob.de/
1714. About Aesthetic Flat Closure. (n.d.)., Retrieved September 9, 2024., https://www.breastcancer.org/treatment/surgery/going-flat-no-reconstruction/aesthetic-flat-closure
1715. Aesthetic Flat Closure - Going Flat Photos & Resources - NPOAS. (n.d.)., Retrieved September 10, 2024., https://notputtingonashirt.org/whatisflatclosure/
1716. ‘Going Flat’ After Breast Cancer - The New York Times. (n.d.)., Retrieved September 10, 2024., https://www.nytimes.com/2016/11/01/well/live/going-flat-after-breast-cancer.html
1717. Resources for Providers - Oncoplastic Mastectomy - Aesthetic Flat Closure - NPOAS. (n.d.)., Retrieved September 9, 2024., https://notputtingonashirt.org/providers/#Articles
1718. Baker, JL, The Era of Flat Closure Mastectomy (Is Still Here). Are You Ready?, Ann Surg Oncol, 2023. 30 (11)(11): p. 6293-6295., https://pubmed.ncbi.nlm.nih.gov/37587363/
1719. Johnson, MK, Cortina, CS, Hsu, TL, Huang, S, Frebault, J, Huang, CC, et.al. National Trends in "Going Flat" After Mastectomy., Ann Surg Oncol, 2023. 30 (11)(11): p. 6374-6382., https://pubmed.ncbi.nlm.nih.gov/37458947/
1720. Crown, A, Buchanan, C, My surgical practice: Presenting aesthetic flat closure as an equal option to mastectomy with reconstruction and technical considerations to optimize cosmesis., Am J Surg, 2022. 223 (2)(2): p. 436-437., https://pubmed.ncbi.nlm.nih.gov/34412900/
1721. Klenotic, E., Ochoa, D., Stephenson, K., Croswell, C., Sullivan, S., Sherman, A., et.al. Flat Aesthetic Mastectomy Closure with the Angel Wing Technique to Address Lateral Adiposity: Technique and Outcome Analysis, 2024/03/25. 2024:, https://pubmed.ncbi.nlm.nih.gov/39742365/
1722. Morrison, KA, Karp, NS, Not Just a Linear Closure: Aesthetic Flat Closure after Mastectomy., Plast Reconstr Surg Glob Open, 2022. 10 (5)(5): p. e4327., https://pubmed.ncbi.nlm.nih.gov/35620492/
1723. Tyner, TE, Lee, MA, Satisfaction Outcomes in Women Who "Choose to Go Flat" After Mastectomy: An Integrative Review., ANS Adv Nurs Sci 44 (1)(1): p. 31-51., https://pubmed.ncbi.nlm.nih.gov/32956091/
1724. Baker, JL, Dizon, DS, Wenziger, CM, Streja, E, Thompson, CK, Lee, MK, et.al. "Going Flat" After Mastectomy: Patient-Reported Outcomes by Online Survey., Ann Surg Oncol, 2021. 28 (5)(5): p. 2493-2505., https://pubmed.ncbi.nlm.nih.gov/33393025/
1725. Baker, JL, Attai, DJ, ASO Author Reflections: Patients Who Go Flat After Mastectomy Deserve an Aesthetic Flat Closure., Ann Surg Oncol, 2021. 28 (5)(5): p. 2506., https://pubmed.ncbi.nlm.nih.gov/33475882/
1726. Wakeley, ME, Bare, CF, Pine, R, Dube, C, Gass, JS, Taneja, C, et.al. A social media survey of women who do not pursue reconstruction after mastectomy for breast cancer: Characterizing the "Going Flat" movement., Breast J, 2020. 26 (7)(7): p. 1455-1457., https://pubmed.ncbi.nlm.nih.gov/32067326/
1727. van der Wielen, A, Negenborn, V, Burchell, GL, Remmelzwaal, S, Lapid, O, Driessen, C, Less is more? One-stage versus two-stage implant-based breast reconstruction: A systematic review and meta-analysis of comparative studies., J Plast Reconstr Aesthet Surg, 2023. 86 (): p. 109-127., https://pubmed.ncbi.nlm.nih.gov/37716248/
1728. Aliotta, RE, Duraes, EFR, Scomacao, I, Morisada, M, Orra, S, Moreira, A, et.al. A controlled cost and outcomes analysis of acellular dermal matrix and implant-based reconstruction., J Plast Reconstr Aesthet Surg, 2021. 74 (6)(6): p. 1229-1238., https://pubmed.ncbi.nlm.nih.gov/33526361/
1729. Azouz, V, Lopez, S, Wagner, DS, Surgeon-Controlled Comparison of Direct-to-Implant and 2-Stage Tissue Expander-Implant Immediate Breast Reconstruction Outcomes., Ann Plast Surg, 2018. 80 (3)(3): p. 212-216., https://pubmed.ncbi.nlm.nih.gov/28984661/
1730. Bennett, KG, Qi, J, Kim, HM, Hamill, JB, Pusic, AL, Wilkins, EG, Comparison of 2-Year Complication Rates Among Common Techniques for Postmastectomy Breast Reconstruction., JAMA Surg, 2018. 153 (10)(10): p. 901-908., https://pubmed.ncbi.nlm.nih.gov/29926077/
1731. Caputo, GG, Vigato, E, Rampino Cordaro, E, Parodi, PC, Governa, M, Comparative study of patient outcomes between direct to implant and two-stage implant-based breast reconstruction after mastectomy., J Plast Reconstr Aesthet Surg, 2021. 74 (10)(10): p. 2573-2579., https://pubmed.ncbi.nlm.nih.gov/33947651/
1732. Casella, D, Di Taranto, G, Onesti, MG, Greco, M, Ribuffo, D, A retrospective comparative analysis of risk factors and outcomes in direct-to-implant and two-stages prepectoral breast reconstruction: BMI and radiotherapy as new selection criteria of patients., Eur J Surg Oncol, 2019. 45 (8)(8): p. 1357-1363., https://pubmed.ncbi.nlm.nih.gov/30827802/
1733. Damen, TH, Wei, W, Mureau, MA, Tjong-Joe-Wai, R, Hofer, SO, Essink-Bot, ML, et.al. Medium-term cost analysis of breast reconstructions in a single Dutch centre: a comparison of implants, implants preceded by tissue expansion, LD transpositions and DIEP flaps., J Plast Reconstr Aesthet Surg, 2011. 64 (8)(8): p. 1043-53., https://pubmed.ncbi.nlm.nih.gov/21317054/
1734. Davila, AA, Mioton, LM, Chow, G, Wang, E, Merkow, RP, Bilimoria, KY, et.al. Immediate two-stage tissue expander breast reconstruction compared with one-stage permanent implant breast reconstruction: a multi-institutional comparison of short-term complications., J Plast Surg Hand Surg, 2013. 47 (5)(5): p. 344-9., https://pubmed.ncbi.nlm.nih.gov/23547540/
1735. Dikmans, RE, Negenborn, VL, Bouman, MB, Winters, HA, Twisk, JW, Ruhé, PQ, et.al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial., Lancet Oncol, 2017. 18 (2)(2): p. 251-258., https://pubmed.ncbi.nlm.nih.gov/28012977/
1736. Dimovska, EOF, Chen, C, Chou, HH, Lin, YL, Cheng, MH, Outcomes and quality of life in immediate one-stage versus two-stage breast reconstructions without an acellular dermal matrix: 17- years of experience., J Surg Oncol, 2021. 124 (4)(4): p. 510-520., https://pubmed.ncbi.nlm.nih.gov/34133023/
1737. Gao, P, Bai, P, Ren, Y, Kong, X, Wang, Z, Fang, Y, et.al. Biological Matrix-Assisted One-Stage Implant-Based Breast Reconstruction Versus Two-Stage Implant-Based Breast Reconstruction: Patient-Reported Outcomes and Complications., Aesthetic Plast Surg, 2021. 45 (6)(6): p. 2581-2590., https://pubmed.ncbi.nlm.nih.gov/34350500/
1738. Hangge, PT, Jogerst, K, Mohsen, A, Kosiorek, H, Cronin, PA, Stucky, CH, et.al. Making an informed choice: Which breast reconstruction type has the lowest complication rate?, Am J Surg, 2019. 218 (6)(6): p. 1040-1045., https://pubmed.ncbi.nlm.nih.gov/31606126/
1739. Hillberg, NS, Ferdinandus, PI, Dikmans, REG, Winkens, B, Hommes, J, van der Hulst, RRWJ, Is single-stage implant-based breast reconstruction (SSBR) with an acellular matrix safe?: Strattice™ or Meso Biomatrix® in SSBR., Eur J Plast Surg, 2018. 41 (4)(4): p. 429-438., https://pubmed.ncbi.nlm.nih.gov/30100676/
1740. Hwang, YJ, Lee, HC, Park, SH, Yoon, ES, A Comparative Study of Breast Sensibility and Patient Satisfaction After Breast Reconstruction: Autologous, 2-Stage Implant-Based, and Prepectoral Direct-to-Implant Reconstruction., Ann Plast Surg, 2022. 88 (3)(3): p. 262-270., https://pubmed.ncbi.nlm.nih.gov/35130204/
1741. Innocenti, A, Melita, D, Affortunati, M, Susini, T, Innocenti, M, Immediate-implant-based-breast-reconstruction with two-stage expander-implant reconstruction versus one-stage-reconstruction with acellular dermal matrix: analysis of patients' satisfaction., Acta Biomed, 2021. 92 (3)(3): p. e2021228., https://pubmed.ncbi.nlm.nih.gov/34212931/
1742. Meshulam-Derazon, S, Shay, T, Lewis, S, Adler, N, Immediate Breast Reconstruction: Comparative Outcome Study of One-Stage Direct-to-Implant and Two-Stage/Tissue Expander Techniques., Isr Med Assoc J, 2018. 20 (6)(6): p. 340-344., https://pubmed.ncbi.nlm.nih.gov/29911752/
1743. Negenborn, VL, Young-Afat, DA, Dikmans, REG, Smit, JM, Winters, HAH, Don Griot, JPW, et.al. Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial., Lancet Oncol, 2018. 19 (9)(9): p. 1205-1214., https://pubmed.ncbi.nlm.nih.gov/30104147/
1744. Negenborn, VL, Smit, JM, Dikmans, REG, Winters, HAH, Twisk, JWR, Ruhé, PQ, et.al. Short-term cost-effectiveness of one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage expander-implant reconstruction from a multicentre randomized clinical trial., Br J Surg, 2019. 106 (5)(5): p. 586-595., https://pubmed.ncbi.nlm.nih.gov/30835827/
1745. Riggio, E, Alfieri, S, Toffoli, E, Borreani, C, A descriptive comparison of satisfaction and well-being between expander-based and direct-to-implant breast reconstruction after Nipple-Sparing Mastectomy., Aesthetic Plast Surg, 2023. 47 (1)(1): p. 30-39., https://pubmed.ncbi.nlm.nih.gov/36018329/
1746. Roostaeian, J, Sanchez, I, Vardanian, A, Herrera, F, Galanis, C, Da Lio, A, et.al. Comparison of immediate implant placement versus the staged tissue expander technique in breast reconstruction., Plast Reconstr Surg, 2012. 129 (6)(6): p. 909e-918e., https://pubmed.ncbi.nlm.nih.gov/22634689/
1747. Sgarzani, R, Pasquali, S, Buggi, F, Tognali, D, Marongiu, F, Mingozzi, M, et.al. Sub-muscular Reconstruction after NAC Sparing Mastectomy: Direct to Implant Breast Reconstruction with Human ADM Versus Tissue Expander., Aesthetic Plast Surg, 2021. 45 (2)(2): p. 413-420., https://pubmed.ncbi.nlm.nih.gov/33078212/
1748. Susarla, SM, Ganske, I, Helliwell, L, Morris, D, Eriksson, E, Chun, YS, Comparison of clinical outcomes and patient satisfaction in immediate single-stage versus two-stage implant-based breast reconstruction., Plast Reconstr Surg, 2015. 135 (1)(1): p. 1e-8e., https://pubmed.ncbi.nlm.nih.gov/25539329/
1749. Theunissen, CIJM, Brohet, RM, Hu, Y, van Uchelen, JH, Mensen, JHC, van Rijssen, AL, Risk of breast implant removal after one- versus two-stage breast reconstructive surgery., J Plast Reconstr Aesthet Surg, 2022. 75 (5)(5): p. 1610-1616., https://pubmed.ncbi.nlm.nih.gov/34975002/
1750. Innocenti, Alessandro, Melita, Dario, Two-stage expander/implant breast reconstruction versus prepectoral breast reconstruction with acellular dermal matrix: a cost analysis, 2022. 45(4): p. 601 - 615., https://doi.org/10.1007/s00238-021-01829-x
1751. Han, HH, Kim, HB, Kim, EK, Eom, JS, Direct-to-Implant as a Frontline Option for Immediate Breast Reconstruction: A Comparative Study With 2-Stage Reconstruction., Ann Plast Surg, 2018. 81 (3)(3): p. 274-279., https://pubmed.ncbi.nlm.nih.gov/29916885/
1752. Damen, TH, Wei, W, Mureau, MA, Tjong-Joe-Wai, R, Hofer, SO, Essink-Bot, ML, et.al. Medium-term cost analysis of breast reconstructions in a single Dutch centre: a comparison of implants, implants preceded by tissue expansion, LD transpositions and DIEP flaps., J Plast Reconstr Aesthet Surg, 2011. 64 (8)(8): p. 1043-53., https://pubmed.ncbi.nlm.nih.gov/21317054/
1753. Negenborn, VL, Dikmans, REG, Bouman, MB, Winters, HAH, Twisk, JWR, Ruhé, PQ, et.al. Predictors of complications after direct-to-implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial., Br J Surg, 2018. 105 (10)(10): p. 1305-1312., https://pubmed.ncbi.nlm.nih.gov/29663320/
1754. Beier, L, Faridi, A, Neumann, C, Paepke, S, Mau, C, Keller, M, et.al. Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study., Breast Care (Basel), 2021. 16 (5)(5): p. 461-467., https://pubmed.ncbi.nlm.nih.gov/34720805/
1755. Thill, M, Faridi, A, Meiré, A, Gerber-Schäfer, C, Baumann, K, Blohmer, JU, et.al. Patient reported outcome and cosmetic evaluation following implant-based breast-reconstruction with a titanized polypropylene mesh (TiLOOP® Bra): A prospective clinical study in 269 patients., Eur J Surg Oncol, 2020. 46 (8)(8): p. 1484-1490., https://pubmed.ncbi.nlm.nih.gov/32336622/
1756. Weinzierl, A, Schmauss, D, Brucato, D, Harder, Y, Implant-Based Breast Reconstruction after Mastectomy, from the Subpectoral to the Prepectoral Approach: An Evidence-Based Change of Mind?, J Clin Med, 2022. 11 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/35683465/
1757. Cook, H, Zargaran, D, Glynou, SP, Hamilton, S, Mosahebi, A, Does the use of acellular dermal matrices (ADM) in women undergoing pre-pectoral implant-based breast reconstruction increase operative success versus non-use of ADM in the same setting? A systematic review protocol., Syst Rev, 2024. 13 (1)(1): p. 153., https://pubmed.ncbi.nlm.nih.gov/38849880/
1758. Kappos, EA, Schulz, A, Regan, MM, Moffa, G, Harder, Y, Ribi, K, et.al. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial., BMJ Open, 2021. 11 (9)(9): p. e045239., https://pubmed.ncbi.nlm.nih.gov/34475143/
1759. Micco, Rosa Di, Banys-Paluchowski, Maggie, Cardoso, Maria-Joao, de Boniface, Jana, Gulluoglu, Bahadir M., Kaidar-Person, Orit, et.al. Abstract PO5-19-02: I-PREPARE: International Prospective REgistry on Pre-pectorAl breast Reconstruction (EUBREAST 11R-NCT 05817175), 2024. 84(9_Supplement): p. PO5-19-02 - PO5-19-02., https://doi.org/10.1158/1538-7445.SABCS23-PO5-19-02
1760. Du, F, Liu, R, Zhang, H, Xiao, Y, Long, X, Post-mastectomy adjuvant radiotherapy for direct-to-implant and two-stage implant-based breast reconstruction: A meta-analysis., J Plast Reconstr Aesthet Surg, 2022. 75 (9)(9): p. 3030-3040., https://pubmed.ncbi.nlm.nih.gov/35961927/
1761. Allué Cabañuz, M, Arribas Del Amo, MD, Navarro Barlés, A, Guemes Sanchez, AT, Influence of radiotherapy on immediate breast reconstruction after skin-sparing mastectomy. Before or after: Does it matter?, Cir Esp (Engl Ed), 2019. 97 (3)(3): p. 156-161., https://pubmed.ncbi.nlm.nih.gov/30545644/
1762. Apte, A, Walsh, M, Balaji, P, Khor, B, Chandrasekharan, S, Chakravorty, A, Single stage immediate breast reconstruction with acellular dermal matrix and implant: Defining the risks and outcomes of post-mastectomy radiotherapy., Surgeon, 2020. 18 (4)(4): p. 202-207., https://pubmed.ncbi.nlm.nih.gov/31636037/
1763. Cordeiro, PG, Albornoz, CR, McCormick, B, Hudis, CA, Hu, Q, Heerdt, A, et.al. What Is the Optimum Timing of Postmastectomy Radiotherapy in Two-Stage Prosthetic Reconstruction: Radiation to the Tissue Expander or Permanent Implant?, Plast Reconstr Surg, 2015. 135 (6)(6): p. 1509-1517., https://pubmed.ncbi.nlm.nih.gov/25742523/
1764. Hamann, M, Brunnbauer, M, Scheithauer, H, Hamann, U, Braun, M, Pölcher, M, Quality of life in breast cancer patients and surgical results of immediate tissue expander/implant-based breast reconstruction after mastectomy., Arch Gynecol Obstet, 2019. 300 (2)(2): p. 409-420., https://pubmed.ncbi.nlm.nih.gov/31144025/
1765. Hille-Betz, U, Kniebusch, N, Wojcinski, S, Henseler, H, Heyl, V, Ohlinger, R, et.al. Breast reconstruction and revision surgery for implant-associated breast deformities using porcine acellular dermal matrix: a multicenter study of 156 cases., Ann Surg Oncol, 2015. 22 (4)(4): p. 1146-52., https://pubmed.ncbi.nlm.nih.gov/25300607/
1766. Korwar, V, Skillman, J, Matey, P, Skin reducing mastectomy and immediate reconstruction: the effect of radiotherapy on complications and patient reported outcomes., Eur J Surg Oncol, 2014. 40 (4)(4): p. 442-8., https://pubmed.ncbi.nlm.nih.gov/24512987/
1767. Loreti, A, Siri, G, De Carli, M, Fanelli, B, Arelli, F, Spallone, D, et.al. Immediate Breast Reconstruction after mastectomy with polyurethane implants versus textured implants: A retrospective study with focus on capsular contracture., Breast, 2020. 54 (): p. 127-132., https://pubmed.ncbi.nlm.nih.gov/33010626/
1768. Masià, J, The largest multicentre data collection on prepectoral breast reconstruction: The iBAG study., J Surg Oncol, 2020. 122 (5)(5): p. 848-860., https://pubmed.ncbi.nlm.nih.gov/32786089/
1769. Naoum, GE, Salama, L, Niemierko, A, Vieira, BL, Belkacemi, Y, Colwell, AS, et.al. Single Stage Direct-to-Implant Breast Reconstruction Has Lower Complication Rates Than Tissue Expander and Implant and Comparable Rates to Autologous Reconstruction in Patients Receiving Postmastectomy Radiation., Int J Radiat Oncol Biol Phys, 2020. 106 (3)(3): p. 514-524., https://pubmed.ncbi.nlm.nih.gov/31756414/
1770. Riggio, E, Toffoli, E, Tartaglione, C, Marano, G, Biganzoli, E, Local safety of immediate reconstruction during primary treatment of breast cancer. Direct-to-implant versus expander-based surgery., J Plast Reconstr Aesthet Surg, 2019. 72 (2)(2): p. 232-242., https://pubmed.ncbi.nlm.nih.gov/30497914/
1771. Salzberg, CA, Ashikari, AY, Berry, C, Hunsicker, LM, Acellular Dermal Matrix-Assisted Direct-to-Implant Breast Reconstruction and Capsular Contracture: A 13-Year Experience., Plast Reconstr Surg, 2016. 138 (2)(2): p. 329-337., https://pubmed.ncbi.nlm.nih.gov/27064232/
1772. Seth, AK, Silver, HR, Hirsch, EM, Kim, JY, Fine, NA, Comparison of Delayed and Immediate Tissue Expander Breast Reconstruction in the Setting of Postmastectomy Radiation Therapy., Ann Plast Surg, 2015. 75 (5)(5): p. 503-7., https://pubmed.ncbi.nlm.nih.gov/25180955/
1773. Sinnott, CJ, Persing, SM, Pronovost, M, Hodyl, C, McConnell, D, Ott Young, A, Impact of Postmastectomy Radiation Therapy in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction., Ann Surg Oncol, 2018. 25 (10)(10): p. 2899-2908., https://pubmed.ncbi.nlm.nih.gov/29978367/
1774. Spear, SL, Seruya, M, Rao, SS, Rottman, S, Stolle, E, Cohen, M, et.al. Two-stage prosthetic breast reconstruction using AlloDerm including outcomes of different timings of radiotherapy., Plast Reconstr Surg, 2012. 130 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/22743866/
1775. Tejera Hernández, AA, Vega Benítez, VM, Rocca Cardenas, JC, Ortega Pérez, N, Rodríguez Ibarria, N, Gutiérrez Giner, MI, et.al. Inverse radiotherapy planning in reconstructive surgery for breast cancer., Int J Surg, 2019. 63 (): p. 77-82., https://pubmed.ncbi.nlm.nih.gov/30708063/
1776. Coudé Adam, H, Frisell, A, Liu, Y, Sackey, H, Oikonomou, I, Docherty Skogh, AC, et.al. Effect of radiotherapy on expanders and permanent implants in immediate breast reconstruction: long-term surgical and patient-reported outcomes in a large multicentre cohort., Br J Surg, 2021. 108 (12)(12): p. 1474-1482., https://pubmed.ncbi.nlm.nih.gov/34694356/
1777. Bernini, M, Meattini, I, Saieva, C, Becherini, C, Salvestrini, V, Visani, L, et.al. Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy., Breast Cancer, 2022. 29 (2)(2): p. 302-313., https://pubmed.ncbi.nlm.nih.gov/34775540/
1778. Cagli, B, Morelli Coppola, M, Augelli, F, Segreto, F, Tenna, S, Cogliandro, A, et.al. Postmastectomy Radiation Therapy in the Setting of Two-Stage Retropectoral Implant-Based Breast Reconstruction: Should It be Delivered Before or After Implant Exchange? A Retrospective Analysis on 183 Patients., Aesthetic Plast Surg, 2022. 46 (6)(6): p. 2643-2654., https://pubmed.ncbi.nlm.nih.gov/35854008/
1779. de Boniface, J, Coudé Adam, H, Frisell, A, Oikonomou, I, Ansarei, D, Ljung Konstantinidou, A, et.al. Long-term outcomes of implant-based immediate breast reconstruction with and without radiotherapy: a population-based study., Br J Surg, 2022. 109 (11)(11): p. 1107-1115., https://pubmed.ncbi.nlm.nih.gov/35949111/
1780. Conte, B, Shermoen, C, Lubarsky, M, Fiser, CK, Liu, SN, Kesmodel, SB, et.al. Post-Mastectomy Implant Complications in the Hispanic Breast Cancer Patient Population., Anticancer Res, 2023. 43 (11)(11): p. 4953-4959., https://pubmed.ncbi.nlm.nih.gov/37909997/
1781. Jeon, HB, Lee, M, Roh, TS, Jeong, J, Ahn, SG, Bae, SJ, et.al. Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis., J Breast Cancer, 2023. 26 (1)(1): p. 25-34., https://pubmed.ncbi.nlm.nih.gov/36852965/
1782. Kooijman, MML, Hage, JJ, Scholten, AN, Vrancken Peeters, MTFD, Woerdeman, LAE, Short-Term Surgical Complications of Skin-Sparing Mastectomy and Direct-to-Implant Immediate Breast Reconstruction in Women Concurrently Treated with Adjuvant Radiotherapy for Breast Cancer., Arch Plast Surg, 2022. 49 (3)(3): p. 332-338., https://pubmed.ncbi.nlm.nih.gov/35832162/
1783. Lee, KT, Kim, J, Jeon, BJ, Pyon, JK, Bang, SI, Mun, GH, Longitudinal analysis of long-term outcomes of abdominal flap-based microsurgical reconstruction and two-stage prosthetic reconstruction., Sci Rep, 2023. 13 (1)(1): p. 4062., https://pubmed.ncbi.nlm.nih.gov/36906629/
1784. Martins, LL, Barbosa, RF, Guerreiro, FC, Andresen, C, Pereira, MJ, Pinho, CJ, et.al. A Two-Year Retrospective Analysis of the Clinical Outcomes of Immediate Submuscular Breast Reconstructions With Native® Acellular Dermal Matrix., Cureus, 2023. 15 (7)(7): p. e41343., https://pubmed.ncbi.nlm.nih.gov/37546031/
1785. Naoum, GE, Ioakeim, MI, Shui, AM, Salama, L, Colwell, A, Ho, AY, et.al. Radiation Modality (Proton/Photon), Timing, and Complication Rates in Patients With Breast Cancer Receiving 2-Stages Expander/Implant Reconstruction., Pract Radiat Oncol, 2022. 12 (6)(6): p. 475-486., https://pubmed.ncbi.nlm.nih.gov/35989216/
1786. Nelson, JA, Cordeiro, PG, Polanco, T, Shamsunder, MG, Patel, A, Allen, RJ, et.al. Association of Radiation Timing with Long-Term Satisfaction and Health-Related Quality of Life in Prosthetic Breast Reconstruction., Plast Reconstr Surg, 2022. 150 (1)(1): p. 32e-41e., https://pubmed.ncbi.nlm.nih.gov/35499580/
1787. Ostapenko, E, Nixdorf, L, Devyatko, Y, Exner, R, Wimmer, K, Fitzal, F, The Impact of Adjuvant Radiotherapy on Immediate Prepectoral Implant-Based Breast Reconstruction., Aesthetic Plast Surg, 2024. 48 (13)(13): p. 2432-2438., https://pubmed.ncbi.nlm.nih.gov/37737875/
1788. Polotto, S, Pedrazzi, G, Bergamini, M, D'Abbiero, N, Cattelani, L, ADM-Assisted Direct-to-Implant Prepectoral Breast Reconstruction in Postmastectomy Radiation Therapy Setting: Long-Term Results., Clin Breast Cancer, 2023. 23 (7)(7): p. 704-711., https://pubmed.ncbi.nlm.nih.gov/37479666/
1789. Safran, T, Al-Badarin, F, Al-Halabi, B, Viezel-Mathieu, A, Dionisopoulos, T, Aesthetic Limitations in Direct-to-Implant Prepectoral Breast Reconstruction., Plast Reconstr Surg, 2022. 150 (1)(1): p. 22e-31e., https://pubmed.ncbi.nlm.nih.gov/35499675/
1790. Saksornchai, K, Ganoksil, P, Rongkavilit, S, Suwajo, P, Impact of radiation on immediate breast reconstruction: a retrospective single institution cohort study., Gland Surg, 2023. 12 (8)(8): p. 1050-1059., https://pubmed.ncbi.nlm.nih.gov/37701294/
1791. Sewart, E, Turner, NL, Conroy, EJ, Cutress, RI, Skillman, J, Whisker, L, et.al. The Impact of Radiotherapy on Patient-reported Outcomes of Immediate Implant-based Breast Reconstruction With and Without Mesh., Ann Surg, 2022. 275 (5)(5): p. 992-1001., https://pubmed.ncbi.nlm.nih.gov/32657919/
1792. Stuart, SR, Munhoz, AM, Chaves, CLG, Montag, E, Cordeiro, TCS, Fuzisaki, TT, et.al. Complications after breast reconstruction with alloplastic material in breast cancer patients submitted or not to post mastectomy radiotherapy., Rep Pract Oncol Radiother, 2021. 26 (5)(5): p. 730-739., https://pubmed.ncbi.nlm.nih.gov/34760307/
1793. Sun, L, Zhu, W, Zhang, J, Zhong, B, Li, S, Li, H, et.al. The risk factors and the relationship between radiation dose and complications and prosthetic reconstruction failure in patients with post-mastectomy breast implant reconstruction: a retrospective cohort study., Gland Surg, 2022. 11 (11)(11): p. 1817-1831., https://pubmed.ncbi.nlm.nih.gov/36518801/
1794. Yin, Z, Wang, H, Liu, Y, Wang, Y, Chang, EI, Yin, J, Single-Institution Algorithm for Prevention and Management of Complications in Direct-to-Implant Breast Reconstruction., Plast Reconstr Surg, 2022. 150 (): p. 48S-60S., https://pubmed.ncbi.nlm.nih.gov/35943963/
1795. Dave, RV, Vucicevic, A, Barrett, E, Highton, L, Johnson, R, Kirwan, CC, et.al. Risk factors for complications and implant loss after prepectoral implant-based immediate breast reconstruction: medium-term outcomes in a prospective cohort., Br J Surg, 2021. 108 (5)(5): p. 534-541., https://pubmed.ncbi.nlm.nih.gov/34043774/
1796. Emanuele Lisa, AV, Salgarello, M, Huscher, A, Corsi, F, Piovani, D, Rubbino, F, et.al. The Effect of Adjuvant Radiotherapy on One- and Two-Stage Prosthetic Breast Reconstruction and on Autologous Reconstruction: A Multicenter Italian Study among 18 Senonetwork Breast Centres., Breast J, 2023. 2023 (): p. 6688466., https://pubmed.ncbi.nlm.nih.gov/37205012/
1797. Pires, G, Marquez, JL, Memmott, S, Sudduth, JD, Moss, W, Eddington, D, et.al. Early Complications after Prepectoral Tissue Expander Placement in Breast Reconstruction with and without Acellular Dermal Matrix., Plast Reconstr Surg, 2024. 153 (6)(6): p. 1221-1229., https://pubmed.ncbi.nlm.nih.gov/37285211/
1798. Lin, AM, Lorenzi, R, Van Der Hulst, JE, Liao, EC, Austen, WG, Webster, A, et.al. A Decade of Nipple-Sparing Mastectomy: Lessons Learned in 3035 Immediate Implant-Based Breast Reconstructions., Plast Reconstr Surg, 2024. 153 (2)(2): p. 277-287., https://pubmed.ncbi.nlm.nih.gov/37141449/
1799. Nava, MB, Pennati, AE, Lozza, L, Spano, A, Zambetti, M, Catanuto, G, Outcome of different timings of radiotherapy in implant-based breast reconstructions., Plast Reconstr Surg, 2011. 128 (2)(2): p. 353-359., https://pubmed.ncbi.nlm.nih.gov/21788827/
1800. Emanuele Lisa, AV, Salgarello, M, Huscher, A, Corsi, F, Piovani, D, Rubbino, F, et.al. The Effect of Adjuvant Radiotherapy on One- and Two-Stage Prosthetic Breast Reconstruction and on Autologous Reconstruction: A Multicenter Italian Study among 18 Senonetwork Breast Centres., Breast J, 2023. 2023 (): p. 6688466., https://pubmed.ncbi.nlm.nih.gov/37205012/
1801. Nelson, JA, Cordeiro, PG, Polanco, T, Shamsunder, MG, Patel, A, Allen, RJ, et.al. Association of Radiation Timing with Long-Term Satisfaction and Health-Related Quality of Life in Prosthetic Breast Reconstruction., Plast Reconstr Surg, 2022. 150 (1)(1): p. 32e-41e., https://pubmed.ncbi.nlm.nih.gov/35499580/
1802. Jagsi, R, Li, Y, Morrow, M, Janz, N, Alderman, A, Graff, J, et.al. Patient-reported Quality of Life and Satisfaction With Cosmetic Outcomes After Breast Conservation and Mastectomy With and Without Reconstruction: Results of a Survey of Breast Cancer Survivors., Ann Surg, 2015. 261 (6)(6): p. 1198-206., https://pubmed.ncbi.nlm.nih.gov/25654742/
1803. Ren, Y, Yu, Y, Xu, K, Li, Z, Wang, X, Meta-Analysis of Immediate Implant-Based Breast Reconstruction Versus Autologous Breast Reconstruction in the Setting of PMRT., Aesthetic Plast Surg, 2024. 48 (10)(10): p. 1940-1948., https://pubmed.ncbi.nlm.nih.gov/37380747/
1804. Matar, DY, Wu, M, Haug, V, Orgill, DP, Panayi, AC, Surgical complications in immediate and delayed breast reconstruction: A systematic review and meta-analysis., J Plast Reconstr Aesthet Surg, 2022. 75 (11)(11): p. 4085-4095., https://pubmed.ncbi.nlm.nih.gov/36202732/
1805. Barnes, LL, Patterson, A, Lem, M, Holland, MC, Lentz, R, Sbitany, H, et.al. Immediate Versus Delayed-Immediate Autologous Breast Reconstruction After Nipple-Sparing Mastectomy., Ann Plast Surg, 2023. 90 (5)(5): p. 432-436., https://pubmed.ncbi.nlm.nih.gov/37146309;, 34921369;, 36928907;, 35245253;, 34270511;, 35135030;, 34028673;, 36474094;, 35796741/
1806. Shammas, RL, Cason, RW, Sergesketter, AR, Glener, AD, Broadwater, G, Hollins, A, et.al. A Comparison of Surgical Complications in Patients Undergoing Delayed versus Staged Tissue-Expander and Free-Flap Breast Reconstruction., Plast Reconstr Surg, 2021. 148 (3)(3): p. 501-509., https://pubmed.ncbi.nlm.nih.gov/34270511/
1807. Shammas, RL, Gordee, A, Lee, HJ, Sergesketter, AR, Scales, CD, Hollenbeck, ST, et.al. Complications, Costs, and Healthcare Resource Utilization After Staged, Delayed, and Immediate Free-Flap Breast Reconstruction: A Longitudinal, Claims-Based Analysis., Ann Surg Oncol, 2023. 30 (4)(4): p. 2534-2549., https://pubmed.ncbi.nlm.nih.gov/36474094/
1808. Pittelkow, E, DeBrock, W, Christopher, L, Mercho, R, Suh, LJ, Fisher, CS, et.al. Advantages of the Delayed-Immediate Microsurgical Breast Reconstruction: Extending the Choice., J Reconstr Microsurg, 2022. 38 (7)(7): p. 579-584., https://pubmed.ncbi.nlm.nih.gov/35135030/
1809. Joosen, MEM, Schop, SJ, Reinhoudt, LL, van Kuijk, SMJ, Beugels, J, de Bruïne, AP, et.al. The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study., Breast Cancer Res Treat, 2021. 188 (2)(2): p. 389-398., https://pubmed.ncbi.nlm.nih.gov/34028673/
1810. Christopher, AN, Morris, MP, Broach, RB, Serletti, JM, A Comparative Analysis of Immediate and Delayed-immediate Breast Reconstruction after Postmastectomy Radiation Therapy., J Reconstr Microsurg, 2022. 38 (6)(6): p. 499-505., https://pubmed.ncbi.nlm.nih.gov/34921369/
1811. Ochoa, O, Garza, R, Pisano, S, Chrysopoulo, M, Ledoux, P, Arishita, G, et.al. Prospective Longitudinal Patient-Reported Satisfaction and Health-Related Quality of Life following DIEP Flap Breast Reconstruction: Effects of Reconstruction Timing., Plast Reconstr Surg, 2022. 149 (5)(5): p. 848e-857e., https://pubmed.ncbi.nlm.nih.gov/35245253/
1812. Marquez, JL, Sudduth, JD, Kuo, K, Patel, AA, Eddington, D, Agarwal, JP, et.al. A Comparison of Postoperative Outcomes Between Immediate, Delayed Immediate, and Delayed Autologous Free Flap Breast Reconstruction: Analysis of 2010-2020 NSQIP Data., J Reconstr Microsurg, 2023. 39 (8)(8): p. 664-670., https://pubmed.ncbi.nlm.nih.gov/36928907/
1813. Wu Young, MY, Garza, RM, Chang, DW, "Immediate versus delayed autologous breast reconstruction in patients undergoing post-mastectomy radiation therapy: A paradigm shift"., J Surg Oncol, 2022. 126 (6)(6): p. 949-955., https://pubmed.ncbi.nlm.nih.gov/35796741/
1814. Beugels, J, Bod, L, van Kuijk, SMJ, Qiu, SS, Tuinder, SMH, Heuts, EM, et.al. Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions., Breast Cancer Res Treat, 2018. 169 (2)(2): p. 349-357., https://pubmed.ncbi.nlm.nih.gov/29399731/
1815. DeBono, R, Thompson, A, Stevenson, JH, Immediate versus delayed free TRAM breast reconstruction: an analysis of perioperative factors and complications., Br J Plast Surg, 2002. 55 (2)(2): p. 111-6., https://pubmed.ncbi.nlm.nih.gov/11987942/
1816. Chang, EI, Chang, EI, Soto-Miranda, MA, Zhang, H, Nosrati, N, Ghali, S, et.al. Evolution of Bilateral Free Flap Breast Reconstruction over 10 Years: Optimizing Outcomes and Comparison to Unilateral Reconstruction., Plast Reconstr Surg, 2015. 135 (6)(6): p. 946e-953e., https://pubmed.ncbi.nlm.nih.gov/26017610/
1817. Dewael, S, Vandevoort, M, Fabré, G, Nanhekhan, L, Immediate versus delayed autologous breast reconstruction: A retrospective matched cohort study of irradiated patients., J Plast Reconstr Aesthet Surg, 2019. 72 (11)(11): p. 1769-1775., https://pubmed.ncbi.nlm.nih.gov/31235319/
1818. Prantl, L, Moellhoff, N, von Fritschen, U, Giunta, RE, Germann, G, Kehrer, A, et.al. Immediate versus secondary DIEP flap breast reconstruction: a multicenter outcome study., Arch Gynecol Obstet, 2020. 302 (6)(6): p. 1451-1459., https://pubmed.ncbi.nlm.nih.gov/32895743/
1819. Manyam, BV, Shah, C, Woody, NM, Reddy, CA, Weller, MA, Juloori, A, et.al. Long-Term Outcomes After Autologous or Tissue Expander/Implant-Based Breast Reconstruction and Postmastectomy Radiation for Breast Cancer., Pract Radiat Oncol, 2019. 9 (6)(6): p. e497-e505., https://pubmed.ncbi.nlm.nih.gov/31238166/
1820. Sternberg, EG, Perdikis, G, McLaughlin, SA, Terkonda, SP, Waldorf, JC, Latissimus dorsi flap remains an excellent choice for breast reconstruction., Ann Plast Surg, 2006. 56 (1)(1): p. 31-5., https://pubmed.ncbi.nlm.nih.gov/16374092/
1821. Maalouf, C, Bou-Merhi, J, Karam, E, Patocskai, E, Danino, AM, The impact of autologous breast reconstruction using DIEP flap on the oncologic efficacy of radiation therapy., Ann Chir Plast Esthet, 2017. 62 (6)(6): p. 630-636., https://pubmed.ncbi.nlm.nih.gov/28760638/
1822. Tran, NV, Chang, DW, Gupta, A, Kroll, SS, Robb, GL, Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy., Plast Reconstr Surg, 2001. 108 (1)(1): p. 78-82., https://pubmed.ncbi.nlm.nih.gov/11420508/
1823. Yoon, AP, Qi, J, Brown, DL, Kim, HM, Hamill, JB, Erdmann-Sager, J, et.al. Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study., Breast, 2018. 37 (): p. 72-79., https://pubmed.ncbi.nlm.nih.gov/29102781/
1824. Zhong, T, Hu, J, Bagher, S, Vo, A, O'Neill, AC, Butler, K, et.al. A Comparison of Psychological Response, Body Image, Sexuality, and Quality of Life between Immediate and Delayed Autologous Tissue Breast Reconstruction: A Prospective Long-Term Outcome Study., Plast Reconstr Surg, 2016. 138 (4)(4): p. 772-780., https://pubmed.ncbi.nlm.nih.gov/27673514/
1825. Khajuria, A, Charles, WN, Prokopenko, M, Beswick, A, Pusic, AL, Mosahebi, A, et.al. Immediate and delayed autologous abdominal microvascular flap breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy: a meta-analysis of clinical and quality-of-life outcomes., BJS Open, 2020. 4 (2)(2): p. 182-196., https://pubmed.ncbi.nlm.nih.gov/32207573/
1826. Kronowitz, SJ, Kuerer, HM, Advances and surgical decision-making for breast reconstruction., Cancer, 2006. 107 (5)(5): p. 893-907., https://pubmed.ncbi.nlm.nih.gov/16862569/
1827. Hsieh, WC, Tee, R, Huang, YT, Kuo, WL, Huang, JJ, Surgical and patient-reported outcomes in an Asian female population with or without adjuvant radiotherapy after immediate free perforator flap breast reconstruction: A retrospective review., JPRAS Open, 2023. 38 (): p. 237-248., https://pubmed.ncbi.nlm.nih.gov/38021323/
1828. Jagsi, R, Momoh, AO, Qi, J, Hamill, JB, Billig, J, Kim, HM, et.al. Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction., J Natl Cancer Inst, 2018. 110 (2)(2): p. 157-65., https://pubmed.ncbi.nlm.nih.gov/28954300/
1829. Liew, B, Southall, C, Kanapathy, M, Nikkhah, D, Does post-mastectomy radiation therapy worsen outcomes in immediate autologous breast flap reconstruction? A systematic review and meta-analysis., J Plast Reconstr Aesthet Surg, 2021. 74 (12)(12): p. 3260-3280., https://pubmed.ncbi.nlm.nih.gov/34565703/
1830. Ly, CL, Khetpal, S, Heller, DR, Higgins, SA, Killelea, B, Alperovich, M, et.al. Comparing complications in irradiated and non-irradiated free-flaps in patients with bilateral immediate breast reconstruction and unilateral post-mastectomy radiotherapy., Microsurgery, 2021. 41 (7)(7): p. 615-621., https://pubmed.ncbi.nlm.nih.gov/33886127/
1831. Williams, JK, Carlson, GW, Bostwick, J, Bried, JT, Mackay, G, The effects of radiation treatment after TRAM flap breast reconstruction., Plast Reconstr Surg, 1997. 100 (5)(5): p. 1153-60., https://pubmed.ncbi.nlm.nih.gov/9326776/
1832. Tran, NV, Evans, GR, Kroll, SS, Baldwin, BJ, Miller, MJ, Reece, GP, et.al. Postoperative adjuvant irradiation: effects on tranverse rectus abdominis muscle flap breast reconstruction., Plast Reconstr Surg, 2000. 106 (2)(2): p. 313-7; discussion 318-20., https://pubmed.ncbi.nlm.nih.gov/10946929/
1833. Rogers, NE, Allen, RJ, Radiation effects on breast reconstruction with the deep inferior epigastric perforator flap., Plast Reconstr Surg, 2002. 109 (6)(6): p. 1919-24; discussion 1925-6., https://pubmed.ncbi.nlm.nih.gov/11994594/
1834. Spear, SL, Ducic, I, Low, M, Cuoco, F, The effect of radiation on pedicled TRAM flap breast reconstruction: outcomes and implications., Plast Reconstr Surg, 2005. 115 (1)(1): p. 84-95., https://pubmed.ncbi.nlm.nih.gov/15622237/
1835. Carlson, GW, Page, AL, Peters, K, Ashinoff, R, Schaefer, T, Losken, A, Effects of radiation therapy on pedicled transverse rectus abdominis myocutaneous flap breast reconstruction., Ann Plast Surg, 2008. 60 (5)(5): p. 568-72., https://pubmed.ncbi.nlm.nih.gov/18434833/
1836. Mirzabeigi, MN, Smartt, JM, Nelson, JA, Fosnot, J, Serletti, JM, Wu, LC, An assessment of the risks and benefits of immediate autologous breast reconstruction in patients undergoing postmastectomy radiation therapy., Ann Plast Surg, 2013. 71 (2)(2): p. 149-55., https://pubmed.ncbi.nlm.nih.gov/23542828/
1837. Taghizadeh, R, Moustaki, M, Harris, S, Roblin, P, Farhadi, J, Does post-mastectomy radiotherapy affect the outcome and prevalence of complications in immediate DIEP breast reconstruction? A prospective cohort study., J Plast Reconstr Aesthet Surg, 2015. 68 (10)(10): p. 1379-85., https://pubmed.ncbi.nlm.nih.gov/26210234/
1838. Cooke, AL, Diaz-Abele, J, Hayakawa, T, Buchel, E, Dalke, K, Lambert, P, Radiation Therapy Versus No Radiation Therapy to the Neo-breast Following Skin-Sparing Mastectomy and Immediate Autologous Free Flap Reconstruction for Breast Cancer: Patient-Reported and Surgical Outcomes at 1 Year-A Mastectomy Reconstruction Outcomes Consortium (MROC) Substudy., Int J Radiat Oncol Biol Phys, 2017. 99 (1)(1): p. 165-172., https://pubmed.ncbi.nlm.nih.gov/28816143/
1839. He, S, Yin, J, Robb, GL, Sun, J, Zhang, X, Li, H, et.al. Considering the Optimal Timing of Breast Reconstruction With Abdominal Flaps With Adjuvant Irradiation in 370 Consecutive Pedicled Transverse Rectus Abdominis Myocutaneous Flap and Free Deep Inferior Epigastric Perforator Flap Performed in a Chinese Oncology Center: Is There a Significant Difference Between Immediate and Delayed?, Ann Plast Surg, 2017. 78 (6)(6): p. 633-640., https://pubmed.ncbi.nlm.nih.gov/27798424/
1840. Pont, LP, Marcelli, S, Robustillo, M, Song, D, Grandes, D, Martin, M, et.al. Immediate Breast Reconstruction with Abdominal Free Flap and Adjuvant Radiotherapy: Evaluation of Quality of Life and Outcomes., Plast Reconstr Surg, 2017. 140 (4)(4): p. 681-690., https://pubmed.ncbi.nlm.nih.gov/28609351/
1841. Myung, Y, Son, Y, Nam, TH, Kang, E, Kim, EK, Kim, IA, et.al. Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction., PLoS One, 2018. 13 (5)(5): p. e0197615., https://pubmed.ncbi.nlm.nih.gov/29782518/
1842. O'Connell, RL, Di Micco, R, Khabra, K, Kirby, AM, Harris, PA, James, SE, et.al. Comparison of Immediate versus Delayed DIEP Flap Reconstruction in Women Who Require Postmastectomy Radiotherapy., Plast Reconstr Surg, 2018. 142 (3)(3): p. 594-605., https://pubmed.ncbi.nlm.nih.gov/29927832 /
1843. Classen, J, Nitzsche, S, Wallwiener, D, Kristen, P, Souchon, R, Bamberg, M, et.al. Fibrotic changes after postmastectomy radiotherapy and reconstructive surgery in breast cancer. A retrospective analysis in 109 patients., Strahlenther Onkol, 2010. 186 (11)(11): p. 630-6., https://pubmed.ncbi.nlm.nih.gov/21072625/
1844. Baumann, DP, Crosby, MA, Selber, JC, Garvey, PB, Sacks, JM, Adelman, DM, et.al. Optimal timing of delayed free lower abdominal flap breast reconstruction after postmastectomy radiation therapy., Plast Reconstr Surg, 2011. 127 (3)(3): p. 1100-1106., https://pubmed.ncbi.nlm.nih.gov/21364413/
1845. Fosnot, J, Fischer, JP, Smartt, JM, Low, DW, Kovach, SJ, Wu, LC, et.al. Does previous chest wall irradiation increase vascular complications in free autologous breast reconstruction?, Plast Reconstr Surg, 2011. 127 (2)(2): p. 496-504., https://pubmed.ncbi.nlm.nih.gov/20966818/
1846. Heiman, AJ, Gabbireddy, SR, Kotamarti, VS, Ricci, JA, A Meta-Analysis of Autologous Microsurgical Breast Reconstruction and Timing of Adjuvant Radiation Therapy., J Reconstr Microsurg, 2021. 37 (4)(4): p. 336-345., https://pubmed.ncbi.nlm.nih.gov/32957153/
1847. Koesters, EC, Chang, DW, Radiation and free flaps: what is the optimal timing?, Gland Surg, 2023. 12 (8)(8): p. 1122-1130., https://pubmed.ncbi.nlm.nih.gov/37701302/
1848. Rakha, EA, Tan, PH, Varga, Z, Tse, GM, Shaaban, AM, Climent, F, et.al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study., Br J Cancer, 2015. 112 (2)(2): p. 283-9., https://pubmed.ncbi.nlm.nih.gov/25422911/
1849. Haque, W, Verma, V, Naik, N, Butler, EB, Teh, BS, Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy., Ann Surg Oncol, 2018. 25 (4)(4): p. 928-936., https://pubmed.ncbi.nlm.nih.gov/29322287/
1850. He, X, Ji, J, Dong, R, Liu, H, Dai, X, Wang, C, et.al. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis., Breast Cancer Res Treat, 2019. 173 (2)(2): p. 329-341., https://pubmed.ncbi.nlm.nih.gov/30341462/
1851. Cserni, G, Quinn, CM, Foschini, MP, Bianchi, S, Callagy, G, Chmielik, E, et.al. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis., Cancers (Basel), 2021. 13 (22)(22):, https://pubmed.ncbi.nlm.nih.gov/34830849/
1852. Gobbi, H, Simpson, JF, Jensen, RA, Olson, SJ, Page, DL, Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas., Mod Pathol, 2003. 16 (9)(9): p. 893-901., https://pubmed.ncbi.nlm.nih.gov/13679453/
1853. Tseng, WH, Martinez, SR, Metaplastic breast cancer: to radiate or not to radiate?, Ann Surg Oncol, 2011. 18 (1)(1): p. 94-103., https://pubmed.ncbi.nlm.nih.gov/20585866/
1854. Al-Hilli, Z, Choong, G, Keeney, MG, Visscher, DW, Ingle, JN, Goetz, MP, et.al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy., Breast Cancer Res Treat, 2019. 176 (3)(3): p. 709-716., https://pubmed.ncbi.nlm.nih.gov/31119569/
1855. Wong, W, Brogi, E, Reis-Filho, JS, Plitas, G, Robson, M, Norton, L, et.al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma., NPJ Breast Cancer, 2021. 7 (1)(1): p. 96., https://pubmed.ncbi.nlm.nih.gov/34294707/
1856. Elimimian, EB, Samuel, TA, Liang, H, Elson, L, Bilani, N, Nahleh, ZA, Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US., JAMA Netw Open, 2021. 4 (4)(4): p. e214123., https://pubmed.ncbi.nlm.nih.gov/33844001/
1857. Lan, T, Lu, Y, Zheng, R, Shao, X, Luo, H, He, J, et.al. The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database., Front Oncol, 2021. 11 (): p. 572230., https://pubmed.ncbi.nlm.nih.gov/33981594/
1858. Chen, Q, Zhou, Q, He, H, He, Y, Yuan, Y, Zou, Q, et.al. Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b., Sci Rep, 2022. 12 (1)(1): p. 871., https://pubmed.ncbi.nlm.nih.gov/35042902/
1859. Ong, CT, Campbell, BM, Thomas, SM, Greenup, RA, Plichta, JK, Rosenberger, LH, et.al. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database., Ann Surg Oncol, 2018. 25 (8)(8): p. 2249-2260., https://pubmed.ncbi.nlm.nih.gov/29855830/
1860. van Olmen, JP, Beerthuizen, AWJ, Bekers, EM, Viegen, I, Drukker, CA, Vrancken Peeters, MTFD, et.al. Management of Benign Phyllodes Tumors: A Dutch Population-Based Retrospective Cohort Between 1989 and 2022., Ann Surg Oncol, 2023. 30 (13)(13): p. 8344-8352., https://pubmed.ncbi.nlm.nih.gov/37639031/
1861. Wei, Y, Yu, Y, Ji, Y, Zhong, Y, Min, N, Hu, H, et.al. Surgical management in phyllodes tumors of the breast: a systematic review and meta-analysis., Gland Surg, 2022. 11 (3)(3): p. 513-523., https://pubmed.ncbi.nlm.nih.gov/35402210/
1862. Rosenberger, LH, Thomas, SM, Nimbkar, SN, Hieken, TJ, Ludwig, KK, Jacobs, LK, et.al. Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines., J Clin Oncol, 2021. 39 (3)(3): p. 178-189., https://pubmed.ncbi.nlm.nih.gov/33301374/
1863. Balogun, Z, Steiman, JG, Schwartz, JL, Lee, JS, Soran, A, Johnson, RR, et.al. Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins., Breast Cancer Res Treat, 2023. 198 (3)(3): p. 569-572., https://pubmed.ncbi.nlm.nih.gov/36807012/
1864. Bogach, J, Sriskandarajah, A, Wright, FC, Look Hong, N, Phyllodes Tumors of the Breast: Canadian National Consensus Document Using Modified Delphi Methodology., Ann Surg Oncol, 2023. 30 (11)(11): p. 6386-6397., https://pubmed.ncbi.nlm.nih.gov/37556009/
1865. Thind, A, Patel, B, Thind, K, Isherwood, J, Phillips, B, Dhaliwal, K, et.al. Surgical margins for borderline and malignant phyllodes tumours., Ann R Coll Surg Engl, 2020. 102 (3)(3): p. 165-173., https://pubmed.ncbi.nlm.nih.gov/31918563/
1866. Toussaint, A, Piaget-Rossel, R, Stormacq, C, Mathevet, P, Lepigeon, K, Taffé, P, Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis., Breast Cancer Res Treat, 2021. 185 (1)(1): p. 21-37., https://pubmed.ncbi.nlm.nih.gov/32935237/
1867. Choi, N, Kim, K, Shin, KH, Kim, Y, Moon, HG, Park, W, et.al. Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08)., Breast Cancer Res Treat, 2018. 171 (2)(2): p. 335-344., https://pubmed.ncbi.nlm.nih.gov/29808288/
1868. Boutrus, RR, Khair, S, Abdelazim, Y, Nasr, S, Ibraheem, MH, Farahat, A, et.al. Phyllodes tumors of the breast: Adjuvant radiation therapy revisited., Breast, 2021. 58 (): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/33865208/
1869. Zeng, S, Zhang, X, Yang, D, Wang, X, Ren, G, Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis., Mol Clin Oncol, 2015. 3 (3)(3): p. 663-671., https://pubmed.ncbi.nlm.nih.gov/26137284/
1870. Chao, X, Chen, K, Zeng, J, Bi, Z, Guo, M, Chen, Y, et.al. Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis., BMC Cancer, 2019. 19 (1)(1): p. 372., https://pubmed.ncbi.nlm.nih.gov/31014268/
1871. Baker, GM, Schnitt, SJ, Vascular lesions of the breast., Semin Diagn Pathol, 2017. 34 (5)(5): p. 410-419., https://pubmed.ncbi.nlm.nih.gov/28676174/
1872. Scow, JS, Reynolds, CA, Degnim, AC, Petersen, IA, Jakub, JW, Boughey, JC, Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience., J Surg Oncol, 2010. 101 (5)(5): p. 401-7., https://pubmed.ncbi.nlm.nih.gov/20119983/
1873. Mark, RJ, Poen, J, Tran, LM, Fu, YS, Selch, MT, Parker, RG, Postirradiation sarcomas. A single-institution study and review of the literature., Cancer, 1994. 73 (10)(10): p. 2653-62., https://pubmed.ncbi.nlm.nih.gov/8174066/
1874. Bjerkehagen, B, Smeland, S, Walberg, L, Skjeldal, S, Hall, KS, Nesland, JM, et.al. Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital., Acta Oncol, 2008. 47 (8)(8): p. 1475-82., https://pubmed.ncbi.nlm.nih.gov/18607853/
1875. Veiga, LHS, Vo, JB, Curtis, RE, Mille, MM, Lee, C, Ramin, C, et.al. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study., Lancet Oncol, 2022. 23 (11)(11): p. 1451-1464., https://pubmed.ncbi.nlm.nih.gov/36240805/
1876. Osman, MH, Rabie, NA, Elmehrath, AO, Bedair, HM, Fala, SY, Ghaith, HS, et.al. Primary and Secondary Breast Sarcoma: Clinical and Pathological Characteristics, Prognostic Factors, and Nomograms for Predicting Survival., Clin Breast Cancer, 2022. 22 (7)(7): p. e753-e763., https://pubmed.ncbi.nlm.nih.gov/35963779/
1877. Abdou, Y, Elkhanany, A, Attwood, K, Ji, W, Takabe, K, Opyrchal, M, Primary and secondary breast angiosarcoma: single center report and a meta-analysis., Breast Cancer Res Treat, 2019. 178 (3)(3): p. 523-533., https://pubmed.ncbi.nlm.nih.gov/31522347/
1878. Ramakrishnan, N, Mokhtari, R, Charville, GW, Bui, N, Ganjoo, K, Management Strategies and Outcomes in Primary Liver Angiosarcoma., Am J Clin Oncol, 2023. 46 (10)(10): p. 439-444., https://pubmed.ncbi.nlm.nih.gov/37580871/
1879. Mito, JK, Mitra, D, Barysauskas, CM, Mariño-Enriquez, A, Morgan, EA, Fletcher, CDM, et.al. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas., Int J Radiat Oncol Biol Phys, 2019. 104 (2)(2): p. 425-435., https://pubmed.ncbi.nlm.nih.gov/30703514/
1880. Rombouts, AJM, Huising, J, Hugen, N, Siesling, S, Poortmans, PM, Nagtegaal, ID, et.al. Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study., JAMA Oncol, 2019. 5 (2)(2): p. 267-269., https://pubmed.ncbi.nlm.nih.gov/30676608/
1881. Sato, F, Yamamoto, T, Breast angiosarcoma after primary breast cancer surgery: A systematic review., J Plast Reconstr Aesthet Surg, 2022. 75 (9)(9): p. 2882-2889., https://pubmed.ncbi.nlm.nih.gov/35907689/
1882. Heitmann, C, Ingianni, G, Stewart-Treves syndrome: lymphangiosarcoma following mastectomy., Ann Plast Surg, 2000. 44 (1)(1): p. 72-5., https://pubmed.ncbi.nlm.nih.gov/10651369/
1883. Rippinger, N, Fischer, C, Sinn, HP, Dikow, N, Sutter, C, Rhiem, K, et.al. Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study., Cancer Med, 2021. 10 (21)(21): p. 7747-7758., https://pubmed.ncbi.nlm.nih.gov/34569185/
1884. Blondeaux, E, Arecco, L, Punie, K, Graffeo, R, Toss, A, De Angelis, C, et.al. Germline TP53 pathogenic variants and breast cancer: A narrative review., Cancer Treat Rev, 2023. 114 (): p. 102522., https://pubmed.ncbi.nlm.nih.gov/36739824/
1885. Choi, M, Kipps, T, Kurzrock, R, ATM Mutations in Cancer: Therapeutic Implications., Mol Cancer Ther, 2016. 15 (8)(8): p. 1781-91., https://pubmed.ncbi.nlm.nih.gov/27413114/
1886. D'Angelo, SP, Antonescu, CR, Kuk, D, Qin, L, Moraco, N, Carvajal, RC, et.al. High-risk features in radiation-associated breast angiosarcomas., Br J Cancer, 2013. 109 (9)(9): p. 2340-6., https://pubmed.ncbi.nlm.nih.gov/24104962/
1887. Torres, KE, Ravi, V, Kin, K, Yi, M, Guadagnolo, BA, May, CD, et.al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer., Ann Surg Oncol, 2013. 20 (4)(4): p. 1267-74., https://pubmed.ncbi.nlm.nih.gov/23224828/
1888. Bousquet, G, Confavreux, C, Magné, N, de Lara, CT, Poortmans, P, Senkus, E, et.al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network., Radiother Oncol, 2007. 85 (3)(3): p. 355-61., https://pubmed.ncbi.nlm.nih.gov/18023492/
1889. Manner, J, Radlwimmer, B, Hohenberger, P, Mössinger, K, Küffer, S, Sauer, C, et.al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema., Am J Pathol, 2010. 176 (1)(1): p. 34-9., https://pubmed.ncbi.nlm.nih.gov/20008140/
1890. Käcker, C, Marx, A, Mössinger, K, Svehla, F, Schneider, U, Hogendoorn, PC, et.al. High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01., Genes Chromosomes Cancer, 2013. 52 (1)(1): p. 93-8., https://pubmed.ncbi.nlm.nih.gov/23012233/
1891. Fernandez-Lao, C., Cantarero-Villanueva, I., Fernandez-de-Las-Penas, C., del Moral-Avila, R., Castro-Sanchez, A. M., Arroyo-Morales, M., Effectiveness of a multidimensional physical therapy program on pain, pressure hypersensitivity, and trigger points in breast cancer survivors: a randomized controlled clinical trial, Clin J Pain, 2012. 28(2): p. 113-21., https://www.ncbi.nlm.nih.gov/pubmed/21705873
1892. Salminen, SH, Sampo, MM, Böhling, TO, Salo, J, Tarkkanen, M, Blomqvist, CP, et.al. Radiation-associated angiosarcoma of the breast: analysis of diagnostic tools in a registry-based population., Acta Radiol, 2022. 63 (1)(1): p. 22-27., https://pubmed.ncbi.nlm.nih.gov/33349000/
1893. Feinberg, L, Srinivasan, A, Singh, JK, Parry, M, Stevenson, J, Jeys, L, et.al. Impact of specialist management on survival from radiation-associated angiosarcoma of the breast., Br J Surg, 2018. 105 (4)(4): p. 401-409., https://pubmed.ncbi.nlm.nih.gov/29405251/
1894. Teng, L, Yan, S, Du, J, Yang, R, Xu, P, Tao, W, Clinicopathological analysis and prognostic treatment study of angiosarcoma of the breast: a SEER population-based analysis., World J Surg Oncol, 2023. 21 (1)(1): p. 144., https://pubmed.ncbi.nlm.nih.gov/37158932/
1895. Pink, D, Andreou, D, Bauer, S, Brodowicz, T, Kasper, B, Reichardt, P, et.al. Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient, Cancers (Basel), 2021. 13 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/33799576/
1896. Salminen, SH, Wiklund, T, Sampo, MM, Tarkkanen, M, Pulliainen, L, Böhling, TO, et.al. Treatment and Prognosis of Radiation-Associated Breast Angiosarcoma in a Nationwide Population., Ann Surg Oncol, 2020. 27 (4)(4): p. 1002-1010., https://pubmed.ncbi.nlm.nih.gov/31773514/
1897. Cohen-Hallaleh, RB, Smith, HG, Smith, RC, Stamp, GF, Al-Muderis, O, Thway, K, et.al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series., Clin Sarcoma Res, 2017. 7 (): p. 15., https://pubmed.ncbi.nlm.nih.gov/28794852/
1898. Yin, M, Wang, W, Drabick, JJ, Harold, HA, Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study., BMC Cancer, 2017. 17 (1)(1): p. 295., https://pubmed.ncbi.nlm.nih.gov/28449661/
1899. Mergancová, J, Lierová, A, Coufal, O, Žatecký, J, Melichar, B, Zedníková, I, et.al. Radiation-associated angiosarcoma of the breast: An international multicenter analysis., Surg Oncol, 2022. 41 (): p. 101726., https://pubmed.ncbi.nlm.nih.gov/35203019/
1900. Palassini, E, Baldi, GG, Sulfaro, S, Barisella, M, Bianchi, G, Campanacci, D, et.al. Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group., Cancer Treat Rev, 2024. 126 (): p. 102722., https://pubmed.ncbi.nlm.nih.gov/38604052/
1901. Li, GZ, Fairweather, M, Wang, J, Orgill, DP, Bertagnolli, MM, Raut, CP, Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival., Ann Surg, 2017. 265 (4)(4): p. 814-820., https://pubmed.ncbi.nlm.nih.gov/28267696/
1902. Depla, AL, Scharloo-Karels, CH, de Jong, MAA, Oldenborg, S, Kolff, MW, Oei, SB, et.al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review., Eur J Cancer, 2014. 50 (10)(10): p. 1779-1788., https://pubmed.ncbi.nlm.nih.gov/24731859/
1903. Ghareeb, ER, Bhargava, R, Vargo, JA, Florea, AV, Beriwal, S, Primary and Radiation-induced Breast Angiosarcoma: Clinicopathologic Predictors of Outcomes and the Impact of Adjuvant Radiation Therapy., Am J Clin Oncol, 2016. 39 (5)(5): p. 463-7., https://pubmed.ncbi.nlm.nih.gov/25521258/
1904. Linthorst, M, van Geel, AN, Baartman, EA, Oei, SB, Ghidey, W, van Rhoon, GC, et.al. Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall., Strahlenther Onkol, 2013. 189 (5)(5): p. 387-93., https://pubmed.ncbi.nlm.nih.gov/23549781/
1905. Degnim, AC, Siontis, BL, Ahmed, SK, Hoskin, TL, Hieken, TJ, Jakub, JW, et.al. Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast., Clin Cancer Res, 2023. 29 (15)(15): p. 2885-2893., https://pubmed.ncbi.nlm.nih.gov/37223927/
1906. van der Burg, SJC, Reijers, SJM, Kuijpers, A, Heimans, L, Scholten, AN, Haas, RLM, et.al. Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study., Breast, 2024. 78 (): p. 103825., https://pubmed.ncbi.nlm.nih.gov/39476458/
1907. NCCN Guidelines, T-cell lymphomas, 1.2023., https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483
1908. Altenhofen, Lutz, Blumenstock, Gunnar, Diel, Franziska, Doebler, Klaus, Geraedts, Max, Jäckel, Wilfried, et.al. Qualitätsindikatoren – Manual für Autoren., 2009/01/01.
1909. Thomas, J., Evans, A., Macartney, J., Pinder, S. E., Hanby, A., Ellis, I., et.al. Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project, Br J Cancer, 2010. 102(2): p. 285-93., https://www.ncbi.nlm.nih.gov/pubmed/20051953
1910. Lebeau, A., [Prognostic factors in ductal carcinoma in situ], Pathologe, 2006. 27(5): p. 326-36., https://www.ncbi.nlm.nih.gov/pubmed/16896676
1911. TNM classification of malignant tumoursJohn Wiley & Sons, Inc., 2017. p. p..
1912. Deb R, Pinder S, Boyd C, Callagy G, Carder PJ, Lee AH, Mir Y, Provenzano E, Quinn C, Rakha E et al., Dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, In., 3rd edn: The Royal College of Pathologists, 2024., https://www.rcpath.org/static/d255f34c-176a-490d-9b5a7d58ac85f3a6/G148-Dataset-for-histopathological-reporting-of-breast-disease-in-surgical-excision-specimens-of-breast-cancer.pdf
1913. Committee, The Consensus Conference, Consensus Conference on the classification of ductal carcinoma in situ., Cancer, 1997. 80(9): p. 1798-802., https://www.ncbi.nlm.nih.gov/pubmed/9351550
1914. Lee, A. H., Rakha, E. A., Hodi, Z., Ellis, I. O., Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast, Histopathology, 2012. 60(7): p. 1166-7., https://www.ncbi.nlm.nih.gov/pubmed/22385388
1915. Christgen, M., Langer, F., Kreipe, H., [Histological grading of breast cancer], Pathologe, 2016. 37(4): p. 328-36., https://www.ncbi.nlm.nih.gov/pubmed/27363708
1916. van Dooijeweert, C, van Diest, PJ, Ellis, IO, Grading of invasive breast carcinoma: the way forward., Virchows Arch, 2022. 480 (1)(1): p. 33-43., https://pubmed.ncbi.nlm.nih.gov/34196797/
1917. Sinn, H. P., Anton, H. W., Magener, A., von Fournier, D., Bastert, G., Otto, H. F., Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy, Eur J Cancer, 1998. 34(5): p. 646-53., https://www.ncbi.nlm.nih.gov/pubmed/9713268
1918. Faverly, D. R., Burgers, L., Bult, P., Holland, R., Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications, Semin Diagn Pathol, 1994. 11(3): p. 193-8., https://www.ncbi.nlm.nih.gov/pubmed/7831530
1919. Lee, A. K., Loda, M., Mackarem, G., Bosari, S., DeLellis, R. A., Heatley, G. J., et.al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome, Cancer, 1997. 79(4): p. 761-71., https://www.ncbi.nlm.nih.gov/pubmed/9024714
1920. Leitner, S. P., Swern, A. S., Weinberger, D., Duncan, L. J., Hutter, R. V., Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0), Cancer, 1995. 76(11): p. 2266-74., https://www.ncbi.nlm.nih.gov/pubmed/8635031
1921. Schnitt, Stuart J., Collins, Laura C., Biopsy interpretation of the breastWolters Kluwer Health/Lippincott Williams & Wilkins, Biopsy interpretation series, 2013. p. xi, 540 p..
1922. Zaorsky, N. G., Patil, N., Freedman, G. M., Tuluc, M., Differentiating lymphovascular invasion from retraction artifact on histological specimen of breast carcinoma and their implications on prognosis, J Breast Cancer, 2012. 15(4): p. 478-80., https://www.ncbi.nlm.nih.gov/pubmed/23346180
1923. Harvey, J. M., Clark, G. M., Osborne, C. K., Allred, D. C., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 1999. 17(5): p. 1474-81., https://www.ncbi.nlm.nih.gov/pubmed/10334533
1924. Remmele, W., Stegner, H. E., [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue], Pathologe, 1987. 8(3): p. 138-40., https://www.ncbi.nlm.nih.gov/pubmed/3303008
1925. Tarantino, P, Viale, G, Press, MF, Hu, X, Penault-Llorca, F, Bardia, A, et.al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer., Ann Oncol, 2023. 34 (8)(8): p. 645-659., https://pubmed.ncbi.nlm.nih.gov/37269905/
1926. Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., et.al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol, 2007. 25(28): p. 4414-22., https://www.ncbi.nlm.nih.gov/pubmed/17785706
1927. Sataloff, DM, Mason, BA, Prestipino, AJ, Seinige, UL, Lieber, CP, Baloch, Z, Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome., J Am Coll Surg, 1995. 180 (3)(3): p. 297-306., https://pubmed.ncbi.nlm.nih.gov/7874340/
1928. Vila, J., Teshome, M., Tucker, S. L., Woodward, W. A., Chavez-MacGregor, M., Hunt, K. K., et.al. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer, Ann Surg, 2017. 265(3): p. 574-580., https://www.ncbi.nlm.nih.gov/pubmed/27735826
1929. Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., Gonzalez-Angulo, A. M., et.al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy, J Clin Oncol, 2011. 29(15): p. 1956-62., https://www.ncbi.nlm.nih.gov/pubmed/21482989
1930. Marmé, F, Lederer, B, Blohmer, JU, Costa, SD, Denkert, C, Eidtmann, H, et.al. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy., Eur J Cancer, 2016. 53 (): p. 65-74., https://pubmed.ncbi.nlm.nih.gov/26693900/
1931. Marme, F., Aigner, J., Lorenzo Bermejo, J., Sinn, P., Sohn, C., Jager, D., et.al. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials, Int J Cancer, 2013. 133(4): p. 1006-15., https://www.ncbi.nlm.nih.gov/pubmed/23400797
1932. Giuliano, A. E., Connolly, J. L., Edge, S. B., Mittendorf, E. A., Rugo, H. S., Solin, L. J., et.al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28294295